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INLEIDING 
Met de studies van Kloppenborg over ,,De secretiesnelheid van aldos-
teron onder normale en pathologische omstandigheden" (Thesis, 1966) 
en van Benraad over de „Bepaling van aldosteron met behulp van een 
dubbel-isotoop methode" (Thesis, 1966), werd het beslag gelegd voor 
de totstandkoming van dit proefschrift. In de Kliniek voor Inwendige 
Geneeskunde te Nijmegen bestond echter reeds langer belangstelling 
voor de water- en zouthuishouding bij de mens, met name door de 
oorspronkelijke waarneming van Majoor over de remming van de 
secretie van aldosteron onder invloed van héparine in 1955, tevens het 
jaar waarin Conn het syndroom „primair aldosteromsme" wereldkun-
dig maakte. Het is dan ook niet verwonderlijk, dat het syndroom 
„primair aldosteromsme" in de Nijmeegse Interne Kliniek, de belang-
stelling van velen heeft genoten, zoals mede tot uiting is gekomen in de 
proefschriften van Caspane (1968), Onessen (1969) en Drayer (1975). 
Een toenemend aanbod van patiënten met primair aldosteromsme en 
ontwikkelingen in diagnostiek en behandeling, waarmee de laatste 
jaren ervaring werd opgedaan, hebben geleid tot studies, waarvan de 
resultaten in dit proefschrift werden neergelegd Deze ontwikkelingen 
waren: 
1. De bepaling van aldosteron in plasma. Hiermee werd het mogelijk 
de regulatie van aldosteron bij patiënten te bestuderen en tevens na te 
gaan in hoeverre het gedrag van aldosteron bij patiënten met primair 
aldosteromsme met en zonder bijnieradenomen, verschillend was 
2 Scintigrafie van de bijnieren Het lokaliseren van aldosteron-produ-
cerende adenomen langs niet invasieve weg. leek een aantrekkelijk en 
voor de patient weinig belastend onderzoek, waarmee het succes van 
een operatie aanzienlijk zou kunnen worden vergroot. 
3 Medicamenteu/e behandeling met Spironolacton of amilonde. De 
waarneming dat amilonde bij sommige patiënten een bruikbaar medi-
camenteus alternatief is voor Spironolacton, heeft geleid tot een verge-
lijkend onderzoek naar het werkingsmechanisme van beide medica-
menten 
Het hier bovengenoemd onderzoek werd vooral gestimuleerd door de 
wetenschap, dat patiënten met primair aldosteromsme zonder bijniera-
denoom (idiopathisch aldosteromsme) over het algemeen niet gunstig 
reageren op een operatieve behandeling Het was daarom nodig om 
over betrouwbare diagnostische methoden te beschikken om deze 
patiënten preoperatief te identificeren en te beschikken over optimale 
medicamenteuze behandelingsmethoden. 
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CHAPTER I 
REVIEW OF DATA IN THE LITERATURE ON 
PRIMARY 
ALDOSTERONISM 
1.1. HISTORY AND CLASSIFICATION 
In 1955 Conn gave a description of a woman aged 34 years with a 
clinical picture of intermittent tetany, paresthesia, periodic severe 
muscular weakness and paralyses, polyuria, polydipsia, hypertension 
and absence of edema. There was a severe hypokalemic alkalosis, that 
could not be corrected permanently by administration of potassium, 
hypernatrcmia and a renal tubular defect in the reabsorption of water. 
In the urine an excess of a sodium retaining corticoid was found, that 2 
years later, after a method for its determination had become available, 
could be identified as aldosterone (Conn 1967). Operative removal of 
an adrenal adenoma 4 cm in size led to disappearance of the complaints 
and a normalization of the blood pressure (Conn 1955b; Conn and 
Louis 1956). The syndrome was given the name of "primary aldostero-
nism" by Conn. As early as 1956 12 cases of primary aldosteronism 
were known to Conn (via "personal communication"). A rapidly 
increasing number of publications made it possible for Conn in 1964 to 
describe the clinically characteristic features of the syndrome on the 
basis of 145 cases that up to that time had been published (Conn et al. 
1964a). Most of the patients were 30 to 50 years old; there were fully 
2.5 times as many women as men. The adenomas, the greater propor-
tion of which were localized in the left adrenal were solitary in 91 % of 
the cases, weighed less than 6 grams and were smaller than 3 cm. In 
70% of the cases the blood pressure became normal on removal of the 
adenoma. The "classical symptoms" were certainly not present in all of 
the patients and some patients (5%) manifested no symptoms what-
ever. Later on it was found from various case reports that an adenoma 
of the adrenal was not revealed at operation in every patient who 
fulfilled all the criteria for making the diagnosis. At operation in such 
cases a bilateral adrenal hyperplasia was established while, in some 
patients, no anomalies were encountered in the adrenals. At first Conn 
was of the opinion that 2 groups of patients with "primary aldostero-
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nism"* without adrenal adenoma could be distinguished (Conn 1961): 
one group with so-called "congenital aldosteronism" - young adults 
and children often with malignant hypertension in whom the blood 
pressure in the majority of cases responded well to a (sub)total 
adrenalectomy (van Buchem et al. 1956, Therien et al. 1959, Kretch-
meretal . 1959, Moran et al. 1960), and another group-adults in whom 
in general the blood pressure did not respond favourably to a (sub)total 
adrenalectomy (only in 1 of the 9 patients who werd diagnosed up to 
1961 did the blood pressure fall after operation). Later on, no more 
cases of "congenital aldosteronism" have been reported in the litera-
ture. It is possible that these first publications were, in fact, dealing 
with patients with a secondary hyperaldosteronism (renin determinati-
ons were not available at that time). Adult patients in whom no adrenal 
adenoma was found became continually better known at the end of the 
sixties, probably because of the extension of the diagnostic possibilities 
(Davis et al. 1967, Katz 1967, Salti et al. 1969). The studies of Biglieri 
et al. and Baer et al. that were published simultaneously in 1970 
showed that this form of "primary aldosteronism" was not so rare as 
was thought at first: in 11 of the 23 patients who from 1959 to 1969 were 
operated on in the Presbyterian Hospital in New York City on account 
of "primary aldosteronism", no adrenal adenoma was found (Baer et 
al. 1970); and the same is true for 14 of the 49 patients operated in the 
San Francisco General Hospital (Biglieri et al. 1970a). A second 
important discovery in both studies was that the patients with and 
without an adrenal adenoma could not be distinguished from each 
other preoperatively although the degree of aldosteronism and the 
metabolic consequences it entailed in patients with an adrenal hyper-
plasia were, in general, less severe. The fact that patients with and 
without adrenal adenoma could not be differentiated on clinical and 
biochemical grounds was, however, not of merely theoretical impor-
tance: in patients without adrenal adenoma the effect of an operation 
(unilateral or (sub)total adrenalectomy) remained limited to a correc-
tion of the metabolic aberrations. In none of these patients was there a 
normalization of the blood presure, in contradistinction to a "cure 
rate" of 83% (Baer et al. 1970) and 60% (Biglieri et al. 1970) in 
patients with adenomatous primary aldosteronism. The discoveries 
that both adrenals of a great proportion of the patients were hyperplas-
tic and the disappointing results of the adrenal surgery raised doubt 
about the "primary" character of the diagnosis of "primary aldostero-
nism" in these patients. For this reason Baer et al. (1970) suggested the 
name "pseudo-primary aldosteronism", and by Biglieri et al. (1970) the 
expression "idiopathic aldosteronism" was advised, a denomination 
that was first used by Liddle in 1962 and that nowadays is used 
* Conn reserved the name "primary aldosteronism" for the cases with an adenoma. 
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almost generally for the definition of patients with primary aldostero-
nism in whom no aldosterone-producing adenoma is found The fin-
dings of Baer et al and of Biglien et al are supported by the 
publications of Distler et al (1969) and George et al (1970), who 
found no adenoma at operation in 50% and 32% of patients with 
primary aldosteronism, respectively, while the blood pressure in gene-
ral did not return to normal values after the performance of (sub)total 
adrenalectomy Also, from recent review articles (Fernss et al. 1978a, 
Weinberger et al. 1979) it is clear that idiopathic aldosteronism exists 
relatively frequently Thus, in the group of patients with primary 
aldosteronism examined by Fernss et al in 14 out of 64 of the operated 
patients (21%) no adenoma was found, whereas Weinberger et al 
reported the aDsence of an adenoma in i l of 51 patients (21%) The 
fact that idiopathic aldosteronism not rarely occurs has from the 
beginning of the seventies led to the development of methods and 
techniques that make possible a pre-operative differentiation between 
idiopathic and adenomatous aldosteronism, the objective of which is to 
save patients with the first mentioned form of primary aldosteronism 
from an unnecessary operation 
Besides the 2 most frequently occurring forms of primary aldostero-
nism - adenomatous and idiopathic - 2 more, but less frequently 
occurring subgroups of the syndrome are distinguished, namely ."glu-
cocorticoid remediable aldosteronism" and "primary aldosteronism as 
the sequel of an aldosterone-producing carcinoma" Glucocorticoid 
remediable aldosteronism is a very rare form of primary aldosteronism, 
that has been found up till today in 5 patients, while research among 
the members of the families of these patients brought to light more 
cases in 4 of the 5 families (Sutherland et al 1966, New et al 1973, 
Miura et al 1968, Giebink et al 1973, Grim et al 1980) It is a familial 
affection that is inherted autosomal dominantly (New et al 1980) The 
affection is characterized by. a slight hypertension, suppressed renin 
activity, a moderate aldosteronism, a complete suppressibihty of the 
aldosterone excretion within 24 hours after the administration of 1 mg 
of dexamethasone, and a normalization of the blood pressure after 10 
to 14 days of treatment with low doses of glucocorticoids In general 
the opinion is that for these reasons patients with primary aldostero-
nism should receive a trial of dexamethasone treatment for 14 days. 
The adrenal lesion in these patients is a bilateral adrenal hyperplasia 
(Sutherland et al 1966) 
The aldosterone-producing adrenal carcinoma is a rare affection, that 
was first reported by Foye and Feichtmeir (1955). Apparently up till 
today less than 20 cases have been reported in detail in the literature. 
For a general review of this subject we refer the reader to chapters 
VIII 6. and IX of this thesis. 
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1.2. DIAGNOSIS OF PRIMARY ALDOSTERONISM AND DIFFERENTIATION 
BETWEEN IDIOPATHIC AND ADENOMATOUS ALDOSTERONISM 
1.2.1. Clinical diagnosis 
The clinical features of the syndrome mostly contribute little to making 
of the diagnosis, in view of the fact that in many patients - and above all 
in patients with idiopathic aldosteronism - these may be partially or 
entirely absent. In the review published by Conn in 1964 muscular 
weakness (73% of the patients), polyuria and nycturia (72% of the 
patients), headache (51 % of the patients) and polydipsia (46% of the 
patients) belonged to the most frequently occurring symptoms. The 
presence of a raised blood pressure proves to be no absolute precondi-
tion in view of the recent report in the literature of 3 patients with 
primary aldosteronism and a normal blood pressure (Snow et al. 1976, 
Zipser and Speckart 1978, Kono et al. 1980). At first it was thought that 
the hypertension only rarely induced vascular complications or the 
development of a malignant hypertension (Kaplan 1963). But it has 
now become evident that patients with primary aldosteronism are not 
exempt from the complications of hypertension (Kloppenborg et al. 
1974, Beevers et al. 1976). Thus, Bcevers et al. (1976) reported that 
2.9% of patients with primary aldosteronism developed malignant 
hypertension, while 22.8% acquired vascular complications. 
1.2.2. Biochemical diagnosis 
The diagnosis of primary aldosteronism is based on the demonstration 
of an inappropriately raised aldosterone production and a suppression 
of the plasma renin activity in patients with hypertension (Conn 
1964b). For the detection of patients with primary aldosteronism the 
demonstration of a spontaneous and persistent hypokalemia is a simple 
aid. In 1966, however. Conn reported the presence of persistently 
normal plasma potassium concentrations in a few patients with histolo-
gically confirmed primary aldosteronism, which caused him to suggest 
that probably a considerable proportion of patients (± 20%) with 
essential hypertension in fact may suffer from primary aldosteronism. 
This suggestion was also based by him on the following considerations: 
1. The occurrence of a suppressed plasma renin activity in primary 
aldosteronism (Conn 1964b) and in 2 1 % of unselected hypertensive 
patients (Brown et al. 1964). 
2. A disturbed carbohydrate tolerance, a frequent finding in patients 
with primary aldosteronism, may - conversely - also be an indication of 
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primary aldosteronism in patients with "essential hypertension" (Conn 
1965). 
3. The occurrence of so-called "non-functioning adrenal adenomas" in 
20% of autopsy patients with essential hypertension (and only in 1.8% 
of patients without hypertension (Shamma et al. 1958)). In this respect 
Conn proceeded from the notion that the "non-functioning" character 
of these adenomas is dubious. 
These propositions were for many research workers an inducement for 
setting up research on the incidence of primary aldosteronism, the 
occurrence of normokalemic hyperaldosteronism and the aldosterone 
and renin values in the total hypertensive population. From these 
studies the following conclusions were drawn: 
1. Primary aldosteronism is a rare affection, the incidence of which is 
probably much lower than 1 % of the hypertensive population (Kaplan 
1969, Gifford 1969, Tucker and Labarthe 1977). 
2. Recent review studies (Ferriss et al. 1978a, Weinberger et al. 1979) 
show that intermittently or persistently normal plasma potassium 
values in both adenomatous and idiopathic aldosteronism are fre­
quently found. The percentages mentioned by Ferriss et al. (28%) and 
Weinberger et al. (22%) are in good agreement. 
3. The aldosterone production in patients with essential hypertension 
and a suppressed plasma renin activity was usually found to be normal 
(Ledingham et al. 1967). Most investigators agree that the incidence of 
low renin essential hypertension in an unselected hypertensive popula­
tion is between 20 and 30 percent (Ganguly and Weinberger 1979). 
1.2.3. The demonstration of an inappropriately raised aldosterone 
production 
Most authors agree that for the demonstration of a raised aldosterone 
production, use must be made of one of the suppression tests that will 
be described here later on. The principle is based on the demonstration 
of an insufficient suppressibility of aldosterone after the performance 
of certain procedures (administration of salt and/or mineralocorticoids) 
with which an expansion of the plasma volume is accomplished. The 
excretion of aldosterone in the urine is not seldom entirely normal in 
patients with primary aldosteronism, if the determination is made while 
the patients use a diet with a normal salt content. Thus Weinberger et 
al. (1979) reported that in 3 1 % of 32 patients with primary aldostero­
nism an excretion of aldosterone was found that was less than 20 μ§/24 
hours, during a diet of normal salt content. Biglieri et al. (1967) showed 
that excretions of aldosterone in the urine may display considerable 
variations from day to day, and occasionally even normal aldosterone 
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values may be found. In addition, Cain et al. (1972) found that the 
values of aldosterone secretion determined during a salt-free diet did 
not show any differences as between normal persons and patients with 
primary aldosteronism. The following suppression tests were described 
in the literature: 
1. Dietary salt loading. To a salt-free diet is added, for 3 to 5 days, 200 
mmol NaVday (Cain et al. 1972, Demanet and Vrijens 1971) or 300 
mmol Na+/day (Collins et al. 1970) and the secretion rate of aldoste-
rone is determined before and during the giving of salt. Cain et al. 
(1972) found a percentile fall of the aldosterone secretion of 40% in 
patients with primary aldosteronism, and of 80% in normal control 
persons. 
2. Intravenous administration of salt: Espiner et al. (1967) and Christ-
lieb et al. (1971) found that giving 2 1 physiological salt for 4 hours on 2 
successive days, caused a fall of 83% in the aldosterone secretion rate 
in normal test persons and of only 16% in patients with primary 
aldosteronism. The test was carried out during a saltless diet. Kern et 
al. (1971) reached the same results after simplification of the test: 
plasma aldosterone determined at 08.00 hours in the morning during a 
normal salt-containing diet (after 2 hours of ambulation) fell in normal 
test persons by 84% after administration of 2 1 physiological salt given 
intravenously within 4 hours. In patients with primary aldosteronism 
the fall was 25%. 
3. Desoxycorticosterone acetate (DOGA). Bilglicri et al. (1967) sho-
wed that administration of DOCA 10 mg/12 hours intramuscularly for 3 
days during a normal salt-containing diet in patients with primary 
aldosteronism, did not cause the aldosterone excretion in the urine to 
decrease (there was, in fact, a rise of 14%), in contrast to what was 
found in normals ( -70%) and patients with essential hypertension 
( -61%) . 
4. 9-alpha-fluorohydrocortisone (Fludrocortisone). Oral administra-
tion of fludrocortisone for 3 days at a dose of 0.4 mg/day (Biglieri et al. 
1970b), 0.8 mg/day (Padfield et al. 1975) or 1.2. mg/day (Horton et al. 
1969, Lund and Nielsen 1980) is a simple test for policlinical use. From 
the study of Horton et al. (1969) it emerges that the plasma aldosterone 
concentration (during a normal diet) falls off by 82% in normals and by 
15% in patients with primary aldosteronism. Padfield et al. (1975), 
however, found after adminstration of fludrocortisone a definite over-
lap between the plasma aldosterone values of patients with essential 
hypertension and those of patients with primary aldosteronism. The 
results of the study by Lund and Nielsen (1980) are convincing and 
show that after administration of fludrocortisone the excretion of 
tetrahydroaldosterone falls off by 67% in normals, by 51 % in patients 
with essential hypertension, and by 11% in patients with primary 
8 
aldosteronism (η=24). The aldosterone values of the first 2 groups 
were also, without exception lower than those of the last mentioned 
group. 
5. Albumin. George et al. (1970) found that the aldosterone excretions 
of patients with both idiopathic and adenomatous aldosteronism 
(determined during a salt-free diet) underwent almost no change after 
infusion of 50 to 100 grams of human serum albumin for 4 days, while, 
in normals a diminution of the aldosterone excretion of 55% was 
found. 
All of the tests mentioned are, in the majority of cases, sufficient for 
the detection of patients with primary aldosteronism, as in the remai­
ning forms of hypertension the aldosterone values lie within the normal 
distribution area after performance of the suppression test. But an 
exception to this is the form of primary aldosteronism that was denomi­
nated as "indeterminate aldosteronism" by Biglieri et al. (1972). In this 
form of primary aldosteronism all the characteristic features of the 
syndrome are present, except the insuppressibility of aldosterone after 
administration of DOCA. 
1.2.4. Differential diagnosis of adenoma and hyperplasia 
The importance of the differential diagnosis between adenomatous and 
idiopathic aldosteronism has been set forth previously. In ± 20% of 
patients with primary aldosteronism the affection is caused by a bilate­
ral adrenal hyperplasia. Because of the fact that an operative treatment 
(total or subtotal adrenalectomy) mostly does not yield the desired fall 
of blood pressure, a number of diagnostic methods that make recogni­
tion of this form of primary aldosteronism possible, have been develo­
ped. In what follows we shall, therefore, discuss the value of the various 
diagnostic procedures. 
1.2.4.1. Mathematical methods 
Aitchison et al. (1971) described the so-called "quadric analysis": a 
method in which, with the aid of statistical analysis of 8 variables 
(plasma sodium, potassium, bicarbonate, renin, aldosterone, systolic 
and diastolic blood pressure and age) a distinction can be made 
between patients with primary aldosteronism with or without adrenal 
adenoma. The method makes use of the fact that the biochemical 
aberrations in patients with idiopathic aldosteronism are less severely 
disturbed, while blood pressure and age of these patients are commonly 
higher than in patients with adenomatous aldosteronism. The method 
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was applied retrospectively in 5 series of patients that were published in 
the literature (a total of 105 patients) and in 95 % of the patients a 
correct diagnosis was made. Another statistical method, the multiple 
logistic analysis (Luetscher et al. 1974) makes use of analysis of 3 
variables (plasma renin, aldosterone and potassium). Both statistical 
methods are reliable but make a computer analysis necessary. Biglieri 
et al. ( 1972) were able on the basis of a linear discrimination analysis of 
the aldosterone values after administration of DOCA for 3 days, and of 
the basal plasma renin values in the recumbent patient, to make a 
correct diagnosis in thirteen patients (11 adenomas and 2 hyperplasias). 
This method is simpler, but is also considered to be less reliable. From 
the researches by Biglieri et al. (1972) and also by Padfield et al. (1975) 
it becomes evident that the suppressibility of aldosterone by adminis-
tration of mineralocorticoids in patients with adenomatous aldostero-
nism is not different from the suppressibility in patients with idiopathic 
aldosteronism. A suppression test is therefore not usable for the 
differential diagnosis. 
1.2.4.2. The influence of body posture on the plasma concentration of 
aldosterone 
In 1973 Ganguly et al. showed that in patients with adenomatous 
aldosteronism (APA) the plasma aldosterone concentration does not, 
as in normals, increase after ambulation in the morning from 08.00 
a.m. to 12.00 noon (Ganguly 1973a, 1973b). Both during use of a diet 
with 300 mmol Na+, and during a salt-free diet the plasma aldosterone 
concentration was found to diminish, in contradistinction to patients 
with idiopathic aldosteronism (IHA) in whom the plasma aldosterone 
concentration after ambulation during the morning displayed an obvi-
ous increase. The findings of Ganguly et al. were confirmed by Biglieri 
et al. (1974, 1979a), who, however, also showed that on the basis of this 
test no absolute distinction between patients with adenomatous and 
idiopathic aldosteronism could be adduced: in 25 % of the patients with 
APA a rise of the plasma aldosterone concentration was seen, although 
this rise (+25%) was considerably less than what was seen in patients 
with IHA ( + 153%). An explanation for the paradoxical decrease of 
plasma aldosterone to the stimulus of "ambulation for 4 hours in the 
morning" in patients with APA was given by Schambelan et al. (1976), 
who showed that the regulation of aldosterone in these patients, even 
in the upright posture, is predominantly under the influence of ACTH 
and not of the renin angiotensin system. On the other hand, in patients 
with IHA, Schambelan et al. (1976) found that aldosterone is primarily 
regulated via the renin angiotension system. But 2 questions remained: 
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1 Why is it that in some patients with APA there is a rise ot the plasma 
aldosterone concentration after the stimulus of "ambulation"9 
2 Why is it that, in patients with IHA, after "ambulation" a definite 
rise of aldosterone is seen, while the plasma renin activity is suppres-
sed, and shows only a small rise in response to "upright posture" 
(Schambelan et al Í976)9 
From recent studies it seems that the renin angiotensin system is not 
entirely excluded from having an influence on the aldosterone regula-
tion in patients with APA Vaughan et al (1981) have shown that after 
a rigorous suppression of the renin angiotensin system with 300 mmol 
NaVday and fludrocortisone 0 5 mg/day for 3 days, plasma aldoste-
rone in all patients with APA decreased after ambulation, in contradis-
tinction to what was found before this volume expansion was applied 
Furthermore, it turns out from the study of Wenting et al. (1978) that 
aldosterone in patients with APA may show a considerable intermdivi-
dual variability tor exogenous administration of increasing doses of 
ACTH and (Asp'-vaP) angiotensin II. Brown et al (1980) showed with 
in vitro studies that in aldosterone-producing adenomas angiotensin 
receptors are present but that these qualitatively, and possibly quanti-
tatively, differ from angiotensin II receptors in normal adrenal tissue. 
But the in vitro response of aldosterone was much more sensitive for an 
increase of the ACTH concentration than for an increase of the 
angiotensin II concentration in the medium An answer to the second 
question can be found in the studies of Wisgerhof et al (1978) and 
Brown et al (1979) who showed that the sensitivity of the adrenal for 
the giving of low doses of angiotensin II to patients with IHA, is 
considerably greater than that which is found in normals On the other 
hand is was found that patients with APA had a diminished sensitivity 
for exogenously administered angiotensin II 
I 2.4 3 Frequent blood sampling for 24 hours for the determination of 
the diurnal and episodic variations of aldosterone, Cortisol and 
renin activity 
From recent researches on the diurnal rhythm of aldosterone and renin 
in patients with adenomatous aldosteronism, the following data have 
become known. 
Cain et al. (1972) demonstrated that the plasma concentrations of 
aldosterone in patients with APA are higher in the morning than m the 
evening Moreover they found that plasma aldosterone displays a 
arcadian rhythm that is parallel to that of Cortisol, which facts were 
confirmed by studies by Kern et al (1973), Vetter et al (1973) and 
Schambelan et al (1976) The plasma aldosterone values show a peak 
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value between 04.(К) hr and 08.00 hr a.m. and a lowest value between 
06.00 hr and 12.00 hr p.m. By means of frequent blood sampling during 
the night hours, Vetter et al. (1974,1978) and Kern et al. (1976) showed 
that in patients with APA synchronous "secretory bursts" of aldoste­
rone and Cortisol occur. The circadian rhythm of plasma aldosterone 
was found not to be influenced by salt loading or bodily posture, but 
was influenced by the administration of dexamethasone (Ganguly et al. 
1973b, Schambelan et al. 1976). The circadian rhythm of aldosterone 
was not found during use of dexamethasone (Kern et al. 1973, Ganguly 
et al. 1973b) nor the "secretory bursts" of aldosterone (Vetter et al. 
1974, Kern et al. 1976). However, there is less agreement in the 
literature about the degree to which the aldosterone values are reduced 
by administration of glucocorticoids (Newton and Laragh 1968, Slaton 
et al. 1969, Kern et al. 1973, Katz et al. 1975). Ganguly et al. (1977) 
showed that dexamethasone in patients with APA has only a tempo­
rary suppression of aldosterone production as its sequel. Within 24 
hours after the beginning of dexamethasone a falling-off of the aldoste­
rone values was observed, while on the second and third days of 
dexamethasone administration the aldosterone values rose again to the 
initial level. This transient effect probably accounts for the conflicting 
reports in the effectiveness of dexamethasone in lowering plasma 
aldosterone in APA, because the results are dependent on the duration 
of dexamethasone treatment. But it is also necessary to take into 
consideration the fact that the degree of the influence of ACTH on the 
aldosterone production can present a considerable interindividual vari­
ability. Thus Wenting et al. (1978) described a subgroup of APA 
patients with ACTH-dependent aldosteronism. These patients mani­
fested a suppression of aldosterone to subnormal values after 1 day's 
treatment with dexamethasone. In contradistinction to patients with 
glucocorticoid remediable aldosteronism (Sutherland et al. 1966), the 
aldosterone values displayed a tendency to return to the pretreatment 
level within 8 days of treatment. 
Less is known about the diurnal variability of the plasma renin activity 
in patients with APA. This is partially ascribable to the fact that in a 
number of studies (Vetter and Vetter 1975, Schambelan et al. 1976) 
renin values are suppressed to values beneath the threshold of detec­
tion. With the aid of a determination of renin, the sensitivity of which 
was magnified by prolongation of the incubation period, Modlinger et 
al. (1976) showed that renin in APA patients also displays a circadian 
rhythm with peak values between 04.00 and 08.00 hr a.m., as in normal 
test persons in recumbency (Gordon et al. 1966). In 6 patients with 
APA, Siebenschein et al. (1979) found typical short-duration secretion 
periods of the renin activity during the early hours of the morning. The 
influence of these renin variations on the diurnal rhythm of aldosterone 
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is probably small. Kem et al. (1973) found no correlation between the 
diurnal rhythm of renin and aldosterone in recumbent patients with 
APA, while Schambelan et al. (1976) detected under comparable 
circumstances only a weak correlation between the two hormones. 
Also on frequent blood sampling during the nocturnal hours, no 
synchronous secretion bursts of aldosterone and renin were observed 
(Kern et al. 1976). 
After this review of the diurnal and episodic variations of aldosterone, 
renin and Cortisol in patients with APA, we shall compare the data with 
what is available in the literature about the diurnal variability of the 
same hormones in patients with IHA. Ganguly et al. (1973b) could not 
demonstrate any diurnal rhythm of aldosterone in the recumbent 
patient, while Schambelan et al. (1976) did, it is true, show a diurnal 
rhythm, parallel to that of Cortisol, but with small variations in the 
aldosterone concentrations. It emerges from frequent blood sampling 
during the night-time that also in patients with IHA, episodic periods of 
secretion of aldosterone occur, which are correlated with those of 
Cortisol (Kern et al. 1976, Vetter et al. 1978). Jn patients with IHA 
there was found, in contradistinction to patients with APA, an impor-
tant influence of the bodily posture on the plasma aldosterone concen-
trations during the day: the plasma aldosterone values were throughout 
the whole day higher than the values during recumbency (Schambelan 
et al. 1976). During ambulation the aldosterone values were no longer 
correlated with Cortisol, but with the plasma renin activity (Ganguly et 
al. 1973b, Schambelan et al. 1976). Treatment with dexamcthasone 
caused the disappearance of the nightly secretory bursts of aldosterone 
(Kem et al. 1976, Vetter et al. 1978), but had no influence on the rise of 
aldosterone during the day under the influence of the upright posture 
(Schambelan et al. 1976). 
It may be said in summary, that the aldosterone production in patients 
with primary aldosteronism takes place autonomously only to a partial 
degree. The aldosterone secretions are found to be subject to modulati-
ons that are brought about via ACTH and the renin angiotensin 
system.In patients with adenomatous aldosteronism ACTH plays a 
predominant role in the regulation of aldosterone, while the influence 
of the renin angiotensin system is apparently of lesser importance. In 
patients with IHA the renin angiotensin system plays a predominant 
role in the regulation of aldosterone during the erect position, whereas 
during the lying down an influence of ACTH on the diurnal aldoste-
rone variations is recognizable. The regulation of aldosterone in 
patients with IHA proceeds not otherwise than in normal test persons 
(Katz et al. 1972, Vagnucci et al. 1974, Armbrurster et al. 1975, 
Lightman et al. 1981) although at a higher level of aldosterone produc-
tion. The abovementioned data from the literature about the regula-
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tion of aldosterone in both forms of primary aldosteronism, have been 
the point of departure for the studies on which a report is made in 
chapters IV and V of this thesis. 
1.2.4.4. Determination of other adrenal steroids than aldosterone 
In the literature there are several studies about the secretion of other 
adrenal steroids in patients with primary aldosteronism: the zona 
glomerulosa steroids deoxycorticosterone (DOC), corticosterone and 
18-OH-corticosterone (18-OH-B), and the zona fasciculata steroid 18-
OH-ll-deoxycorticosterone (18-OH-DOC). It is claimed by a few 
authors that determination of these steroids could contribute to the 
differentiation of adenomatous and idiopathic aldosteronism. Biglieri 
et al. (1968) found raised secretion values of DOC and corticosterone 
in, respectively, 4 out of 23, and 7 out of 23 patients with APA. 
Recently, Biglieri et al. (1979) reported that the plasma values of 18-
OH-B, determined at 08.00 hr in the morning, in patients with APA 
(n=9) were higher than 100 ng/100 ml, while the values in patients 
with IHA (n=14) were lower than 50 ng/100 ml. The conversion of 
18-OH-B into aldosterone takes place under the influence of 18-
dehydrogenase (type 2 methyl-oxydasc). The activity of this enzyme is 
probably dependent on the potassium concentration. In view of the fact 
that in patients with APA the potassium values were lower than in 
patients with IHA, an explanation is forthcoming for the presence of 
higher ratios of 18-OH-B/aldosterone in patients with APA than in 
those with IHA (Biglieri et al. 1979). The 18-OH-ll-deoxycorticoste-
rone (18-OH-DOC) is a weak mineralocorticoid that is synthesized in 
the zona fasciculata. It is almost exclusively dependent for its secretion 
on ACTH (Melby et al. 1972). The 18-OH-DOC may possibly play a 
role in certain forms of experimental and human hypertension (Melby 
and Dale 1976, Ulick 1976). Melby et al. (1971) found normal excretion 
values of 18-OH-TIIDOC in 10 patients with primary aldosteronism. 
An increase of the secretion rate of 18-OH-DOC in vitro and in vivo 
was shown by Ulick (1976) in 1 patient with APA, while 2 patients with 
IHA had normal secretion values. We found no confirmation of this 
finding in the literature later on. In connection with our research on the 
influence of ACTH on the regulation of aldosterone, determinations 
were made of the plasma concentrations of aldosterone, Cortisol and 
18-OH-DOC, after which the reciprocal correlations between these 3 
hormones were calculated. The plasma 18-OH-DOC concentrations 
were not significantly different in the 3 groups examined by us (chapter 
IV). 
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I 2 5 Lateralization procedures 
The following procedures were developed for the preoperative locali-
zation of an aldosterone-producing adrenal tidenoma 
1 Adrenal phlebography and adrenal venous sampling 
2 Adrenal scintigraphy 
3 Adrenal computerized tomography 
In general the diagnosis of "idiopathic aldosteronism" is arrived at, if a 
lateralization procedure has not led to the revealing of a unilateral 
adrenal lesion, in view of the fact that the chance of a bilaterally 
localized adrenal adenoma being present, is negligibly small 
12 5 1. Adrenal phlebography and adrenal venous sampling 
Arteriography of the adrenals has turned out to be not a suitable 
method for the demonstration of aldosterone-producing adrenal ade-
nomas, because these tumors are relatively avascular. Selective adrenal 
arteriography is a cumbersome examination (Khan et al. 1971) as the 
arterial blood supply to the adrenal runs along 3 sides (superior, middle 
and inferior suprarenal arteries). As the venous drainage of the adre-
nals on both sides runs mostly via one vein only (on the right towards 
the vena cava inferior, and on the left towards the vena renalis) adrenal 
phlebography is the best method for showing up the adrenal angiograp-
hically An adrenal adenoma is manifested by a distorsion of the veins 
that he alongside the tumor The right adrenal vein is difficult to 
cathetenze as it is short and can at various levels flow into the vena 
cava inferior. Perforation of adrenal veins and intra-adrenal hemorrha-
ges and infarctions occur in 5% of the catheterizations (Bayliss et al 
1970) Remission of primary aldosteronism after phlebography has 
been described (Fisher et al 1971) Adrenal adenomas smaller than 0 8 
cm are not shown up (Nicohs et al 1972) These limitations are of 
much less significance if the catheterization of the adrenal veins is being 
done for determination of adrenal steroids in adrenal venous blood. 
Only a small amount of contrast medium is given for controlling the 
way the catheters he. The ratio of aldosterone/cortisol in blood samples 
from the right and left adrenal veins, is compared with the ratio that is 
found in the vena cava inferior According to some authors (Scoggins 
et al 1972, Fukuchi et al 1975, Lund et al 1980), this lateralization 
procedure is not less accurate if only the aldosterone/cortisol ratios of 
the left adrenal vein and the vena cava inferior are compared Dunnick 
et al. (1979a) and Weinberger et al (1979) are of the opinion that 
artefacts that are the sequel of the episodic secretion of aldosterone, 
can be prevented when the examination is carried out during the 
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administration of ACTH. The table 1-1 gives a general survey of the 
literature on the results of adrenal phlebography and adrenal venous 
sampling. From the percentages it appears that adrenal venous samp-
ling is a good method for localization of adrenal adenomas and for their 
differentiation from bilateral adrenal hyperplasia. From these figures it 
is also apparent that the performance of an adrenal phlebography has 
become superfluous to a considerable degree. The fact that the method 
is invasive is, however, a disadvantage that does not apply to adrenal 
scintigraphy and computerized tomography. 
Table 1-1. 
Diagnostic accuracy of adrenal phlebography and adrenal venous samp-
ling in patients with primary aldosteronism 
Melby 1967 
Cerny 1970 
Kahn 1971 
Horton 1972 
Nicolis 1972 
Scoggins 1972 
Fukuchi 1975 
Dunnick 1979a 
Weinberger 1979 
Vetter 1980 
Lund 1980 
number of 
patients 
7 
17 
20 
14 
7 
11 
18 
10 
44 
30 
16 
surgery 
adenoma 
7 
17 
14 
14 
7 
11 
18 
10 
36 
21 
16 
hyperplasia 
0 
0 
6 
0 
0 
0 
0 
0 
8 
9 
0 
adrenal 
venous 
sampling 
100% 
-
85% 
100% 
100% 
9 1 % 
100% 
100% 
9 1 % 
7 1 % 
100% 
venography 
29% 
70% 
70% 
7 1 % 
57% 
33% 
— 
— 
66% 
57% 
-
1.2.5.2. Adrenal scintigraphy 
In 1970 Beierwaltes reported the first successful visualization of human 
adrenals in vivo by means of adrenal scintigraphy. For this use was 
made of l31I-19-Cholesterol, synthesized in 1969 by Counsell et al. This 
radiocholesterol compound is, after intravenous administration at a 
dose of 2 mCi, concentrated in the cortex of functioning adrenal tissue, 
and the adrenals are visualized scintigraphically about 7 days later. In 
1975 the development of a new adrenal scanning agent, the 131I-6ß-
Iodomethyl-19-Nor-Cholesterol was described simultaneously by Bas-
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madjian et al. and by Kojima et al. The latter compound is more 
rapidly and intensively concentrated than the ^'I-IQ-Cholestero!, so 
that disturbing background activity is reduced. The first successful 
localization of an aldosterone-producing adenoma by means of adrenal 
scintigraphy was described by Conn et al. in 1971. Hogan et al. (1976) 
confirmed the value of adrenal scintigraphy with l31I-19-Iodocholeste-
rol in patients with primary aldosteronism with regard to localization of 
adenomas and the preoperative differentiation between adenoma and 
hyperplasia: in 10 of the 12 patients who had an aldosterone-producing 
adenoma on biochemical grounds, an asymmetrical uptake of radioacti-
vity was found in the adrenals, while this was found only in 1 of the 13 
patients in whom the diagnosis of idiopathic aldosteronism was made 
on biochemical grounds. Only a slight asymmetry in the uptake of 
activity was, however, established in small adrenal adenomas and in 
adrenals with macronodular hyperplasia (Seabold et al. 1976). So, to 
increase the specificity of the examination, the dexamcthasone 
suppresion scan was developed by Conn (Conn et al. 1972, 1976). 
Dexamcthasone at a dosage of 2 mg/day for 48 hours before administe-
ring mI-19-Iodocholesterol gave almost complete suppression of the 
normal adrenal. The accuracy with which the adenoma was lateralized 
was found to be 88%, and 7 1 % when no dexamcthasone was given. 
The dexamethasonc suppression scan was found to be of particular 
value in the differentiation between tumor and hyperplasia. The sup-
pression scan in 6 patients with histologically proven adrenal hyperpla-
sia showed no - or practically - no accumulation of activity, whereas, 
without the use of the dexamethasonc, the diagnosis of adenoma would 
have been made in 2 out of the 6 patients on the grounds of an 
asymmetric distribution of the activity. On the other hand, 2 of 17 
patients with an adenoma, that was correctly lateralized on the suppres-
sion scan, would have been incorrectly classified as having hyperplasia 
on the basis of a symmetrical activity distribution in scintigraphy 
without dexamcthasone. Since '3'l-6ß-Iodomethyl-19-Nor-Cholesterol 
has become available the use of dexamethasonc has proved to be of 
special importance because of the intense uptake of this compound into 
the adrenals. But there is still insufficient clarity in the literature about 
the dose and duration of dexamethasonc treatment preceding the 
administration of this new radiocholesterol compound. In Conn's study 
(1976) it was found that also in the normal adrenal accumulation of 
activity can occur, beginning 5 to 6 days after administration of 131I-19-
lodocholesterol in spite of the continued use of dexamethasonc. This 
was confirmed for the new radiocholesterol compound by the prospec-
tive research of Gross et al. (1979), among healthy volunteers. Uptake 
of radioactivity, although weak, was seen 3 to 5 days after giving the 
tracer during the use of high doses of dexamcthasone (8 mg) beginning 
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48 hours before the examination The uptake into the adrenals was 
delayed ± 2 days if dexamethasone at a dose of 4 mg was given. 
beginning 7 days before the examination It remains unexplained why 
during the use of dexamethasone and suppression of the steroid 
production, concentration of radioactivity still takes place in the nor-
mal adrenals From the research of Gross et al (1979) it can be 
deduced that long-lasting pretreatment with dexamethasone causes a 
more effective suppression of the normal adrenal and therefore can 
contribute to a more optimal lateralization of adenomas Experiences 
with the niI-6ß-Iodomethyl-19-Nor-Cholesterol in the diagnosis of 
primary aldosteronism have been reported in a number of studies 
(Sarkar et al. 1977, Freitas et al 1979, Miles et al 1979) If the results 
of these studies are taken as a whole it will be seen that 22 of 23 
adenomas were correctly localized, while in 6 out of 7 adrenal hyper-
plasias a correct diagnosis was made These results concern only those 
patients in whom the scintigraphic diagnosis was verified histologically 
We have left out the 20 patients in these studies in whom no operation 
was done Dexamethasone was started 2 days (Freitas et al 1979, Miles 
et al 1979) or 7 days (Sarkar et al 1977) before the examination, at a 
dose of 2 mg/day (Miles et al 1979) or 4 mg/day (Sarkar et al. 1977, 
Freitas et al 1979) The dose of the radiocholesterol compound given 
in these 3 studies was comparable and varied from 1 to 2 mCi The 
scintigraphic diagnosis could be made within 5 days after its administra-
tion, which is considerably shorter than the 7 or more days with the use 
of niI-19-Iodocholesterol. Uptake of radioactivity, unilaterally or bila-
terally, within 5 days after administration of the radiocholesterol during 
the abovementioned dexamethasone suppression schemes, was in 
agreement with, respectively an aldosterone-producing adrenal ade-
noma or a macronodular hyperplasia. There are indications that scinti-
graphy in micronodular hyperplasia in essence yields the same results 
as in normal adrenals, that is to say, an image of both adrenals later 
than 5 days after administration of the dose (Sarkar et al 1977) In 
conclusion it may be said that the adrenal scintigraphy of recent years 
has turned out to be an important acquisition in the diagnosis of 
primary aldosteronism. The accuracy with which adenomas are locali-
zed and unilateral and bilateral adrenal affections are differentiated 
approximates to the results of the adrenal venous sampling technique, 
that has always been regarded as the "gold standard" in the diagnosis. 
For the future the following developments in adrenal scintigraphy arc 
desirable. 
1 Reduction of the dose of radioactivity given, thus making less the 
dose of irradiation of the gonads 
2 Optimalization of the dexamethasone suppression schemes. 
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1.2.5.3. Computerized tomography of the adrenal glands 
Montagne et al. in 1978 described the visualization of the human 
adrenals by means of computerized tomography. The left adrenal is 
depicted as an inverted V or Y, mostly in the section just above the top 
of the left kidney. The right adrenal has a linear form or that of an 
inverted V, the posterior arm of which is longer than the lateral arm, 
and is laid in the section above the top of the right kidney, immediately 
behind the vena cava inferior. By this time 3 studies have appeared in 
which the value of CT scanning in the diagnosis of primary aldostero-
nism has been evaluated. If we take the results of the 3 studies (Linde 
et al. 1979, Dunnick et al. 1979b, White et al. 1980) together, it 
emerges that of the aldosterone-producing adenomas that were remo-
ved, 24 adenomas (80%) were detected preoperatively by CT scan-
ning. The tumors that were localized, varied in size from 1.1 to 6 cm, 
while the 6 adenomas that were not localized had the following 
diameters: 0.9- 1 .0-0.5-1.0- 1.0 and 2.0 cm. In the study by White et 
al. (1980) 6 patients with primary aldosteronism, on the basis of 
absence of a demonstrable adenoma, were classified under the diagno-
sis of idiopathic aldosteronism. However, histological confirmation of 
this diagnosis was not forthcoming. The conclusion for the time being is 
that CT scanning is a usable and rapid method for the localization of 
adenomas that are greater than 1.0 cm. According to the review of the 
literature by Conn et al. (1964) the percentage of adenomas greater 
than 1 cm amounts to 92%. If in the future CT scanners become 
available with a greater resolving power, the diagnostic accuracy can be 
further promoted (Linde et al. 1979). 
1.3. MEDICAMENTOUS TREATMENT 
1.3.1. Spironolactone 
After it had been shown by Salassa in 1958 that short-lasting admini-
stration of spironolactone caused the metabolic anomalies of primary 
aldosteronism to disappear, Laidlaw found in 1961, that prolonged 
administration of this aldosterone antagonist brougth about a fall in the 
blood pressure of 2 patients with APA to normal values. In the studies 
of Spark and Melby (1968) it then was found that spironolactone at a 
dose of 400 mg for 3 to 5 weeks normalized the blood pressure in 20 
patients with APA, in contradistinction to the absence of a hypotensive 
effect in 20 patients with hypertension and secondary aldosteronism. 
Correction of the electrolyte disorders, however, occurred both in 
patients with primary and with secondary aldosteronism, after a few 
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days of treatment. Furthermore a remarkable fact was that the body 
weight fell with this treatment in patients with APA by 3.6 kg and in 
patients with secondary aldosteronism by only 0.9 kg, thus giving 
evidence of an expansion of the extracellular volume under the influ-
ence of aldosterone in patients with APA, but not in patients with 
hypertension and secondary aldosteronism. The effect of spironolac-
tone on the blood pressure, however, turned out to be not specific for 
primary aldosteronism (Crane and Harris 1970): in 32 out of 43 patients 
with an essential hypertension and a lowered PRA a normalization of 
the blood pressure occurred after 3 weeks of treatment with spironolac-
tone, 400 mg per day. Therefore, the hypotensive effect of spironolac-
tone was found to be unusable for the tracing of patients with primary 
aldosteronism (Crane and Harris 1970), but proved useful for the 
prediction of a fall in blood pressure by adrenal surgery (Spark and 
Melby 1968). The results of long-lasting treatment of patients with 
primary aldosteronism by spironolactone were reported fully by Brown 
and colleagues (Brown et al. 1969, Brown et al. 1972, Brown et al. 
1975), whereas more recent experiences of the Glasgow group were 
described by Ferriss et al. (1978c). These results can be summarized as 
follows: 
1. Normalization of the blood pressure occurred in 46% of patients 
with APA (n=37) and in 50% of patients with IHA (n=14). 
2. A highly significant correlation was worked out between the lowe-
ring effect on blood pressure of spironolactone and that of operation, in 
patients with APA (systolic r=0.86, p<0.001, diastolic r=0.75, 
p<0.001, n=34). In patients with IHA this correlation was only 
weakly positive. 
3. Correction of the plasma electrolytes occurred in all patients, inde-
pendently of the hypotensive effect. 
4. Spironolactone caused the following metabolic effects: a significant 
lowering of the plasma sodium, total exchangeable sodium, total body 
water, extracellular volume, plasma volume and plasma total CCb 
concentration. There was a significant increase of the plasma potas-
sium, total exchangeable potassium, urea, renin and angiotensin con-
centration. The plasma aldosterone concentration did not change 
significantly. Ganguly et al. (1973) found a rise of renin and aldoste-
rone during treatment with spironolactone, that was greater in patients 
with IHA than in patients with APA. This finding could not be 
confirmed by Ferriss et al. (1978c). 
5. The occurrence of side effects in the dosage of spironolactone used 
(50 to 400 mg/day, in most cases 300 to 400 mg/day, on the average for 
9.7 months) led to stopping of the medication in only 3 patients, but the 
percentage of patients with side effects was not mentioned. To these 
side effects were reckoned: fatigue, upper abdominal pain, Raynaud's 
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phenomenon, gynecomastia, menstrual disorders, impotence, excessive 
sweating and pigmentations of the skin. From the study by Crane and 
Harris (1970) it was found that at a dosage of 400 mg/day about half of 
the patients showed side effects, while Ferriss et al. (1978c) wrote only 
that "the drug has been well tolerated in the great majority". 
The mechanism of action of spironolactone on the blood pressure and 
the metabolism of aldosterone is still partially clarified. Although 
spironolactone was introduced as a competitive antagonist at the site of 
the aldosterone receptors in the distal tubuli of the kidney (Kagawa 
1960) it was found in in vitro studies of Erbler (1972 and 1973) that this 
substance is also active at the level of the adrenal. Spironolactone, that 
has a chemical structure related to the adrenal steroids, is subject to an 
extensive metabolism, in which hydroxylating adrenal enzymes play a 
role. It is probable that competition with the 11 beta- and 18-hydroxy-
lases, that are concerned in the adrenal in the conversion respectively 
of DOC into corticosterone (В) and В into 18-OH-B, cause a diminu­
tion of the synthesis of aldosterone in vitro. The effects in vivo were 
studied by Abshagen et al. (1976), who, after giving spironolactone to 
normal test persons, found signs of an initial inhibition of the aldoste­
rone synthesis, that after a few days was compensated by activation of 
the renin angiotensin system. These findings were not confirmed in the 
studies of Gaillard et al. (1980). In vivo a restraining effect on the 
synthesis of aldosterone can be camouflaged because antiregulation 
mechanisms (renin, ACTH, potassium) are called in. In patients with 
primary aldosteronism it was found from the study of Spark and Melby 
(1968) that the rate of secretion of aldosterone rises. But it was 
noticeable that this rise (with a factor of 1.5) was clearly behindhand in 
the rising of the plasma renin activity (by a factor of 12!). A single case 
report (Sundsfjord et al. 1974) related a lowering of aldosterone during 
treatment with spironolactone. Conn and Hinerman (1977) found in 
patients with primary aldosteronism a falling-off of aldosterone excre­
tion during the first weeks of spironolactone treatment and, at the same 
time an increase of the number of "spironolactone bodies" in the 
glomcrulosa zone of adrenals that were removed in this period (see 
chapter VIII). After, on the average, 6 weeks, there occurred an 
increase of the excretion of aldosterone to above the values before the 
treatment. Thus, the data indicate that spironolactone also in patients 
with primary aldosteronism has an inhibiting influence on the synthesis 
of aldosterone. Because the renin angiotensin system in these patients 
is suppressed it lasts longer than in normals, before the production of 
aldosterone begins once more to rise. From these data it is not clear 
whether an inhibition of the biosynthesis of aldosterone contributes to 
the antihypertensive effect of spironolactone. The hypotensive action 
of spironolactone in patients with mineralocorticoid hypertension is 
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ascribed to a non-specific diuretic effect (Bravo et al. 1973) as well as to 
a specific antimineralocorticoid effect (Spark and Melby 1971, Spark et 
al 1974. Benraad et al 1978) 
1.3 2. Amiloride 
Amiloride is a weak diuretic that diminishes the potassium secretion 
and sodium reabsorption in the distal kidney tubules independently of 
the presence or absence of aldosterone (Baer et al. 1967). Braren et al. 
reported in 1968 that amilonde given at a dose of 20 to 40 mg per day 
for 10 days, to a patient with an aldosterone-producing adenoma, 
normalized the plasma sodium and potassium concentrations Lowe-
ring of the blood pressure was not observed. But an antihypertensive 
effect was, indeed, observed by Kremer et al. (1973a) after 6 weeks 
treatment with amilonde 40 mg per day in a woman with primary 
aldosteronism in whom the spironolactone medication had to be stop-
ped because of a duodenal ulcer. In the subsequent studies of Kremer 
et al. (1973b and 1977) the antihypertensive effect of amilonde in 19 
patients with primary aldosteronism was confirmed, although the hypo-
tensive effect was less than with spironolactone or with operation 
(Kremer et dl
 x1977, Ferriss et al 1978c). Amiloride was well tolerated 
and only in few patients did transitory upper abdominal complaints 
occur From a comparison of the tables in the study by Fernás et al. 
(1978c) it turned out that the effects of amilonde on the concentration 
of sodium in the plasma, the exchangeable sodium, the plasma potas-
sium concentrations and the exchangeable potassium, are comparable 
with those of spironolactone Furthermore it will be noticed that the 
plasma aldosterone concentration after treatment with amilonde rises 
significantly, but does not essentially change after treatment with 
spironolactone. This is remarkable because the renin and angiotensin 
concentrations after spironolactone display quite clearly a greater rise 
than after amilonde. Although Ferriss et al. (1978c) do not interpret 
the findings as such, one can find likewise an indication for a diminu-
tion of the aldosterone synthesis by spironolactone, as described above 
Amiloride seems to be a suitable alternative for spironolactone for the 
treatment of patients with primary aldosteronism in whom unaccepta-
ble side effects occur from spironolactone. 
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CHAPTER II 
PATIENTS AND RESEARCH METHODS 
In the appendix of this thesis and in chapter IX a description is given of 
the clinical and pathological histories of 28 patients with primary 
aldosteronism, who were referred to the department of internal medi­
cine in the period 1961 to 1979. The clinical, diagnostic and therapeutic 
data are reported for each patient, insofar as these are relevant for the 
clinical picture. For simplification each clinical history is divided into 
headings 1 to 8, in which the following subjects are discussed: 
1. General clinical data 
2. The diagnosis of "primary aldosteronism" 
3. The day and night rhythm of the plasma aldosterone concentration 
4. Adrenal scintigraphy 
5. Medicamentous treatment 
6. Operation 
7. Pathology of the adrenals 
8. Clinical follow-up 
The headings are summarized in chapter III (headings 1, 5, 6, 8), 
chapters IV and V (headings 2 and 3), in chapter VI (heading 4), 
chapter VII (heading 5) and chapters VIII and IX (heading 7). The 
reason for discussing each case individually as well, is in accordance 
with the plan of this thesis, in which we endeavour, in addition to the 
more scientific aspects, to give practical information about the patient 
with the relatively rare syndrome of "primary aldosteronism". Further­
more, in many patients more or less exceptional findings are recorded 
and these may be easily overlooked in a somewhat brief survey. The 
patients were selected with reference to the following criteria: 
1. The demonstration of a raised aldosterone secretion rate and a low 
plasma renin activity, virtually unresponsive to stimulation by a salt-
free diet. 
2. The histological confirmation of the diagnosis of "primary aldoste­
ronism" after anatomicopathological examination of adrenal tissue 
obtained by operation or at autopsy. In 3 patients (Τ, ν Ε-v U, C-J) no 
histological material was available, but the results of adrenal scinti­
graphy made it probable that these patients had an adrenal hyperplasia, 
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or, rather, had no aldosterone-producing adenoma as the cause of their 
primary aldosteronism. 
In this chapter we describe the methods by which the data were 
collected for each of the headings 1 to 8, as mentioned above. It will be 
clear that not each of these headings applies to every patient, in view of 
the fact that some methods of research have only quite recently come 
into usage (for instance the determination of the plasma concentration 
of aldosterone and adrenal scintigraphy). 
II. 1. GENERAL CLINICAL DATA 
Under this heading we go into the question of what symptoms and signs 
have in the end led to the setting up of search for the presence of 
"primary aldosteronism' . Then scores are given for the presence of the 
following complaints: headache, visual symptoms, nycturia, polyuria, 
polydipsia, paraesthesias, muscular weakness, muscular paresis or 
paralysis, and edemas. The duration of the hypertension, the presence 
of the hypertension of pregnancy and the time lag between the diagno-
sis of "hypertension" and of "primary aldosteronism" are potentially 
important factors in the assessment of the results of the medicamentous 
or operative treatment. The relevant data of physical examination are: 
the blood pressure at the first consultation and during the stay in the 
clinic, edemas, central venous pressure, size of the heart, abdominal 
vascular murmurs and fundoscopy. The laboratory examination is 
mostly limited to the examination of the urine and the values of the 
plasma electrolytes, creatinine and urea, as found at the first consulta-
tion. The electrocardiogram was interpreted according to the presence 
of signs of left ventricle hypertrophy, myocardial ischemia and hypoka-
lemia. The following radiological examinations were considered to be 
relevant: a chest film for estimation of the size of the heart, intravenous 
pyelography for exclusion of renal hypertension, renal arteriography 
for exclusion of renal artery stenosis. In the latter examination 
attempts were frequently made to show up both adrenals. Adrenal 
phlebography (combined or not with determinations of venous adrenal 
aldosterone) and presacral insufflation of gas were done in only a few 
patients; and this applies also to computerized tomography of the 
adrenals. 
II.2. THE DIAGNOSIS OF "PRIMARY ALDOSTERONISM" 
All patients were admitted into the clinic for determinations of the 
aldosterone secretion rate (ASR) under standardized conditions. In the 
36 
majority of the patients, for this purpose the antihypertensive medica­
tion was stopped for a considerable time before admission (2 to 4 
weeks). The aldosterone secretion rate measured in urine collected 
during 24 hours of bed rest, was determined before and after salt 
loading in order to find out the suppressibility of the aldosterone 
secretion under the influence of increasing salt intake. All of the 
patients throughout the whole of their stay in the clinic used a salt-free 
diet, to which no, 6 grams or 18 grams of extra salt were added. 
Measurements of the aldosterone secretion rate were done when 
equilibrium in the ingestion and excretion of salt was reached i.e. after 
4 to 5 days of constant ingestion of salt. The aldosterone secretion rate 
was initially measured with a double isotope dilution derivative assay 
(Benraad and Kloppenborg 1965) and from 1972 onwards with a 
radioimmunoassay of aldosterone acetylated to 21-monoacetate, after 
hydrolysis at pH 1 (de Man and Benraad 1977). The values obtained 
according the first method showed good agreement with those obtained 
according to the second method. The aldosterone secretion rate measu­
red in healthy adults, varies from 200 to 500 μg/24 hr during the taking 
of a salt-free diet; from 80 to 180 μg/24 hr while taking a diet with 6 
grams of salt and from 40-80 μg/24 hr while taking 18 grams of salt. The 
plasma renin activity (PRA) was determined after 5 days of salt-free 
diet, at 11.30 a.m. after 3 hours of ambulation. The PRA was at first 
measured by a bioassay (Boucher et al. 1964) with modifications 
(Driessen 1969) and from 1973 onwards by a radioimmunoassay 
(Draycr and Benraad 1975). The results of both methods of determina­
tion were in good agreement with each other (Drayer and Benraad 
1975). The PRA measured after 5 days of salt-free diet and 3 hours of 
ambulation, varies in healthy adults from 115 to 595 ng/10 ml/3 hr. 
The diagnosis of "primary aldosteronism" was made when in patients 
with hypertension the aldosterone secretion rate was raised and was 
not, or insufficiently, suppressible by loading with salt, while the 
plasma renin activity after the usual methods of stimulation yielded a 
value lower than normal. At the same time as the measurement of the 
aldosterone secretion rate, determinations were made of sodium, 
potassium and creatinine in plasma and urine. The ingestion of potas­
sium with the diet was estimated to be 50 to 70 mmol/24 hr and the 
patients obtained no extra potassium. 
II.3. THE DAY AND NIGHT RHYTHM OF THE PLASMA ALDOSTERONE CONCEN­
TRATION 
In chapter I a general survey is given of studies of the circadian rhythm 
of aldosterone, the episodic variations of aldosterone, the correlations 
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between the plasma levels of aldosterone and Cortisol, and between 
those of aldosterone and renin, the influence of body posture, and the 
effect of giving dexamethasone on the concentration of plasma aldoste-
rone in patients with primary aldosteronism. As explained, probably 
ACTH plays an important rôle in the regulation of the aldosterone 
production in patients with an aldosterone-producing adrenal ade-
noma. In patients with an idiopathic aldosteronism the relative impor-
tance of the various regulating mechanisms (ACTH and renin) is still 
insufficiently known. Also so far there is no uniformity in the literature 
reports on the effect on the plasma level of aldosterone of giving 
dexamethasone to patients with adenomatous or idiopathic aldostero-
nism. It was on the basis of these considerations that the protocol of the 
study described later on (II.3.2.) was formulated. 
11.3.1. Patients 
The study was carried out in 12 patients with primary aldosteronism. 
Eight patients (S-R, S-Kr, Η-S, K-Η, H, M-G, N-M, P-R) proved later 
on at operation to have an aldosterone-producing adenoma. In one 
patient (K) at autopsy a bilateral adrenal hyperplasia was found, and in 
3 patients (Τ, ν Ε-v U, C-J) the diagnosis of "idiopathic aldosteronism" 
was made after fto indications of an adenoma were found on the 
adrenal scintigram. Furthermore, 7 patients (F, vd V, O-K, vd K-M, K-
H, M-G, N-M) were examined after removal of an aldosterone-produ­
cing adenoma. Three of these patients (K-Η, M-G, and N-M) were also 
examined preoperatively. The postoperatively examined patients had 
after operation a normal or low secretion of aldosterone, with the 
exception of the woman M-G, who had developed a recurrent primary 
aldosteronism as the sequel of an aldosterone-producing adenoma in 
the contralateral adrenal. The results of the examination of patients 
with primary aldosteronism are discussed in chapter V, while in chapter 
IV these results are compared with those in patients after removal of an 
aldosterone-producing adenoma. 
11.3.2. Methods 
Figure II.-l. shows a diagrammatic representation of the study proto­
col. During the study the patients took a salt-free diet, to which 6 grams 
of salt were added per day. The potassium ingestion with the diet 
varied from 50 to 70 mmol/day. The patients took the diet for at least 3 
days before the beginning of the study. The antihypertensive medica­
tion was stopped 3 weeks before admission to the clinic. During their 
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Figure ll-l. Design of the study protocol 
stay the patients took no medicines, and especially no supplementary 
potassium. The urine was collected during the 5 days of the study for 
determination of the 24 hours excretion of sodium, potassium, creati­
nine and the aldosterone-18-glucuronide The blood samples were 
examined as to the concentrations of aldosterone, Cortisol and 18-
hydroxy-11-deoxycorticosterone (18-OH-DOC). The blood samples 
taken at the points of time 12.00 hr, 16 00 hr and 20 00 hr were also 
examined as to the activity of plasma renin. The blood was collected in 
2 different ways during the last part of the night (from 04 45 to 07 45 
hr) use was made of a method that will be described later on (II 3 3 ) 
It is in essence a continuous collection of blood specimens ("integrated 
samples") During the day (12 00, 16.00 and 20.00 hr) blood samples 
were collected by repeated punctures of veins ("casual samples") The 
time interval of 04 45-07 45 hr was chosen because, during these hours 
the circadian rise of ACTH-activity occurs Frequent blood sampling 
during this period makes it possible to work out correlations between 
the plasma concentrations of the 3 hormones mentioned above In view 
of the fact that Cortisol and 18-OH-DOC are almost entirely dependent 
for their secretion upon ACTH, one would expect to find a significant 
correlation between the plasma concentrations of both hormones. One 
can obtain an impression of the influence of ACTH on the plasma 
concentrations of aldosterone by comparing the correlation coefficients 
between the plasma concentrations of aldosterone and Cortisol and of 
aldosterone and 18-OH-DOC with those between Cortisol and 18-OH-
DOC. Correlation calculations are done of the values during the night 
period (n=12) and of the values during the night, day 1 and day 2 
(n=18). The influence of body posture on the plasma concentrations 
of aldosterone is investigated by contrasting the values at the time 
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points of 12.00 hr, 16.00 hr and 20.00 hr of day 1 (during ambulation) 
with the concentrations at the same time points of day 2 (during supine 
position). Further, the influence of changing body posture on the 
plasma aldosterone concentrations is studied, by comparing the values 
found on day 1 at 07.45 hr with the values at 12.00 hr after 4 hours of 
ambulation. The time points for blood sampling during the day (12.00 
hr, 16.00 hr, and 20.(K) hr) were so chosen that any influence of the 
meal on the plasma aldosterone concentrations was eliminated as far as 
possible. The samples of blood at 12.00 hr and 16.00 hr were taken 
before the meal, and those of 20.00 hr about 3 hours after the meal. 
Dexamethasone 2 mg/day was given in 4 divided doses of 0.5 mg, 
spread over 24 hours. On days 4 and 5 of the study protocol (the second 
and third day of dexamethasone medication) the examination was 
repeated in a manner identical with the procedure described above. 
II.3.3. Description of the method for continuous collection of blood 
("integrated blood sampling") 
Continuous blood collection for several hours calls for the necessary 
measures for the prevention of coagulation in the collecting system. 
For this, use was made of commercially available non-thrombogenic 
venous catheters (Cormed Inc., Middleport, USA). The catheters 
acquire their non-thrombogenic property from a coating of the wall of 
the catheter lumen with heparin as described by Grode et al. (1969). 
The clinical utility of this catheter was demonstrated by Kowarski et al. 
(1971). The non-thrombogenic catheter was connected to a fraction 
collector, that was adapted for the purpose of this study by the 
Technical Service Department of the Sint Radboud Hospital. For 
reception of blood, use was made of heparinized tubes of 0.1 ml calibre, 
24 of which can be placed in the fraction collector. A continuous blood 
flow is maintained by means of a vacuum that is created via a rotating 
pump (see figure II-2.). The periods within which the fractions are 
collected (in this study it was always 15 minutes), can be determined by 
a time clock mounted on the fraction collector, or by hand. The 
apparatus needed was placed on a trolley table at the head end of the 
bed and near the patient. The non-thrombogenic catheter was at 24.00 
hr inserted into an antecubital vein and connected with a 50 cc syringe 
by which, via an infusion pump with a rate of 5 cc/hour, 5 % glucose was 
infused. At the start of the continuous blood sampling at 04.45 hr the 
catheter was filled with heparin and connected with the fraction 
collector. Then for 3 hours blood was delivered at a speed of 10 to 11 cc 
per fraction of 15 minutes. From the data of table II-l one can obtain 
an impression of the accuracy of the sampling rate (cc per 15 min) in 7 
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Table II-l. 
Variability of the quantity of blood that was collected every 15 minutes 
during continuous blood sampling 
patient 
S-R 
S-Kr 
H-S 
K-H 
H 
N-M 
M-G 
distribution 
(ml) 
10.0-12.6 
8,0-12.8 
10.0-11.8 
10.4-11.8 
9.Ü-11.4 
10.0-11.0 
10.2-12.0 
average ± SD 
(ml) 
10.8±().7 
11.0±1.2 
11.3±0.5 
11.2±0.6 
10.910.6 
10.7±0.4 
11.2±0.6 
number of samples 
n=ll 
n=12 
n=12 
n=12 
n=12 
n=12 
n=12 
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patients in whom the quantity of each sample was accurately measured. 
After the expiry of a period of 15 minutes the blood was immediately 
taken out of the fraction collector and centrifuged. The plasma was 
pipetted off and kept at -20CC. Measures were taken to avoid 
disturbance of the normal night's rest of the patient. The research was 
carried out in a peaceful room without the presence of other patients. 
The room remained in darkness and the blood collection apparatus 
went on working practically without any noise. The patient was 
screened off by a curtain. The majority of the patients were not 
disturbed in their sleep by the test. 
II.3.4. Radioimmunoassays 
Plasma aldosterone was measured by radioimmunoassay with an anti­
serum raised in sheep against aldosterone-21-monohemisuccinate con­
jugated to bovine serum albumin (BSA), after chromatography in a 
Bush B
s
 type system, toluene/methanol/water (10:5:5) on Whatman-1 
paper (de Man et al. 1980). Plasma 18-OH-DOC was measured by 
radioimmunoassay raised in sheep against the 21-hemisuccinate of 18-
OH-DOC conjugated to BSA, after chromatography in the Bush Bj 
system on Whatman-1 paper (Hoefnagels et al. 1978). Plasma Cortisol 
was measured by Radioimmunoassay as described by Vecsei (1974). 
The antiserum was raised in rabbit against cortisol-21-hemisuccinate-
BSA. The protocol described in paragraph II.3.2. was, as mentioned 
above, also carried out in 6 patients after removal of an adrenal 
adenoma. In addition the protocol was carried out in 2 healthy adults. 
The distribution of the hormone concentrations measured in these 8 
subjects (table II-2) are regarded as control values for this study. 
Table 11-2. 
Concentrations of plasma aldosterone, Cortisol and 18-OH-DOC during 
the night and day in 8 control persons 
plasma aldosterone plasma Cortisol plasma 18-OH-DOC 
(ng/100 ml) (μπιοΙ/Ι) (ng/100 ml) 
night (n=96) 1.0-13.4 0.03-0.70 2.8-45.2 
day (n=48) 1.0-29.5 0.06-1.02 2.0-33.9 
II.4. ADRENAL SCINTIGRAPHY 
Since 1973, in the department of Nuclear Medicine (principal: Prof. 
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Dr. I. Kazem) scintigraphic examination has been regularly done in 
patients with primary aldosteronism. The aim of this examination is 
twofold: 
1. Differentiation between an aldosterone-producing adenoma and a 
bilateral adrenal hyperplasia. The differentiation is of importance, as in 
the case of a bilateral adrenal hyperplasia no operative exploration of 
the adrenals should be done (see chapter I). 
2. Lateralization of an aldosterone-producing adenoma, to make pos­
sible a unilateral operative approach to the adrenal concerned. 
11.4.1. Patients 
The investigation was carried out in 18 patients with primary aldostero­
nism. Thirteen patients had an aldosterone-producing adenoma (vdV, 
O K , vd K-M, W-S, S-R, S-Kr, K-H, Η-S, H, M-G, N-M, P-R, S-Kl). In 
4 patients (Τ, ν Ε-v U, C-J and K) the diagnosis of idiopathic aldostero­
nism was made, and in 1 woman patient (L-v G) an aldosterone-
producing carcinoma of the adrenal was found. 
11.4.2. Methods 
Up to 1978 the examination was carried out with the radiocholesterol 
compound i;"l-19-Iodocholesterol (Beierwaltes et al. 1971) and from 
1978 onwards with the agent 131I-6ß-Iodomethyl-19-Nor-Cholesterol 
(Basmadjian et al. 1975). The radiocholesterol compounds were given 
intravenously in doses varying from 1-2 mCi. The uptake of the freely 
circulating radioactive iodide in the thyroid gland was blocked by oral 
administration of 1 drop of Sol Lugoli Fortior 3 times a day, beginning 
2 to 3 days before giving the radiocholesterol. A more effective 
blockade of the thyroid gland was found to be feasible by giving 200 mg 
potassium Perchlorate four times a day, beginning one day before 
giving the radiocholesterol (Barbarino et al. 1975). Adrenal scinti-
grams were prepared on the third, fifth, seventh and ninth day after 
giving the radiocholesterol. A Picker II С gamma camera connected 
with a PDP-8 computer was used for working out the data. 
The first days after giving the radiocholesterol the patient took a 
laxative, in order to eliminate as far as possible the disturbing activity 
of the liver, bile ducts and gastrointestinal tract. An optimal image was 
mostly obtained 5 to 7 days after administration of the radiocholeste­
rol. On the seventh day a renal scintigraphy was done with the aid of 
"Tc-ironascorbate complex in order to obtain a correct localization of 
the adrenal activity. Before and during the examination, dexametha-
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soné was given to all of the patients, at a dose varying from 2 to 4 mg 
per day When using the radiocholesterol compound 131I-19-Iodocho-
lesterol, dexamethasone was given in a dose of mostly 4 mg/day, 
starting about 3 days before injection of the tracer On the later use of 
13II-6ß-Iodomethyl-19-Nor-Cholesterol there was a change-over to 
giving dexamethasone in a dose of 2 mg per day beginning 2-3 weeks 
before giving the tracer The considerations that led to the long-lasting 
giving of dexamethasone in the second procedure, will be dealt with in 
due course (chapter VI) 
II 5 MEDICAMENTOUS TREATMENT 
Under this heading the effects of the medicamentous treatment with 
the aldosterone antagonist spironolactone (AldactonR) and the weak 
potassium-saving diuretic amilonde (MidamorR) will be discussed In 
order to obtain more insight into the mechanism of action of both 
medicaments on the blood pressure, the aldosterone metabolism, and 
other parameters, in a prospective study - of which a report is given in 
the article published in chapter VII - the effects of both medicaments 
in patients with primary aldosteronism are compared with the effects in 
patients with essential hypertension In chapter III, General clinical 
data, the results of medicamentous treatment are summarized and 
compared with the results of surgical operation, according to the 
protocol which is described in II 5 2 
II 5 1 Treatment with spironolactone versus amilonde 
For the plan of the study protocol we refer the reader to the section 
"Methods" of the article published in chapter VII 1 he patients with 
primary aldosteronism who participated in this study were 4 patients 
with adenomatous primary aldosteronism (S-R, S-Kr, Η-S, H) and 2 
patients with idiopathic aldosteronism (Τ, ν Ε-v U) Besides these, 4 
patients with primary aldosteronism took part in this study, but are not 
discussed in this thesis These 4 patients satisfied the criteria for the 
diagnosis of primary aldosteronism (hypertension, a low PRA after the 
usual methods of stimulation, a raised aldosterone secretion rate after 
loading with 18 grams of salt) In them no examination was made as to 
the diurnal variations of plasma aldosterone, and no adrenal scinti­
graphy or operation was done So, in view of the fact that in these 
patients there were no indications of the nature of the primary aldoste­
ronism (adenomatous or idiopathic) they are left out of further discus­
sion in this thesis 
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11.5.2. Medicamentous versus operative treatment 
The lowering effect on blood pressure of high doses of spironolactone 
in 13 patients with an aldosterone-producing adenoma, and in 3 
patients with an adrenal hyperplasia, could be compared with the blood 
pressure lowering effect of operation. In this context the blood pres-
sure after 3 to 4 weeks of policlinical treatment with spironolactone at a 
dose of 400 mg/day, was compared with the policlinically measured 
blood pressure 2 to 3 months after the operation. The postoperative 
period of 2 to 3 months was considered sufficiently long for the 
appearance of a blood pressure lowering effect, while, if it did not 
occur, the patients were still not treated with antihypertensives. The 
level of the untreated blood pressure before operation was determined 
by reference to the average of the blood pressure values measured 
during stay in the clinic for measuring of the aldosterone secretion rate. 
II.6. OPERATION 
Operations on the adrenals were done in 22 patients. In the case of an 
adenoma the adrenal concerned was removed in toto, while, in the case 
of a bilateral adrenal hyperplasia (v N, S-B, J), a subtotal adrenalec-
tomy was done. The adrenals were approached operatively by the 
abdominal (G-J, Br) or lumbar route. In one woman patient (Ba) in 
whom the search for the adrenal adenoma by the abdominal route was 
unsuccessful, the adenoma was removed later on by the lumbar route. 
In 6 of the 18 patients for whom a lumbar approach to the adrenals was 
chosen, a bilateral incision had to be made: in 3 patients because of 
adrenal hyperplasia (v N, S-B, J) in 3 patients (v W, F, S) because of an 
adenoma localization on the other side than that where the incision was 
made in the first instance. In 9 patients the lumbotomy took place via a 
"low" incision, that is to say, below or at the height of the 12th rib, 
while in the remaining 9 patients a "high" incision was made, in the 
10th or 11th intercostal space. With the latter approach the operator 
obtains a wider operation field of the retroperitoneal area at the level 
of the adrenals. For this reason in recent years a "high" incision has 
been preferred. 
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CHAPTER III 
SUMMARY OF THE CLINICAL FINDINGS IN 
PATIENTS WITH PRIMARY ALDOSTERONISM 
III.l. PATIENTS 
The 28 patients with primary aldosteronism who are discussed in this 
thesis were referred to the department of Internal Medicine of the Sint 
Radboud Hospital in the period of 1961-1979. 
The sex and age distribution of the patients does not differ much from 
what is reported in this connection in the literature generally (Conn et 
al. 1964, Ferriss et al. 1978a, Weinberger et al. 1979): the ratio of men 
to women in the group of patients with an adenoma (n=18) was 4:14 
(22 against 78%), while in the group of patients with a hyperplasia the 
sex distribution was normal: 5 men to 4 women (table III.-l.). The 
mean age at which the diagnosis of primary aldosteronism was made 
was 43.9 ± 10.5 years in patients with an adenoma, and 49.3 ± 8.4 
years in patients with a hyperplasia. In table III.-l. a comparison is 
made of: the age at which the raised blood pressure was found, the age 
at which the diagnosis of primary aldosteronism was made, and the age 
at which the patients were submitted to operation. The average time 
interval between the age at which the raised blood pressure was found 
and that at which the diagnosis of primary aldosteronism was made 
amounted to 5.9 years (range 0-18 years) in the group of patients with 
an adenoma, and 5.0 years (range 0-17 years) in the group of patients 
with hyperplasia. The mean time interval between the making of the 
diagnosis and the operation was 1.7 years (range 0-7 years) in patients 
with an adenoma. The long time interval between establishing the 
hypertension and the operation proves to have various causes: 
1. Some patients have a long-lasting history of hypertension. Although 
this is not capable of proof, the impression is gained that primary 
aldosteronism in some patients developed only after these patients had 
had hypertension for a considerable time (patients O-K, vd K-M, H-S, 
M-G, N-M) 
2. In a few patients in the first instance no exploratory operation was 
done because of problems in the diagnosis (adenoma or hyperplasia; 
patients S-R, S-Kr, H-S) 
3. Also in a few patients (Ba, W-S) the operative search for the 
adenoma caused problems. 
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Table III-l. 
Patients with primary aldosteronism and the age at which a raised blood 
pressure was found, the age at which the diagnosis of primary aldostero-
nism was made and the age at which the operation was done. The 
patients are listed according to the date of the operation (or autopsy) 
patie 
ADE 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
nt 
ÌNOMA 
G-J 
Br 
ν W 
F 
Ba 
vd V 
O K 
vdK-M 
W-S 
S-R 
S-Kr 
H-S 
K-H 
II 
M-G 
N-M 
P R 
S-Kl 
ΗΥΡΓΚΡΙ ASIA 
19 
20 
21 
22 
23 
24 
24 
26 
27 
v N 
S 
L 
S B 
J 
τ 
ν h-v U 
С J 
к 
CARCINOMA 
28 L-vG 
cf'? 
? 
Cf 
Cf 
er 
$ 
? 
9 
9 
9 
9 
9 
9 
9 
Cf 
9 
9 
9 
9 
Cf 
Cf 
9 
9 
cf 
Cf 
? 
9 
Cf 
9 
dale of birlh 
17 10 1925 
31 05 1917 
19 07 1922 
11 04 1926 
29 12 1920 
18 05 1941 
25 02 1919 
04 11 1926 
29 12 1958 
21 10 1931 
10 11 1931 
24 08 1919 
27 02 1945 
07 01 1941 
13 06 1920 
02 01 1923 
13 05 1931 
27 11 1933 
X ± S D 
25 05 1916 
30 03 1913 
03 10 1914 
30 08 1928 
09 07 1927 
19 02 1924 
11 03 1937 
05 04 1923 
21 04 1913 
X±SD 
28 12 1930 
age 
hypertension 
39 
39 
45 
44 
46 
31 
37 
35 
15 
42 
35 
40 
29 
34 
40 
48 
45 
40 
38 0±7 7 
50 
52 
54 
42 
46 
44 
34 
30 
47 
44 3±8 0 
46 
agc 
diagnosis 
39 
47 
49 
46 
46 
32 
55 
48 
15 
43 
41 
57 
32 
35 
57 
54 
48 
47 
43 9±10 5 
52 
55 
55 
42 
46 
51 
37 
42 
64 
49 3+8 4 
49 
agc 
operation 
(autopsy) 
39 
47 
49 
47 
53 
33 
55 
49 
17 
47 
47 
59 
33 
37 
58 
55 
48 
47 
45 6±10 4 
52 
58 (aut) 
57 (aut) 
43 
46 
-
-
-
66 (aut) 
49 
year 
operation 
(autopsy) 
1964 
1964 
1971 
1973 
1974 
1974 
1974 
1975 
1975 
1978 
1978 
1978 
1478 
1978 
1978 
1978 
1979 
1980 
1968 
1971 (aut) 
1971 (aut) 
1971 
1973 
-
-
-
1979 (aut) 
1979 
III 2 COMPLAINTS, SYMPTOMS AND DIAGNOSES WITH WHICH THE PATIENTS 
WERE REFERRED 
The diagnosis of primary aldosteronism was only rarely suspected on 
the basis of specific and spontaneous complaints by the patient. Only 
50 
once was primary aldosteronism thought of on the grounds of the 
patient's complaints: this was in the case of the woman vd K-M who 
developed a paralysis of the legs shortly after beginning a diuretic 
therapy for hypertension. Table III -2. gives a survey of the complaints 
and symptoms that were the reasons for the referral, or that gave the 
Table 111-2. 
Complaints, symptoms and diagnoses with which the patients were 
referred to the department of Internal Medicine of the Sint Radboud 
Hospital 
patient 
ADENOMA 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
16 
17 
18 
G-J 
Br 
v W 
F 
Ba 
vd V 
OK 
vdK-M 
w-s 
S-R 
S-Kr 
H-S 
K-H 
H 
MG 
NM 
P-R 
S-Kl 
HYPERPLASIA 
19 
20 
21 
22 
23 
24 
25 
26 
27 
vN 
S 
L 
SB 
J 
τ 
v E - v U 
C-J 
К 
CARCINOMA 
28 L-vG 
complaints and symptoms 
Cerebral hemorrhage Hypertension 
and hypokalemia 
Hypertension with deterioration of renal 
function and transient ischemic attacks 
Hypertension and transient ischemic 
attacks 
Hypertension 
Nervosity and weight loss 
Attacks of unconsciousness, headache, 
vomiling Hypertension, hypokalemia 
Fatigue Hypertension, hypokalemia 
IntermittenWparalysis during treatment 
with diuretics Hypertension, hypokalemia 
Hypertension 
Ankle edema Hypertension and 
hypokalemia 
Hypertension Unsuccessful treatment 
Hypertension, hypokalemia 
Hypertension, hypokalemia 
Hypertension, hypokalemia 
Hypertension, intermittent hypokalemia 
Hypertension Unsuccessful treatment 
Hypertension Unsuccessful treatment 
Hypertension Unsuccessful treatment 
Hypertension Unsuccessful treatment 
Hypertension Unsuccessful treatment 
Hypertension Unsuccessful treatment 
Hypertension 
Hypertension Unsuccessful treatment 
Hypertension Unsuccessful treatment 
Hypertension 
Hypertension Unsuccessful treatment 
Hypertension, hypokalemia 
Hypertension, hypokalemia 
referred by 
internist 
internist 
internist 
family doctor 
cardiologist 
internist 
internist 
internist 
internist 
internist 
family doctor 
internist 
internist 
internist 
internist 
internist 
family doctor 
internist 
cardiologist 
family doctor 
family doctor 
surgeon 
family doctor 
family doctor 
family doctor 
family doctor 
internist 
internist 
tentative diagnosis 
primary aldosteronism 
malign hypertension 
hypertension 
hypertension 
hyperthyroidism 
primary aldosteronism 
primary aldosteronism 
primary aldosteronism 
hypertension 
primary aldosteronism 
hypertension 
primary aldosteronism 
primary aldosteronism 
primary aldosteronism 
hypertension 
hypertension, chronic 
pyelonephritis 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
hypertension 
primary aldosteronism 
recurrence of 
primary aldosteronism 
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inducement for the search for primary aldosteronism. It also lists the 
referring doctor and the diagnosis under which the patient was sent for 
consultation. A striking fact was that the patients with an adrenal 
adenoma were often sent for investigation by an internist of some other 
hospital (14 of the 28 patients). In 6 of these 14 patients the diagnosis of 
primary aldosteronism was not considered. Patients with an idiopathic 
aldosteronism were mostly referred by the family doctor (6 out of the 9 
patients) and only on one occasion was the diagnosis of primary 
aldosteronism considered to be a possibility (by the referring internist). 
Five of the 18 patients with an adenoma came with neurological 
symptoms. An unsatisfactory result of the treatment of hypertension 
was the reason for referral in 10 patients. In all of the patients except 
the woman Ba, the blood pressure was found to be raised on referral. 
In half of the patients with an adenoma and in 1 patient with idiopathic 
aldosteronism, the occurrence of hypokalemia was mentioned by the 
referring doctor. 
III.3. COMPLAINTS DUE TO PRIMARY ALDOSTERONISM 
The complaints and phenomena with which the clinical picture of 
primary aldosteronism is accompanied, were summarized by Conn et 
al. in 1964 with reference to 103 patients with an aldosterone-producing 
adenoma that had been published in the literature up to that time. The 
symptomatology was classified by Conn according to the cause under 
the following headings: 
1. Renal (polydipsia, polyuria, nycturia). 
2. Muscular (muscular weakness, paralysis, tetany, paresthesias). 
3. Hypertensive (headache, visual disorders). 
In almost all of the patients who are described in this thesis one or more 
of these symptoms were found, although asymptomatic patients existed 
(table III-3). The frequency with which the symptoms were manifested 
are in good agreement with the percentages mentioned by Conn. In 
patients with adrenal hyperplasia we found much fewer symptoms than 
in patients with an adenoma. A peculiar feature is that 33% of our 
patients had a history of edema formation, although on examination 
edema was rarely found. According to Conn et al. (1964) in patients 
with primary aldosteronism edema was almost never ascertained. 
Nevertheless "edema" was an item in the history that was mentioned 
by 10% of the 103 patients. After comparison of the percentages of 
table III-3, it is remarkably that in the survey collected together by 
Conn, muscular weakness was very frequent (73%), in contrast to the 
findings in our patients (28%). In our patients "fatigue" was the most 
frequent complaint: probably "fatigue" is an insufficiently specific 
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Table ІІІ-З 
Complaints and symptoms in patients with primary aldosteronism com­
pared with the survey of literature published by Conn (Conn et al 1964) 
Fatigue 
Headache 
Nycturia 
Polydipsia 
Edema 
Muscle weakness 
Visual disturbances 
Paresthesias 
Tetany 
Intermittent paralysis 
No symptoms 
adenoma (n=18) 
13/18(72%) 
12/18(67%) 
10/18(56%) 
8/18 (44%) 
6/18(33%) 
5/18 (28%) 
4/18 (22%) 
4/18 (22%) 
3/18(17%) 
2/18(11%) 
1/18 ( 5%) 
hyperplasia (n=9) 
5/9(55%) 
1/9(11%) 
4/9(44%) 
2/9(22%) 
3/9(33%) 
0/9 ( 0%) 
0/9 ( 0%) 
1/9(11%) 
0/9 ( 0 % ) 
0/9 ( 0%) 
3/9(33%) 
adenoma (η=1(Π) 
Conn et al 1964 
19% 
5 1 % 
72% 
46% 
-
7 3 % 
2 1 % 
24% 
2 1 % 
2 1 % 
6% 
complaint and is in fact "muscular weakness" Finally, it can be 
realized from table III-3 that the percentage of symptomless patients is 
comparably low (5%) with the percentage mentioned by Conn (6%) 
In patients with a hyperplasia, however, 3 out of the 9 patients were 
entirely without symptoms A relatively high percentage of symptom­
less patients in the group with "idiopathic aldosteronism" fits in with 
the fact that these patients in general have a milder form of primary 
aldosteronism (Fernss et al 1978b) Moreover, it is to be expected that 
in the future the percentage of symptomless patients will rise By an 
extension of the diagnostic possibilities (routine determination of 
plasma renin activity and plasma aldosterone) it seems probable that 
the diagnosis of primary aldosteronism will be performed on a greater 
scale, before pronounced complaints have developed 
III 4 PREGNANCY 
In 8 of the 14 women (57%) who had undergone pregnancies their 
clinical histories showed that the blood pressure had risen during those 
pregnancies Comparison of the years in table III-4 reveals that, with a 
few exceptions, a considerable time interval lies between the last 
pregnancy and the detection of hypertension or the diagnosis of 
primary aldosteronism m both women who had, and others who had 
not, gone through a pregnancy marked by hypertension Thus, 
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Table III-4. 
The occurrence of hypertension during pregnancy in 14 women in 
whom later on the diagnosis of primary aldosteronism was made 
patient 
G-J 
O K 
vdK-M 
S-R 
S-Kr 
H-S 
K-H 
M-G 
N-M 
P R 
S-Kl 
ν E-v U 
C-J 
L-vG 
number of 
pregnancies 
3 
4 
3 
3 
3 
10 
3 
7 
5 
2 
2 
3 
3 
3 
hypertension during 
pregnancies 
— 
-
+ 
+ 
+ 
+ 
-
-
+ 
-
-
+ 
+ 
+ 
(1-3) 
(2.3) 
(D 
(1-10) 
(1-5) 
(3) 
(1-3) 
(1-3) 
last preg­
nancy in 
1958 
1950 
1959 
1963 
1966 
1959 
1973 
1957 
1961 
1961 
1959 
1971 
1951 
1966 
hypertension 
detected in 
1964 
1956 
1961 
1972 
1966 
1959 
1974 
1960 
1971 
1976 
1973 
1971 
1953 
1966 
diagnosis pri 
aldosteroms 
1964 
1974 
1974 
1974 
1972 
1977 
1977 
1977 
1977 
1979 
1980 
1974 
1965 
1967 
although the percentage of women with hypertension of pregnancy is 
strikingly high, as measured by these chronological data, there are no 
clear indications that primary aldosteronism has contributed to the 
development of hypertension during the pregnancy. From the litera­
ture it is evident that primary aldosteronism during pregnancy is only a 
rare event (Crane et al. 1964, Gordon et al. 1967). On the other hand it 
must be borne in mind that a beginning overproduction of aldosterone 
quite early and especially in the pregnancy can have contributed to the 
development of hypertension. According to Conn et al. (1967) a rise of 
blood pressure and suppression of the renin activity are the first signs of 
a developing primary aldosteronism, while hypokalemia appears only 
at a later stage. 
Furthermore, little is known about the influence of the taking of oral 
contraceptives on the development of a primary aldosteronism or its 
early manifestation. The patients K-Η and S-Kl had taken oral contra­
ceptives a short time before the phenomena of primary aldosteronism 
revealed themselves. Recently Leichtmann et al. (1980) reported the 
presence of primary aldosteronism in 2 women patients who at that 
moment had been taking oral contraceptives for 8 and 5 years, respecti­
vely. 
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Table Ш-5 
Hypertension 
patient 
ADENOMA 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
G-J 
Br 
ν W 
F 
Ba 
vd V 
O-K 
vdK-M 
w-s 
S-R 
S-Kr 
H-S 
K-H 
H 
M-G 
N-M 
P-R 
S-Kl 
HYPERPLASIA 
19 
20 
21 
22 
23 
24 
25 
26 
27 
v N 
S 
L 
S-B 
J 
Τ 
v E - v U 
C-J 
К 
CARCINOMA 
28 L-v G 
and its complications 
blood pressure (mmHg) 
172/114 (n=50) 
225/136 (n=33) 
186/123 (n=10) 
155/103 (n=13) 
151/86 (n= 8) 
184/125 (n= 12) 
154/100 (n=10) 
212/127 (n=15) 
193/121 (n= 9) 
198/121 (n=16) 
174/110 (n= 9) 
183/106 (n=24) 
177/115 (n=17) 
199/125 (n=16) 
207/123 (n=15) 
237/138 (n= 19) 
185/121 (n=21) 
205/117 (n = 12) 
243/124 (n=14) 
185/98 (n= 8) 
215/131 (n=22) 
173/105 (n=12) 
169/118 (n=16) 
199/127 (n=27) 
150/100 (n= 9) 
186/106 (n = 10) 
223/139 (n=14) 
155/100 (n=20) 
complications 
Cerebral hemorrhage Slight enlarge­
ment of the heart 
Motor aphasias and angina pectoris 
Hypertensive retinopathy grade III, 
impaired renal function 
Transient ischemic attacks, impaired 
renal function 
None 
Diffuse coronary ischemia 
Attacks of unconsciousness 
Slight enlargement of the heart 
None 
None 
Slight enlargement of the heart 
None 
Epileptic manifestations 
Enlargement of the heart 
None 
Enlargement of the heart Hyperten­
sive retinopathy Slightly impaired 
renal function 
Enlargement of the heart Hyperten­
sive retinopathy grade IV 
Enlargement of the heart 
None 
None 
Enlargement of the heart 
Enlargement of the heart and impaired 
renal function 
None 
None 
None 
None 
None 
Cerebral vascular accident 
Myocardial infarction 
None 
55 
111.5 HYPERTENSION AND ITS COMPUCATIONS 
Table III-5 gives a survey of the blood pressure values and the 
hypertensive complications in 28 patients with primary aldosteronism. 
The reported blood pressure values are the mean values that were 
measured during stay in the clinic for measurement of the secretion 
rate of aldosterone. Although some patients had only a slightly raised 
blood pressure, the blood pressure in the majority of the patients was 
seriously raised, especially when it is remembered that the blood 
pressure values were measured under clinical circumstances. The seri­
ousness of the blood pressure is also apparent from the number of 
patients in whom organ damage was found as the sequel of hyperten­
sion. A striking feature is the relatively great number of patients with 
neurological complications (G-J, Br, ν W, vd V, H-S, K). Furthermore, 
in 11 patients cardiovascular complications were demonstrable, varying 
from myocardial hypertrophy to diffuse coronary ischemia and myocar­
dial infarct, while in 4 patients a diminished kidney function was 
observed. The existence of an accelerated or malignant hypertension, 
estimated by the degree of hypertensive retinopathy, was ascertained in 
3 patients. In 6 of the 28 patients (=21%) the complications were 
regarded as serious (G-J, Br, ν W, M-G, N-M, K). At first the blood 
pressure in patients with primary aldosteronism was described as 
"relatively mild" (Conn et al. 1964). Hypertension progressing into an 
accelerated or malignant phase was reported only sporadically (Kaplan 
1963, del Greco et al. 1966, Aloia and Beutow 1974). From our data 
and from recent studies (Ferriss et al. 1978a, Clarke et al. 1979) it is 
apparent that patients with primary aldosteronism are by no means 
safeguarded against the well-known complications of a raised blood 
pressure. 
II1.6. PLASMA ELECTROLYTES 
In table III-6 are given the concentrations (mean ± SD) of plasma 
sodium, potassium, chloride and bicarbonate, measured during 3 levels 
of salt intake. The measurements were made on or about the 5th day of 
each period. The plasma sodium values in patients with adenomatous 
aldosteronism (APA, n=18) varied from 136 to 146 mmol/1 during a 
salt-free diet; from 137 to 146 mmol/1 during intake of 6 grams of salt, 
and from 139 to 149 mmol/1 during intake of 18 grams of salt. The 
values during intake of salt proved significantly higher than during a 
salt-free diet. The sodium values were lower than 140 mmol/1 in only 5 
of the total of 50 determinations that were made during the various salt 
intakes. Also in the patients with idiopathic aldosteronism (IHA, 
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Table 111-6. 
The influence of dietary sodium intake on plasma electrolyte 
concentrations (mean values ± SD) in 18 patients with adenomatous 
(APA) and 9 patients with idiopathic (¡HA) aldosteronism 
Plasma Na+ 
(mmol/l) 
Plasma K' 
(mmol/l) 
Plasma СГ 
(mmol/l) 
Plasma HCOj" 
(mmol/l) 
APA 
IHA 
APA 
IHA 
APA 
IHA 
APA 
IHA 
11·) ттоІПІЬі 
144 0±2 3 
144 4±3 4 
2H±0 4 
3 2±0 3 
101714Ü 
104 8±5 4 
31 1±2 6 
27 9± 1 9 
p<0 005 
p<0 01 
p<0 01 
η s 
p<0 025 
η s 
η s 
π s 
SODIUM INTAKE 
(n = 18) 
(n= 9) 
(n=18) 
(n= 9) 
(n=18) 
(n= 9) 
(n=18) 
(n= 9) 
15 mmol/2J ht 
141 8±2 4 
141 8±1 7 
3 1±04 
3 4±0 4 
99 8±4 5 
103 2±3 0 
314±3 2 
29 2±4 5 
p<0 05 
η s 
p<0 05 
η s 
p<0 005 
η s 
η s 
η s 
(n = 14) 
(n= 6) 
(n=14) 
(n= 6) 
(n=14) 
(n= 6) 
(n = 14) 
(n= 6) 
3Π minol/24 hr 
143 4±2 7 
142 2±3 2 
2 8±0 5 
3 0±0 5 
103 4±4 2 
104 213 2 
31 4±4 0 
28 4±2 8 
n=9) the plasma sodium values were higher than 140 mmol/l, with the 
exception of 2 of the total of 24 determinations. It can therefore be put 
on record that plasma sodium values that on repetition are lower than 
140 mmol/l, in general are only rarely found in patients with primary 
aldosteronism. Moreover, it turned out that 57 of the 74 sodium 
determinations (of both groups of patients) lie within the normal area 
of distribution used by our laboratory (138-144 mmol/l). 
The mean plasma potassium values were in patients with APA some­
what lower than in patients with IHA, but the differences were not 
statistically significant. In patients with APA hypokalemia was a con­
stant finding: during a salt-free diet the values varied from 2.2 to 3.8 
mmol/l; during the intake of 6 grams of salt from 1.9 to 3.5 mmol/l; and 
during the intake of 18 grams of salt from 1.9 to 3.5 mmol/l. On only 
one occasion was a plasma potassium value found that was within the 
normal distribution area (3.8 to 4.6 mmol/l). In patients with IHA, 4 
out of the total of 24 determinations were found to lie within the 
normal distribution area. In both groups, salt intake was found to lower 
the plasma potassium values. This lowering was statistically significant 
only in the APA group. 
The mean plasma chloride values were lower in patients with APA 
than in those with IHA, but the values did not differ significantly. 
Chloride values lower than normal (101 to 107 mmol/l) were frequently 
found in patients with APA: 21 of the total of 50 determinations were 
lower than 101 mmol/l, while only on 4 occasions was a value higher 
than 107 mmol/l found. Taking salt with the diet turned out to cause a 
significant rise of plasma chloride concentrations in patients with APA. 
The mean plasma bicarbonate values, were higher in patients with 
APA than in patients with IHA. Only during intake of 6 grams of salt 
this difference was also statistically significant (p<0.0()5). Taking salt 
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gave no significant change in the bicarbonate values in either of the 
groups. In patients with APA the plasma bicarbonate concentrations 
were raised: 44 of the total of 50 determinations, while 6 determina­
tions lay within the normal distribution area (26 to 28 mmol/1). In 
patients with IHA plasma bicarbonate was raised in 15 of 24 determina­
tions. 
III.7. THE SODIUM AND POTASSIUM EXCRETION IN THE 24 HOURS URINE 
In table III-7 can be seen the mean values of the sodium and potassium 
excretion, measured on the 5th day of each of the 3 periods of salt 
intake, at an estimated potassium intake of 50 to 70 mmol/day. The 
values of the sodium and potassium excretion did not vary significantly 
in the patients of either of these groups. After salt loading there was in 
both groups of patients a significant increase of the potassium excretion 
to be seen. With one exception, the excretion of potassium in all 
patients during uptake of 18 grams of salt, was greater than 80 mmol/24 
hr. A significant increase of the potassium excretion after acute or 
chronic loading with salt in patients with primary aldosteronism, is in 
good agreement with the findings reported in the literature (Rovner et 
al. 1965, Espiner et al. 1967, Christlieb et al. 1971) and is explained by 
an increased rejection of potassium in the distal tubules of the kidney. 
Table 111-7. 
The influence of dietary sodium intake on the 24 hours urinary 
excretions of sodium and potassium (mean values ± SD) in 18 patients 
with adenomatous (APA) and 9 patients with idiopathic (IHA) 
aldosteronism 
SODIUM INTAKE 
If) mmol 24 hr 15 ттоІ/24 hr 315 тл)оІ/24 hr 
Urinary Na ' APA 121 3±V7 0 p<() 001 (n = 18) 24 9±13 7 p<0 001 (n = 14) 304 9±75 2 
(mmol/24 hr) IHA 169 4±66 6 p<0 001 (n= 7) 23 1±20 2 p<0 001 (n= 6) 377 5±66 1 
Urinary КГ APA 78 5±11 4 p<0 05 (n = 17) 68 0±29 2 p<0 001 (n = 13) 112.1±33 9 
(mmol/24 hr) IHA 67 5±26 1 η s (n= 7) 48 4±23 0 p<0 02 (n= 6) 93 3± 8 1 
III.8. THE PLASMA RENIN ACTIVITY 
In 16 patients with APA during a salt-free diet the plasma renin activity 
(PRA) was assayed at 11.30 hr a.m. after 3 hours ambulation. The 
PRA values varied from 15 to 66 ng/10 ml/3 hr (mean value ± SD: 
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38.2 ± 17.1 ng/10ml/3hr, n=16). The PRA of healthy adults, 
measured under comparable conditions, varies from 115 to 595 ng/10 
ml/3 hr. So, in all of the patients with APA markedly suppressed renin 
values were found. The PRA in patients with IHA varied from 21 to 
147 ng/10 ml/3 hr (mean value ± SD: 67.0 ± 41.5 ng/10ml/3hr, 
n=9). The plasma renin activity in the group of patients with APA 
was significantly lower than in the IHA group (p<0.025). The results 
of the plasma renin determinations are, like those of the plasma 
electrolytes, a confirmation of the current notion, that idiopathic 
aldosteronism is a relatively mild form of primary aldosteronism (Dis-
tler et al. 1969, Baer et al. 1970, Luetscher er al. 1974, Ferriss et al. 
1978b), which is expressed in less serious biochemical deviations. 
III.9. M E D I C A M E N T O U S TREATMENT VERSUS OPERAЛON 
In figure III-l the results of treatment with high doses of spironolac­
tone are compared with the results of operative treatment in 13 patients 
with an adenoma and 3 patients with a hyperplasia. Treatment with 
spironolactone 400 mg/day for 3-4 weeks resulted in a significant 
lowering of blood pressure from 193.4 ± 23.7/119.2 ± 9.5 mmHg to 
155.9 ± 28.3/102.5 ± 16.5 mmHg (n=16, p<0.001). The blood 
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Figure Ill.-l. Comparison of the results of medicamentous treatment 
with spironolactone and the results of operation in 13 patients with 
adenomatous and 3 with idiopathic aldosteronism 
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Table III-8. 
Follow-up after operation (or diagnosis), blood pressure and antihyper­
tensive treatment at the last policlimcal control and complications or 
causes of death in 28 patients with primary aldosteronism 
patients 
ADENOMA 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
G-J 
Br 
ν W 
F 
Ba 
vd V 
O K 
vdK-M 
w-s 
S-R 
S-Kr 
H-S 
K-H 
H 
M-G 
N-M 
P R 
SKI 
HYPERPLASIA 
19 
20 
21 
22 
23 
24 
25 
26 
27 
v N 
S 
L 
S B 
J 
Τ 
v E - v U 
C-J 
К 
CARCINOMA 
28 
•No 
L-vG 
follow up 
(months) 
60 
66 
69 
72 
83 
84 
80 
69 
75 
35 
34 
28 
28 
30 
27 
30 
20 
5 
138 
28* 
31" 
54 
84 
45* 
81" 
192" 
17" 
18 
blood pressure 
(mmHg) antihypertensives 
130/95 
245/145 
112/95 
132/89 
146/88 
180/116 
160/100 
120/88 
138/98 
125/85 
135/100 
170/100 
125/90 
148/90 
185/110 
170/106 
120/80 
135/85 
160/85 
180/95 
180/110 
124/88 
150/98 
176/118 
130/88 
150/94 
150/100 
110/80 
None 
Methyldopa 
Propranolol, chlor­
thalidone, hydralazine 
None 
None 
Chlorthalidone 
None 
Metoprolol 
Chlorthalidone 
Metoprolol, 
chlorthalidone 
None 
None 
None 
Propranolol 
Prazosine 
Spironolactone 
None 
None 
Chlorthalidone 
Rauwolfia 
Hydralazine 
None 
None 
Amiloride 
Spironolactone 
Spironolactone 
Metoprolol 
None 
operation Follow up after diagnosis of primary aldosteronism 
complications/causes of death 
tl4 6 71 encephalopathy, renal 
insufficiency 
tl4 1 77 cause unknown 
myocardial infarction 
angina pectoris 
tl8 9 80 bronchus carcinoma 
tl3 1 74 acute pancreatitis 
t 2 3 71 dissecting aneurysm aortae 
t 5 1 76 respiratory insufficiency 
tl6 3 79 myocardial infarction 
cerebrovascular accident 
local recurrence of 
tumor 
pressure values during treatment with spironolactone did not differ 
significantly from the values recorded 2 to 3 months after operation: 
155 9 ± 28.3/102.5 ± 16.5 mmHg versus 157.4 ± 28 8/105 2 ± 
15.9 (n=16, n.s.). As appears from the correlation coefficients 
between the blood pressure values after treatment with spironolactone 
and those after operation (figure III-l) it is possible on the grounds of 
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the blood pressure after 3 to 4 weeks treatment with spironolactone to 
obtain a reliable impression about the blood pressure that may be 
expected after operation. These results are in agreement with what was 
reported in the literature by Spark and Melby (1968), Brown et al. 
(1969 and 1972), Crane and Harris (1970) and Ferriss et al. (1975 and 
1978c). The spironolactone test is less accurate in predicting the 
postoperative fall in blood pressure in patients without adenoma 
(Ferriss et al. 1978c), although in our 3 patients with a hyperplasia the 
medicamentous and postoperative blood pressure values were in good 
agreement with each other. 
Table ПІ-9. 
Literature review of the results of operation in patients with primary 
aldosteronism, expressed in percentages of patients in whom the blood 
pressure normalized after operation 
Conn et al. 1968 
Distler et al. 1969 
George et al. 1970 
Biglieri et al. 1970 
Baer et al. 1970 
Cain et al. 1972 
Ferriss et al. 1975 
Ferriss et al. 1978c 
Philipp et al. 1978 
Weinberger et al. 1979 
Auda et al. 1980 
Vaughan et al. 1981 
ADENOMA 
unilateral 
adrenalectomy 
63% 
80% 
56% 
60% 
83% 
75% 
50% 
56% 
50% 
68% 
64% 
71% 
HYPERPLASIA 
unilateral or (sub)total 
adrenalectomy 
_ 
20% 
0% 
0% 
0% 
— 
20% 
15% 
17% 
20% 
21% 
-
III. 10. FOLLOW-UP 
After the operation (or after the making of the diagnosis of primary 
aldosteronism, see table III-8) the patients were followed up for 5 to 
192 months (average 56.5 ± 39.8 months). Seven patients died during 
the follow-up: 3 patients (Br, L, K) as the sequel of vascular complica­
tions of a persisting hypertension, and 3 patients (M-G, S, S-B) as the 
consequence of other causes. Patient ν W died suddenly and no 
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autopsy could be performed. Also in the table are set forth the blood 
pressure values that were measured in the last policlinical control and 
the antihypertensives with which the patient was being treated at that 
moment. The blood pressure values show that in the majority of the 
patients who had undergone operation (18 patients with an adenoma, 3 
with a hyperplasia and one with a carcinoma) the effect on the blood 
pressure, even after a longlasting follow-up, was favourable: only in 2 
of the 22 patients (9%) no important fall in the blood pressure was 
achieved, not even after antihypertensive treatment was started again 
(Br, M-G). In 11 patients (50 % ; ν W, vd V, O-K, vd K-M, W-S, S-R, S-
Kr, Η-S, Η, N-M, ν N) a definite fall of the blood pressure occurred 
after the operation. In these patients there remained a slightly raised 
blood pressure that mostly was found to be effectively treated by 
simple antihypertensive therapy. In 9 patients (41 %; G-J, F, Ba, K-H, 
P-R, S-Kl, S-B, J, L-v G) the blood pressure after operation fell off to 
normal values without the use of antihypertensive medication. In the 
case of patient Br the failure of a lowering of blood pressure to occur 
after operation is ascribable to a progressive worsening of kidney 
function. In the woman M-G, the operation remained without result as 
the consequence of a recurrent primary aldosteronism. On the other 
hand this woman also had a diminished kidney function because of a 
serious nephrosclerosis, which was discovered at autopsy. The opera­
tion data are less favorable than one might expect from the data in the 
literature. Table III.-9. shows that, according to the literature, removal 
of an adenoma causes the blood pressure to fall to normal values in 50 
to 80% of the patients. On the contrary, in patients with idiopathic 
aldosteronism, operation induces a normal blood pressure in only 0 to 
2 1 % of the patients. A normalization of the blood pressure was 
achieved in the group examined by us in 6 of the 18 patients (33 %) with 
an adenoma and in 2 of the 3 patients with a hyperplasia. To sum up: it 
seems to us likely that the less favorable results are ascribable to the 
following factors: a long-lasting hypertension before the diagnosis of 
primary aldosteronism was made (patients O-K, vd K-M, H-S, 
N-M); recurrence of primary aldosteronism (M-G); kidney disorders 
(Br and ν W). The results of operation in our patients with idiopathic 
aldosteronism are remarkable but do not allow any conclusions to be 
drawn because of the limited size of the group. But, in any case they 
give no grounds for rejection of the notion that we also maintain, 
namely, that patients with idiopathic aldosteronism must be treated 
preferably by medicaments. 
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CHAPTER IV 
THE VALUE OF ESTIMATIONS OF ALDOSTERONE 
FOR THE DIAGNOSIS OF PRIMARY 
ALDOSTERONISM AND FOR THE DISTINCTION 
OF THE ADENOMATOUS AND IDIOPATHIC 
FORMS 
In this chapter evaluations are given successively of the results of 
estimations of the rate of secretion of aldosterone, the rate of excretion 
of a metabolite in the urine, the 18-glucuronide of aldosterone, and of 
the levels of aldosterone in peripheral venous blood under varying 
conditions. In chapter V a prospective study is made on variations in 
the blood level during 24 hours, and, especially, during the early 
morning, in a group of patients with the adenomatous form of primary 
aldosteronism and in 4 patients with idiopathic aldosteronism. In this 
chapter additional observations in a group of patients "after removal of 
an aldosterone-producing adenoma" are compared with the results in 
the abovementioned study. 
IV. 1. THE ALDOSTERONE SECRETION RATE 
As set forth in chapter II.2. the measurements of the aldosterone 
secretion rate (ASR) were made under standardized conditions during 
continued use of a strictly salt-free diet with about 15 mmol sodium per 
day and a potassium content that in the individual diets varied from 50 
to 70 mmol/day. Secretion measurements of aldosterone were done 
after 6 grams of salt had been given in divided doses for 5 days (ASR 
115), then after no extra salt had been added for 5 days (ASR 15), and, 
finally after giving 18 grams of salt per day for 5 days (ASR 315). In 
table IV. 1. the results are displayed. For the sake of comparison the 
values obtained among normal test persons under identical conditions 
are given. Figure IV-1 shows that after loading with 18 grams of salt 
(ASR 315) all of the values in patients with adenomatous primary 
aldosteronism (group I) and those from others with the idiopathic form 
(group II) were, without exception, higher than in the control group. 
For ASR 115 it is also true that all the secretion values in group I were 
higher than in normal persons. However. 3 out of the 9 measurements 
in group II lie within the normal distribution area. With regard to ASR 
15 there is a very obvious "overlap" of values between the group of 
normals and the I and II patient groups. There is even no statistically 
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significant difference between the values of both patient groups and 
normal persons. These data illustrate the fact that in none of the levels 
of salt intake do measurements of the aldosterone secretion rate make 
Table IV-1. 
The secretion rates of aldosterone in 18 patients with adenomatous, and 
in 9 patients with idiopathic aldosteronism, measured during the inge­
stion of 15 mmol Na+I24 hr (ASR15), 115 mmol Na+/24 hr (ASR115) 
and 315 mmol Na+/24 hr (ASR315) 
ASR15 ASR115 ASR115 
ADENOMA 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
G-J 
Br 
ν W 
F 
Ba 
vd V 
O-K 
vdK-M 
w-s 
S-R 
S-Kr 
H-S 
K-H 
H 
M-G 
N-M 
P R 
S-KI 
HYPERPLASIA 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
v N 
S 
L 
S-B 
J 
τ 
v E - v U 
C-J 
к 
396 
1255 
1750 
516 
732 
-
-
-
-
920 
-
-
400 
908 
230 
470 
-
240 
481 
281 
418 
-
426 
-
460 
468 
160 
370 
1257 
429 
408 
551 
248 
1944 
851 
440 
544 
862 
642 
331 
702 
270 
353 
385 
259 
476 
401 
222 
242 
340 
474 
250 
143 
108 
-
— 
— 
-
-
-
1721 
981 
455 
266 
793 
1079 
459 
666 
215 
253 
387 
244 
— 
_ 
219 
388 
432 
199 
163 
108 
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feasible any difference between the groups I and II. The ASR 15 values 
in patients from group I varied from 230-1750 μg/24 hr (mean ± SD, 
711 ± 469 μg/24 hr, n = l l ) and in patients from group II from 160-
481 μg/24 hr (mean ± SD, 385 ± 120 μg/24 hr, n=7, n.s.). The 
secretion values during uptake of 6 grams of salt varied in group I from 
248 to 1944 μg/24 hr (mean ± SD, 603 ± 424 μg/24 hr, n = 18) and 
were statistically significantly higher (p<0.025) than the values in 
group II that varied from 108 to 474 μg/24 hr (mean ± SD, 295 ± 135 
μg/24 hr, n=9). The ASR 315 values manifest no statistical difference 
Aldos terorv 
(>ig/24h) 
5 0 0 i 
4 0 0 -
300-
200-
100-
' 
5 secretion rate­
1 1 
A. 
! 
i 
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• 
Χ 
• 
• 
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• 
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t 
• 
M · · 
: 
A 
A · 
• 
• 
• 
* 
A 
A 
A 
15 mmol Na+ 115 mmol Na+ 315 mmol Na* 
Figure IV-1. Aldosterone secretion rates in patients with adenomatous 
(·) and idiopathic (A) aldosteronism, measured during an intake of 
15 mmol Na+/day, 115 mmol Na+/day and 315 mmol Na*/day 
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between the two groups- in group I the values varied from 215 to 721 
μg/24 hr (mean ± SD. 627 ± 453 μg/24 hr, n = 12) and in group II 
from 108 to 432 μg/24 hr (mean ± SD, 251 ± 129 μg/24 hr, n=6) 
The ASR values in group I as in group II prove to be not significantly 
influenced by salt loading Nevertheless m group I, in 7 out of 11 
patients, and in group II in 5 out of 7 patients, the ASR 115 values were 
lower than the ASR 15 values On comparison between the ASR 115 
and the ASR 315 values there was found in group I in 6 out of 12 
patients, and in group II in 3 out of 6 patients that the values were 
lower after increasing the salt intake 
IV.2. THE URINARY EXCRLTION or AIDOSTERONL-IS-GIUCURONIDE 
During each of the 5 days of the study, the protocol of which was set 
forth in chapter II 3 2., measurements were made of the excretions of 
the metabolite aldosterone-18-glucuronide in: 
1. 8 patients with adenomatous primary aldosteronism (group I) 
2 4 patients with idiopathic aldosteronism (group II) 
3 6 patients in whom in the past an aldosterone-producing adenoma 
had been removed (group III) 
According to the arrangement of the study, the effect of the body 
posture on the rate of excretion of the metabolite can be studied by 
comparing the values of day 1 (ambulation) with day 2 (rest in bed). 
and of day 4 with day 5 (ambulation and rest in bed. respectively, 
during the use of dexamethasone) Besides, one can ascertain the 
influence of giving dexamethasone for 3 days on the excretion of 
aldosterone. Table IV-2 and figure IV-2 give the individual data and 
the mean values In the same way that was valid for the secretion values 
of aldosterone with the use of 6 grams of salt per day, it can be seen that 
the excretion values of the aldosterone metabolite can provide no strict 
borderline between the groups I and II, on either day 1 (during 
ambulation) or on day 2 (during rest in bed) The excretion values in 
group III (after removal of an aldosterone-producing adenoma) are, 
with a single exception, lower than those in the groups I and II. The 
influence of body posture on the excretion of aldosterone-18-glucuro-
nide under basal conditions is seen by comparing the values of day 1 
with those of day 2. The influence of the body posture during dexame­
thasone can be obtained by comparing the values of day 4 with those of 
day 5. In the group of patients with an adenoma no effect of body 
posture is seen, either under basal conditions, or during dexametha­
sone treatment In the groups II and III one sees, with one single 
exception, somewhat lower values on the days of complete bedrest than 
on the days in which the patients are out of bed, in both basal 
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Table IV-2 
The 24-hours excretions of aldosterone-18-glucuronide and the influ­
ence on it of body posture before and during the use of dexamethasone 
in patients with adenomatous aldosteronism, idiopathic aldosteronism, 
and "after removal of an aldosterone-producing adenoma' 
I ADENOMA 
S-R 
S-Kr 
H-S 
K-H 
H 
N-M 
P-R 
M-G 
II HYPCRPLASIA 
I 
ν Ε-v U 
C-J 
К 
III ADENOMA AFTER OPERATION 
N-M 
K-H 
K-M 
vd V 
O-K 
F 
day 1 
J 
40 0 
34 0 
36 1 
19 3 
65 4 
14 3 
20 0 
25 0 
23 8 
24 6 
34 3 
10 3 
6 0 
4 0 
7 8 
15 0 
9 0 
7 0 
day 2 
O—Í 
36 0 
36 0 
33 8 
12 6 
71 0 
9 0 
56 0 
28 0 
23 8 
23 6 
11 6 
8 7 
6 0 
3 0 
5 6 
8 2 
8 0 
1 5 
dexamethasone 2 
lda> 3 
I 
36 0 
no 
22 7 
6 9 
28 2 
110 
16 0 
15 0 
22 9 
20 6 
22 0 
6 4 
4 0 
3 0 
7 5 
12 0 
6 0 
3 0 
dav 4 
I 
50 0 
12 0 
33 0 
7 7 
44 9 
15 0 
29 0 
17 4 
28 6 
17 2 
21 2 
9 7 
4 0 
4 0 
6 4 
15 0 
10 0 
6 0 
mg/da> 
dav Si 
о—с 
17 0 
30 0 
64 3 
10 7 
35 8 
6 0 
36 0 
22 5 
23 7 
11 8 
15 2 
8 3 
4 0 
3 0 
5 0 
13 0 
9 0 
4 0 
conditions and during dexamethasone From table IV-2 and figure IV-2 
it will be seen also that the excretion of the aldosterone-18-glucuronide 
on the first dav ol dexamethasone (day 3) was lower in every patient 
from every group than on dav 1 (on both days the patients were out of 
bed) On the second and third days of dexamethasone administration 
(days 4 and 5) the excretion values in the groups I and III did not differ 
sigmficantlv from those on the corresponding days 1 and 2 The data 
from group II do not lend themselves to any statistical compilation 
Evidently, there is a short-lasting effect of suppression of ACTH by 
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4 0 n 
D ADENOMA * * p < 0 . 0 2 
Ш HYPERPLASIA * ρ < 0.05 
Ш ADENOMA AFTER OPERATION 
DEXAMETHASONE 2 mg/day 
Figure IV-2. The influence of body posture and dexamethasone treat­
ment on urinary aldosterone excretion in patients with adenomatous-
and idiopathic aldosteronism and in patients "after removal of an 
aldosterone-producing adenoma" 
dexamethasone on the excretion of the aldosterone-18-glucuronide: on 
the first day when it is given, the excretion falls off in both groups with 
primary aldosteronism as in the group "after removal of an adenoma". 
IV.3. MEASURING ALDOSTERONE IN PERIPHERAL VENOUS BLOOD 
In every patient of the three groups examined (adenomatous aldostero­
nism, idiopathic aldosteronism and "after removal of an adenoma") a 
number of samples of blood were collected in accordance with the 
protocol described in chapter II.3.2. With this protocol design an 
impression can be obtained about the aldosterone concentrations at 
various moments of the day and night. In the study published in 
chapter V the results in patients with primary aldosteronism are 
discussed. In this paragraph the results are compared with those in a 
group of 6 patients in whom the research was carried out after removal 
of an aldosterone-producing adenoma on some previous occasion 
(group III). 
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IV.3.1. Levels of aldosterone in blood during the night 
In table IV-3 and figure IV-3 the individual and mean values per 
patient and per group are placed alongside each other. From this it will 
be seen that: 
I. The mean nocturnal hormone values in group I, varying from 19.6 
± 3.5 (SD) to 65.0 ± 5.6 ng/100 ml, are much higher than those in 
group II (7.7 ± 1.6 to 14.4 ± 5.2 ng/100 ml) and in group III (5.7 ± 
3.0 to 13.5 ± 3.2 ng/100 ml). Also on comparison of the nocturnal 
values per individual from group I with those of the patients from the 
Table IV-3. 
The variability of the plasma aldosterone concentrations in patients with 
adenomatous aldosteronism, idiopathic aldosteronism and "after remo­
val of an aldosterone-producing adenoma" 
104 45 hr-07 45 hr 
mean range 
I A D E N O M A o — e 
S-R 
S-Kr 
H-S 
K-H 
H 
N-M 
P R 
M-G 
36.9 
46.7 
65.0 
51.3 
61.5 
19.6 
36.4 
32.3 
II HYPERPLASIA 
Τ 
ν E-v 
C-J 
U 
7.7 
10.0 
13.4 
31.8-45.7 
32.2-57.9 
54.9-73.4 
27.6-66.0 
39.4-80.7 
15.5-26.8 
25.7-47.7 
25.5-37.9 
5.3- 9.8 
4.1-14.8 
9.4-17.5 
07 45hr 
o - < 
32.7 
32.2 
71.2 
47.5 
60.7 
20.8 
35.9 
28.4 
8.9 
13.7 
13.3 
12 00hr 
I 
34.7 
54.6 
52.6 
18.3 
72.1 
24.9 
13.0 
23.7 
12.1 
28.1 
49.6 
16 00 hr 
I 
22.3 
33.9 
45.5 
15.6 
78.7 
15.8 
20.3 
6.8 
16.9 
40.7 
40.2 
20OOhHll2OUhr 
I 
14.6 
32.9 
7.1 
26.7 
17.8 
8.8 
8.9 
9.0 
11.1 
11.2 
21.7 
o—< 
30.3 
42.3 
30.3 
22.9 
42.4 
20.1 
49.8 
36.0 
14.0 
12.3 
18.3 
16 00 hr 20 00 hd 
о—С 
14.7 
24.8 
16.2 
10.2 
41.0 
16.6 
37.8 
18.5 
13.2 
21.2 
18.4 
о—с 
10.7 
28.2 
11.6 
15.5 
76.4 
9.3 
26.3 
10.0 
14.9 
12.4 
8.9 
К 14.4 5.5-19.8 5.5 21.8 9.4 16.0 11.5 7.7 7.4 
IH ADENOMA AFTER OPERATION 
K-H 
N-M 
vd K-M 
vd V 
O-K 
F 
11.4 
10.5 
13.5 
6.5 
13.1 
5.7 
7.4-14.3 
4.9-21.9 
9.1-18.5 
4.0-12.4 
11.7-14.7 
2.2-10.9 
7.4 
4.9 
11.0 
4.0 
13.4 
8.5 
13.1 
25.3 
29.5 
16.6 
16.9 
9.3 
16.6 
22.9 
22.2 
15.9 
11.6 
9.7 
11.5 
9.0 
20.7 
7.8 
11.7 
9.7 
9.1 
10.4 
10.5 
5.7 
11.5 
6.2 
9.6 
13.6 
11.6 
2.8 
6.4 
7.7 
6.5 
2.0 
4.2 
8.6 
3.6 
5.4 
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Figure lV-4. Effects of treatment with dexamethasone 2 mglday on 
nocturnal and daytime aldosterone concentrations in patients with ade­
nomatous and idiopathic aldosteronism and in patients "after removal of 
an aldosterone-producing adenoma" 
75 
groups II and III it will be seen that practically all aldosterone values of 
the patients with an aldosterone-producing adenoma, between 04 45 
and 07.45 hr, are considerably higher than those of the patients from 
both of the other groups In the woman patient N-M trom group I, at 
some points of time in the night, values were found that were lower 
than those of the patient K, who had highest values in group II, the 
woman patient N-M also had the lowest excretion values of aldoste-
rone-18-glucuronide in group I, according to table IV-2 
2. The mean aldosterone values in the late night in patients with 
idiopathic aldosteronism are strikingly low and do not differ signifi-
cantly from the values that were measured in patients from whom an 
adenoma had been removed in the past 
3 The plasma aldosterone concentrations during the late night in all 
patients manifested considerable variations, as may be seen in the 
distribution of the values in the individual patients (table IV-3) and 
from the figures presented in the case histories of the individual 
patients (see appendix) To what extent episodic variations of aldoste-
rone (caused by short-lasting spurts of secretion) play a rôle in this, 
cannot be said for certain, because the method for collection of the 
blood samples (a continuous blood sampling) is unsuitable for showing 
very rapid changes in the hormone concentrations. 
In figure IV-4 the aldosterone concentrations (mean ± standard error 
of mean) during treatment with dexamethasone 2 mg/day arc compa-
red with the corresponding aldosterone values under basal conditions 
m all of the three groups of patients The aldosterone values during the 
last part of the night (that is to say, 21 to 24 hours after giving the first 
dose of dexamethasone) in groups I and III were found to be signifi-
cantly lower than the comparable basal values. But it appeared on 
careful comparison of all individual values (tables IV-3 and IV-4) that 
in 1 patient from group I (N-M) there could be no question of 
suppression by dexamethasone, as 9 of the 12 nocturnal values were 
higher during dexamethasone administration than on the basal day. 
'I his woman was also remarkable quite otherwise the excretion of the 
aldosterone-18-glucuronide was the lowest of group I, and so, too, was 
the plasma level in the first night of sampling Further, in one patient of 
group II (T) and in one of group III (F), a number of nocturnal plasma 
values during dexamethasone were higher than on the control day. In 
general it is obvious that the degree of suppression of the nocturnal 
aldosterone level on the first day of the administration of dexametha-
sone is rather variable (for this compare with the data per patient 
reported in the figures of the appendix) 
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Table IV-4. 
The variability of the plasma aldosterone concentrations in patients with 
adenomatous aldosteronism, idiopathic aldosteronism and "after remo­
val of an aldosterone-producing adenoma" during administration of 
dexamethasone 2 mglday 
day 4 day5 
І04 45 hr-07 45 hr 
mean range 
I A D E N O M A 0 - < 
S-R 
S-Kr 
H-S 
K-H 
H 
N-M 
P R 
M-G 
23.6 
8.6 
24.7 
7.9 
29.4 
25.7 
20.7 
9.4 
II HYPERPLASIA 
Τ 
v E-v 
C-J 
К 
и 
8.9 
1.4 
10.2 
2.4 
21.6-25.0 
6.1-10.6 
20.7-26.4 
5.7-11.3 
17.4-45.2 
20.8-29.2 
16.0-27.0 
6.5-15.6 
5.0-12.8 
0.9- 2.5 
6.5-18.2 
1.4- 4.3 
07 45 hr 
о—с 
23.6 
9.6 
26.4 
11.3 
17.4 
25.7 
22.0 
12.7 
5.0 
1.0 
6.5 
2.5 
12 00hr 
I 
45.6 
8.3 
36.1 
10.4 
52.8 
33.4 
40.0 
18.0 
23.4 
24.7 
63.0 
13.5 
leoohr 
I 
36.3 
7.2 
33.5 
7.3 
19.5 
32.0 
15.0 
10.3 
16.5 
16.1 
63.5 
13.0 
20 00hHll2()0hr 
1 
38.2 
3.8 
17.3 
8.3 
32.8 
10.0 
17.0 
7.9 
12.1 
7.7 
37.7 
8.0 
o—< 
17.7 
20.9 
52.9 
10.1 
11.0 
8.9 
25.0 
15.1 
14.4 
12.1 
16.9 
11.4 
16 00 hr 
о—с 
15.6 
12.5 
42.0 
10.1 
43.9 
6.4 
14.0 
9.3 
15.3 
6.7 
27.4 
6.7 
ZOOOhH 
о—с 
11.2 
14.6 
29.2 
8.3 
9.3 
3.8 
16.0 
8.9 
10.1 
3.7 
21.0 
-
Ill A D E N O M A AFTER OPERATION 
K-H 
N-M 
vdK-M 
vd V 
O-K 
F 
2.2 
3.6 
3.2 
2.4 
6.1 
4.3 
2.0-
2.0-
1.Ο­
Ι.4-
4.4-
2.3-
3.9 
7.5 
6.2 
4.7 
7.5 
6.2 
3.9 
2.8 
2.6 
1.4 
5.8 
3.4 
13.7 
-
27.6 
13.7 
17.3 
6.6 
10.4 
22.6 
24.8 
20.4 
21.9 
9.5 
7.8 
7.0 
15.7 
17.3 
9.3 
7.5 
3.0 
4.6 
5.5 
2.9 
7.9 
3.9 
4.4 
9.9 
11.0 
9.9 
9.0 
8.7 
6.1 
3.9 
3.4 
1.2 
9.2 
5.3 
IV.3.2. Levels of aldosterone in blood during the day 
From table IV-3 and figure IV-3 it is evident that the aldosterone 
values in plasma determined at the points of time 12.(X), 16.00 and 
20.00 hr have a tendency to decrease in the course of the day, on both 
day 1 (during ambulation) and on day 2 (during rest in bed). Statisti­
cally suchlike appears significant only in group I (Friedman test: for 
day 1 p<0.05 and for day 2 p<0.02). Moreover, a strict differentia­
tion between the 3 groups is not to be found: only at the point of time 
77 
12.(X) hr of day 2 do the aldosterone values in group 1 appear without 
exception to be higher than in the other 2 groups. With reference to the 
last values of the nocturnal sampling period (between 07.30 and 07.45 
hr and the value at 12.00 hr on the first day, the effect of change of 
body posture on the aldosterone levels can be compared in the 3 
groups. Table IV-3 shows that ambulation during the morning causes a 
rise of the aldosterone level in all of the patients in the groups II and 
III, while in the group of patients with adenomatous primary aldostero-
nism a falling-off occurred in 4 of the 8 patients. The absence of a clear 
rise after the stimulus of "ambulation during the morning" is conside-
red by some authors as a criterion for the differentiation of patients 
with adenomatous aldosteronism from patients with idiopathic aldoste-
ronism. Our data illustrate that this assumption is only to a very small 
degree correct. Table IV-4 and figure IV-4 show the effect of dexame-
thasone on the aldosterone levels in blood on the days 4 and 5, that is to 
say, on the second and third days of administration of dexamethasone. 
In the paragraph, in which the excretion values of the aldosterone-18-
glucuronide are commented on, the conclusion was that on the second 
and third days of dexamethasone, no suppressive effect was recogniza-
ble any longer. This applies also to the aldosterone levels in blood: in 
comparisons of the values during days 1 and 5 (during ambulation) and 
those of days 2 and 5 (during rest in bed) there is no evidence of 
systematic lower values in any of the groups on the days on which 
dexamethasone is used. In the published study that is reproduced in 
chapter V it is stated that during administration of dexamethasone the 
aldosterone level rises significantly in patients with adenomatous aldos-
teronism during ambulation in the morning (from 18.3 ± 6.6 to 30.6 
± 16.5 ng/10() ml), while under basal conditions, there was no 
significant change. Figure IV-4 and table IV-4 show that also in the 
group of patients "after removal of an adenoma" the aldosterone levels 
rise as well as under basal conditions as during dexamethasone. A 
possible explanation of this phenomenon in patients with adenomatous 
primary aldosteronism, will be seen in the discussion in chapter V. 
Furthermore, an impression can be gained about the effect of body 
posture on blood levels of aldosterone, if the aldosterone values 
measured at the points of time 12.00. 16.00 and 20.00 hr of day 1 
(ambulation) are compared with those at the same points of time on 
day 2 (rest in bed). In the same way the effect of body posture can be 
followed up by comparing the values of aldosterone at the same points 
of time on day 4 with those on day 5 (ambulation and rest in bed. 
respectively, during the administration of dexamethasone). If the 
results of the comparisons under basal conditions and during dexame-
thasone are added together (figure IV-5) it turns out that during bed 
rest (day 2 and 5) the plasma aldosterone values in the groups II and III 
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almost without exception are lower than during ambulation (days 1 and 
3). On the contrary, in group I such an effect of body posture on the 
aldosterone concentrations is not recognizable Finally, the measure­
ments of plasma renin activity at the points of time 12 00, 16 00 and 
20.00 hr of day 1 (during ambulation) are compared with the values of 
day 2 (during bed rest). In the same way comparison is made of the 
values obtained under identical conditions during administration of 
dexamethasone (days 4 and 5) In figure IV-6 the values of plasma 
renin activity under basal conditions and under dexamethasone are 
added together and grouped among the body postures. It becomes 
apparent that during an intake of 6 grams of salt, the PRA values do 
not differ significantly from each other in the three groups In groups II 
and III the values in the recumbent posture are mostly lower than those 
obtained during upncht posture In group I, however, no clear effect of 
body posture on the plasma renin activity was detectable 
Plasma aldosterone ( ng /100 ml ) 
ADENOMA 
8 0
Ί 
6 0 
4 0 
2 0 
Figure IV-5. The influence of body posture on plasma aldosterone 
concentrations in patients with adenomatous and idiopathic aldostero­
nism and in patients "after removal of an aldosterone-producing ade­
noma" 
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Figure IV-6. The influence of body posture on plasma renin activity in 
patients with adenomatous and idiopathic aldosteronism and m patients 
"after removal of an aldosterone-producmg adenoma" 
IV.4. THL INFLUENCE OF ACTH ON ALDOSTERONE 
In a number of case records (see appendix) reference is made to the 
relation between the levels of aldosterone and those of Cortisol and 18-
OH-DOC as representives of the zona fasciculata activity in patients 
with primary aldosteronism. In the three groups of patients who were 
studied according to the protocol described earlier, these 3 corticoste­
roids were measured in all of the samples of blood. From the results of 
the measurements, the correlation coefficients were calculated between 
the values of the three hormones (table IV-5) It will be noticed that 
the correlation coefficients of the values of Cortisol and 18-OH-DOC 
are significant for each patient in the three groups. Therefore, it can be 
argued that the finding of a significant correlation coefficient between 
these hormones, is an indirect measure for ACTH-dependent hormone 
secretion If with this a comparison is made with the correlation 
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Table IV-5. 
The correlation coefficients between the plasma concentrations of aldos­
terone, Cortisol and 18-OH-DOC in patients with adenomatous aldoste­
ronism, idiopathic aldosteronism and "after removal of an aldosterone-
producing adenoma" 
aldosterone vs Cortisol aldosterone vs 18-OH-DOC Cortisol vs 18-OH-DOC 
night, days 1 and 2 
I ADENOMA 
S-R 
S-Kr 
H-S 
K-H 
H 
N-M 
P-R 
M-G 
0.82*** 
0.57** 
0.44 
0.90*** 
0.53* 
0.44 
0.21 
0.34 
II HYPERPLASIA 
Τ 
ν Ε-v U 
C-J 
К 
0.55* 
0.34 
-0.14 
0.11 
night, days 1 and 2 
0.85*** 
0.45* 
0.72*** 
0.96*** 
0.72*** 
0.65** 
0.70*** 
0.28 
-0.06 
0.03 
-0.12 
0.46* 
III ADENOMA AFTER OPERATION 
K-H 
N-M 
v d K - M 
vd V 
O K 
F 
• p<0 05 
** p<0 01 
*** p<0 001 
0.02 
0.10 
0.16 
0.27 
0.31 
0.81*** 
0.40 
-0.03 
0.31 
0.35 
0.24 
0.76*** 
night, days 1 and 2 
0.95*** 
0.76*** 
0.63** 
0.89*** 
0.85*** 
0.92*** 
0.56* 
0.82*** 
0.56* 
0.62** 
0.98*** 
0.77*** 
0.70*** 
0.85*** 
0.91*** 
0.95*** 
0.53* 
0.95*** 
coefficients between the values of aldosterone and Cortisol and 
between those of aldosterone and 18-OH-DOC, it becomes obvious 
that the correlation coefficients between the values of aldosterone and 
those of both of the zona fasciculata steroids, less frequently reach the 
level of statistical significance, especially in groups II and III. From this 
it can be deduced that the secretion of aldosterone in patients with 
adenomatous aldosteronism is more under control of ACTH than in 
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patients from either of the other groups. However, the influence of 
ACTH on aldosterone in patients with adenomatous aldosteronism 
mav show a rather wide intenndividual variation. 
IV 5. SUMMARY 
For a discussion of the results we refer the reader also to the "discus-
sion" in chapter V 
From determinations of the secretion of aldosterone, at 3 levels of salt 
intake with the diet, emerges the value of salt loading for establishing 
the diagnosis of primary aldosteronism; exclusively at a sodium intake 
of 315 mmol/day it turns out that the values of secretion of patients with 
primary aldosteronism, without exception, are found to be higher than 
in normal test persons. At a sodium intake of 15 mmol/day a clear 
"overlap" was found between the values of patients and normal test 
persons. These results are in good agreement with the studies in which 
likewise determinations of secretion were done after oral salt loading 
for several days (Collins et al. 1970, Demanet and Vnjens 1971, Cain et 
al. 1972). On the other hand we conclude that a "normal" rate of 
secretion of aldosterone during a moderate salt loading with 115 mmol/ 
day, by no means excludes the diagnosis of primary aldosteronism. 
Also, it was recently shown by Weinberger et al (1979), that during a 
diet with a normal salt content the values of aldosterone excretion in 
3 1 % of their patients with primary aldosteronism were "normal". 
Measuring the secretion rate of aldosterone before and after salt 
loading proved to have no value for the differentiation between adeno-
matous and idiopathic aldosteronism. Also in the literature we did not 
find any indications that measuring aldosterone before and after giving 
salt and/or mineralocorticoids would contribute to a differentiation 
between the two affections. This conclusion holds equally true for 
measunngs of the rate of excretion of the aldosterone-18-glucuronide, 
although these were measured in our study only during a moderate 
dietary salt intake But such a difference can be brought out with the 
aid of measurement of aldosterone in blood, as will be shown in chapter 
V. 
The measurements of the excretion of the aldosterone-18-glucuronide 
in relation to the body posture showed that the excretion values, both 
basally and during dexamethasone, in practically all patients in the 
groups II (IHA) and III ("after removal of an adenoma") were higher 
during ambulation than during recumbency, while no influence of the 
body posture was found in group I (APA). The influence of the body 
posture on the aldosterone values in plasma was in agreement with the 
influence on the aldosterone values in urine: a rise of aldosterone 
82 
during "ambulation" in the groups II and III and no appreciable 
influence in group I (figure IV-5). 
A similar but less consistent influence of the body posture, was found 
for the plasma renin values which during "ambulation" were in general 
higher in the groups II and III, but not in group I (figure IV-6). In still 
another respect the findings in patients "after removal of an adenoma" 
are comparable with that which is found in patients with IHA: relati-
vely low aldosterone values during the night with a marked rise of the 
values during the following day during "ambulation" (figure IV-3). In 
patients with APA, on the contrary, remarkably higher nocturnal 
values were found and a decrease of aldosterone during the following 
day when performing "ambulation". Finally, the findings in group III 
were comparable with those in group II as regards the slight influence 
of ACTH on the aldosterone values during the day and the night. The 
influence of ACTH as derived from the correlation coefficients 
between aldosterone and Cortisol and between aldosterone and 18-OH-
DOC was, on the contrary, more clearly recognizable in patients with 
APA (table IV-5) 
The conclusions run as follows: the regulation of aldosterone before 
and after removal of an aldosterone-producing adenoma, is essentially 
different. We have shown that before operation the influence of ACTH 
on the day and night regulation of aldosterone is clearly recognizable 
(albeit with intermdividual variations), whereas after operation the 
renin angiotensin system displays a far clearer relation to the plasma 
aldosterone values In the second place we found that the influence of 
the various manoevres on the plasma aldosterone concentrations in 
patients with idiopathic aldosteronism was comparable qualitatively 
with that which was found in patients in whom an aldosterone-produ-
cing adenoma had been removed The regulation of aldosterone in the 
groups II and III is in essence not otherwise than what was found in the 
literature with regard to normal test persons (Vagnucci et al 1974, 
Armbruster et al 1975, Katz et al. 1975, Lightman et al. 1981) 
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CHAPTER V 
NOCTURNAL, DAYTIME, AND POSTURAL 
CHANGES OF PLASMA ALDOSTERONE BEFORE 
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This chapter was published in the "Journal of Clinical Endocrinology 
and Metabolism" 51: 1330-1334, 1980 
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V.l. ABS ι RAGT 
The relative importance of ACTH and the renin angiotensin system for 
control of aldosterone was studied in eight patients with adenomatous 
primary (APA) and four with idiopathic aldosteronism (IHA). Plasma 
aldosterone (PA) and Cortisol (PC) were measured in blood collected 
during the night at 15-min intervals between 05.00-08.00 hr by integra­
ted sampling on day 1 and in casual samples during the daytime while 
patients were in the upright and in the supine position (days 1 and 2, at 
12.00, 16.00 and 20.00 hr). 
PRA was measured in all daytime samples. On days 3, 4 and 5, 2 mg 
dexamethasone were given, and the same protocol for blood sampling 
was repeated on days 4 and 5. 
During the night, mean PA in IHA patients was markedly lower than 
that in APA patients. PA significantly correlated with PC in both 
groups. Dexamethasone reduced the mean nocturnal PA in both 
groups to equal proportions. 
In the daytime, the mean recumbent PA in IHA patients was also 
significantly lower than that in APA patients but was equal in both 
groups while subjects were in the upright posture. Daytime PA signifi­
cantly correlated with PC in APA patients and with PRA in IHA 
patients. During upright posture, dexamethasone did not reduce day­
time PA in either group. In the supine position, dexamethasone 
reduced daytime PA values in APA but not in IHA patients. 
Thus, short time fluctuations of PA during the night are equally 
influenced by ACTH in APA and IHA patients, though at markedly 
different levels of aldosterone production. During the daytime, the 
influence of ACTH on PA remains apparent in the group with APA. 
However, the renin-angiotensin system seems to play a predominant 
role in the control of PA during the daytime in patients with IHA. 
During dexamethasone and ACTH suppression, PA in APA patients 
rises in response to upright posture as it does in IHA patients. 
V.2. INTRODUCTION 
ACTH plays a significant role in the control of plasma aldosterone 
(PA) in patients with aldosterone-producing adenomas (APA). The 
quantitative correlation between circadian hormone levels of PA and 
plasma Cortisol (PC) (Cain et al. 1972, Ganguly et al. 1973, Kern et al. 
1973, Schambelan et al. 1976, Biglieri et al. 1974); the synchronicity of 
episodic secretions of PA and PC, as assessed by frequent blood 
sampling techniques (Vetter et al. 1974, Katz et al. 1975, Kern et al. 
1976, Vetter et al. 1978); and the exaggerated response of PA to the 
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infusion of physiological amounts of synthetic ACTH (Kern et al 1978) 
support this thesis In patients with idiopathic hyperaldosteromsm 
(IHA), there is some evidence that PA is under the control of both 
ACTH (Ganguly et al. 1973, Schambelan et al. 1976, Kern et al 1976, 
Vetter et al 1978) and the renin-angiotensin system (Ganguly et al. 
1973, Schambelan et al. 1976, Vetter et al 1978). 
Conflicting results have been reported with respect to the effectiveness 
of dexamcthasone treatment in reducing PA in patients with primary 
aldosteronism (Newton and Laragh 1968, Slaton et al 1969, Vetter and 
Vetter 1975) A variable ACTH dependency of aldosterone production 
might explain these discrepancies (Wenting et al 1978) In addition, 
however, differences in doses and duration of dexamcthasone treat-
ment may account for some of the reported differences Ganguly et al. 
(1977) found a transient fall and a subsequent return of PA within 3 
days of dexamethasone treatment 
This study was designed to further evaluate the role of ACTH and the 
renin-angiotensin system in the control of aldosterone production in 
patients with primary aldosteronism Special attention has been paid to 
the effectiveness of dexamethasone treatment m reducing PA in 
patients with APA and IHA and to postural changes of PA in these 
disorders 
V 3 MATERIAIS AND METHODS 
V 3 1 Patients 
Eight patients with APA and 4 with IHA were studied In all patients, 
the diagnosis of primary aldosteronism was based on the concurrence 
of hypertension, mild or frank hypokalemia, suppressed PRA during 
upright posture after 5 days of sodium restriction (Drayer et al 1975), 
and a high secretory rate of aldosterone which failed to suppress to 
normal values after a daily sodium intake of 315 mmol during 5 days 
(Kloppenborg et al 1972) The clinical and biochemical characteristics 
are presented in table V-l The diagnosis of APA was based on 
biochemical data and an adrenal scintigram using n'l-6ß-Iodomethyl-
19-Nor-Cholesterol (Sarkar et al 1977). Scintigrams were performed 
after treatment with dexamethasone (2 mg/day) during the 2 weeks 
before the administration of the isotope In seven of eight patients with 
APA, the adrenal scintigram correctly identified an adrenal adenoma, 
which was confirmed by operation In one patient with histologically 
proven APA, the adrenal scintigram failed to show an accumulation of 
radioactivity in either adrenal In the four patients with IHA, the 
diagnosis was based on biochemical data, which showed the characte-
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Table V-l. 
Clinical and biochemical data in 12 patients 
patient 
no 
ADENOMA 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
HYPERPLASIA 
9. 
10. 
11. 
12. 
* measured after 5 
** measured after 5 
age 
45 
45 
57 
33 
36 
54 
38 
57 
53 
40 
55 
64 
sex 
F 
F 
F 
F 
M 
F 
F 
F 
M 
F 
F 
M 
days sodium 
days sodium 
blood pressure 
(mmHg) 
180/140 
155/100 
180/100 
165/110 
194/120 
240/140 
200/120 
204/126 
198/120 
160/108 
186/106 
238/146 
with primary aldosteronism 
potassium 
(mEq/l) 
2.9 
3.2 
1.9 
3.0 
2.9 
2.0 
2.9 
3.0 
2.5 
3.9 
3.4 
2.8 
restriction (Ν: 115-595) 
loading (Ν: 55± 17) 
PRA* 
(ng/10 
ml/3hr) 
20 
29 
63 
38 
44 
66 
26 
53 
34 
112 
147 
69 
ASR** 
^g/24hr) 
266 
793 
1079 
459 
666 
253 
387 
215 
432 
199 
163 
108 
ristics of a relatively mild hyperaldosteronism. The presence of an 
adrenal adenoma was excluded by the absence of an asymmetrical 
adrenal uptake of the isotope on the scintigrams performed after 2 
weeks of treatment with dexamethasone. In patient 12, who died after 
a cerebrovascular accident complicated by a myocardial infarction, the 
diagnosis of IHA was histologically confirmed by postmortem exami­
nation. 
V.3.2. Protocol 
Antihypertensive treatment was discontinued for at least 2 weeks 
before the start of the study. Studies were carried out in a metabolic 
ward after an equilibration period of 3 days. The patients used a salt-
restricted diet containing 10 meq sodium and 50-70 meq potassium per 
day. Sodium chloride (6 g/day) was added to the diet in weighed 
capsules. None of the patients used supplementary potassium. The 
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study period lasted for 5 days. At 23.00 hr on the day before the first 
day of the study, a nonthrombogenic catheter was inserted into an 
antecubital vein, through which a 5 % glucose infusion was started. At 
04.45 hr on the first day of the study, the catheter was connected to a 
withdrawal pump and a fraction collector. Twelve integrated blood 
samples of 11 cc/15 min were automatically collected from 04.45 hr -
07.45 hr. Special attention was paid so as not to disturb the patients' 
sleep. Blood samples were centrifuged immediately after completion of 
a 15-min collection period and were kept frozen at -20oC until 
determination of PA and PC. Subsequently, casual blood samples were 
drawn on day 1 at 12.00, 16.00 and 20.00 hr while patients were 
ambulatory from 08.00 to 22.00 hr, and on day 2 at 12.00, 16.00 and 
20.00 hr, on which day the patients remained supine for 24 hr. 
Dexamethasone (0.5 mg four times a day) was administered on days 3, 
4 and 5. The protocol for blood sampling, as described above, was 
repeated on days 4 and 5, starting with the integrated nocturnal blood 
sampling on day 4 at 04.45 hr. 
PA was measured by RIA using a chromatographical purification step 
and antiserum generated in sheep against aldosterone-21-monohemi-
succinate-bovine serum albumin (Man de et al. 1980). In eight normal 
individuals, mean PA values during the night, as assessed by integrated 
blood sampling, ranged from 1.0-13.4 ng/100 ml. PC was measured by 
RIA, according to the method described by Vecsei (1974). PRA was 
measured by RIA, as described earlier (Drayer et al. 1975). 
Results are presented as the mean ± SEM. Student's t tests for paired 
and nonpaired data were employed for comparison of data within or 
between groups of patients. Calculation of the correlation coefficient 
according to Pearson was used for regression analysis. For calculation 
of the correlation coefficients between hormones, normalized values 
were used to eliminate the disparity of ranges in hormone concentra-
tions among the individual patients. 
V.4. RESULTS 
V.4.1. Effects of dexamethasone on nocturnal PA in APA and ¡HA 
patients (figure V-l) 
The mean of the 12 PA values obtained in each patient by integrated 
blood sampling during the night ranged from 19.6 ± 1.0 to 65.0 ± 
1.6 ng/100 ml in APA patients and from 7.6 ± 0.5 to 13.5 ± 1.5 ng/ 
100 ml in IHA patients. The mean nocturnal PA level of all patients 
with APA was significantly higher than that of all patients with IHA. 
During dexamethasone treatment, the mean of the 12 nocturnal PA 
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values in patients with APA ranged from 7 9 ± 0 5 t o 3 0 5 ± 2 5 n g / 
100 ml, and in patients with IHA, it ranged from 1 4 ± 0 1 to 10 4 ± 
1 2 ng/100 ml Dexamethasone induced a fall in nocturnal PA values in 
7 of 8 patients with APA and in 3 of 4 patients with IHA The mean 
nocturnal PA levels were significantly lower during dexamethasone 
than before treatment, both in patients with APA as well as in those 
with IHA Mean nocturnal PA values after dexamethasone treatment 
were still significantly higher in APA than in IHA patients 
V 4 2 Effects of dexamethasone on daytime PA in APA and IHA 
patients (figure V-l) 
No differences in PA values were found during upright posture (day 1) 
between patients with APA and IHA However, during the supine 
posture, PA values were significantly higher in patients with APA than 
in those with IHA Treatment with dexamethasone did not significantly 
reduce the upngth daytime PA values in patients with APA or IHA 
However, during the supine posture, dexamethasone treatment redu-
ced the daytime PA values in patients with APA but not in those with 
IHA 
V 4 3 Effect of upright posture on PA before and during dexametha-
sone m APA and IHA patients (figure V-l) 
No significant difference was found between upright and supine day-
time PA values before (27 4 ± 4 1 vs 25 7 ± 3 3 ng/100 ml, p=n s ) 
and during dexamethasone treatment (22 5 ± 3 0 v s l 7 4 ± 2 6 ng/100 
ml, p=ns) in patients with APA However, in patients with IHA, 
upright and supine daytime PA values differed significantly both before 
(23 2 ± 3 9 vs 13 3 ± 13 ng/100 ml, p<0 01) and during dexame-
thasone treatment (24 9 ± 5 7 vs 13 2 ± 1 9 ng/100 ml, p<0 02) 
In patients with APA, 12 00 hr upright PA values, after 4 hr of 
ambulation, were not significantly different from mean nocturnal PA 
values (36 7 ± 7 4 vs 43 4 ± 17 ng/KX) ml, p=n s ) However, after 
dexamethasone treatment PA rose significantly after 4 hr of ambula-
tion, from 18 5 ± 1 0 to 30 6 ± 5 8 ng/H)0 ml (p<0 05) In all four 
patients with IHA, 12 00 hr upright PA values were markedly higher 
than the mean nocturnal PA values before (27 9 ± 7 9 vs 10 9 ± 0 6 
ng/100 ml) and during dexamethasone treatment (31 1 ± 11 0 vs 5 9 
± 0 6 ng/100 ml) 
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Figure V-I. Comparisons of PA values during the night (N), in the 
daytime during upright posture (DU), and in the daytime during supine 
position (DS) in eight patients with APA and four patients with IH A 
before and during dexamethasone treatment 
V.4.4. PRA in APA and IHA patients 
Ambulatory PRA values obtained by casual blood sampling at 12.00 
hr, 16.00 hr and 20.00 hr did not differ significantly from supine PRA 
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values in APA patients (33 ± 5 vs 35 ± 5 ng/10 ml/3 hr; p=n.s.). 
However, in patients with IHA, ambulatory PRA values were signifi­
cantly higher than supine values (64 ± 10 vs 45 ± 7 ng/10 т1-3 hr; 
p<0.01). 
Dexamethasone treatment did not result in a significant change in 
ambulatory or supine PRA values in patients with APA (38 ± 5 vs 39 
± 6 ng/10 ml/3 hr; p=n.s.) or IHA (76 ± 15 vs 50 ± 9 ng/10 ml/3 hr; 
p=n.s.) 
A significant correlation between the normalized daytime values of PA 
and PRA (days 1 and 2) was found both in patients with APA 
(r=0.31; n=48; p<0.05) and in patients with IHA (r=0.43; 
n=24; p<0.05). However, during treatment with dexamethasone, 
the normalized values of daytime PA and PRA (days 4 and 5) no longer 
showed a significant correlation in patients with АРА (r=0.01; 
n=48; p=n.s.), whereas in patients with IHA, the correlation 
between PA and PRA reached a higher level of statistical significance 
than under basal circumstances (r=0.78; n=24; p<0.001). 
V.4.5. PC in APA and IHA patients 
PC levels during the night, obtained by integrated blood sampling, 
were similar in pafients with APA and IHA (12.7 ± 0.5 vs 11.3 ± 
0.5 μ£/1()0 ml; p=n.s.) . In addition, plasma daytime Cortisol values 
(days 1 and 2) did not differ significantly in the two groups (7.3 ± 0.5 
vs 7.8 ± 0.8 μg/100 ml; p=n.s.). 
During the night, the normalized values of PC and PA were signifi­
cantly correlated both in patients with APA (r=0.35; n=93; 
p<0.001) and in those with IHA (r=0.52; n=45; p<0.001). 
However, in the individual patients, the correlation of normalized PA 
and PC values showed a wide variation, ranging from r=0.12 
(n=12) to r=0.77 ( n = l l ) in APA patients and from r=-0.22 
( n = l l ) to r=0.78 (n=12) in IHA patients. In fact, four of eight 
patients with APA and one of four patients with IHA showed no 
significant correlation between the two nocturnal hormone levels. 
During the daytime (days 1 and 2), the normalized PA and PC values 
were significantly correlated in patients with APA (r=0.32; n=48; 
p<0.05), but not in patients with IHA (r=0.31; n=24; p=n.s.). 
In all patients studied, dexamethasone treatment resulted in PC levels 
lower than 3.6 μg/100 ml, indicating normal suppressibility of this 
hormone. 
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V.5. DISCUSSION 
In this study it was found that PA levels during the late hours of the 
night, as assessed by integrated blood sampling, were markedly lower 
in the group of patients with IHA than in those with APA. 
ACTH activity during the late hours of the night, as derived from the 
levels of PC, did not differ significantly between the two groups of 
patients and, therefore, cannot account for the observed differences in 
the levels of nocturnal PA. On the other hand, the short time fluctua-
tions of PA during the late hours of the night seemed to be influenced 
by ACTH equally in both groups of patients, as is apparent from the 
significant correlations between the normalized values of PA and PC. 
In addition, in both groups of patients, the mean nocturnal PA levels 
showed a similar percent decrease after treatment with dexametha-
sone, whereas PC decreased adequately in all patients to values found 
in subjects with normal ACTH suppressibility. Therefore, we conclude 
that PA production during the night is under the control of ACTH in 
both groups of patients, and that the ACTH control occurs at different 
levels of adrenal aldosterone production. These data are in accordance 
with the data of Kern et al. (1978), who found that patients with APA 
and IHA are uniformly hyperresponsive to the administration of 
physiological doses of ACTH. It has to be emphasized that in our 
study, nocturnal PA and PC did not correlate significantly in four of 
eight patients with APA and in one of four patients with IHA. 
Therefore, within the groups of patients with primary aldosteronism, 
the individual degree of ACTH-dependent aldosterone production 
may show a rather wide variation, as was reported earlier by Wenting 
et al. (1978). 
The nocturnal PA level measured in patients with APA was invariably 
higher than that in patients with IHA in our study. In the study of Kern 
et al. (1976) nocturnal PA levels in two of three patients with IHA were 
in the same range as those found in four patients with APA, and only 
one patient with IHA showed markedly lower PA values averaging 10 
ng/100 ml. In the study of Vetter et al. (1978) three of eight patients 
with IHA had low nocturnal PA values, not exceeding 20 ng/100 ml 
during the period of study. In three of the five patients with IHA 
reported by Schambelan et al. (1976), PA values at 04.00 hr were 
consistently lower than the 04.00 hr values found in six patients with 
APA. Therefore, it seems reasonable to conclude that patients with 
IHA are not a homogenous group with respect to the levels of 
nocturnal PA. A subgroup of patients with IHA is apparent in which 
nocturnal PA values arc markedly lower than those in patients with 
APA. 
In contrast to the marked differences in PA levels during the night, the 
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daytime PA values during ambulation were similar in both groups 
During supine posture (day 2), PA values in APA patients were slightly 
higher than those in IHA patients It is well known that patients with 
IHA, compared to patients with APA, usually demonstrate a relatively 
mild form of hyperaldosteronism (Fernss et al 1978) Yet, the two 
groups cannot be separated on the basis of their 24 hr aldosterone 
secretion rates because of a considerable overlap, as was also found in 
this study The finding of low nocturnal PA values may be helpful, at 
least in some patients, to differentiate between patients with APA and 
IHA 
In accordance with earlier studies (Cam et al 1972, Ganguly et al 
1973, Kern et al 1973, Schambelan et al 1976, Biglien et al 1974), the 
daytime PA values (days 1 and 2) in patients with APA were, regard­
less of the stimulus of upright posture, primarily under the control of 
ACTH, demonstrating л diurnal pattern significantly correlated to the 
diurnal pattern of PC Although PRA in these patients was markedly 
suppressed, a significant correlation was also calculated between the 
normalized PA and PRA daytime values (days 1 and 2) However, it is 
unlikely that PRA contributed to the fall of PA, since PA was not 
significantly correlated to PRA during dexamethasone treatment (days 
4 and 5) In contrast, the daytime PA values in patients with IHA were 
primarily under the control of the renin-angiotensin system, PA values 
rose significantly in response to upright posture, PA and PC were not 
significantly correlated, and, finally, the positive and significant corre­
lation between PA and PRA values before dexamethasone treatment 
(days 1 and 2) reached an even higher level of siginificance during 
dexamethasone treatment (days 4 and 5) 
In patients with IHA, treatment with dexamethasone did not reduce 
the daytime PA values during ambulation or while in the supine 
position The rise of PA in response to upright posture remained 
unaltered during dexamethasone treatment In patients with APA, 
upright and supine basal PA values did not differ significantly Howe­
ver, during dexamethasone treatment, supine PA values were signifi­
cantly reduced, while upright PA values remained essentially unchan­
ged In addition, a significant rise of PA during dexamethasone treat­
ment was observed after 4 hr of ambulation on the morning of day 4, 
contrary to the well known absence of such a postural rise before 
dexamethasone administration In previous reports, the postural chan­
ges in PA during dexamethasone in patients with primary aldostero­
nism have not been studied in detail According to Ganguly et al 
(1977), the postural decrease of PA after ambulation in the morning 
remained unchanged on the first 2 days of dexamethasone treatment in 
six patients with APA In the study of Schambelan et al (1976), two 
patients with APA did not show a postural rise, while one patient with 
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APA had marked postural increase of PA during dexamethasone 
treatment. This rise of PA in response to upright posture apparently 
was not mediated by the renin-angiotensin system, since PRA values 
throughout the day were low and unresponsive to change of posture, 
both before and during dexamethasone treatment. Although the meta-
bolic clearance rate (MCR) of aldosterone was not measured, we 
believe that a decrease of MCR, as has been described during dexame-
thasone treatment (Zager et al. 1976), might be responsible for the 
observed postural increase of PA in patients with APA. 
In recent years, numerous investigators have tried to unravel the 
complex interplay of factors known to regulate aldosterone in normal 
man and patients with aldosteronism. The present study indicates that 
attention to circadian factors and posture as well as to subtle differen-
ces in sensitivity of the zona glomerulosa to ACTH and angiotensin 
might lead to a more complete knowledge of aldosterone physiology 
and pathophysiology, such as in classical APA and IHA. 
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VI 1 ABSTRACT 
Dexamethasone-modified adrenal scintigrams were performed on 13 
patients with an aldosterone-producing adenoma and on one patient 
with an aldosterone-producing carcinoma Adrenal scintigrams using 
niI-19-Iodocholesterol were obtained after short pre-treatment with 
dexamethasone, while niI-6ß-Iodomethyl-19-Nor-Cholesterol scinti-
grams were performed after long-term pre-treatment with dexametha-
sone during 9-21 days Using the former procedure the adrenal scinti-
grams correctly identified the adenoma in 3 of 8 patients, while with the 
latter procedure the adrenal scintigrams localized the adenomas in 8 
out of 9 patients, including 3 patients in whom the former procedure 
had failed The adrenal carcinoma was not visualized with Π11-6β-
Iodomethyl-19-Nor-Cholesterol Thus, the sensitivity of niI-19-Iodo-
cholesterol scintigrams to detect aldosterone-producing adenomas was 
only 37 5 % Uptake of radioactivity in the normal contralateral adre­
nal gland accounted for the low detection rate On the other hand, the 
nil-6ß-Iodomethyl-19-Nor-Cholesterol scintigrams, performed after 
long-term pre-treatment with dexamethasone, had a sensitivity of 
89 % It is suggested that long-term pre-treatment with dexamethasone 
contributed to the improved sensitivity by a more effective suppression 
of radioactivity uptake in the normal adrenal gland 
Nebenmerenszintigraphie bei primaren Aldosteronismus 
Nebennierenszintigraphien wurden bei 13 Patienten mit primärem 
Aldosteronismus und chirurgisch nachgewiesenen Adenomen und bei 
einer Patientin mit einem Aldosteronproduzierenden Karzinom durch-
geführt Bei Verwendung von n'l-19-Iodocholesterol nach kurzfristi-
ger Vorbehandlung mit Dexamethason wurden nur bei 3 der 8 
Patienten die Adenome korrekt diagnostiziert Bei Verwendung des 
neueren Präparats 6ß-n'l-Iodomethyl-19-Nor-Cholesterol und langfris-
tiger (9 bis 21 Tage) Vorbehandlung mit Dexamethason wurden 8 von 
9 Adenomen richtig lokalisiert, darunter 3, die mit der alteren Technik 
nicht gefunden wurden Bei der Patientin mit einem primaren Aldoste-
ronismus infolge eines Karzinoms, konnte der Nebennierennndentu-
mor nicht abgebildet werden Kurzfristige Vorbehandlung mit Dexa-
methason und die Applikation von n'l-19-Iodocholebterol genügen 
nicht fur die Lokahsation von Aldosteronproduzierenden Adenomen 
Mit dem neueren 6ß-Derivat des Cholestérols können nach einer ein-
bis dreiwöchigen Vorbehandlung mit Dexamethason die Adenome in 
einem hohen Prozentsatz der Falle richtig lokalisiert werden, da die 
langzeitige Vorbehandlung mit Dexamethason anscheinend die Radio-
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activitatsaufnahme durch die normale Nebenniere stärker unterdrückt. 
VI.2. INTRODUCTION 
Since the introduction of ' ' 'l-l^Iodocholesterol in 1971 as a radio-
pharmaceutical suitable for imaging the human adrenal glands 
(Beierwaltes et al. 1971), its usefulness in the diagnosis of a variety of 
functional and structural disorders of the adrenals has now been well 
established in the literature (Barliev 1979, Chatal et al. 1976, Forman et 
al. 1974, Hoefnagels et al. 1976, Hogan et al. 1976, Lieberman et al. 
1971, Moses et al. 1974, Seabold et al. 1976). The development of the 
radiopharmaceutical niI-6ß-Iodomethyl-19-Nor-Cholesterol in 1975 
(Basmadjian et al. 1975, Kojima et al. 1975) has further contributed to 
the improvement of the quality of adrenal visualization. The higher 
adrenal uptake of this radiopharmaceutical and the more favourable 
target-to-background ratio account for more optimal adrenal imaging. 
In primary aldosteronism, adrenal imaging is a reliable method to 
localize aldosterone-producing adenomas (Conn et al. 1971, Conn et 
al. 1972, Freitas et al. 1979, Hogan et al. 1976). In addition, pre-
treatment with dexamethasone not only enhances the asymmetrical 
adrenal uptake by suppression of the normal adrenal gland, but also 
facilitates the differential diagnosis between adenomatous hyperaldos-
tcronism and idiopathic aldosteronism due to bilateral (micro- and 
macronodular) hyperplasia (Conn et al. 1976, Sarkar et al. 1977, 
Seabold et al. 1976). In the period from 1972 to 1979, radiocholesterol 
scintigrams were performed in our Institute, on 13 patients with 
aldosterone-producing adenomas and on one patient with an aldoste-
rone-producing carcinoma. Preliminary results in four patients were 
reported earlier (Hoefnagels et al. 1976). The present study reports on 
additional experiences with ' ' 'l-^-Iodocholesterol in primary aldoste-
ronism and presents the results of adrenal imaging with the newer 
radiopharmaceutical mI-6ß-Iodomethyl-19-Nor-Cholesterol in pa-
tients with adenomatous hyperaldosteronism. Special attention was 
paid to the value of long-term pre-treatment with dexamethasone for 
the better recognition of aldosterone-producing adenomas. 
VI.3. PATIENTS 
Table VI-1 presents the clinical and biochemical characteristics of the 
patients included in this study. All patients had hypertension, hypoka-
lemia, suppressed plasma renin activity after 5 days of salt restriction 
and an elevated aldosterone secretory rate after 5 days sodium loading. 
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Table Vl-1. 
Clinical and biochemical data in 14 patients with primary aldosteronism 
patient 
no 
1. 
2.a 
b* 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
sex 
F 
F 
F 
F 
F 
F 
F 
M 
F 
F 
F 
F 
F 
F 
age 
35 
17 
55 
49 
46 
46 
58 
37 
33 
55 
48 
58 
45 
49 
blood pressure 
(mmHg) 
185/120 
195/125 
195/120 
165/105 
210/125 
200/120 
175/110 
185/105 
200/125 
175/115 
240/140 
185/120 
210/125 
205/117 
155/100 
plasma К" 
(mmol/1) 
2.7 
2.0 
2.8 
1.9 
2.7 
2.9 
3.2 
1.9 
2.9 
3.0 
2.0 
3.2 
3.0 
3.0 
1.9 
PR А " 
(ng/lO ml/3hr) 
21 
44 
25 
25 
53 
20 
29 
63 
53 
38 
66 
26 
44 
43 
6 
ASR*** 
(μ6/24ΗΓ) 
555 
455 
315 
1721 
981 
266 
793 
1079 
666 
459 
253 
387 
215 
244 
683 
* After removal of the right adrenal gland 
** Plasma renin activity on the 5th day of a 15 mmol sodium diet (Normal values: 115-
595) 
*** Aldosterone secretion rate on the 5th day of a 315 mmol sodium diet (Normal 
values: 55±17) 
In patients 1-13 the diagnosis aldosterone-producing adenoma was 
confirmed by histologic examination of the surgically removed adrenal 
gland and by the decrease of urinary aldosterone excretion to subnor­
mal values immediately after operation. Patient 14 had a recurrence of 
the syndrome of primary aldosteronism. 12 years after removal of a 
benign aldosterone-producing adenoma of the right adrenal gland. At 
operation a carcinoma, subcapsularly located at the upper pole of the 
right kidney, was removed. Postoperatively aldosterone excretion and 
blood pressure normalized. In patient 2, the initially removed right 
adrenal gland was found normal at histologic examination. Post-opera-
tively blood pressure and aldosterone secretion remained elevated. 
One year later, after removal of a classical adenoma from the left 
adrenal gland, blood pressure and aldosterone excretion returned to 
normal. 
Patients did not receive the aldosterone antagonist spironolactone 
during the study because of the known interference of this drug with 
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the biosynthesis of aldosterone (Hoefnagels et al. 1980). Spironolac-
tone was withdrawn at least 4 weeks before the administration of the 
radiopharmaceutical. If necessary, spironolactone medication was 
replaced by amiloride 20 mg/day combined with chlorthalidone 100 mg/ 
day. 
VI.4. MATERIALS AND METHODS 
The radiopharmaceutical '^'l-lfModocholesterol* and n 'l-6ß-Iodome-
thyl-19-Nor-Cholesterol** were obtained commercially. Each new 
batch was controlled for radiochemical purity by paper chromato-
graphy. niI-19-IodochoIesterol was administered intravenously in a 
dose of 1-2 mCi and n'l-6ß-Iodomethyl-19-Nor-Cholesterol in doses 
varying from 0.6-2.0 mCi. Thyroid uptake was blocked by either 
Lugol's iodide 3 drops a day, starting 3 days before administration of 
the tracer or by potassium Perchlorate 200 mg q.i.d., starting the day 
before radiocholesterol was administered. Thyroid blocking was conti-
nued till completion of the study. Adrenal scintigrams were obtained 
by a Picker ΙΓ gamma camera, with an on line PDP-8 computer for data 
processing. Scintiphotos were made daily between the 2nd and the 9th 
day after injection of the tracer. With both radiopharmaceuticals, 
optimal imaging was obtained from the 5th to the 9th day p.i. All 
scintigraphic investigations were performed during dexamethasone 
suppression. Dexamethasone was given in a dose of 2-4 mg/day, 
starting 1 to 8 days before administration of the tracer and continued 
during the examination period. However, when niI-6ß-Iodomethyl-19-
Nor-Cholesterol was used, dexamethasone 2 mg/day was given 9-21 
days before the tracer injection. Because of the higher adrenal uptake 
of this radiopharmaceutical compared to ' ' 'l-^-Iodocholesterol, we 
deliberately opted for a longer dexamethasone suppression to prevent 
adrenal uptake in the normal adrenal glands. 
VI.5. RESULTS 
Patients 1-4 were examined using mI-19-Iodocholesterol, whereas 
patients 9-13 received the newer agent l3'l-6ß-Iodomethyl-19-Nor-
Cholcsterol. In patients 5-8 both radiopharmaceuticals were used with 
an interval of at least one year. The results are presented in tables 
VI-2 and VI-3 and in figures VI-1 and VI-2 In patients 1, 3 and 4, the 
* (Sonn. Sdluggia. Italy) 
** (Byk Malinckrodt. Dictzcnbach-Steinburg. Germany) 
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Table Vl-2. 
Results of adrenal scintigraphy with 1311-19-Iodocholesterol in 8 patients 
with primary aldosteronism, performed after a short pretreatment with 
dexamethasone 
patient 
1. 
2.8 
b " 
3. 
4 a 
b 
5. 
6. 
7. 
8. 
• _ _ 
" SCI in 
dexamethasone 
dose djys of therapy 
1 
4 mg 
4 mg 
4 mg 
4 mg 
4 mg 
4 mg 
4 mg 
2 mg 
2 mg 
4 mg 
Tcforc tracer 
ІП|ССІІОІ1 
3 days 
2 days 
2 days 
8 days 
2 days 
3 days 
1 day 
1 day 
6 days 
3 days 
no visualization + = 
igraph) pc irformed afti 
thyroid blockade '^ 
lugol 3 dd 1 git 
lugol 3 dd 1 git 
KClOj 4 dd 200 mg 
lugol 3 dd 1 gtt 
lugol 3 dd 1 gtt 
lugol 3 dd 1 gtt 
lugol 3 dd 1 gtt 
KC104 4 dd 200 mg 
KClOj 4 dd 2(X) mg 
KC104 4 dd 200 mg 
discernible visualization + + 
:r right adrenalcclom) 
l-19-lodocholcsterol 
dose (ι V ) 
2 1 mCi 
1.9 mCi 
2.0 mCi 
2 0mCi 
2 0 mCi 
15 mCi 
l O m C i 
2.0 mCi 
2 0mCi 
2 0 mCi 
scintigram' 
left 
-
-
-
+ + 
+ + 
+ + 
+ + 
+ 
+ + 
-
= unequivocal visualization 
right 
+ + 
+ + 
+ 
+ 
-
+ + 
+ + 
+ + 
-
pathology 
adenoma 2 cm R 
normal adrenal R 
adenoma 1 5 cm L 
adenoma 2 cm L 
adenoma 1 cm L 
see table Vl-3 
see table Vl-3 
see table Vl-3 
see table VI-3 
Table Vl-3. 
Results of adrenal scintigraphy with n,I-6ß-lodomethyl-19-Nor-Choles-
terol, performed after long-term pretreatment with dexamethasone in 10 
patients with primary aldosteronism 
patient 
no 
5 
6. 
7. 
8. 
9. 
10 
11. 
12 
13 
14 
dexamethasone 
do»· 
2 mg 
2 mg 
2 mg 
2 mg 
2 mg 
2 mg 
2 mg 
2 mg 
2 mg 
2 mg 
davs o í Ihcrapv 
bcfori. IrdCcr 
injCLlllin 
14 days 
9 days 
13 davs 
15 days 
21 davs 
14 days 
21 days 
14 days 
14 days 
21 days 
' For legends sec table Vl-2 
thyroid blockade 
KCIOj 4 dd 200 mg 
KCIOj 4 dd 200 mg 
KCIOj 4 dd 200 mg 
КСЮ4 4 dd 200 mg 
KCIOj 4 dd 2(K) mg 
KCIOj 4 dd 200 mg 
KC104 4 dd 200 mg 
KCIOj 4 dd 200 mg 
KCIOj 4 dd 200 mg 
KCIOj 4 dd 200 mg 
"'l-ulModomethyl-
19-Nor-Cholestcrol 
dose 
1 9 mCi 
1 7 mCi 
1.8 mCi 
1 6mCi 
17mCi 
0 6 mCi 
1 9mCi 
2 0 mCi 
2.1 mCi 
1.9 mCi 
scintigram* 
left 
+ + 
-
+ + 
-
+ + 
-
+ + 
-
-
± 
nghl 
+ 
+ + 
+ 
_ 
-
+ + 
-
+ + 
+ + 
+ 
pathology 
adenoma 1 5 cm L 
adenoma 1 3 cm R 
adenoma 2 0 cm L 
adenoma 1 5 cm L 
adenoma 1 4 cm L 
adenoma 1 0 cm R 
adenoma 1 8 cm L 
adenoma 2 5 cm R 
adenoma 1 9 cm R 
carcinoma 3 cm R 
'•"I-IQ-Iodocholesterol scans correctly identified the adrenal adenoma. 
In patient 2, the right adrenal gland was surgically removed because of 
an increase of radioactivity in the right adrenal gland, with complete 
suppression of the left adrenal gland. The radioactivity uptake of the 
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Figure Vl-l. Adrenal scintigrams in patients 5 and 7, performed with 
ml-19-lodocholesterol after short pretreatment with dexamethasone 
show an equal uptake of activity in both adrenal glands (5A and 7A). 
The scintigrams of the same patients using iMl-ófì-lodomethyl-W-Nor-
Cholesterol and long-term pretreatment with dexamethasone show a 
marked asymmetrical uptake with a clear visualization of the adenoma-
harboring gland and an almost complete suppression of the normal 
gland (5B and 7B) 
9B WS 12B 
Figure VI-2. Adrenal scintigrams in patients 9, 10 and 12 performed 
with {Ml-6ß-Iodomethyl-19-Nor-Cholesterol after long-term pretreat-
ment with dexamethasone (9B, 108, 128). In patient 10 the adrenal 
scintiscan is superimposed on a renal scintigram performed with WmTc-
ironascorbate. Accumulation of activity, corresponding to the site of the 
tumor, is found in the left (98), the right (108) and the right (128) 
adrenal gland. The normal contralateral glands are completely sup-
pressed 
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removed gland measured on the 16th day after administration of the 
radiopharmaceutical, was about 1 цСі, after correction for decay. 
Histologic examination of the adrenal tissue did not reveal an adreno­
cortical adenoma, nor adrenocortical hyperplasia. After operation, 
signs and symptoms of hyperaldosteronism persisted (table VI-1). 
After one year the adrenal suppression scan with n'l-19-Iodocholeste-
rol was repeated and did not show any uptake of radioactivity in the 
remaining left adrenal gland. However, at operation, a 1.5 cm adenoma 
was removed, with subsequent post-operative normalization of blood 
pressure and aldosterone excretion. In patient 4, the scintigrams sho­
wed asymmetrical uptake during the first investigation. Because the 
result was considered inconclusive, adrenal scintigraphy with П1І-19-
lodocholesterol was repeated after one year. At this time the adrenal 
scintiscans identified unequivocally an adenoma of 1 cm in the left 
adrenal gland while the right adrenal gland was completely suppressed. 
In patients 5, 6 and 7 the '^I-lÇ-Iodocholesterol scans showed a 
bilateral adrenal uptake without definite asymmetrical distribution of 
the tracer. These patients were suspected to have a bilateral adrenal 
hyperplasia. For this reason surgical exploration was not performed. 
However, adrenal scintiscans in these patients were repeated after the 
radiopharmaceutical "lI-6ß-Iodomethyl-19-Nor-Cholesterol became 
available. The scintigrams with the newer radiocholesterol showed a 
clear lateralization of the radioactivity and the presence of an adrenal 
adenoma at the suspected side was confirmed by operation. In patient 
8, no accumulation of radioactivity over the adrenal regions was found 
both after niI-19-Iodocholesterol scintigraphy and after niI-6ß-Iodome-
thyl-19-Nor-Cholesterol scintigraphy. 
In the patients 9-12, the niI-6ß-Iodomethyl-19-Nor-Cholesterol scans 
showed accumulation of radioactivity at the site of the adenoma with 
almost complete suppression of the normal gland. In patient 14, the 
adrenal scintigrams showed poor concentration of the radioactivity 
over both adrenal regions. At operation, a 3 cm adrenocortical carci-
noma, located subcapsularly at the upper pole of the right kidney, was 
removed. 
VI.6. DISCUSSION 
Adrenal scintigraphy with niI-6ß-Iodomethyl-19-Nor-Cholesterol 
during long-term dexamethasone suppression correctly identified an 
aldosterone-producing adenoma in 8 out of 9 patients (89%). In 
contrast niI-19-Iodocholesterol scintigraphy during short-term dexa-
methasone suppression, demonstrated the adenoma correctly in only 3 
out of 8 patients (37.5%). We suggest that the short-term dexametha-
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soné suppression and not the radiopharmaceutical 131I-19-Iodocholes-
terol itself accounts for the rather poor results with this scanning agent. 
In patients 5, 6 and 7, '""l-19-Iodocholesterol scintiscans during short-
term dexamethasone treatment, showed a bilateral, almost symmetrical 
uptake. Based on these findings these patients were suspected to have a 
bilateral adrenal hyperplasia. Spurious interpretation of these adrenal 
scans was merely caused by substantial uptake of radioactivity in the 
normal adrenal gland, which was thought to be suppressed by dexame-
thasone treatment. Indeed, in patient 2 the right adrenal gland, visuali-
zed on a dexamethasone suppression scan with mI-19-Iodocholesterol, 
contained 1 цСі radioactivity (= 0.05% of the administered dose), 
although no adrenal pathology was found. Conn et al. reported that the 
normal adrenal gland, contralateral to the tumor, may escape from the 
suppressive action of dexamethasone, when scanning is delayed beyond 
6-7 days after administration of '-"I-IQ-Iodocholesterol. However, a 
marked asymmetric distribution of radioactivity usually persists to ± 
19 days p.i. In contrast, we found on the 6th and 8th day p.i. symmetric 
distribution of radioactivity in patients 5 and 7 (figure VI-1). The 
availability of the newer radiopharmaceutical l3'l-6ß-Iodomethyl-19-
Nor-Cholestcrol,. which has been reported to have a 5-fold higher 
adrenal uptake than mI-19-Iodocholesterol (Basmadjian et al. 1975, 
Kojima et al. 1975), prompted us to prepare patients with primary 
aldosteronism by a longer pre-treatment with dexamethasone, starting 
about 14 days before injection of the tracer. Long-term dexamethasone 
administration caused an almost complete suppression of the normal 
adrenal gland in all patients and did not prevent clear visualization of 
the adenomatous gland in 8 out of 9 patients. In patient 8 both 
radiopharmaceuticals failed to concentrate in the adrenal adenoma. On 
a previous adrenal scintigram, performed elsewhere without dexame-
thasone suppression, both adrenals were imaged with symmetrical 
distribution of the radioactivitity. Therefore, it is unlikely that the 
failure to visualize the adrenal adenoma in this patient was caused by 
dexamethasone treatment. Indeed, Seabold et al. (1976) found that 
treatment with dexamethasone did not influence the uptake of radioac-
tivity in the adenoma: the percentages of administered radioactivity per 
gramme of tissue in the adenomas, assayed post-operatively, were 
comparable in patients with and without dexamethasone treatment. 
In patient 14 the concentration of the radiopharmaceutical apparently 
was insufficient to visualize the aldostcrone-producing carcinoma. Fail-
ure to detect hormonal active adrenal carcinomas with radiocholesterol 
has been ascribed to the insufficient tracer uptake per gramme in tumor 
tissue (Moses et al. 1974). In contrast, metastatic adrenocortical tumors 
detected by radiocholesterol have been reported by several authors 
(Chatal et al. 1976, Forman et al. 1974, Sarkar et al. 1975). The results 
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of our experience reported in this paper lead us to the conclusion that 
n
'l-6ß-Iodomelhyl-19-Nor-Cholesterol adrenal scintigraphy is a relia-
ble non-invasive method for the correct localization of aldosterone-
producing adenomas. In the group of patients in whom n'l-19-Iodo-
cholesterol was used as scanning agent, the failure to detect an aldoste-
rone-producing adenoma in at least 3 patients was caused by accumula-
tion of radioactivity in the normal contralateral gland. A longer pre-
treatment period with dexamethasone (during 14-21 days) may result in 
a more effective suppression of the normal adrenal gland. Long-term 
dexamethasone treatment does not prevent an adequate visualization 
of the adenoma-harboring adrenal gland. 
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CHAPTER VII 
SPIRONOLACTONE AND AMILORIDE IN 
HYPERTENSIVE PATIENTS WITH AND WITHOUT 
ALDOSTERONE EXCESS 
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This chapter was published in "Clinical Pharmacology and Therapeu-
tics" 27: 317-323, 1980 
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VILI. ABSTRACT 
The antihypertensive action of spironolactone has been ascribed to 
both a nonspecific diuretic and a specific antimineralocorticoid effect. 
To better evaluate the relative importance of these effects, we compa-
red its effects with the mineralcorticoid-independent drug amiloride. 
Spironolactone (400 mg/day) and amiloride (40 mg/day) were given to 
10 patients with essential hypertension (EH) and to 10 patients with 
hypertension and supranormal aldosterone secretion (SNA). After 6 
wk, blood pressure responded better to spironolactone (-20.5%) 
than to amiloride (-10.4%) in patients with SNA, but the response 
was similar in patients with EH ( -7 .4% and —6.5%). The decrease 
in body weight - as a measure of volume depletion - was greater after 
spironolactone than after amiloride both in patients with SNA 
( - 4 . 6 % and - 0 . 8 % ) and in patients with EH ( -3 .7% and 
—0.6%). After both drugs, plasma sodium decreased ( -3 .4% and 
- 2 . 6 % ) and plasma potassium increased (+37.2% and +32.6%) to 
the same extent in patients with SNA, reflecting a similar degree of 
antimineralocorticoid - like activity. After spironolactone patients with 
SNA showed a greater rise in PRA than after amiloride (412% and 
82%). Despite the greater rise in PRA, the rise in aldosterone excre-
tion was in the same range after both drugs (113% and 195%), 
pointing to inappîopriately low aldosterone excretion after treatment 
with spironolactone. We conclude that differences in volume depletion 
or antimineralocorticoid-like activity cannot explain the better res-
ponse in blood pressure of patients with SNA after spironolactone than 
after amiloride. Our data provide evidence for a specific antialdoste-
rone effect of spironolactone in lowering the blood pressure, especially 
in patients with aldosterone excess. 
VII.2. INTRODUCTION 
Amiloride increases natriuresis and potassium resorption in the distal 
tubules of the kidney (Baer et al. 1967, Bull and Laragh 1968, Lant et 
al. 1969). Although its mode of action is independent of aldosterone, a 
marked fall in blood pressure was observed in a patient with hyperal-
dosteronism (Kremer et al. 1973a). This report was later confirmed, 
describing significant falls in blood pressure after treatment with amilo-
ride in 19 patients with hyperaldosteronism, as well as in 5 patients with 
suspected mineralocorticoid excess. The weak diuretic amiloride indu-
ced only a modest fall in blood pressure in patients with essential 
hypertension (Kremer et al. 1973b, Kremer et al. 1977). 
Spironolactone competes with aldosterone for the cytosol receptors in 
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the kidney and antagonizes the aldosterone-mediated sodium-potas-
sium exchange in the distal renal tubules (Kagawa et al. 1964). Spiro-
nolactone has a well-known blood pressure-lowering effect in patients 
with hyperaldosteronism, as well as in some patients with essential 
hypertension. Its action has been ascribed to a nonspecific diuretic 
effect (Bravo et al. 1973, Hoffbrand et al. 1976, Jose et al. 1970, Liebau 
and Jarosch-v. Schweder 1974) and to a specific antimineralocorticoid 
effect (Spark and Melby 1971). Spironolactone, or some of its metabo-
lites, has been shown to interfere with the biosynthesis of aldosterone 
by competition for the adrenal 11- and 18-hydroxylases (Cheng et al. 
1976). It is unclear whether the inhibition of aldosterone synthesis is 
related to the spironolactone induced fall in blood pressure (Laidlaw 
1977). An intrapatient comparison of the effects of the aldosterone-
independent diuretic amiloride and the aldosterone-dependent diuretic 
spironolactone might shed light on its specific antialdosterone action in 
relation to its blood pressure-lowering effect. In our study, amiloride 
and spironolactone were given in high doses to 10 patients with and 10 
patients without aldosterone excess. Special attention was paid to the 
disparate effects of both drugs on blood pressure and the renin-
angiotensin-aldosterone system. 
VII.3. PATIENTS AND METHODS 
Patients. For this study, 20 patients were selected from our outpatient 
clinic, including 10 patients with hypertension and supranormal aldos-
terone secretion after salt loading (Kloppenborg et al. 1972) and 10 
patients with essential hypertension and normal aldosterone values. 
The data of the patients are presented in table VII-1 All patients had a 
casual off-treatment, diastolic blood pressure of at least 95 mmHg. The 
blood pressure values given in the table were measured at the end of 
the placebo period by Arteriosonde. The measurements are known to 
be lower than casual blood pressure measurements (Drayer et al. 
1976). The diagnosis "supranormal aldosterone" was based on clinical 
and biochemical criteria: hypertension, spontaneous mild or frank 
hypokalemia (plasma potassium <3.8 mmole/1), low plasma renin 
activity (PRA) after stimulation with chlorthalidone 100 mg/day during 
5 days, (Drayer et al. 1975) and high aldosterone secretory rate (ASR) 
measured after dietary sodium loading with 315 mmole sodium per day 
during 5 days (Kloppenborg et al. 1972). Four of these patients had 
surgically proved adrenal adenomas (Nos. 1, 5, 6 and 8). The second 
group of 10 patients were considered to have essential hypertension, 
with no evidence of pheochromocytoma, renovascular disease, or renal 
impairment. They had low (n=4) or normal (n=6) stimulated PRA. 
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Table VU-1. 
Clinical and biochemical data in 10 patients with supranormal aldoste­
rone secretion and in 10 with essential hypertension 
parient age sex MAP* PRA** ASR*** plasma K' plasma 
no (yr) (mmHg) (pmole.hr '.ml ') (nmole/24 hr) (mmole/l) creatinine 
(μπιοΙε/Ι) 
HYPERTENSION AND SUPRANORMAL ALDOSTERONE 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
46 
44 
40 
48 
46 
58 
45 
36 
48 
53 
F 
F 
F 
F 
F 
F 
M 
M 
M 
M 
108 
131 
105 
117 
136 
124 
127 
131 
111 
121 
1.23; 
3.93 
2.25 
2.82 
0.60 
1.89 
2.73 
1.59 
0.90 
2.52 
196 
415 
551 
366 
737 
989 
548 
845 
460 
197 
2.6 
3.4 
3.5 
3.5 
2.2 
3.3 
3.3 
2.8 
3.8 
3.7 
68 
65 
60 
75 
61 
86 
93 
72 
70 
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ESSENTIAL HYPERTENSION 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
* 
+ + 
*** 
+ * * * 
35 
51 
40 
44 
40 
43 
23 
47 
41 
35 
F 
F 
M 
M 
F 
F 
F 
M 
M 
M 
108 
110 
НЮ 
117 
117 
107 
100 
112 
97 
104 
3.00**** 
1.68 
5.16 
1.65 
17.73 
23.25 
18.93 
8.28 
12.48 
9.09 
89 
166 
205 
249 
-
-
— 
-
-
— 
3.7 
4.4 
3.9 
3.9 
4.2 
3.9 
4.0 
3.7 
4.1 
4.3 
Measured with the arteriosonde after 6 wks placebo, normal value 
Measured after chlorthalidone, normal value 8.25-30.0 
Measured after sodium loading, normal 
Measured after a sodium restricted diet, 
value 152±47 
normal value 3.45-17.85 
65 
68 
74 
82 
69 
80 
50 
102 
82 
88 
64-102 
In the patients wiht low PRA, aldosterone excess was excluded by the 
presence of a normal ASR after 5 days sodium loading with 315 mmole 
sodium per day. In the other patients ASR was considered to be 
normal in view of normal PRA and normal potassium values. The 
aldosterone excretion measured at the end of the placebo period was 
normal in these patients. All patients were off antihypertensive treat­
ment for at least 4 wk before the experiment. During the first 6 wk they 
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were given spironolactone, 200 mg/day during the first 2 wk, and 400 
mg/day during the remaining 4 wk. A placebo period followed, lasting 6 
wk. Finally, amiloride was given for 6 wk, 20 mg/day in the first 2 wk, 
and 40 mg/day during the remaining 4 wk. The patients received tablets 
and capsules of identical appearance during the study in a dose of 4 
tablets and 4 capsules a day. The patients were seen on an outpatient 
basis at 2-wk intervals. Blood pressure was measured by Arteriosonde. 
The representative blood pressure was chosen to be the average of the 
mean arterial pressures calculated from the measurements obtained 
during 30 min recumbency at 5-min intervals. The patients were 
weighed and blood was taken for measurements of plasma electrolytes 
and plasma urea. At the end of each treatment period after 2-hr 
ambulation an additional blood sample was drawn at noon for measu-
rements of PRA and plasma electrolytes. The aldosterone excretion 
and sodium excretion were measured in urine collected during the last 
24 hr before the visit at the end of each treatment period. Excluding 
major changes in dietary sodium intake throughout the study, the 24-hr 
sodium excretions at the end of each study period were not significantly 
different (180 ± 20 mmole after spironolactone, 186 ± 17 mmole 
after placebo, and 210 ± 12 mmole after amiloride). 
Methods. Plasma electrolytes were measured by flame photometry with 
internal standard. The average of the 2 measurements obtained at the 
end of each treatment period was used for calculation. Plasma urea was 
measured by a standard laboratory procedure. PRA and aldosterone 
excretion and secretion were measured by radioimmunoassay (Drayer 
and Benraad 1975, de Man and Benraad 1977). The measurements at 
the end of each treatment period with an active drug were expressed as 
a percentage of the measurements at the end of the placebo period. For 
intrapatient comparison of the effects of the 2 drugs, the percentage 
changes after amiloride were subtracted from those after spironolac-
tone. Student's t test and Wilcoxon test for pair differences were 
employed for statistical analysis within groups of patients, and Stu-
dent's t test for nonpaired data was used for comparisons between 
groups. The data are presented as mean ± SEM. Regression analysis 
was performed by means of the Spearman rank test. 
VII.4. RESULTS 
Patients with supranormal aldosterone (n = 10; Figure VI1-1). Spirono-
lactone and amiloride treatment resulted in a decrease in blood 
pressure ( -20 .5% and -10.4%), rise in aldosterone excretion 
( + 113% and +195%), fall in plasma sodium (-3 .4% ± 0.8%and 
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SUPRANORMAL ALDOSTERONE ( n = 10) 
SPIRONOLACTONE AMILORIDE 
ΔΎο MAP 
- 5 -
- 1 0 -
- 1 5 -
- 2 0 -
Δ·0/0 BODY WEIGHT 
'»»#* 
Δ0/0 PR A 
2 
4 
6 0 0 -
4 0 0 -
2 0 0 ^ 
J 
'»»»» 
I * * 
Δ0/ο ALDOSTERONE EXCRETION 
3 0 0 т 
2 0 0 
1 0 0 4 
Δ0/οPLASMA POTASSIUM _. 
40-, JL 
3 0 -
2 0 
1 OH 
**» 
• n.s. 
Р^
П
·
5
· 
L. 
ι 
»*• 
n.s.= not significant 
• ρ < 0.02 
»• ρ < 0.01 
·*« ρ < 0.005 
»»** ρ < 0.001 
Figure Vll-l. Mean changes ± SEM in some clinical and biochemi­
cal variables after treatment with spironolactone and amiloride in 
patients with supranormal aldosterone secretion (n=10) 
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ESSENTIAL HYPERTENSION ( η = 10 ) 
SPIRONOLACTONE AMILORIDE 
Δ0/ο MAP 
- I C H 
Δο/
ο
ΒΟ0Υ WEIGHT 
Τ 
«« 
_ 4 J ^Ш«»»» 
Δ0/0 PR A 
8 0 0 n 
6 0 0 
4 0 0 
2 0 0 
i. 
A0/o ALDOSTERONE EXCRETION 
4 0 0 η 
3 0 0 -
2 0 0 -
1 0 0 
Δ0/ο PLASMA POTASSIUM 
2 0 -
10-
.n.s. 
n.s. = not significant 
« ρ < 0.02 
»» ρ < 0.01 
· * · ρ < 0.005 
*»*» ρ < 0.001 
'n.s. 
n.s. 
i 
· « · 
Figure VII-2. Mean changes ± SEM in some clinical and biochemi­
cal variables after treatment with spironolactone and amiloride in 
patients with essential hypertension (n=10) 
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- 2 . 6 % ± 0.7%), rise in plasma potassium (+37.2% and 
+32.6%), and plasma urea (+78.9% ± 7.6% and +22.8% ± 
7.4%). There were significant changes in body weight (-4.6%) and 
PRA (+412%) only after spironolactone. 
Patients with essential hypertension (n=10; Figure VII-2). The mean 
decreases in blood pressure after spironolactone and amiloride were 
small but significant ( - 7 . 4 % and —6.5%). Both drugs induced 
changes in aldosterone excretion (+363% and +273%) and plasma 
sodium ( - 2 . 9 % ± 0.5% and - 1 . 0 % ± 0.6%). Significant 
changes in body weight (-3.7%), PRA (+523%), and plasma urea 
(+32.7% ± 9.0%) were found only after spironolactone. Plasma 
potassium was not changed by spironolactone but was followed by a 
small and significant rise after amiloride ( + 8 . 0 % ) . 
Intrapatient comparison of the effects of spironlactone and amiloride 
(table VII-2). 
Patients with supranormal aldosterone. Spironolactone induced a grea­
ter fall in blood pressure and body weight and a greater rise in PRA 
and plasma urea. The increase in aldosterone excretion was much the 
same for both drugs, so also for plasma sodium and potassium. 
Patients with essential hypertension. The decreases in blood pressure 
induced by each drug were small and did not differ significantly. 
Table VII-2. 
Differences between the effects of spironolactone and amdoride in 
patients with supranormal aldosterone (n=I0) and in patients with 
essential hypertension (n=10) 
parameter 
Δ % MAP 
Δ % Body weight 
Δ % Aldosterone 
excretion 
Δ % PRA 
Δ % Sodium 
Δ % Potassium 
Δ % Urea 
supranormal aldosterone 
(spironolactone-amilonde) 
-10.1±1.6 p<0.001 
- 3.7±0.5 p<0.001 
- 8 1 ± 8 2 n.s. 
+329±165 p<0.01 
- 0.8±0.5 n.s. 
+ 4.6±4.5 n.s. 
+56.1±6.3 p<0.01 
essential hypertension 
(spironolactone-amilonde) 
- 0.9±1.9 n.s. 
- 3.1±0.8 p<0.005 
+ 152±116 n.s. 
+446±170 p<0.01 
- 1.9±0.6 p<0.02 
- 7.1±2.1 p<0.01 
+25.9±7.3 p<0.01 
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Spironolactone induced a greater decrease in body weight, a greater 
rise in PRA, and a greater rise in plasma urea, but, aldosterone 
excretion rose to the same extent after both treatments. Spironolactone 
induced a significant greater fall in plasma sodium, amiloride a greater 
increase in plasma potassium. 
All patients (n=20). The fall in blood pressure after treatment with 
spironolactone correlated with the PRA after stimulation with chlor-
thalidone ( r = - 0 . 6 1 , n=16; p<0.05) and with the ASR after so-
dium loading (r=-l-0.53, n=14; p<0.05). The increase in aldosterone 
excretion after spironolactone correlated inversely with the aldoste-
rone excretion measured at the end of the placebo period ( r=-0 .84 , 
p<0.001). The fall in blood pressure after amiloride did not correlate 
with stimulated PRA (r=0.18) or with the ASR after sodium loading 
(r=0.20). The changes in aldosterone excretion after amiloride were 
not related to placebo values (r=— 0.40). 
VII.5. DISCUSSION 
In patients with supranormal aldosterone (SNA), both spironolactone 
and amiloride induced a fall in blood pressure. They induced only a 
moderate fall in blood pressure in patients with essential hypertension 
(EH). Spironolactone induced more than 10% fall in MAP in all 
patients with SNA and in only 2 patients with EH. Amiloride induced a 
greater than 10% fall in blood pressure more frequently in patients 
with SNA (6 patients) than in patients with EH (2 patients). The mean 
fall in blood pressure was in the same range for both drugs in the 
patients with EH. The mean fall in blood pressure in the patients with 
SNA was greater after spironolactone than after amiloride. Possible 
reasons for the greater response of blood pressure after spironolactone 
in patients with SNA, include (1) differences in degree of volume 
depletion; (2) differences in antimineralocorticoid effects; (3) inhibi-
tion of aldosterone biosynthesis by spironolactone. In patients with 
SNA, spironolactone induced more volume depletion than amiloride. 
Similar differences in volume depletion were, however, found in 
patients with EH in the presence of comparable falls in blood pressure 
after both drugs. It therefore seems unlikely that spironolactone caused 
a more pronounced fall in blood pressure than amiloride in patients 
with SNA, only because of the greater volume depletion it induced. 
The drugs differ in sodium and potassium handling in the kidney. 
Spironolactone exerts an antimineralocorticoid effect by blocking the 
mineralocorticoid receptors in the tubular cells of the distal nephron. 
Amiloride does not have a specific antimineralocorticoid effect but 
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causes comparable changes in plasma electrolytes by blocking the 
sodium-potassium exchanges at the luminal side of the tubular cells of 
the distal nephron. 
Assuming a relationship between the antimineralocorticoid effect of 
spironolactone, as defined here, and the fall in blood pressure, one 
could argue that a better response of the blood pressure to this drug 
will be accompanied by greater changes in plasma electrolytes. We 
found that the plasma sodium and potassium change in patients with 
SNA were of the same order for both drugs. Marked differences were 
found in the response of the blood pressure, and therefore, the antimi-
neralocorticoid effect of spironolactone, indicated by changes in 
sodium and potassium, cannot explain the greater fall in blood pressure 
after spironolactone in patients with SNA. The difference in blood 
pressure response could imply that spironolactone, apart from its 
antimineralocorticoid effect on plasma electrolytes, induces an additio-
nal effect on blood pressure. 
Another factor in the greater blood pressure response after spironolac-
tone in patients with SNA might be the inhibitory effect of spironolac-
tone on the biosynthesis of aldosterone. This inhibitory effect was first 
demonstrated in vitro by Erbler (1972). It was also reported that 
spironolactone may interfere with biosynthesis of aldosterone in nor-
mal man (Abshagen et al. 1976 Erbler 1974, Erbler et al. 1976) and 
patients with hyperaldosternism (Bravo et al. 1975, Maniero et al. 
1973, Sundsfjord et al. 1974). Conn and Hinerman (1977) discerned 
two phases of the effects of spironolactone treatment on aldosterone 
excretion in patients with hyperaldosternism: phase I which lasted for 4 
to 6 wk, in which aldosterone excretion diminished (this was ascribed to 
the inhibitory effect of spironolactone on the biosynthesis of aldoste-
rone), and phase II, in which an increase in aldosterone excretion was 
observed. According to Conn and Hinerman the increase in aldoste-
rone excretion of 50 % to 100 % in phase II was most likely the result of 
prolonged stimulation by angiotensin II and the chronic state of sodium 
dejiciency. 
We found a marked rise in PRA and aldosterone after 6 wk treatment 
with spironolactone. Patients with SNA had a large rise in PRA and 
more marked signs of volume depletion after spironolactone than after 
amiloride. Despite the presence of stronger stimuli for aldosterone 
secretion after spironolactone, the increase in aldosterone excretion 
was of the same order after both drugs. These findings point to an 
inappropriately low aldosterone secretion after spironolactone. From 
the comparison of the effects of both drugs on aldosterone secretion, 
we tend to conclude that inhibition of aldosterone biosynthesis was 
present in patients with SNA after 6 wk on spironolactone and there-
fore resulted in greater blood pressure response. We also found 
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indirect evidence for inhibition of aldosterone biosynthesis by spirono-
lactone in patients with EH, biu the signs of inhibition of aldosterone 
secretion by spironolactone in this group of patients were less striking. 
Moreover, the difference in blood pressure response between spirono-
lactone and amiloride in patients with EH was not significant. In fact, 
the greatest inhibition of aldosterone biosynthesis and the greatest 
hypotensive effect of spironolactone was found in patients with supra-
normal aldosterone. 
The negative correlation between the aldosterone excretion at the end 
of the placebo period and the increase in aldosterone excretion after 
treatment with spironolactone in the whole group of patients, emphasi-
zes the greater aldosterone inhibition in patients with SNA. Such a 
correlation was not found after amiloride. The greater inhibition of 
aldosterone secretion in patients with SNA after treatment with spiro-
nolactone may account for the greater fall in blood pressure in these 
patients. It has been demonstrated (Weber et al. 1977) that in patients 
treated with chlorthalidone, blood pressure fell most in patients with 
the least increase in aldosterone during treatment. This relationship 
was independent of volume depletion. The authors postulated a direct 
pressor action of aldosterone to explain this phenomenon. Our data 
support this hypothesis. 
A significant positive correlation confirming earlier data (Benraad et 
al. 1978) was found in the whole group of patients between supranor-
mal aldosterone - ASR after sodium loading - and the blood pressure 
fall after spironolactone. Such a correlation was not found with amilo-
ride. 
We therefore conclude that our data provide indirect evidence for 
specific antialdosterone effects of spironolactone, enhancing the fall in 
blood pressure after treatment with spironolactone, especially in 
patients with supranormal aldosterone secretion. 
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CHAPTER Vili 
THE PATHOLOGICAL ANATOMY OF THE 
ADRENALS IN PATIENTS WITH PRIMARY 
ALDOSTERONISM 
VIII. 1. INTRODUCTION 
In 25 of the 28 patients with primary aldosteronism who are discussed 
in this thesis, the pathology of the adrenal tissue obtained by operation 
or autopsy could be studied. The findings of the anatomicopathologist 
in the individual patients are reported in the clinical histories that are 
discussed later on (see appendix). In this paragraph the macroscopic 
and microscopic findings are summarized, the following points being 
dealt with in particular: 
1. The macroscopic pathology of the adrenal tissue removed in rela-
tion to the functional pathology. In this connection we shall go into the 
question of whether there is a correlation between the size of the tumor 
and the rate of secretion of aldosterone. 
2. The microscopic pathology of the aldosterone-producing adrenal 
adenomas. Although adrenal adenomas are mostly built up of cells 
resembling those of the zona fasciculate, the histological architecture 
can be of a varied pattern. The cell types are classified and the findings 
are compared with the classical histopathological classification of 
Neville and Symington (1966). 
3. The microscopic pathology of the adrenal cortex lying outside the 
adrenal adenoma. As appears from the descriptions in individual 
clinical histories (see appendix), anomalies are frequently found in the 
adrenal cortex lying outside the adenoma. The anomalies in this part of 
the adrenal cortex may vary from a slight or an obvious widening of the 
zona glomerulosa to a micronodular or macronodular hyperplasia of 
the adrenal cortex. 
4. "Spironolactone bodies". Treatment with the aldosterone antago-
nist spironolactone causes in some patients the formation of cytoplas-
matic inclusions in aldosterone-producing cells, the so-called "spirono-
lactone bodies". The literature mentions as possible factors in the 
formation of "spironolactone bodies": the total quantity of spironolac-
tone used, the duration of the medication and the time interval 
between the medication and the operation. These factors will be 
examined. 
131 
5 Adrenal carcinoma and primar) aldosteronism The presence of an 
adrenal carcinoma with a selective overproduction of aldosterone is a 
very rare finding A description of the pathological findings in the 
woman patient L-G is given in chapter IX of this present thesis by 
Boers et al (1981) After that article had gone to press a local 
recurrence of an aldosterone-producing carcinoma was removed from 
her in 1980 We therefore made an addendum to chapter IX with 
regard to the clinical and pathological findings in this recurrent tumor 
In paragraph VIII-6 we give a synoptic survey of the literature on 11 
patients with an aldosterone-producing carcinoma The problems that 
arise in the histopathological differentiation between benign and malig-
nant aldosterone-producing tumors will be discussed 
VIII 2 . T u b MACROSCOPIC PATHOLOGY OF THF ADRENALS 
In the 18 patients with an aldosterone-producing adrenal adenoma the 
adrenal tissue to be examined was obtained by operation In the 
woman M-G an adenoma in the contralateral adrenal was found as well 
at autopsy In 15 patients a unilateral adrenalectomy was done, in 2 
patients (F and W-S) a subtotal adrenalectomy (in the woman patient 
W-S by means of 2 operations) and in 1 woman patient (Ba) a total 
adrenalectomy The weights of the adenoma-containing adrenals 
varied from 3.8 to 30 grams (12 patients, see table VIII-1). 
Taking the normal weight of adrenals to be from 5 to 5 7 grams 
(established by Kremer and Dohm (1979) in sudden death patients) the 
weight of the adrenal had increased in 10 of the 12 patients, while in 2 
patients the weight was lower than normal. The adenomas were not 
weighed after removal of the adjacent adrenal tissue According to 
Conn et al. (1964) the weight of an aldosterone-producing adenoma is 
mostly less than 6 grams and only exceptionally more than 10 grams 
The maximal diameter of the adrenal adenomas varied from 0 8 to 3 cm 
(see table VIII-1) It is well known that the diameter of aldosterone-
producing adenomas is only rarely more than 3 cm (Conn et al 1964) 
In 2 patients (Br and S-R), on making serial sections of the adrenal, a 
smaller adenoma was found in an otherwise atrophic adrenal cortex, 
while in 3 patients (v W, M-G, N-M) macronoduh were encountered in 
the adjacent adrenal cortex The presence of a bilaterally localized 
tumor (patient M-G) is mentioned only sporadically in the literature 
(Kawasaki et al 1971) In the majority of patients with primary 
aldosteronism the tumor is solitary (91%), whereas multiple tumors 
are mostly unilaterally localized (Neville and Symington 1966) The 
adenomas were more frequently localized in the left adrenal, in 
approximate agreement with the percentage of 73 % that was reported 
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Table VIII-1. 
The adrenal pathology in relation to the functional pathology inpatients 
with an aldosterone-producing adenoma 
patient 
G-J 
Br 
ν W 
F 
Ba 
vd V 
O-K 
vdK-M 
W-S 
S-R 
S-Kr 
H-S 
K-H 
H 
M-G 
N-M 
P-R 
S-Kl 
tf/Ç 
9 
cf 
Cf 
cf 
9 
? 
9 
9 
9 
9 
9 
9 
9 
cf 
9 
9 
9 
9 
adrenal 
weight 
(g) 
-
30 
9 
-
-
11.5 
— 
6.2 
— 
3.8 
4.1 
8.4 
7.3 
-
9.5 
— 
12.5 
11.3 
8.2 
maximum diameter 
of the adenoma 
2.0 
2.5 
1.9 
0.8 
1.0 
2.0 
2.0 
3.0 
1.5 
1.5 
1.3 
2.0 
1.4 
1.5 
2.5 
1.8 
1.0 
1.8 
1.9 
(cm) 
and 0.2 
(+ macro-
noduli) 
and 0.3 
(+ macro-
noduli) 
(+ macro-
noduli) 
(+ macro-
noduli) 
adenoma 
localization 
L(cfl) R(ight) 
L 
L 
L 
L 
R 
R 
L 
L 
R 
L 
R 
L 
L 
L 
R 
L 
R 
L 
R 
aldosterone 
secretion 
(μ6/24 hr) 
370 
1257 
429 
408 
551 
248 
1941 
851 
440 
544 
862 
642 
331 
702 
270 
353 
385 
259 
by Conn et al. (1964). On section all adrenal adenomas showed the 
yellow colour that is characteristic for this type of tumor, and were 
localized intraglandularly or projected above the surface of the gland. 
The size of the tumor, measured by the maximal diameter, proved to be 
not significantly correlated with the secretion of aldosterone measured 
during a diet with 6 grams of salt (r=0.28, n=18; n.s., table VIII-1). 
But it did turn out that a significant correlation existed as between the 
weight of the adrenal containing the adenoma and the secretion of 
aldosterone during such a diet (r=0.48, n=12; p<0.05, table Ш-
1). In assessing these correlations it is necessary to take into account 
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Table VIII-2. 
The adrenal pathology in relation to the functional pathology inpatients 
with idiopathic aldosteronism 
patient cf/9 adrenal microscopic pathology aldosterone secretion 
weight ^g/24 hr) 
(g) 
ν N d" - hyperplasia of the zona 476 
glomerulosa 
S cf 50 (L+R) hyperplasia 401 
L $ 20 (L+R) micronodular hyperplasia 222 
S-B $ 7 (2/3L+R) hyperplasia of the zona 242 
glomerulosa 
J Cf - hyperplasia of the zona 340 
glomerulosa 
К cf 70 (L+R) micronodular hyperplasia 108 
the fact that the interval of time between the measuring of aldosterone 
and the operation varied from a few weeks to even several years. We 
have not found any mention in the literature of a correlation between 
the rate of secretiorf of aldosterone and the size of the tumor (or the 
weight of the adrenal). In the 6 patients in whom no adrenal adenoma 
was found, the adrenal tissue was obtained at autopsy (S, L and K) or 
by operation (v N, S-B and J). It is a striking fact that the weight of 
these adrenals varied considerably, and so, too, did the values of the 
aldosterone secretion (table VIII-2). The very obvious increase in size 
of the adrenals of the patiens S, L and K, in whom the tissue was 
obtained at autopsy, can probably be explained by the severe illnesses 
that preceded their death. In the patient К the greatest weight of the 
adrenal and lowest secretion of aldosterone were found. In none of the 
6 patients macroscopic anomalies of the adrenal cortex were found, 
except for a widening of the adrenal cortex in patient K. According to 
Neville and O'Hare (1979) no macroscopic anomalies are found in the 
adrenals of most patients with idiopathic aldosteronism, whereas in a 
minority (20%) of these patients macronoduli are found. 
VIII.3. THE MICROSCOPIC PATHOLOGY OF THE ADRENALS 
Although no close relationship exists between the morphology and the 
function of the three histologically distinguishable layers of the adrenal 
cortex (zona glomerulosa, zona fasciculate and zona reticularis), the 
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biosynthesis of aldosterone, in contradistinction to most other adrenal 
steroids, is restricted to one zone, namely, the zona glomerulosa. The 
extraordinary fact that precisely the aldosterone-producing adenomas 
have turned out to be built up by cells that are not distinguishable by 
light microscopy from the cells of the normal zona fasciculata is a 
paradoxical discovery that so far has not been elucidated. However, the 
preponderant fasciculata-like cell type already suggests (as we show 
elsewhere in this thesis) that the steroid production of the tumor takes 
place to a considerable degree under the influence of ACTH. Accor-
ding to the classic description of Neville and Symington (1966), cells of 
the zona glomerulosa - and zona reticularis (or "compact") - type are 
also to be found in adenomas. Furthermore, cells are encountered that 
have cytological properties of the zona glomerulosa and of the zona 
fasciculata and are therefore called "hybrid cells". Hybrid cells are like 
fasciculata-like cells, but are smaller. The nucleus-cytoplasm ratio is 
more in agreement with that of the zona glomerulosa cells. Although 
all 4 cell types may be present, the histological picture is mostly 
dominated by the great, clear, lipid-laden cells of the fasciculata type. It 
is still not sufficiently known whether, and, if so, to what extent, each of 
the 4 cell types mentioned contributes to the production of aldoste-
rone. But it has been ascertained from in vitro studies that adenomas 
produce not only aldosterone but also corticosterone and Cortisol, 
although in vivo the secretion values of both of the latter hormones are 
not raised (Biglieri et al. 1963, Kaplan 1967). This shows that not only 
morphologically, but also biochemically, the adenoma cells display a 
hybrid character. Thus Brode et al. (1962) demonstrated that the 
steroid production of the adenomas in vitro, expressed in the ratio 17-
hydroxy-/17 deoxysteroids yielded a ratio that lays between that of a 
normal zona glomerulosa and a normal zona fasciculata. It is also 
probable that zona glomerulosa and zona fasciculata type cells both 
morphologically and functionally, can reciprocally change over to one 
another, as was shown by Hornsby et al. (1974) by means of "mono-
layer cultures" of the zona glomerulosa of the rat. Furthermore, it is 
known from electron microscopic studies of adenoma cells, that the 
morphology of mitochondria and agranular endoplasmatic reticulum in 
many cases agrees with that of zona glomerulosa cells (Kovacs et al. 
1974, Kano et al. 1979, Eto et al. 1979). In table VIII-3 a survey is given 
of the various cell types that were encountered in 19 adenomas. 
In all tumors, except in the 4 last mentioned in table VIII-3, the zona 
fasciculata cell type was predominant. In the tumors of varied composi-
tion all 4 cell types were represented. In one adenoma (from patient F) 
exclusively zona glomerulosa cells were found, which is a well known, 
but rare histological variant of an aldosterone-producing adrenal ade-
noma (Neville and O'Hare 1979). The photographs give an illustration 
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Table VIII-3. 
Classification of cell types in 19 adenomas 
cell types 
Fasciculata type 
Fasciculata and reticularis type 
Fasciculata and "hybrid" type 
Fasciculata and glomerulosa type 
Glomerulosa type 
Varied composition 
Total 19 
of adenomas 
7 
6 
1 
1 
1 
3 
see figure 
VIII-l 
VIII-2 
VIII-3 
VIII-4 
VII 1-5, 
VIII-6 
of the various histological pictures. The light microscopic findings in 
patients with an idiopathic aldosteronism have already been reported 
in table VIII-2. When the zona glomerulosa was clearly recognizable 
and focally or diffusely showed an increase, the term hyperplasia of the 
zona glomerulosa was used. When an increase of the width of the 
cortex was found, without clearly recognizable increase of the zona 
glomerulosa, "hyperplasia" was reported in the table. When, as well, 
light microscopic cortical noduli were met, micronodular hyperplasia 
was the term used. 
In patients with idiopathic aldosteronism probably the overproduction 
of aldosterone takes place in the hyperplastic zona glomerulosa, while 
the micro- or macronoduli make no contribution to the production of 
aldosterone (Neville and O'Hare 1979). Various authors regard the 
presence of cortex noduli as the sequel rather than the cause of the 
hypertension (Shamma et al. 1958, Dobbie et al. 1969, Neville 1978). 
The precence of cortex noduli in the adrenal (both micro- and macro-
noduli) is a frequent finding at autopsy of patients without functional 
anomalies of the adrenals (Shamma et al. 1958). In contradistinction to 
what was assumed earlier, no functional significance is assigned to 
cortex noduli in adrenals of patients with primary aldosteronism. In 
vitro it was proven that these noduli, in contrast to the classic solitary 
adenomas, produce no aldosterone, while the cells from which the 
noduli are built up, are devoid of the ultrastructural features of cells 
that produce aldosterone (Neville 1978). "Spironolactone bodies" (see 
also the following paragraph) were never found in such noduli. Dobbie 
(1969) has suggested that the occurrence of cortex noduli, indepen-
dently of the presence or absence of functional adrenal pathology, is 
the sequel of hyaline thickenings of the vascular walls, and proliferation 
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Figure VIlI-1. Patients S-Kl. Part of the adenoma composed of lip id-
laden clear cells similar to those of the normal zona fasciculata. HE; 
ХІ40 (upper figure). Detail of upper figure. The cells are arranged in 
small alveoli separated by fine fibrovascular connective tissue. HE; x350 
(lower figure) 
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Figure VIII-3. Patient K-Η. Peripheral part of the adenoma shows 
nests or cords of zona glomerulosa-type cells between the capsule (upper 
left) and zona fasciculata-type cells (center). HE; xl40 
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Figure VIII-4. Patient F. Zona glomerulosa-type cells are almost the 
sole component of this adenoma. Rounded intracytoplasmatic inclusions 
(spironolactone bodies) can be observed in practically each cell. HE; 
xl40 (upper figure) Detail of upper figure. Numerous laminated spiro-
nolactone bodies ( \ ) are easily identified in the cytoplasm of the zona 
glomerulosa-type cells. HE; x550 (lower figure) 
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Figure VIII-5. Patient v-W. Two examples of the various cellular 
components in an adenoma are illustrated: zona fasciculata-type (left) 
and dark zona reticularis-type (or compact) cells in the right part of the 
picture. HE; xl40 (upper figure). Elsewhere in the adenoma zona 
fasciculata-type cells containing spironolactone bodies ( ] ) seem to be 
present. HE; xl40 (lower figure) 
140 
Figure VI 11-6. Patient Ba. A focus of zona fasciculata-type cells is seen 
on the left with small dark, eosinophilic compact (or zona reticularis-
type) cells on the right. HE; xl40 (upper figure). Outside the adenoma a 
broadened layer of zona glomerulosa cells extends inward in a tongue-
like manner between the cords of zona fasciculata cells. HE; xl40 (lower 
figure) 
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Figure VI ¡1-7. Patient F. Part of a zona glomerulosa cell containing an 
osmiophilic spironolactone body in an advanced phase of development. 
In the surrounding cytoplasm several rounded or elongated mitochon-
dria with lamellar cristae ( ]} can be seen. The endoplasmic reticulum 
appears vesicular. x21.700 (upper figure). Outer portion of a spironolac-
tone body exhibiting the regular concentric orientation of numerous 
smooth membranes. There is continuity ( 1 ) of these membranes with 
vesicular smooth endoplasmic reticulum suggesting derivation from this 
organelle. x21.700 (lower figure) 
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of the intima of the capsular arteries. Apparently by local ischemia and 
atrophy of the adrenal cortex, compensatory hyperplasia occurs in the 
cortical parts that are supplied with blood by the arteriae comitantes, 
that in general are less liable to arteriopathic changes (Dobbie and 
Symington 1966). In point of fact, cortex noduli are found more 
frequently in advancing age and in patients with hypertension 
(Shamma et al. 1958, Dobbie et al. 1967). 
Vili.4. MICROSCOPIC PATHOLOGY OF THE ADRENAL CORTEX LYING OUTSIDE 
THE ADENOMA 
In the earliest publications on adrenal pathology in primary aldostero-
nism, in general, little attention was devoted to the adrenal cortex lying 
outside the adenoma. In the original publication by Conn (1956), it was 
reported that the contralateral adrenal cortex was "somewhat thinner 
than normal". Microscopical examination showed this to be due to a 
diminution of the zona fasciculata*. Brode et al. (1962) were the first to 
report a hyperplasia of the adjacent zona glomerulosa, in which some-
times the zona glomerulosa extended deeply into the cortex. Neville 
and O'Hare (1979) reported in their review, based on the pathological 
findings in 80 patients with primary aldosteronism, that the adjacent 
zona glomerulosa in all of the adrenals with adenoma examined by 
them, presented a hyperplasia accompanied or not by micronoduli. 
Also, in the adrenals examined by us there was regularly a focal or 
diffuse increase of the adjacent zona glomerulosa to be observed. In 
assessing the width of the zona glomerulosa it is necessary to take into 
account the fact that this layer in the normal adult adrenal - and 
certainly during advancing age (Symington 1969) - is often only focally 
present and sometimes can not be identified histologically. For these 
reasons a zona glomerulosa that is present as a continuous layer in the 
periphery of the adrenal cortex, must be considered as hyperplastic. In 
17 patients with 18 adenomas the adjacent adrenal cortex could be 
assessed and a hyperplastic zona glomerulosa was found in ten adrenals 
(figure VIII-6). In 3 patients the adrenal cortex of the contralateral 
adrenal could be examined and two of them turned out to have a 
hyperplastic zona glomerulosa. Moreover, as well as a hyperplasia of 
the adjacent adrenal cortex, micronoduli of the cortex were found in 7 
patients; these were built up by cells of the zona fasciculata type. 
* Based on these grounds and on the presence of the fasciculata cell type in the adenoma 
that was removed - it was concluded by Conn that aldosterone is produced in the zona 
fasciculata. But shortly afterwards Ayres et al. (1956) showed that the production of 
aldosterone takes place exclusively in the zona glomerulosa. 
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The finding that in a considerable part of the patients with an aldoste-
rone-producing adenoma the zona glomerulosa is not atrophic, as 
might have been expected, strongly supports the suggestion that a 
hyperplasia of the zona glomerulosa precedes the development of an 
adenoma that produces aldosterone. 
VIII.5. "SPIRONOLACTONE BODIES" 
In 1963, 6 years after the aldosterone antagonist spironolactone was 
introduced for clinical use (Liddle 1957), Janigan reported the occur­
rence of cytoplasmatic inclusions in zona glomerulosa cells of 18 
patients with liver cirrhosis who had been treated with spironolactone 
in a total dose varying from 0.6 - 16 grams. The eosinophile inclusions, 
in which 2 to 4 concentric rings were recognizable, measured 2-25 μ, 
and were surrounded by a clear halo. The chemical composition proved 
to be a phospholipide-protein complex. On electron microscopic exa­
mination, spironolactone bodies proved to be built up of concentric 
membranes closely packed together, with a central lipoid nucleus. 
There was a continuous connection between the outer membrane of a 
spironolactone body and the agranular endoplasmatic reticulum. On 
these grounds it was supposed that the spironolactone body was built 
up of windings of the smooth endoplasmatic reticulum (Jenis and 
Hertzog 1969). The first publications on the presence of "spironolac­
tone bodies" dealt with autopsy material of patients who had been 
treated with spironolactone because of liver cirrhosis or cardiac decom­
pensation. An autopsy artefact could not, therefore, be entirely exclu­
ded. In 1973 Kovacs et al., however, reported the presence of "spirono­
lactone bodies" in an adrenal removed operatively from a woman with 
primary aldosteronism and adrenal hyperplasia. In the widened zona 
glomerulosa and, especially, in its outer layer, many "spironolactone 
bodies" were met. "Spironolactone bodies" were later on also found in 
an adenoma, that produced aldosterone, in a patient who had been 
treated preoperatively with spironolactone (Cain et al. 1974). In the 
zona glomerulosa adjacent to the adenoma no "spironolactone bodies" 
were met. The functional significance of these "spironolactone bodies" 
was at first unclear. The construction, consisting of membranes from 
the endoplasmatic reticulum (in which many of the enzymes concerned 
with the synthesis of aldosterone are localized) pointed to "spironolac­
tone bodies" being the morphological expression of an increased 
aldosterone production during treatment with spironolactone (Kovacs 
1974). However, it remained unexplained why "spironolactone bodies" 
were never found in adrenal adenomas of patients who had not been 
treated with spironolactone, not even in tumors that produced conside-
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rabie quantities of aldosterone In 1977, Conn and Hinerman wrote a 
clarifying study on the functional significance of "spironolactone 
bodies" in aldosterone-producing adenomas. The number of inclusions 
in the adenomas of all 23 patients in whom the adenoma-harboring 
adrenal was removed during spironolactone medication, was found to 
depend on the length of time of the treatment with spironolactone, and 
not on the dose used After a rapid increase of the number of inclusions 
during the first 40 to 60 days, a gradual decrease was seen from the 50th 
to the 170th day of spironolactone medication. In addition it was 
shown, that the excretion of aldosterone during the first weeks of 
spironolactone treatment, diminished and subsequently - about one 
month later - increased to above the level of the basal excretion. In 
view of the period of rapid increase of the number of spironolactone 
bodies coinciding with a diminution of the excretion of aldosterone, it 
was probable that the appearing of the spironolactone bodies formed 
the morphological expression of inhibition of the production of aldoste­
rone The absence of spironolactone bodies in the zona glomerulosa 
outside the adenoma was in agreement with the concept that the zona 
glomerulosa there contributes nothing to the production of aldoste­
rone. Further, from the absence of spironolactone bodies in the zona 
fasciculata, it was concluded that the inhibition of aldosterone induced 
by spironolactone probably takes place after the biosynthesis of corti­
costerone. The gradual increase of the excretion of aldosterone after 4 
to 6 weeks of treatment with spironolactone was explained as the result 
of the natnuresis and rise of the plasma renin activity induced by 
spironolactone. In the group examined by us there were 18 patients 
who had been treated with spironolactone (table VIII-4) for 1 to 53 
months. Spironolactone bodies were found in only 4 patients. This low 
incidence may be founded on both a relative long average duration of 
medication and on the time interval between stopping the medication 
and the operation In 2 patients with an adenoma (F and ν W, figures 
VIII-4, VII 1-5 and VIII-7) the spironolactone bodies were localized in 
the adenoma, and in patient F, also in the zona glomerulosa lying 
outside the adenoma as well as in the contralateral adrenal. If it is 
agreed with Conn that spironolactone bodies are the pharmacological 
hallmarks of cells with raised aldosterone production, it must be 
accepted that the overproduction of aldosterone m patient F has not 
been limited to the adrenal adenoma In 2 patients with an adrenal 
hyperplasia (ν N and S) "spironolactone bodies" were spread over the 
zona glomerulosa of both adrenals It is a remarkable fact that 3 out of 
4 patients with "spironolactone bodies" had taken the medication up to 
the day of the operation. In one patient (F) the aldosterone values were 
measured in the immediate preoperative phase. On the day before the 
operation low plasma aldosterone values were obtained: in the mor-
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Table Ш-4. 
Dose and duration of spirolactone medication in relation to the origina­
tion of "spirolactone bodies" 
patient 
v W 
F 
Ba 
v d V 
O K 
vdK-M 
W-S 
S-R 
S-Kr 
H-S 
K-H 
H 
M G 
N-M 
S-Kl 
v N 
S B 
J 
adrenal pathology 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
adenoma 
hyperplasia 
hyperplasia 
hyperplasia 
duration of 
medication 
(months) 
1 
4 
2.5 
7 
9 
4.5 
4 
28 
53 
8 
1.5 
27 
2 
7 
4 
3.5 
2.5 
3 
total dose 
spironolac­
tone (g) 
14 
48 
10 
61 
52 
54 
30 
169 
218 
47 
19 
111 
20 
85 
22 
22 
24 
9 
time lag between 
medication and 
operation 
0 
9 
5.7 
5.5 
3 
3 
7 
12 
11 
3 
8 
27 
2 
1 
3 
0 
0 
3 
days 
days 
years 
months 
months 
months 
months 
days 
days 
days 
days 
days 
months 
day 
months 
days 
days 
months 
"spirono­
lactone 
bodies" 
+ 
+ 
— 
-
-
-
— 
— 
-
— 
-
-
— 
— 
-
+ 
+ 
— 
ning at 9.00 hr 4.9 ng/100 ml, and at 12.00 hr, after 3 hours of 
ambulation, 12.6 ng/100 ml. Also, at that moment the plasma potas­
sium concentration was normal (4.5 mmol/1) and, so too, was the blood 
pressure (130/80 mmHg). The number of "spironolactone bodies" in 
this patient was very high and the relation between the inhibition of the 
aldosterone production and "spironolactone bodies" is suggestive. In 
connection to the discussion of this paragraph it is relevant to recall 
that an indirect indication of an interference of spironolactone with the 
biosynthesis of aldosterone was obtained from the comparison of the 
aldosterone excretions after 6 weeks of treatment with spironolactone, 
400 mg per day, and those after 6 weeks treatment with a placebo and 
after 6 weeks treatment with amiloride, in patients with a raised 
aldosterone production (chapter VII). The arguments for a relative 
inhibition of the biosynthesis of aldosterone under the influence of 
spironolactone were derived from the fact that in patients with a raised 
basal aldosterone excretion the output of aldosterone after 6 weeks of 
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treatment with spironolactone 400 mg per day, did, it is true, show a 
significant rise, but dit not vary essentially from the excretion of 
aldosterone after 6 weeks treatment with amiloride 40 mg per day, in 
spite of the fact that the plasma renin activity and the degree of volume 
depletion after treatment with spironolactone showed a greater rise 
than after treatment with amiloride (Hoefnagels et al. 1980, see also 
the discussion in chapter VII). 
VIII.6. THE ALDOSTERONE-PRODUCING CARCINOMA OF THE ADRENALS 
Among the causes of death from malignant tumors, the carcinoma of 
the adrenals, with its 0.2%, occupies a modest place (Richie and Gittes 
1980). The hormonally active adrenal carcinomas - and they constitue 
approximately the half of such tumors (Greenberg and Marks 1978) -
can be the source of clinical symptoms that in a number of cases make 
early recognition possible. The endocrine manifestations of an adrenal 
carcinoma may be: Cushing's syndrome, virilization, feminization, 
pubertas praecox, primary aldosteronism, or a combination of these 
affections. Adrenal carcinomas that manifest themselves mainly by an 
overproduction of mineralocorticoids are described only by reference 
to examples, and the total of cases so far reported is probably less than 
20 (Foye and Feichtmeir 1955, Brooks et al. 1957, Zimmerman et al. 
1959, Crane et al. 1965, Santander et al. 1965, Neville and Symington 
1966, Alterman et al. 1969, Brooks et al. 1972, Filipecki et al. 1972, 
Revach et al. 1977). A few cases of DOC-producing adrenal carcino-
mas have been published (Crane et al 1965, Powell-Jackson et al. 1974) 
and a few aldosterone-producing carcinomas arising from ectopic adre-
nal tissue in ovaries (Ehrlich et al. 1963, Tedesco et al. 1975) or kidney 
(Boers et al. 1981). 
The first publication of an aldosterone-producing adrenal carcinoma 
(Foye and Feichtmeir 1955) is also remarkable because the authors give 
a good clinical description of the syndrome of primary aldosteronism 
(muscular weakness, thirst, polyuria, hypertension, hypokalemic alka-
losis) without knowing about Conn's earlier publication (1955), as 
appears from their references to the literature. However, the patient 
apparently did not satisfy one of the criteria for the making of the 
diagnosis of primary aldosteronism (Conn 1955): the urinary excretion 
of the 17-ketosteroids was markedly raised. From the case reports of 
patients with carcinomas of the adrenals that produce aldosterone (see 
table VIII-5) that were subsequently published, it turned out that the 
clinical picture was often indistinguishable from that of primary aldos-
teronism due to a benign aldosterone-producing adenoma: namely, 
muscular weakness, tetany, thirst, polyuria, hypertension and hypoka-
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Table VIII-5. 
Literature review of some clinical and pathological findings in 11 
patients with an aldosterone-producing adrenal carcinoma 
Foye 1955 
Brooks 1957 
Zimmerman 195' 
Crane 1965 
Santander 1965 
Neville 1966 
Alterman 1969 
Brooks 1972 
Filipecki 1972 
Revach 1977 
CfôO 
years 
СГ35 
years 
$ 38 
years 
$ 64 
years 
$ 50 
years 
9 26 
years 
Cf 68 
years 
Cf 35 
years 
$ 3 4 
years 
$ 3 1 
years 
Boers 1981 
patient pathology of the tumor 
removed by operation 
tumor of 4 cm (right) 
consisting of hybrid and 
glomerulosa type cells 
tumor of 1400 g (left), 
necroses, vascular thrombi, 
giant cells, hybrid and 
compact type cells 
tumor of 583 g (right), 
necroses, bleedings and 
compact type cells 
tumor of 1010 g (left), 
necroses, bleedings, large 
cells with eosinophile 
cytoplasm 
tumor of 90 g (right) 
with cells of fasciculata 
and compact type (autopsy) 
tumor of 2032 g (right), 
bleedings, necroses. 
thick-wallcd vessels with 
thrombi, glomerulosa and 
hybrid type cells 
tumor of 30 g (left), 
necroses and bleedings on 
the cut surface, pol> nuclear 
cells, invasion of blood 
and lymph vessels 
tumor of 1000 g (left), 
necroses, pleomorphic 
cells cysts 
tumor of 320 g (right). 
encapsulated, necroses. 
calcifications, invasion 
of vessels and capsule, 
polynuclear cells 
tumor of 6x3,5x3 cm (right), 
encapsulated, a few mito­
ses, rich vascularization. 
calcification, no capsule 
or vessel invasion, glome­
rulosa type cells 
$ 50 tumor of 3 cm. subcapsular in 
years right kidney, cut surface 
bleedings and necroses, 
partial encapsulation, fi­
brous bands, atypical cells. 
frequent mitoses, vascular 
thrombi, vessel and capsule 
invasion 
postoperative 
survival period 
6 months 
5 weeks 
not known 
12 weeks 
6 weeks 
autopsy 
metastases in 
lungs, liver and 
bone marrow 
none 
lung and verteb­
ral metastases 
metastases in 
lungs, liver and 
abdominal lymph 
nodes 
metastases of 
lung and liver 
not known not known 
4 months 
not known 
metastases in 
pituitary gland, 
lung, pleura, 
bones 
metastases in 
lungs 
living, no indications of re­
currence or metastases 
(follow-up 6 months) 
2 1/2 years tumor recurrence 
in right adrenal 
region, metastases 
in liver, spleen 
and mesentery 
local recurrence 
one year after 
operation No 
signs of recur­
rence or metasta­
sis up to 5 
months after re­
section of the 
recurrent tumor 
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lemic alkalosis occurred in many patients. There were no overt clinical 
symptoms of excessive production of other adrenal steroids, but urine 
metabolites of adrenal steroids other than aldosterone were regularly 
found in a number of patients (Crane et al. 1965, Brooks et al. 1972). 
The excretion of 17-ketosteroids was, with a single exception (Revach 
et al. 1977, Boers et al. 1981), practically always raised. Clinical 
symptoms that might indicate a malignant tumor as the cause of the 
primary aldosteronism in the patients mentoined in table VII1-5, were: 
emaciation, fever, pain in the upper abdomen or back, a palpable 
tumor in the upper abdomen and hepatomegaly. An intravenous 
pyelogram often showed a caudal shift of the kidney on the side where 
the adrenal tumor was lying. The diagnosis of carcinoma of the adrenal 
was subsequently made in most patients by anatotnopathological exa-
mination of the extirpated tumor. It is well known that in assessing 
adrenal and other endocrine tumors, the histopathological criteria that 
in general are used for the establishment of the presence of malignancy, 
may not, without further consideration, be applied for this type of 
tumor. Thus, multiplicity of mitoses, invasion of the capsule and 
vessels, polymorphism of cells or nuclei, are not histological features 
that are found exclusively in malignant tumors, while their absence 
does not exclude malignancy (Hough et al. 1979). Absolute certainty 
about the malignancy of an adrenal tumor is obtained only by the 
demonstration of metastases some distance away (Symington 1969). 
Thus, the tumor removed by Revach et al. and described by them in the 
first instance as benign (1977) had to have its designation changed later 
on when metastases appeared. Some clinical and pathological findings 
in 11 patients with adrenal carcinoma producing aldosterone are repor-
ted in table V1I1-5. Of the 11 patients - 4 men and 7 woman - 6 were 
found to be younger than 40 years of age. The tumor was mostly of 
considerable size (up to more than 2000 grams), but there were also 
small malignant tumors (Alterman et al. 1969, Boers et al. 1981). The 
most frequent pathological findings were: bleedings and necroses on 
the cut surface of the tumor, thickwalled vessels with thrombi, and 
invasion of the capsule and vessels. The tumors consisted of one or 
more of the 4 cell types, that are also found in benign aldosterone-
producing adenomas. Metastases were met in the liver, lungs and bone 
marrow, while on several occasions recurrent tumor growth was obser-
ved. It is noteworthy that the average survival was generally less than 
six months, with the exception of the patients described by Revach et 
al. (1977) and Boers et al. (1981). 
Without referring in detail to the discussion of the case of the woman 
patient L-v G as set forth in chapter IX (Boers et al. 1981), we can 
conclude in summary that this patient had in total developed the 
syndrome of primary aldosteronism 3 times; on 2 occasions this was 
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due to a malignant tumor. The case history differs in the following 
points from most of the cases of adrenal carcinomas producing aldoste-
rone that have been described up till today. 
1. No previous report has been made of an aldosterone-producing 
carcinoma that developed after removal of a benign aldosterone-
producing adenoma. 
2. There are arguments (see discussion in chapter IX) for the assump-
tion that the carcinoma has developed from heterotopic adrenal tissue 
localized in the right kidney. 
3. An adrenal carcinoma with, exclusively, overproduction of aldoste-
rone, has so far been reported only twice in the literature (Santander et 
al. 1965, Revach et al. 1977). In both cases, however, the number of 
measured steroids was limited. 
4. The clinical course seems up to the present time to be considerably 
more favourable than the cases of aldosterone-producing carcinoma 
reported in the literature. 
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IX. 1. SUMMARY 
To our knowledge only 3 patients with selective and excessive produc-
tion of aldosterone due to a carcinoma of the adrenal gland have been 
reported. Heterotopic benign adrenal tissue inducing primary aldoste-
ronism has been reported in one patient. In this paper, we describe a 
patient in whom the syndrome of primary aldosteronism recurred 12 
years after removal of an aldosterone-producing adenoma of the right 
adrenal gland. Overproduction of 18-hydroxycorticosterone and aldos-
terone appeared to be due to an adrenal carcinoma located subcapsu-
larly, at the upper pole of the right kidney. Removal of the tumor led to 
normalization of blood pressure, plasma potassium, 18-hydroxycorti-
costerone, and aldosterone. 
IX.2. INTRODUCTION 
The syndrome of primary aldosteronism in adult patients is in approxi-
mately 80 percent of cases due to a single adenoma of the adrenal 
cortex. In the remaining patients, the syndrome occurs in the presence 
of multiple, sometimes bilateral, adenomas, diffuse bilateral hyperpla-
sia, or even in the presence of histologically normal adrenal glands 
(Conn et al. 1964 and 1971, Neville and Mackay 1972). Only 15 cases of 
primary aldosteronism due to an adrenal carcinoma are reported in the 
literature in detail (Santander et al. 1965, Alterman et al. 1969, Brooks 
et al. 1972, Filipecki et al. 1972, Revach et al. 1977, Vetter et al. 1978). 
In 12 of these patients clinical and laboratory data suggest hypersecre-
tion of glucocorticoids, androgens, as well as aldosterone by the tumor. 
Therefore, these patients do not fulfill Conn's criteria of the syndrome 
of primary aldosteronism (Conn et al. 1964). In the remaining 2 cases, 
selective and excessive production of aldosterone was present (Santan-
der et al. 1965, Revach et al. 1977), thus establishing Conn's syndrome. 
Two cases of primary aldosteronism in patients with virilizing carci-
noma of the ovary are reported (Ehrlich et al. 1963, Tedesco et al. 
1975). The tumor of these patients contained areas of heterotopic, 
adrenocortical tissue. The syndrome has also been reported in 2 
patients with metastases from a bronchial carcinoma in the adrenal 
gland (Mach et al. 1957, Spaulding et al. 1966). Adrenal hyperplasia 
without evidence of metastasis to the adrenal gland has been reported 
in a patient with advanced carcinoma of the prostate (Kohier 1959). 
Benign extra-adrenal tissue rarely produces the syndrome of primary 
aldosteronism. Only one case has been published, in whom the syn-
drome was due to a benign adrenocortical adenoma located in the 
kidney (Flanagan and McDonald 1967). We present a patient with the 
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syndrome of primary aldosteronism without evidence suggesting over­
production of other adrenal hormones, caused by an adrenal carci­
noma. The carcinoma was attached subcapsularly to the right kidney. 
Twelve years earlier, the right adrenal gland had been removed 
because of hyperaldosteronism due to a pathologically and clinically 
benign adrenocortical adenoma. 
IX.3. METHODS 
Aldosterone secretion rate (ASR) was measured by radioimmunoassay 
(Man de and Benraad 1977) in urine collected during 24 hours of 
recumbency after a dietary intake of 0, 6 and 18 grams of NaCl per day 
for at least 4 days. Plasma aldosterone (Man de et al. 1980), 11-
deoxycorticosterone (DOC) and 18-hydroxy-ll-deoxycorticosterone 
(18-OH-DOC (Hoefnagels et al. 1978)), 11-deoxycortisol (S (Smals et 
al. 1978)), Cortisol (F (Man de et al. 1980)) were measured by radioim­
munoassay. Corticosterone (В) and 18-hydroxycorticosterone (18-OH-
B) were measured with the method described for 18-OH-DOC using 
specific antibodies for these hormones. Plasma renin activity (PRA) 
was measured by radioimmunoassay (Drayer and Benraad 1975), in 
blood collected at noon after 3 hours of ambulation during a dietary 
intake of 0 and 6 grams of NaCl per day for at least four days. 
Excretion of 17-hydroxysteroids and keto-steroids in 24 hours urine 
samples were measured by standard methods (Appleby et al. 1955). 
Plasma electrolytes and serum creatinine were measured using routine 
laboratory techniques. Adrenal scintigraphy was performed 1, 4 and 6 
days after intravenous administration of 1.9 mCi 13lI-6ß-Iodomethyl-
19-Nor-Cholesterol, after pretreatment with dexamethasone (0.5 mg 
qid for 3 weeks) and potassium Perchlorate (0.2 g qid for one day). 
Dexamethasone and potassium Perchlorate were continued throughout 
the scintigraphy study. 
IX.4. CASE REPORT 
The patient, a woman born in 1930, had a history of hypertension 
during pregnancies in 1960 and 1964. She was found to have sustained 
hypertension since her last pregnancy in 1966. She was referred to the 
hospital in 1967, at age 37, because of tiredness, headaches, dizziness, 
palpitations and uncontrollable hypertension. Her blood pressure was 
160 over 105 mmHg. Physical examination was otherwise normal. 
Laboratory tests (table IX-1) revealed hypokalemia, alkalosis, and 
normal creatinine values. The ASR was clearly elevated and the PRA 
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Table IX-1. 
Clinical and biochemical data at the time of the removal of the adrenal 
adenoma (I A), during the symptom-free follow-up (IB), and at the time 
of the removal of the adrenal carcinoma (1С) 
nonnal values 1967 1%7 1969 1976 1979 1979 
рлог lo suf|teT> aílcí surgery pnor lo surgery aflcr surgery 
1A I B 1C 
Blood pressure mmHg 
supine 
upright 
Potassium 
Bicarbonate 
Creatinine 
ASR,;, 
ASRe, 
ASR,Bg 
PRAÎ·, 
PRAM 
Cortisol 
9 a m 
5 p m 
17-h>droxy-
stcroids 
17-kelo-
steroids 
3 8-4 6 
26-28 
60-100 
200-500 
75-175 
30-80 
115-595 
— 
0 19-0 55 
0 06-0 24 
17-52 
26-62 
mmol/1 
mmol/1 
μπιοΙιΙ 
μ§/24 hr 
μ^24 hr 
μ
Ε
/24 hr 
ng/10 ml'3 hr 
-
μιηοΐ'ΐ 
μιποΙ/Ι 
μπιο1/24 hr 
μπιο1/24 hr 
160/105 
180/120 
20 
38 9 
62 
3711 
1960 
-
0 
0 
0 40 
0 22 
465 
35 4 
115/70 
125/75 
4 6 
22 9 
77 
-
64 
-
320 
5 
040 
0 25 
-
-
130/83 
140/85 
4 3 
212 
-
-
-
-
-
-
-
-
-
-
160/95 
155/105 
37 
26 
77 
-
-
-
193 
-
-
-
-
-
170/110 
175/110 
22 
33 7 
76 
721 
808 
683 
6 
12 
0 25 
0 18 
35 
32 
140/90 
130/80 
4 1 
28 1 
80 
-
65 
-
-179 
0 28 
0 12 
40 
23 
* Aldosterone secretion rale measured during recumbency and after a dietary intake of 0 6 and IR g NaCI 
"* Plasma renin activity measured at noon after Ì hr of ambulation and a dietary intake of 0 and 6 g NaCI per da> for at least four days 
undetectably low. Plasma Cortisol levels were normal as was the 
excretion of 17-hydroxy- and keto-steroid compounds in the urine. 
Arteriography showed an enlarged right adrenal gland. Right lumbo-
tomy was performed and an adrenal tumor was found. The tumor was 
removed as a whole and the remaining adrenal tissue for technical 
reasons in at least three pieces. The tumor weighed 6.3 g and the 
remaining right adrenal gland 4 g. Microscopic examination of the 
tumor (figure IX-1) revealed adrenal cortical tissue consisting of relati-
vely large polygonal cells with abundant, mostly eosinophylic, someti-
mes vacuolated cytoplasm. The cells contained centrally located round 
nuclei, generally containing one or more small basophylic or eosinop-
hylic nucleoli. The cells were growing in trabecular and alveolar 
structures, sometimes in sheets. Small conglomerates or ribbons of 
eosinophylic cells were seen in a rather loose connective tissue, sur-
rounding wide endothelium lined lumina. Especially in these areas the 
tissue resembled the zona glomerulosa of a normal adrenal cortex. In 
other areas the typical structure of the zona fasciculata is seen. Scatte-
red giant cells were present in the tumor, with large polyploid or 
multiple nuclei and some cells showed slight to moderate nuclear atypia 
with prominent nucleoli. Mitoses were scarce. There was no necrosis. 
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Figure IX-l. Adrenocortical adenoma. Although some small and large 
atypical cells with coarse nuclear chromatin and prominent nucleoli are 
found, the overall picture is rather monotonous. Mitoses are scarce 
(H&E. x78) 
It is known to be often very difficult to predict the future behaviour of 
an adrenocortical tumor from its morphology as no definite criteria 
have emerged as diagnostic, but the absence of vascular or capsular 
invasion, necrosis and marked nuclear pleomorphism did seem to 
justify the diagnosis of adrenocortical adenoma. The remaining adrenal 
gland showed an atrophic cortex with a zona glomerulosa, fasciculata 
and reticularis in normal proportions. After surgery blood pressure, 
plasma potassium, bicarbonate, ASR and PRA normalized (table IX-
1). The patient denied any symptoms. Symptoms recurred in 1976 and 
blood pressure was found to be elevated at that time. The oral 
contraceptive medication which she was using since 1968 was disconti-
nued. However, blood pressure remained elevated. Plasma potassium 
was just below normal at that time, but plasma aldosterone and PRA 
were normal. Antihypertensive therapy was started using spironolac-
tone and Oxprenolol. Blood pressure fell to 130 over 85 mmHg. The 
patient was not without headaches during treatment. In the following 
years blood pressure rose to 170 over 110 mmHg and in 1979 antihyper-
tensive treatment was discontinued to allow further evaluation. The 
patient had a hypokalemic alkalosis (table IX-l). The ASR was clearly 
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Table IX-2. 
Adrenocortical hormone concentrations in plasma before and after 
surgery and the content of these hormones in the removed tumor 
Deoxycorticosterone 
(DOC) 
18-hydroxydeoxycorti 
costerone 
(18-OH-DOC) 
Corticosterone 
(В) 
18-hydroxy-corti-
costerone 
(18-OH-B) 
Aldosterone 
11-deoxycortisol 
(S) 
Cortisol 
(F) 
normal values 
in plasma 
4-14 
ng/100 ml 
- 3-13 
ng/100 ml 
130-820 
ng/100 ml 
25-70 
ng/100 ml 
3-25 
ng/100 ml 
30-200 
ng/100 ml 
0.19-0.55 
цтоі/і at 
9 a.m. 
plasma 
prior to surgery 
15 
5 
198 
184 
134 
186 
0.25 
values 
dfter surgery 
2 
4 
199 
28 
7 
168 
0.29 
tumor values 
ng/g tumor tissue 
24 
7 
38 
601 
336 
3 
21 
elevated but to a lower level than the values measured in 1967. The 
PRA was low. Plasma Cortisol and urinary excretion of 17-hydroxy-
and keto-steroids were normal. Assays of adrenocortical hormones in 
blood taken prior to surgery (table IX-2) showed normal values except 
for plasma aldosterone and its immediate precursor 18-OH-B. Routine 
laboratory tests were normal, including ESR (8 mm) and serum creati­
nine. Chest X-ray and intravenous pyelography were normal. Adrenal 
scintigraphy showed poor concentration of radioactivity located above 
both kidneys. Again a right lumbotomy was performed and just below 
the diaphragma a very small (diameter 0.2 cm) nodule of macroscopi-
cally and histologically normal adrenal tissue was found. Moreover a 
tumor with a diameter of 3 cm was seen attached to the right kidney, 
located subcapsularly, about 4 cm from the upper pole of the kidney. 
The tumor could easily be isolated. After enucleation of the tumor, the 
adjacent kidney tissue was removed. The tumor consisted of a lobula-
ted friable mass of soft yellow-brown tissue, containing areas of necro­
sis and hemorrhage. The tumor was partly surrounded by an irregular 
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fibrous capsule, which was continuous with fibrous strands between the 
lobuli. In certain parts of the tumor, the histology was similar to that of 
the adenoma which had been resected 12 years earlier. Other parts of 
the tumor showed predominantly atypical cells (figure IX-2) with very 
large nuclei, large eosinophylic nucleoli, and a coarse chromatin struc-
ture. Some of the large nuclei were vacuolated. In these areas frequent 
mitoses were seen up to 5 per high power field. In many parts of the 
tumor broad areas of necrosis and hemorrhage were present associated 
with trombosed blood vessels. Occasional giant cells were found, some 
with marked atypia. Between the noduli of tumor cells broad septa of 
fibrous tissue were present, invaded by groups and strands of prolifera-
ting cells. Infiltrative growth in vessel walls and peripheral capsular 
tissue could readily be found (figure IX-3). All signs indicative of 
malignancy (O'Hare et al. 1979, Hough et al. 1979) were present and 
the diagnosis of adrenal cortical carcinoma was made. The kidney 
tissue adjacent to the tumor showed microscopically formation of an 
irregular zone of fibrous tissue with scattered glomeruli and atrophic 
tubuli, surrounded by a diffuse and perivascular lymphocytic infiltra-
tion. More distally, signs of interstitial nephritis gradually decreased. 
The superficial renal cortex adjacent to the localization of the tumor 
was covered with capsular tissue which was not continuous with the 
pseudocapsular tissue of the tumor bed. In an extract of the tumor cells 
measurements of adrenocortical hormones were performed. The 
results are compared to those obtained in plasma taken before and 
after removal of the tumor (table IX-2). High levels of 18-OH-B and 
aldosterone were found both in plasma taken prior to surgery and in 
the extract of the tumor cells. After surgery blood pressure fell (table 
IX-1). Blood values of potassium, bicarbonate, PRA, 18-OH-B and 
plasma aldosterone normalized (table IX-1 and -2). During follow-up 
for 5 months, the patient did not reveal any symptoms. 
IX.5. DISCUSSION 
The diagnosis of primary hyperaldosteronism was made in this patient 
at age of 37 and 12 years later at age 49. Signs and symptoms of the 
syndrome disappeared at both occasions after removal of an aldoste-
rone-producing tumor. The firstly removed tumor did not show histo-
pathological signs indicative of malignancy, although it has to be 
admitted that the pathological diagnosis of malignancy of adrenal 
tumors may be difficult (O'Hare et al. 1979, Hough et al. 1979). As 
mentioned before no definite single criterion for establishing the 
benign or malignant potential of adrenocortical tumors is available. 
Criteria as multiplicity of mitosis, invasion of the capsule and vessels, 
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Figure ΙΧ-2. Adrenocortical carcinoma. The histologic appearance is 
essentially the same as that of the adenoma. However, atypia is more 
pronounced and mitoses (arrow) are easily found (H&E xl25) 
f* t* Ч - - ' > * »i- * * ^ : 
Figure ІХ-3. Adrenocortical carcinoma. Tumor cells invade a capsular 
vessel (Elastin von Gieson stain x78) 
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polymorphism ot cells or nuclei, and necrosis are not histological 
features that are found exclusively in malignant tumors However, the 
occurrence of several of these histological features in the same tumor 
will be sufficient for a reliable diagnosis of malignancy The tumor 
removed 12 years later showed all hislopathological features indicative 
of adrenocortical carcinoma The clinical follow-up after the first 
procedure could be an argument against the hypothesis that the second 
tumor was a metastasis of the first one Since the adrenal carcinoma 
developed after a total adrenalectomy at the same side, we have to face 
several possibilities with respect to the origine of the carcinoma As 
mentioned earlier, the right adrenal gland and the adenoma were 
removed in at least 3 pieces and not as one mass. Therefore, it seems 
not unlikely that an adrenal remnant was left in the right suprarenal 
area at that time. It is well known in experimental endocrinology that 
adrenal tissue will regenerate after adrenalectomy, when the adrenal 
capsule is left behind The localization of the carcinoma in this patient. 
subcapsularly attached to the right kidney, does not support the idea of 
regeneration and subsequently degeneration, of an adrenal remnant 
The remote possibility cannot completely ruled out thai the second 
tumor was a metastasis grown via lymphatic and blood vessels into the 
subcapsular regio of the right kidney from adrenocortical cells disper-
sed in the area of the right adrenal during the adrenalectomy in 1967, 
which have shown malignant degeneration afterwards. Heterotopic 
adrenal tissue was found indeed in this patient, during the second 
surgical procedure, just below the diaphragma However, no signs of 
malignancy were found in this adrenal tissue Heterotopic, both corti-
cal and medullary, adrenal tissue had been demonstrated to be present 
in up to 30% of random post mortem examinations (Flanagan and 
McDonald 1967) Accessory cortical tissue has been found in the pen-
adrenal and pen-nephnc area, along the great vessels, in the ovary. 
broad ligament, intestine, spermatic cord, pancreas and in the root of 
the mesentery Adrenal rests are found in 1 % of kidneys studied at 
autopsy (Allen 1951) Usually, ectopic adrenal cortical tissue is hormo-
nally inactive. Only one case has been reported of a benign adrenocor-
tical adenoma in the kidney producing the syndrome of primary 
aldosteronism (Flanagan and McDonald 1967) We speculate that in 
this patient malignant degeneration of heterotopic adrenal tissue, 
located subcapsulary in the right kidney, caused the syndrome of 
recurrent primary aldosteronism, 12 years after removal of a benign 
aldosterone-producing adrenal adenoma of the right adrenal gland 
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IX.6. ADDENDUM TO CHAPTER IX 
In view of the developments that took place in this patient after the 
article of Boers et al. (1981) had gone to press, we give here the sequel 
of this clinical history. 
After, in this patient on 11.10.79 an aldosterone-producing carcinoma 
localized subcapsularly in the right kidney had been removed operati-
vely, the blood pressure and the mineral spectrum normalized comple­
tely, while the excretion of aldosterone in the 24 hours urine fell off to 
1.9 μg/24 hours. At policlinical control on 6.8.80 the patient was found 
to be suffering from headaches, and edema of the ankles in the 
evening. But the plasma electrolytes and the plasma aldosterone values 
were entirely normal. On 8.10.80 the headache increased, there was 
intensification of the edema of the ankles and the blood pressure had 
risen to 180/110 mmHg. The mineral spectrum showed a serious 
hypokalemia of 1.8 mmol/1 and the plasma concentration of aldoste­
rone had risen to 60 ng/100 ml. On admission to hospital on 13.10.80 
the blood pressure had slightly increased to 165/90 mmHg. The body 
weight was unchanged and was 48.1 kg. There were no edemas. 
Physical examination also revealed no further abnormal findings. 
Determination of the aldosterone secretion rates showed a recurrent 
primary aldosteronism (table IX-3). 
The excretion of the 17-ketosteroids in the 24 hours urine was normal 
Table IX-3. 
Aldosterone secretion rates and additional clinical and biochemical 
findings in patient L-v G, one year after surgical removal of an aldoste­
rone-producing carcinoma 
SODIUM INTAKE 
15 mmol/24 hr 115 mmol/24 hr 315 mmol/24 hr 
Blood pressure 
Sodium (mmol/l) 
Potassium (mmol/1) 
Creatinine (цтоі/і) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR (μ
β
/24 hr) 
139 
2.2 
81 
31 
59 
10.4 
43 
1087 
146/103 
(n=9) 
145 
1.9 
73 
188 
60 
10.5 
33 
642 
143 
1.6 
75 
202 
78 
10.2 
-
740 
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on repetition, varying from 1.0 to 3.5 mmol/mmol creatinine (n=17). 
The BSE was 15 mm. The liver functions were normal. The Hgb was 
8.5 mmol/1. For the detection of the aldosterone-producing tumor the 
following examinations were done: X-ray of the chest: no anomalies of 
heart or lungs. The heart-lung quotient was 12 : 37. IVP: partial 
nephrectomy of the right kidney. Normal position of the kidneys. CT 
scan: no indications of local recurrence of the tumor. No indications of 
metastases in the liver or retroperitoneally. Aortography, coeliaco-
graphy and renal arteriography: no anomalies. Liver, spleen and 
skeleton scintigraphy: no anomalies. Adrenal scintigraphy with mI-6ß-
Iodomethyl-19-Nor-Cholesterol: on the 2nd, 6th, 8th, 9th and 10th days 
after intravenous injection of the isotope at a dose of 2 mCi, no 
accumulation of the tracer inside or outside the adrenal region was 
observed. The examination was made after giving dexamethasone 2 
mg/day for 3 weeks. Venous catheterization with blood sampling: the 
plasma aldosterone concentrations in blood samples that were collec-
ted at varying levels in the vascular area of the vena cava yielded no 
convincing indication of the localization of the tumor: peripheral vena 
cava inferior 28 ng/100 ml, proximal vena cava inferior 29 ng/100 ml, 
left renal vein 29 ng/100 ml, right renal vein 29 ng/100 ml, hepatic vein 
31 ng/100 ml, right atrium 41 ng/100 ml. On 12.12.80 the right adrenal 
region was explored via a pararectal-thoracic, transabdominal incision. 
There was found a well encapsulated tumor of 4x3x2 cm, localized 
retroperitoneally, firmly adherent to the psoas muscles. The tumor lay 
3 cm above and lateral to the upper pole of the right kidney, without 
being attached to it. The tumor could be easily removed in toto. The 
extirpated tumor weighed 8 grams and was entirely surrounded by a 
capsule. On the cut surface the tumor presented a nodular structure 
with local bleedings and areas of necrosis. On microscopic examination 
the tumor was seen to be made up of nodes of medium-size to large 
cells with eosinophile clear cytoplasm and atypical nuclei. The nodes 
were separated from each other by thin septa of connective tissue. 
Mitoses were easily found. Here and there, there was commencing 
necrosis and invasion of blood vessels. In the capsule of varying 
breadth (in which there was topically both fatty and muscular tissue) 
there were several tumor foci manifesting the picture of an infiltrative 
growth. Conclusion: adrenal cortex carcinoma. 
Postoperatively the blood pressure fell to 120/85 mmHg. The mineral 
spectrum normalized and the plasma aldosterone concentration was 
lowered to 5 ng/100 ml. During a follow-up of 6 months no indications 
were found of recurrence of tumor or of metastases. The blood 
pressure remained entirely normal. 
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SUMMARY 
In this thesis some clinical and pathological aspects of "primary aldos-
teronism" are discussed on the basis of studies that were made in 28 
patients. Attention has been devoted to both the individual clinical 
histories of these patients (Appendix) and to the summaries of the most 
important aspects they present (chapters III up to and including 
chapter IX). The patients were referred to the department of Internal 
Medicine in the period 1961 to 1979. The consequence of this long time 
interval is that a number of data (chapters III and VIII) could be 
compiled only by retrospective research, with all the shortcomings 
inherent in such investigations. On the other hand data of prospective 
research are set forth in chapters IV, V, VI and VII. 
In chapter I there are a number of references to the literature about the 
diagnosis and treatment of the adenomatous and idiopathic forms of 
primary aldosteronism. 
In chapter II a description is given of the methods by which the data 
were collected that concerned the aspects of "primary aldosteronism" 
that in this thesis receive special attention. These aspects were: "gene-
ral clinical data", "the diagnosis of primary aldosteronism", "the day 
and night rhythm of the plasma aldosterone concentration", "adrenal 
scintigraphy", "medicamentous treatment", "operation", "pathology 
of the adrenals" and "clinical follow-up". 
In chapter III anamnestic data about the patients studied are reported, 
with some emphasis on the first complaints and signs with which the 
illness was initiated. A remarkable feature is the number of patients 
who had already a raised blood pressure for a long time before the 
diagnosis of "primary aldosteronism" was definitely made. The blood 
pressure was mostly seriously raised as was apparent from the frequent 
occurrence of complications, that were the sequel of the hypertension. 
The theme then dwells upon the influence of deprivation or loading of 
salt upon the electrolytes in plasma and urine. The adenomatous form, 
in comparison with the idiopathic form, shows clearer signs of aldoste-
ronism, with which the difference in plasma renin activity between the 
two groups is in agreement. From the comparison of the effectiveness 
of medicamentous treatment by spironolactone and by surgery, it 
became apparent in our study that the effect produced by spironolac-
tone was of prognostic value with regard to the results to be expected 
from treatment by surgery. The results of surgical treatment in this 
group of patients show that the operation, according to a long-lasting 
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follow-up. leads to a permanent normal blood pressure in only a 
minority of the patients. 
In chapter IV, the importance of salt loading for the diagnosis of 
"primary aldosteronism" is elucidated. Measurements of aldosterone 
in the 24 hours urine under various conditions - after salt loading, 
changing of body posture, administration of dexamethasone-however, 
prove not to contribute to a differentiation between idiopathic and 
adenomatous aldosteronism. On the contrary it did prove possible to 
differentiate the two forms of primary aldosteronism on the basis of 
measuring aldosterone in blood during the night and the day. We 
summarize these data on the basis of the article published in chapter V. 
Also in chapter IV a report is made on the fact that the regulation of 
aldosterone in the blood in patients "after removal of an adenoma", 
measured under varying circumstances - night versus day, basally 
versus dexamethasone, standing up versus lying down - is essentially 
different from the regulation of aldosterone in patients before the 
removal of an adenoma. Moreover it was found that there is a striking 
agreement in the behaviour of aldosterone in patients "after removal of 
an adenoma" and that in patients with idiopathic aldosteronism. 
In chapter V the differences in the diurnal plasma aldosterone concen-
trations in 8 patients with adenomatous (APA) and 4 with idiopathic 
aldosteronism (IHA), were featured by the following findings. During 
the night the plasma aldosterone concentration in patients with APA 
was noticeably higher than in patients with IHA, and also during the 
day if the patients were resting in bed. But if the patients were out of 
bed by day there was no difference in the height of the aldosterone 
level in the two groups. In patients with APA the concentration of 
aldosterone in the plasma was especially under the influence of ACTH. 
This became clear from the day and night rhythms of the aldosterone 
concentrations that manifested a significant correlation with the con-
centrations of plasma Cortisol. In patients with IHA on the contrary, 
the values of aldosterone and Cortisol in the plasma were significantly 
correlated solely during the night. The values of aldosterone in the 
plasma were, during the day, significantly correlated with the renin 
activity in the plasma and, during the days on which the patients were 
out of bed, manifested significantly higher values than on the days 
when the patients were resting in bed. Therefore, plasma aldosterone 
concentrations in patients with IHA were during daytime predomi-
nantly under control of the renin angiotensin system. 
The influence of short-lasting administration of dexamethasone on the 
day and night variations of aldosterone showed that, as was to be 
expected, the nocturnal aldosterone values in both groups were redu-
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eed in particular The findings after administration of dexamethasonc 
yielded no additional data that can contribute to a further differentia­
tion between adenomatous and idiopathic aldosteronism Yet, in this 
connection an exception must be made. The influence of change of 
body posture from lying down to standing up during the morning of day 
1, did not lead in the group with APA to a rise of the plasma 
aldosterone concentration, on the contrary, to what was observed in 
patients with IHA However, during administration of dexamethasonc 
there was seen, under the influence of the same stimulus, for unexplai­
ned reasons, a definite rise of the plasma aldosterone concentration, 
comparable with that in patients with IHA 
In chapter VI the value is assessed of short and long-lasting administra­
tion of dexamethasonc for the scintigraphic localization of aldosterone-
producing adenomas With the did of the radiocholesterol compound 
niI-19-Iodocholesterol and short-lasting dexamethasonc administra­
tion the adenoma was correctly localized in only 3 out of 8 patients, 
whereas with the more recent radiocholesterol compound Π11-6β-
Iodomcthyl-19-Nor-Cholesterol and long-lasting pretreatment with 
dexamethasonc the adenoma was correctly localized in 8 out of the 9 
patients, including 3 patients in whom, with the former procedure, no 
lateralization was established The importance of a long-lasting admini­
stration of dexamethasonc resides in the fact that thereby an uptake of 
the radiocholesterol compound into the "normal" adrenal is blocked in 
a more effective manner than after short-lasting dexamethasonc admi­
nistration The uptake of radioactivity into the adrenal containing the 
adenoma has been found to be not blocked by long-lasting administra­
tion of dexamethasonc 
In chapter VII the results of treatment with the aldosterone antagonist 
spironolactone were compared with those of the weak potassium-
saving diuretic amilonde, in order to gain more insight into the 
hypotensive action of spironolactone. Spironolactone (400 mg/day) and 
amilonde (40 mg/day) were given to 10 patients with primary aldoste­
ronism (group I) and 10 patients with essential hypertension (group II). 
In patients with primary aldosteronism a greater fall of blood pressure 
occurred after treatment with spironolactone than after treatment with 
amilonde, whereas in patients with essential hypertension a compara­
ble slight fall of blood pressure occurred. The decrease of body weight 
- as a measure for the depletion of volume - was greater after 
treatment with spironolactone than after treatment with amiloride in 
both group I and group II. In patients with primary aldosteronism, 
after both medicaments, qualitatively and quantitatively comparable 
changes of the plasma sodium and the plasma potassium were obser-
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ved, which point to a similar degree of antimineralocorticoid activity. 
In group II the changes of plasma sodium and potassium were only 
small. Furthermore, it was noticed that in the group with primary 
aldosteronism the aldosterone excretion after treatment with spirono-
lactone displayed a rise that was comparable with the aldosterone 
excretion after treatment with amiloride. This was remarkable as after 
treatment with spironolactone the plasma renin activity showed a 
considerably greater rise than after treatment with amiloride. This 
finding was interpreted as the consequence of a relative inhibition of 
the secretion of aldosterone by interference with the biosynthesis of 
this hormone. In the discussion the question is debated of to what 
extent the hypotensive action of spironolactone as well as having a 
diuretic and antimineralocorticoid effect, is also based on a specific 
antialdosterone effect. 
In chapter VIII the morphological anomalies in the adrenals of patients 
with primary aldosteronism are discussed. The macroscopic adrenal 
pathology, measured by the weight of the adrenal and/or the size of the 
adenoma - showed only little agreement with the functional pathology, 
as measured by the secretion rate of aldosterone. The microscopic 
architecture of the adrenal adenomas was assayed according to the 
classical description of Neville and Symington. In 15 of the 19 adeno-
mas the histological pattern was dominated by the zona fasciculata type 
of cells, while the most frequent anomaly in the adrenals of patients 
with idiopathic aldosteronism consisted of a focal or diffuse broadening 
of the zona glumerulosa. Also a remarkable finding was that the zona 
glomerulosa of the adrenal cortex lying outside the adenoma in the 
majority of the adrenals examined presented a diffuse broadening. In 4 
of the 18 patients who were treated preoperatively with spironolactone 
the presence of intracellular eosinophile inclusion bodies ("spironolac-
tone bodies") was demonstrated. There are good indications that these 
"spironolactone bodies" are the morphological expression of an inhibi-
tion of the biosynthesis of aldosterone under the influence of spirono-
lactone. The presence of "spironolactone bodies" in the adrenal tissue 
of only 4 of the 18 patients who were treated with spironolactone, is 
possibly explained by differences in the duration in time of treatment 
and the time interval before the adrenal was removed. Finally, in this 
chapter, at the instigation of a woman patient with an aldosterone-
producing carcinoma (chapter IX) a review is given of the pathological 
findings in this rare variant of primary aldosteronism. 
In chapter IX a case report is presented of a woman patient with an 
aldosterone-producing carcinoma. This patient has in total developed 
on 3 occasions the syndrome of primary aldosteronism, 2 of which were 
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the sequel of a malignant tumor. In the literature no earlier report has 
been made of an aldosterone-producing carcinoma that has developed 
after removal of an aldosterone-producing adenoma. There are indica-
tions that the malignant tumor arose from heterotopic adrenal tissue 
localized in the right kidney. 
In the Appendix the case histories of the patients are reported. 
173 

SAMENVATTING 
In dit proefschrift worden enkele klinische en pathologische aspecten 
van „primair aldosteromsme" besproken aan de hand van studies die 
werden verricht bij 28 patiënten. Er werd aandacht besteed aan zowel 
de individuele ziektengeschiedemssen van deze patiënten (Appendix) 
als aan de samenvattingen van de belangrijkste aspecten daarvan 
(hoofdstukken III tot en met IX) De patiënten werden venvezen naar 
de afdeling Inwendige Geneeskunde in de periode 1961-1979 Dit lange 
tijdsinterval heeft tot gevolg, dat een aantal gegevens (hoofdstukken 
III en VIII) slechts door retrospectief onderzoek verzameld kon wor-
den, met alle beperkingen die aan dit soort van onderzoek inherent 
zijn. Anderzijds werden gegevens van prospectief onderzoek neerge-
legd in de hoofdstukken V, VI en VII 
In hoofdstuk I zijn een aantal literatuurverwijzingen bijcengezet over 
de diagnostiek en behandeling van de adenomateuze en idiopathische 
vorm van primair aldosteromsme. 
In hoofdstuk II wordt een beschrijving gegeven van methoden waar-
mee de gegevens werden verzameld betreffende die aspecten van 
,,primair aldosteromsme" die in dit proefschrift bijzondere aandacht 
kregen Deze aspecten waren: „algemene klinische gegevens", ,,de 
diagnose primair aldosteromsme", ,,het dag en nacht nthme van de 
plasma aldosteron concentratie", „bijmerscintigraphie", „medicamen-
teuze behandeling", „operatie", „pathologie van de bijnier" en „klini-
sche follow-up". 
In hoofdstuk III worden anamnestische gegevens van de bestudeerde 
patiënten vermeld, met enige nadruk op de eerste klachten en ver-
schi|nselen waarmee de ziekte debuteerde Het is opvallend dat een 
aantal patiënten reeds langdurig een verhoogde bloeddruk hadden, 
alvorens de diagnose „primair aldosteromsme" definitief werd gesteld 
De bloeddruk was meestal ernstig verhoogd, zoals bleek uit het fre-
quent optreden van complicaties, die daarvan het gevolg waren. Ver-
volgens wordt stilgestaan bi| de invloed van zoutonthouding en zoutbe-
lasting op de elcctrolyten in plasma en urine De adenomateuze vorm 
toont in vergelijking met de idiopathische, duidelijker tekenen van 
aldosteromsme waarmee ook het verschil in plasma renine activiteit 
tussen beide groepen in overeenstemming is. Uit vergelijking van 
effectieve medicamenteuze behandeling door Spironolacton en door 
chirurgie bleek ook in onze studie dat het bloeddrukverlagend effect 
door Spironolacton een voorspellende waarde heeft voor het te ver-
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wachten behandelingsresultaat door chirurgie. De resultaten van chi-
rurgische behandeling in deze groep patiënten tonen aan dat de 
ingreep, bij een langdurige follow-up, slechts bij een minderheid van de 
patiënten tot een blijvende normale bloeddruk leidt. 
In hoofdstuk IV wordt het belang van zoutbelasting voor de diagnos-
tiek van „primair aldosteronisme" aangetoond. Metingen van aldoste-
ron in de 24-uurs urine onder diverse omstandigheden - na zoutbelas-
ting, verandering van lichaamshouding, toediening van dexamethason 
- bleken echter niet bij te dragen tot een differentiatie tussen idiopa-
thisch en adenomateus aldosteronisme. Het bleek daarentegen wel 
mogelijk om beide vormen van primair aldosteronisme te onderschei-
den op basis van metingen van aldosteron in bloed gedurende de nacht 
en de dag. Deze gegevens vatten wij samen aan de hand van het 
gepubliceerde artikel in hoofdstuk V. In hoofdstuk IV wordt voorts 
melding gemaakt van het feit dat de regulatie van aldosteron in bloed 
bij patiënten ,,na verwijdering van een adenoom", gemeten onder 
verschillende omstandigheden - nacht vs dag, basaal vs dexamethason, 
staand vs liggend - essentieel verschillend is met de regulatie van 
aldosteron bij patiënten vóór verwijdering van een adenoom. Boven-
dien bleek er een opvallende overeenkomst in het gedrag van aldoste-
ron bij patiënten ,,na verwijdering van een adenoom" en dat bij 
patiënten met idiopathisch aldosteronisme. 
In hoofdstuk V worden de verschillen in de diurnale plasma aldoste-
ronconcentraties bij 8 patiënten met adenomateus (APA) en 4 met 
idiopathisch aldosteronisme (IHA), gemarkeerd door de volgende 
bevindingen. Gedurende de nacht was de plasma aldosteron concentra-
tie bij patiënten met APA aanmerkelijk hoger dan bij patiënten met 
IHA, evenals gedurende de dag wanneer de patiënten bedrust hadden. 
Wanneer de patiënten echter gedurende de dag „op" waren was er 
geen verschil in de hoogte van aldosteronspiegels in de beide groepen. 
Bij patiënten met APA bleek de concentratie van aldosteron in plasma 
vooral onder invloed te staan van ACTH. Dit werd duidelijk uit het 
dag- en nachtritme van de aldosteronconcentraties, die een significante 
correlatie toonden met de concentraties van plasma Cortisol. Bij 
patiënten met IHA, daarentegen, waren de waarden van aldosteron en 
Cortisol in plasma, uitsluitend gedurende de nacht significant gecorre-
leerd. De waarden van aldosteron in plasma waren gedurende de dag 
significant gecorreleerd aan de renine activiteit in het plasma en 
toonden gedurende de dag waarop de patiënten „op" waren significant 
hogere waarden, dan op de dag waarop de patiënten bedrust hadden. 
De invloed van kortdurende toediening van dexamethason op de dag-
en nachtvariaties van aldosteron toonde aan dat overeenkomstig de 
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verwachting, vooral de nachtelijke aldosteronwaarden in beide groe-
pen werden gereduceerd. De bevindingen na toediening van dexame-
thason leverden geen additionele gegevens op die kunnen bijdragen tot 
een verdere differentiatie tussen adenomateus en idiopatisch aldostero-
nisme. In dit verband moet echter één uitzondering worden gemaakt. 
De invloed van verandering van lichaamshouding van liggen naar staan 
gedurende de ochtend van dag 1, leidde in de groep met APA niet tot 
een stijging van de plasma aldosteronconcentratie, in tegenstelling tot 
hetgeen bij patiënten met IHA werd waargenomen. Echter, tijdens de 
toediening van dexamethason werd onder invloed van dezelfde stimu-
lus, om onverklaarde redenen, wel een stijging van de plasma aldoste-
ronconcentratie gezien, vergelijkbaar met die bij patiënten met IHA. 
In hoofdstuk VI wordt de waarde geëvalueerd van kort- en langdurige 
toediening van dexamethason voor scintigrafische localisering van 
aldosteronproducerende adenomen. Met behulp van de radiocholeste-
rolverbinding 131I-19-Iodocholesterol en kortdurende dexamethason-
toediening werd bij slechts 3 van de 8 patiënten het adenoom correct 
gelocaliseerd, terwijl met de nieuwere radiocholesterolverbinding 13II-
6ß-Iodomethyl-19-Nor-Cholesterol en langdurige voorbehandeling met 
dexamethason het adenoom bij 8 van de 9 patiënten correct werd 
gelocaliseerd, inclusief 3 patiënten bij wie met de eerste procedure 
geen lateralisatie was vastgesteld. Het belang van een langdurige 
toediening van dexamethason is gelegen in het feit dat hierdoor een 
opname van de radiocholesterolverbinding in de „normale" bijnier op 
een meer effectieve wijze wordt geblokkeerd dan na kortdurende 
dexamethason toediening. De opneming van radioactiviteit in de ade-
noomhoudende bijnier blijkt door langdurige toediening van dexame-
thason niet te worden geblokkeerd. 
In hoofdstuk VII werden de resultaten van behandeling met de aldoste-
ron-antagonist Spironolacton vergeleken met die van het zwakke kali-
umsparende diureticum amiloride, teneinde meer inzicht te verkrijgen 
in de bloeddrukverlagende werking van Spironolacton. Spironolacton 
(400 mg/dag) en amiloride (40 mg/dag) werden gegeven aan 10 
patiënten met primair aldosteronisme (groep I) en 10 patiënten met 
essentiële hypertensie (groep II). Bij patiënten met primair aldostero-
nisme trad een grotere bloeddrukdaling op na behandeling met Spiro-
nolacton dan na behandeling met amiloride, terwijl bij patiënten met 
essentiële hypertensie een vergelijkbaar geringe bloeddrukdaling 
optrad. De daling van het lichaamsgewicht - als een maat voor de 
volumedepletie - was na behandeling met Spironolacton groter dan na 
behandeling met amiloride zowel in groep I als in groep II. Bij 
patiënten met primair aldosteronisme werden na beide medicamenten 
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kwalitatief en kwantitatief vergelijkbare veranderingen van het plasma 
natrium en het plasma kalium waargenomen die duidden op een/elfde 
mate van antimineralocortitoide activiteit In groep II waren de veran-
deringen van plasma natrium en kalium slechts gering Voorts werd 
geconstateerd dat in de groep met primair aldostcromsme de 
aldosteronexcreties na behandeling met Spironolacton een stijging 
vertoonden die vergelijkbaar was met de aldosteronuitscheiding na 
behandeling met amilonde Dit gegeven was opmerkelijk omdat na 
behandeling met Spironolacton de plasma renine activiteit een aanzien-
lijk grotere stijging toonde dan na behandeling met amilonde Deze 
bevinding werd geduid als het gevolg van een relatieve inhibitie van de 
secretie van aldosteron door interferentie met de biosvnthese van dit 
hormoon In de discussie wordt ingegaan op de vraag in hoeverre de 
bloeddrukverlagende werking van Spironolacton, behalve op een diure-
tisch en antimineralocorticoid effect, ook berust op een specifiek anti-
aldosteron effect 
In hoofdstuk VIII worden de morfologische afwijkingen aan de bijnie-
ren van patiënten met primair aldostermsme besproken De macrosco-
pische bijmerpathologie, gemeten aan het gewicht van de bijnier en/of 
grootte van het adenoom - toonde maar weinig overeenkomst met de 
functionele pathologie, zoals gemeten aan de secretie snelheid van 
aldosteron De microscopische architectuur van de bijmeradenomen 
werd getoetst aan de klassieke beschrijving van Neville en Symington 
In 15 van de 19 adenomen werd het histologisch beeld beheerst door 
cellen van het zona fasciculatatvpe, terwi|l de meest frequente afwij-
king in de bijnieren van patiënten met idiopathisch aldosteromsme 
bestond uit een focale of diffuse verbreding van de zona glomerulosa 
Een opmerkelijke bevinding was voorts dat de zona glomerulosa van 
de bijnierschors gelegen buiten het adenoom bij het merendeel van de 
onderzochte bijnieren een diffuse verbreding vertoonde Bij 4 van de 
18 patiënten die pre-operatief waren behandeld met Spironolacton 
werd het voorkomen van intracellulaire cosmophiele insluitsels ( spi-
ronolactone bodies") aangetoond Er zijn goede aanwijzingen dat deze 
„spironolactone bodies" de morfologische expressie zijn van een inhi-
bitie van de biosvnthese van aldosteron onder invloed van Spironolac-
ton Het voorkomen van ,,spironolactone bodies" m het bi|nicrweefsel 
van slechts 4 van de 18 patiënten die met Spironolacton werden 
behandeld, wordt mogelijk verklaard door verschillen in tijdsduur van 
behandeling en het tijdsinterval voordat de bijnier werd verwijderd 
Tenslotte wordt in dit hoofdstuk, naar aanleiding van een patiente met 
een aldosteronproducerend carcinoom (hoofdstuk IX) een literatuur 
overzicht gegeven van de pathologische bevindingen bij deze zeldzame 
variant van primair aldosteromsme 
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In hoofdstuk IX wordt een case report weergegeven van een patiënte 
met een aldosteronproducerend carcinoom. Deze patiënte heeft in 
totaal 3 maal het syndroom van primair aldosteronisme ontwikkeld, 
waarvan 2 maal tengevolge van een maligne tumor. In de literatuur 
werd niet eerder melding gemaakt van een aldosteronproducerend 
carcinoom dat zich heeft ontwikkeld na verwijdering van een aldoste-
ronproducerend adenoom. Er zijn aanwijzingen dat de maligne tumor 
is ontstaan uit heterotopisch bijnierweefsel gelocaliseerd in de rechter 
nier. 
In de Appendix worden de ziektegeschiedenissen van de patiënten 
vermeld. 
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Panent 1 (Ç, G-J, 17 10 25) 
1 The patient is a 38 years old woman, who was referred to the department of internal medicine in May 
1964, because of hypertension and spontaneous hypokalemia Two months earlier the patient was 
admitted to the department of neurology of a hospital elsewhere after a sudden loss of consciousness 
Examination had revealed a marked hypertension with blood pressure values varying from 220/120 to 
280/180 mmHg A neurosurgical decompression was performed for a left sided intracerebral hemorr-
hage Hypokalemia, with plasma potassium values as low as 2 2 mmol/l, was repeatedly found and 
primary aldosteronism was suspected The patient's history did not reveal the presence of hyperten-
sion during any of her 3 pregnancies (1952, 1954, and 1958) She had been without complaints until a 
few months before the cerebrovascular accident, when she developed headache, fatigue, polyuria and 
nycturia Medical treatment with rauwolfia alkaloids at the department of neurology had decreased 
blood pressure to 165/105 mmHg Physical examination revealed a hemiparesis of the right arm and 
leg and an expressive aphasia Blood pressure was 175/105 mmHg Fundoscopy did not disclose the 
presence of exudates or hemorrhages Central venous pressure was normal (R-5 cm H2O) No edema 
was found The heart was slightly enlarged Abdominal vascular bruits were absent Laboratory 
Urinalysis did not reveal glucosuria or proteinuria Plasma electrolytes sodium 141 mmol/l, potassium 
3 2 mmol/l, chloride 105 mmol/l, and bicarbonate 26 9 mmol/l Renal function was unimpaired 
Roentgenography X-rays of the chest showed a slight increase of the heart size Intravenous 
pyelography did not disclose any abnormalities Seldinger arteriography of the renal arteries did not 
show abnormalities of the renal arteries After presacral gas insufflation, both adrenal glands were 
visualized the right adrenal gland appeared normal, while the left gland appeared to contain a round 
tumor with a diameter of 2 5 cm 
2 Aldosterone secretion rates were measured before and after moderate sodium loading (table A-l) 
Assay for determination of PRA was not yet available in 1964 However, aldosteronism in the absence 
of known causes of secondary aldosteronism strongly suggested the presence of primary aldostero-
Table A-l 
Aldosterone secretion rates and additional clinical and biochemical findings in patient G-J 
SODIUM INTAKE 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (цтоі/і) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
ASR ^g/24 hr) 
5 mmol/24 hr 
144 
3 4 
-
5 
37 
396 
172/114 (n=50) 
115 mmol'24hr 
145 
3 1 
58 
42 
51 
370 
6 On September 8th 1964. the adrenal glands were surgically explored via a median abdominal incision 
The left adrenal gland appeared to contain a tumor and was removed in loto The gallbladder was also 
removed because of a cholelithiasis 
7 The surgically removed adrenal gland contained a yellow tumor whose greatest diameter was 2 cm 
The tumor was sharply separated from the surrounding adrenal cortex Light microscopy the tumor 
was composed of large clear cells with vacuolated cytoplasm and round nuclei, which varied in size 
The cells were arranged in solid fields, separated by thin septa of connective tissue, or in columns 
Focally, cells with a more eosinophilic and nonvacuolated cytoplasm were found The adjacent 
adrenal cortex showed an atrophic zona glomerulosa Conclusion Adrenocortical adenoma compo 
sed of zona fasciculata-type cells Focally, zona reticulans-type cells Atrophy of the zona glomerulosa 
in the adjacent cortex 
8 Aldosterone secretion rates were measured clinically, one month after operation ASR measured 
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during a sodium-reslncted die! was 292 μ§/24 h Blood pressure decreased lo 105-120/70-95 mmHg 
and remained normal without the use of antihypertensive medicaments In 1969, 5 years after 
operation, blood pressure was 130/95 mmHg and the patient was discharged from further control 
visits At that time her neurologic symptoms had markedly improved 
Patient 2 (Cf, Br, 31 05 17) 
The patient is a man aged 44 years, who in November 1961 was referred to the department of internal 
medicine Since five years he had a history of severe, increasing hypertension, for which he had 
received no mcdicamentous treatment He had been admitted to a hospital elsewhere on account of 
dizziness, headache and a transitory motor aphasia At that time the blood pressure was 240/110 
mmHg and the renal function had deteriorated The patient complained of headache and pain in the 
chest on effort He also had a penod of visual disturbances and difficulty in walking The blood 
pressure was 245/115 mmHg On fundoscopy exudates and retinal edema were found The plasma 
mineral spectrum showed hypernatremia (150 and 146 mmol/l) and hypokalemia (2 6 and 3 0 mmol/l) 
The IVP and the lumbar aortography revealed no anomalies in the kidneys or the renal artenes 
During treatment with guanethidme and reserpine (1962-1964) the blood pressure fell off to 150/110 in 
the supine and 100/80 mmHg in the upright position In 1964 the patient was admitted to the clinic for 
determinations of the aldosterone secretion rate and for retroperitoneal insufflation of gas In the 
latter examination suspicion of a tumor of 3 5 cm in the left adrenal was expressed 
The aldosterone secretion rale was measured during continuous use of antihypertensive medication 
(reserpine and hydralazine) In the table A-2 are arranged the values of the aldosterone secretion 
rate, determined during the taking of 0 and 6 grams of salt, and presented together with some other 
parameters The very high secretion values during a sall-restnctive diet were found to be not 
suppressible after moderate salt loading so that the diagnosis of primary aldosteronism was made 
Table A-2 
Aldosterone secretion rales and additional clinical and biochemical findings in patient Br 
SODIUM INTAKE 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (цтоі/і) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
ASR (Mg/24 hr) 1255 1257 
On December 16th 1964 both adrenals were explored by operation through a median incision in the 
upper abdomen The left adrenal was found to contain an adenoma 2 cm in size and the left adrenal 
was removed in toto 
The weight of the adrenal was 30 grams On dissection a second node 2 mm in size was found in the 
adrenal cortex Light microscopy the adenoma was composed of large cells with foamy cytoplasm and 
a small round nucleus The cells were indistinguishable from the type that is encountered in a normal 
zona fasciculata Sections of the adrenal cortex lying outside the adenoma showed a narrow zona 
glomerulosa The zonae fasciculata and reticularis ranged from normal to widened Conclusion 
adenoma consisting of cells of the zona fasciculata-type 
The blood pressure remained raised after operation During the stay in the clinic, one month after 
operation, an average value of 178/127 mmHg was found The plasma mineral spectrum was 
normalized and the aldosterone secretion rate had fallen to normal values (225 and 154 Hg/24 hr, 
during salt-free diet and with 6 grams of salt respectively) At the policlmical controls from 1964 to 
1971 the blood pressure remained seriously raised in spite of the medicamentous treatment At the 
15 mmol/24 hr 
139 
3 0 
221 
17 
29 
115 mmol/24 hr 
225/136 (n=33) 
142 
2 5 
248 
67 
60 
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end of 1970 the palienl was admitted to the clinic because of repeated subcoma with transitory 
paralyses, speech disorders and a rapidly deteriorating renal function Death occurred on June 14th 
1971. 
Patient 3 (cf ν W. 19 07 22) 
1. The patient is a man aged 49 years, who was referred to the department of nephrology in February 
1971 for analysis and treatment of hypertension Blood pressure was found to be raised in 1967, when 
he complained of fatigue From 1961 on he had developed complaints of headache m the early 
morning Hypertension analysis by another internist had revealed a marked hypertension (230/140 
mmHg), an impairment of renal function (creatinine 206 μηιοΙ/Ι), an increase of heart size (heart-to-
lung quotient: 18.35) and hypertensive retinopathy (hemorrhages) Antihypertensive treatment with 
rauwolfia alkaloids, had been unsuccessful In January 1971 the patient developed a transient ischemic 
attack with speech disturbances and paresis of the right arm and leg. On admission the patient 
complained of fatigue, headache, drowsiness, polydipsia and nycturia Physical examination Blood 
pressure 260/170 mmHg Central venous pressure was R-6 cm I I 2 0 No edema was found Fundo-
scopy revealed arteriovenous nicking and segmental constriction of the arterioles Hemorrhages and 
exudates were absent There were no abdominal bruits Laboratory. Urinalysis revealed a mild 
proteinuria of less than 1 g/24 hr Urine sediment was normal Urine culture remained stenle Plasma 
electrolytes sodium 143 mmol/1, potassium 2 5 mmol/1, chloride 98 mmol/1 and bicarbonate 33 2 
mmol/1 Creatinine 268 цтоі/і The endogenous creatinine clearance was diminished to 38 ml/mm. An 
oral glucose tolerance test showed a decreased carbohydrate tolerance. Roentgenography X-rays of 
the chest showed a heart-lo-lung quotient of 15 5:34 5. An intravenous pyelogram revealed a 
diminished excretion of the contrast material on both sides The left kidney measured 12 5x6 cm and 
the right kidney 12x5 5 cm Scldinger artenography disclosed no abnormalities of the renal arteries. 
Electrocardiography sinus rhythm with signs of left strain, ST-scgmcnt depression and T-inversion in 
leads I, II, AVL, AVFjnd V1-V4 
2. Aldosterone secretion rates were measured before and after moderate sodium loading (table A-3). 
For the interpretation of the results it should be noted that the measurements were performed during 
(he use of antihypertensive treatment (rauwolfia alkaloids, guanethidinc. methyldopa and chlorthali­
done) The findings were in accordance with the diagnosis of primary aldosteronism An impairment 
of renal function of unknown origin, might also have contributed to the development and mainte­
nance of hypertension. 
Table A-3. 
Aldosterone secretion rates and additional clinical and biochemical findings m patient ν W 
SODIUM INTAKF 
15mmol/24hr 115mmol/24hr 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potassium (mmol/1) 
Creatinine (μπιοΙ/Ι) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR ^g/24 hr) 
186/123 
142 
3 8 
197 
27 
130 
17.3 
<15 
1750 
(n=10) 
144 
3 0 
200 
153 
163 
18 9 
-
429 
5 Clinical treatment with spironolactone 400 mg/day for 3 weeks resulted in an increase of blood 
pressure from 186/123 mmHg (= the mean blood pressure value that was reached with other 
antihypertensive agents) to 203/141 mmHg (n=6). 
6 On May 4lh 1971 the right adrenal gland was surgically explored by a right lumbotomy The gland had 
to be detached from the perirenal adipose tissue and from the diaphragm No adrenal tumor was 
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found on palpation of the gland Subsequently the left adrenal gland was explored by л left 
lumbotomy The left gland was normal m size and a tumor could be easily palpated The left gland was 
surgically removed 
7 The adrenal gland measured 7x4x1 S cm and weighed 9 gram The cut surface showed, besides a 
yellow tumor of 1 4 cm, several other small adrenocortical nodules Light microscopy The adrenal 
adenoma was neither surrounded by a capsule nor sharply separated from the surrounding tissue The 
tumor was composed of small eosinophilic cells with an alveolar arrangement These cells frequently 
contained spironolactone bodies Large clear cells, as found normally m the zona fasciculata, were 
located in the periphery of the tumor The tumor gradually shaded off into the adjacent adrenal 
cortex The adrenal cortex was widened and composed of zona fasciculata and zona reticularis cells, 
while the zona glomcmlosa was only focally present 
8 The postoperative penod was complicated by clinical shock and anuna on the day after operation, 
most probably caused by mineralocorticoid deficiency Plasma sodium was 127 mmol/1 and plasma 
potassium 6 0 mmol/1 The patient was successfully treated with massive doses of mmeralocorticoids 
Subsequently the patient developed prolonged fever and, probably, pulmonary embolism, for which 
he was treated with hepann and oral anticoagulants On discharge from hospital, blood pressure 
values were still raised 152/117 mmHg (n=7) Unnary aldosterone excretion, measured on the fifth 
day after operation had decreased to 1 S γ/24 hr Subsequently, blood pressure responded satisfacto­
rily to medical treatment with chlorthalidone, hydralazine and propranolol Plasma creatinine showed 
a gradual decrease to 155 цтоІ/І On January 14th 1977, 6 years after operation, the patient died 
suddenly Post mortem examination was not performed Blood pressure, measured one month before 
death, was 112/95 mmHg 
Patient 4 (cf, F. 11 04 26) 
1 The patient is a 46 years old medical doctor, who visited the department of nephrology in August 
1972 Hypertension had been detected in 1970 (160/120 mmHg) He had taken many antihypertensive 
medicaments (chlorthalidone, alprcnolol, propranolol, Oxprenolol, Clonidine, methyldopa), without 
any effective decrease of blood pressure, but with many side effects The patient had also taken 
prednisone 10 mg/day for several months, because he supposed himself to be suffering from a 
temporal arteritis A biopsy taken from a temporal artery however, had been completely norrtial 
During prednisone treatment he had experienced a marked subjective improvement and a decrease of 
blood pressure to levels as low as 130/80 mmHg, with a return of hypertension after discontinuation of 
this therapy His previous history revealed a hepatitis-B infection in 1953, and a laminectomy in 1963 
for a hernia nuclei pulposi Antihypertensive therapy at his first visit chlorthalidone 10O mg/day, 
triamterene 50-100 mg/day and prednisone 5-10 mg/day He complained of fatigue and headache 
Nycturia, polydipsia, tetany, muscle weakness and paresthesia were absent At the first visit blood 
pressure was 190/110 mmHg He had a slight Gushing face The pulse rate was irregular, due to 
premature beats Central venous pressure was normal No edema was found The heart was not 
enlarged No abdominal vascular bruits were heard over the abdomen Fundoscopy revealed no 
Table A-4 
Aldosterone secretion rates and additional clinical and biochemical findings in patient F 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potassium (mmol/1) 
Creatinine (цтоі/і) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR ^g/24 hr) 
IS mmol'24 hr 
143 
3 2 
84 
52 
110 
20 
15 
-
SODIUM INTAKE 
115 ininol/24 hr 
155/103 (n = 
146 
3 5 
84 
220 
123 
18 6 
-
516 
•13) 
315 mmol/24 
144 
3 5 
86 
196 
195 
18 3 
-
408 
186 
abnormalities Laboratory Urine negative for protein and glucose Unne culture remained sterile 
Plasma electrolytes sodium 144 mmol/l potassium 2 4 mmol/1 chloride 96 mmol/1 and bicarbonate 
24 2 mmol/1 Renal function was unimpaired Electrocardiography showed a sinus rhvthm with U-
waves Premature beats arising from two different ventricular foci were seen Roentgenography of the 
chest showed a heart-to-lung quotient of 13 5 33 5 The 1VP was normal Scldmger arteriography of 
the renal arteries showed a minimal stenosis of the right renal artery at 3 cm from its origin This 
stenosis was considered to be of no hemodynamic importance 
The finding of elevated aldosterone secretion rates before and after sodium loading, concurrent with a 
low PRA. confirmed the diagnosis of primary aldosteronism (table A-4) 
Diurnal rhythms of plasma aldosterone (figure A - l ) were determined, 6 years after resection of a 
small adrenocortical adenoma of 0 8 cm Plasma aldosterone values were low and showed only slight 
variations during the night and during daytime The correlation coefficients between the basal values 
of the three adrenocortical hormones showed an almost equal influence of A C T H on the regulation of 
the three hormones, both during the night and dunng the night, days 1 and 2 
night night days 1 and 2 
( n = l l ) (n=17) 
Aldosterone vs Cortisol 0 85 ( p < 0 001) 0 81 ( p < 0 001) 
Aldosterone vs 18-OH-DOC 0 91 ( p < 0 ( X ) l ) 0 76 ( p < 0 001) 
Cortisol vs 18-OH-DOC 0 93 ( p < 0 001) 0 95 ( p < 0 001) 
Dexamethasone treatment only slightly reduced the mean nocturnal plasma aldosterone value from 
5 7 ng/100 ml to 4 3 ng/100 ml Daytime aldosterone values remained essentially unchanged under 
dexamethasone 
Treatment with spironolactone 400 mg/day for 4 weeks, resulted in a normalization of blood pressure 
Blood pressure measurements at the weekly control visits showed the following values 170/110, 160/ 
105, 120/85, 125/80 mmHg -
On August 16th 1973 the right adrenal gland was explored via a right lumbotomy and appeared 
normal on palpation Half of the right adrenal gland was resected Subsequently, the left adrenal 
gland was removed in toto via a left lumbotomy, although no tumor could be palpated 
On dissection of the left adrenal gland, a small adrenocortical adenoma was found, with a maximal 
diameter of 0 8 cm The tissue removed from the right adrenal gland looked normal upon dissection 
Light microscopy the adrenocortical adenoma was sharply separated from the adjacent cortex and 
was composed of relatively small eosinophilic cells arranged in alveolar fields Almost every cell 
contained one or two laminated cytoplasmic inclusions, surrounded by a clear halo (spironolactone 
bodies) The adrenal cortex outside the tumor showed a slightly nodular architecture caused by an 
increase of both the zona glomcrulosa and the zona fasciculata The zona glomerulosa cells of the 
adjacent cortex also contained spironolactone bodies but less abundantly than the tumor did 
The adrenal tissue from the right adrenal gland showed an adrenal cortex varying in width, with a 
normal zonation into three layers At several places the zona glomerulosa cells contained spironolac­
tone bodies Conclusion Adrenocortical adenoma composed of zona glomerulosa-type cells A 
slightly nodular hyperplasia of the adjacent adrenal cortex of the left gland Spironolactone bodies in 
the tumor cells and. to a lesser extent, in the zona glomerulosa cells of the left and the right adrenal 
cortex 
' Spironolactone was withdrawn on August 6th 1973 and on August 10th the patient was admitted to hospital Plasma 
aldosterone values were determined on August 15th after 5 days of a 115 mmol sodium diet At that time blood 
pressure was normal (130/80 mmHg) plasma sodium was 147 mmol/1 and plasma potassium 4 5 mmol/1 Remarka­
bly plasma aldosterone values were low both at 09 00 hr in the supine position (4 9 ng/100 ml) and after 3 hoursof 
ambulation at 12 00 hr (12 6 ng/lOO ml) It might be that these low aldosterone values were caused by an interference 
of aldosterone biosynthesis with spironolactone The finding of spironolactone bodies m the adrenal glands, 
surgically removed on August 16th (see also 7) is in accordance with this supposition, as has been discussed in 
chapter Ш 
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Figure A-l Diurnal variations of plasma aldosterone, Cortisol and 18-OH-DOC in patient F, 6 years 
after reset lion of an adenoma 
8 Six weeks after operation, the patient was admitted to hospital for postoperative evaluation Blood 
pressure was 134/88 mmHg, plasma sodium 140 mmo!/l. and potassium 4 2 mmol/1 Aldosterone 
secretion rate measured after a 1 IS mol sodium diet for S days, was 32 Hg/24 hr Blood pressure values 
measured during a clinical observation in 1979. 6 years after operation (sec also 4). were normal (132/ 
89 mmHg. n=7) without antihypertensive treatment 
Patient 5 ( Ç , Ba. 29 12 20) 
1 The patient is a 46 years old woman, who was referred to the department of internal medicine in 
September 1966 A few months earlier she had visited a cardiologist elsewhere complaining of 
backache Physical examination had revealed hypertension (190/115 mmHg) and enlargement of the 
thyroid gland The patient was referred to our institute for evaluation of thyroid function At her first 
visit she complained of nervousness and weight loss of 9 kg m the last 6 months, despite a good 
appetite She had a marked polyuria, polydipsia and nyctuna For 3 vcars she had had ankle edema in 
the evening There were no complaints of headache paresthesia or muscle weakness Her previous 
history recorded an orthopedic operation of the lumbar spine in 1950 and an appendectomy in 1964 
She had never been pregnant and had nol used oral contraceptive agents Physical examination 
revealed a nervous woman without overt signs of hyperthyroidism Body weight 82 3 kg Height 1 70 
m Central venous pressure was R-6 5 cm H.O No edema was found Blood pressure was 190/105 
mmHg The thyroid gland was not enlarged but contained a small solitary nodule No pathologic 
lymph nodes were found The heart was slightly enlarged and an early systolic souffle was heard over 
the apex Abdominal bruits were absent Fundoscopv revealed no signs of hypertensive retinopathy 
Laboratory Urinalysis no abnormalities Plasma electrolytes sodium 143 mmol/1. potassium 2 8 
mmol/1, chloride 103 mmol/1. bicarbonate 30 3 mmol/1 Renal function was unimpaired FBI was 
normal After oral glucose loading a slightly diminished carbohydrate tolerance was delected 
Roentgenography of the chest showed a hcart-to-lung quotient of 13 5 28 5 The IVP revealed a 
normal excretion of the contrast material on both sides In both kidneys small renal calculi were 
found The adrenal glands were not visualized after presacral insufflation of gas Electrocardiography 
sinus rhythm with ST Τ depressions in leads I, AVL, and V4-V6 No signs of left ventricular 
hypertrophy 
2 Aldosterone secretion rates were measured 
a In February 1967 
b In April 1967 after surgical removal of the left adrenal and half of the right adrenal gland 
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с In August 1967 before cholccyslectomy and exploration of the remaining half of the right adrenal 
gland 
d In September 1967 after cholccyslectomy and surgical failure to remove the adrenal remnant 
с In February 1974 before pyelotomy of the nght kidney (for obstructive renal disease) and 
successful removal of an aldosleronc-producing adenoma 
The results of the clinical evaluation in February 1967 (table A-5) revealed a mild hypertension, 
hypokalemia, hyporcninemia and aldosteronism after moderate sodium loading These findings were 
in accordance with the diagnosis of primary aldosteronism For a comment on the findings mentioned 
under the headings b, c, d and c, see "follow-up" (8) 
Medical treatment with aminoglutcthimide (an inhibitor of adrenal steroidogenesis) at a dosage of 
750 mg/day was given from October 1967 to February 1974 Aminoglutcthimide as used in this dosage 
did not significantly lower the blood pressure Plasma potassium values however, were markedly 
higher during treatment 
without treatment aminoglutcthimide 
(during slay in 750 mg/day (from 
the clinic from October 1967 to 
August to October February 1974) 
1967) 
Ρ systolic 156 6(130 190)n=24 153 I(125-I85)n=48 
Ρ diastolic 103 5( 85-130)n=24 99 2( 85-120)n=48 
Plasma tia' 142 8(140 145)n = 10 143 1(Π7-149)η=35 
Plasma Κ* 2 2(17 2 7)n = 10 3 4(2 7-4 6)n = 35 
Absence of a significant blood pressure lowering effect during this treatment was acceptable m view of 
Ihe relatively mild hypertension There were no side effects Polydipsia nyctuna and muscle 
weakness disappeared during treatment 
a On February 24th 1967 both adrenal glands were explored through a transverse abdominal incision 
The right adrenal gland was normal in size and no tumor could be palpated Subsequently the left 
adrenal gland was explored and appeared also lo be normal in appearance and on palpation The left 
adrenal was removed in toto while half of the right gland was resected 
b On August 8th 1967 a cholccystcclomy was performed because of cholelithiasis, recurrent 
gallstone colics and jaundice The surgeon was asked to remove the remnant of the right adrenal 
gland A tissue fragment suspected of adrenal tissue was resected 
с On February 14th 1974 a pyelotomy of the right kidney was performed after a lumbotomy below 
the 12th rib Two renal calculi were removed Subsequently the suprarenal region was explored and 
adrenal tissue containing a tumor was found just below the liver The removed adrenal tissue 
contained a classical yellow tumor 
a After dissection of the left adrenal gland and the partially resected right adrenal gland, no tumor 
was found The macroscopic aspect of the adrenal cortex was normal Light microscopy The adrenal 
cortex of the left gland did not show the charactcrislics of micronodular hyperplasia Focally, 
however the zona glomcrulosa was widened extending inward in a tongue-like manner The 
microscopic findings of the right gland were identical with those of the left gland 
b The removed fragments did not contain adrenal tissue 
с Macroscopv a yellow tumor with a maximal diameter of 1 cm and several adrenal tissue fragments, 
together measuring 10x8x6 mm Insptclion of Ihe lamcllaled gland showed a diffuse adrenocortical 
hyperplasia Light microscopy The fragmented adenoma was partially surrounded by a thin capsule 
and was composed of clear cells of the rona fasciculata-typc In between these cells, so-called "hybrid 
cells were found while focally also zona glomcrulosa cells were present At several levels, a gradual 
transition of clear cells into dark eosinophilic cells (zona reticulans-type cells) was noted The adrenal 
cortex outside the tumor showed a normal architecture with a focal widening of Ihe zona glomcrulosa 
Conclusion Adrenocortical adenoma of the right gland composed of four different cell types 
The effects of subtotal adrenalectomy were evaluated in March-April 1967 Clinical and biochemical 
data arc presented in table A 5b Although blood pressures were somewhat lower than before 
operation aldosterone secretion rates were still markedly elevated, concurrently with hypernalremia, 
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ГаЫеА-5 
Aldosterone secretion rates and additional clinical and biochemical findings m patient Ba 
Medicaments 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (μπιοΙ/Ι) 
U V sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR ^g/24 hr) 
a January 1967 
sodium intake 
b April 1967 
sodium intake 
15 mmol/24 hr 115 mmol/24 hr 15 mmol/24 hr 115 тліоІ/24 hr 
151/% (n= 
142 
3 2 
64 
29 
60 
115 
57 
732 
=8) 
144 
2 3 
-
89 
74 
10 7 
<28 
551 
127/84 
145 
3 3 
54 
14 
73 
8 8 
86 
617 
(n=6) 
141 
3.4 
44 
144 
97 
8 6 
43 
329 
Table A-5 (continued) 
Aldosterone secretion rates and additional clinical and biochemical findings in patient Ba 
с August 1967 
sodium intake 
15 mmol/24 hr 115 mmol/24 hr 
141/95 (n=6) 
141 143 
2 4 2 4 
d September 1967 
normal diel 
e February 1974 
sodium mlake 
115 mmol/24 hr 
18 
57 
9 3 
788 
90 
119 
9 5 
864 
- dexametha- amino-
sonc 2 mg/day glutcthimide 
750 mg/day 
160/107 (n=3) 172/115 (n=3) 172/115 (n=2) 173Ί02 (n=2) 
143 140 143 140 
2 3 18 3 0 2 6 
52 
215 194 70 117 
90 
13 2 
31 
466 375 236 835 
hypokalemia and hyporemncmia In August 1967 the patient was admitted to the hospital for 
observation of unexplained abdominal pain Signs and symptoms of primary aldosteronism were 
unaltered (table A -5c) Subsequently, a cholecystectomy was performed, after the patient had 
developed typical gallstone colics and jaundice Unfortunately, the surgeon could not trace the 
remnant of the right adrenal gland, despite a careful exploration of the right suprarenal region The 
failure was apparent on histologic examination of the removed tissue and the postoperative determi­
nation of aldosterone secretion rate (table A-5d) It was therefore decided to treat the patient 
medically with aminoglutcthimidc The presence of glucocorticoid remediable aldosteronism was 
excluded, since treatment with dcxamethasone 2 mg/day for 10 days did not reduce the aldosterone 
secretion rale to normal values (table A-5d) In February 1974 the patient was admitted to hospital 
because of recurrent renal colics After discontinuation of aminoglutethimide, the aldosterone 
secretion rate appeared still markedly elevated (table A-5e) One month after operation aldosterone 
secretion rate was measured during a 115 mmol sodium diet and concurrent adrenal substitution 
therapy with cortisone 25 mg/day and 9-a-fluorohydrocortisone 0 1 mg'day The findings of a low 
secretion rale (4 μg/24 hr), a normal blood pressure (117/78 mmHg, n=3) and normal plasma 
electrolytes were in accordance with the successful resection of an aldostcrone-producing adenoma 
Blood pressure values remained normal during the follow-up period of 6 years (averaging 138/84 
mmHg. n=32) 
190 
Patient 6 ( $ , vd V, 18 05 41) 
The patient is a woman aged 32 years who was referred to the department of endocrinology on March 
20th 1973 A tentative diagnosis of primary aldosteronism had been made by an internist elsewhere 
On December 7th 1972 the patient was admitted to a hospital elsewhere because of headache, 
vomiting and tetany Blood pressures varied from 180/100 to 200/120 mmHg Hypernatremia (140-147 
mmol/1) and hypokalemia (2 8-3 3 mmoL'l). resistent to potassium suppletion. were repeatedly found 
On admission to our institute the patient complained of headache and nycturia (2-3x) She had no 
edema or muscle weakness Her previous history was uneventful She had never been pregnant and 
she had never used oral contraceptives Physical examination Blood pressure on admission was 210/ 
140 mmHg Central venous pressure R-4 cm HiO No edema The heart was not enlarged 
Fundoscopy except for a few crossing phenomena, no abnormalities Vascular bruits over the 
abdomen were not found Laboratory no proteinuria or glucosuria was found Urine culture 
remained stenle Sodium 144 mmol/l potassium 2 7 mmol/1 Renal function was unimpaired An oral 
glucose tolerance test showed a diminished carbohydrate tolerance, probably as a result of hypokale­
mia Roentgenography The heart-to-lung quotient was normal The IVP showed no abnormalities 
Seldmger arteriography of the renal arteries did not reveal renal artery stenosis The adrenal glands 
were not visualized Adrenal venography Catheterization of the right adrenal vein was unsuccessful. 
while venography of the left adrenal gland did not reveal the presence of a tumor After retroperito­
neal gas insufflation the right adrenal gland was visualized and appeared to be normal The left 
adrenal gland was not visualized 
The elevated aldosterone secretion rates measured at a sodium intake of 115 mmol/day (1973 and 
1974) and at a sodium intake of 315 mmol/day (1974) concurrently with hypertension, hypokalemia 
and hyporcmnemia, established the diagnosis of primary aldosteronism (table A-6) 
Table A-6 
Aldosterone secretion rates and additional clinical and biochemical findings 
15 mmol/ 
24 hr 
Blood pressure (mmHg) 
Sodium (mmol/1) 146 
Potassium (mmol/1) 3 2 
Creatinine (μπιοΙ/Ι) 55 
UV sodium (mmol/24 hr) 4 
UV potassium (mmol/24 hr) 41 
UV creatinine (mmol/24 hr) 8 2 
PRA (ng/10 ml/3 hr) 21 
ASR (Hg/24 hr) 
March 1973 
sodium intake 
115 mmol/ 
24 hr 
184/125 
(n=12) 
148 
2 7 
56 
224 
55 
9 0 
-
248 
315 mmol/ 
24 hr 
149 
2 7 
46 
400 
91 
110 
-
-
in patient vd V 
Jan 1974 
sodium 
115 mmol/ 
24 hr 
158/108 
(n = 13) 
145 
3 7 
96 
121 
% 
12 6 
58 
281 
April 1974 
intake 
315 mmol/ 
24 hr 
162/113 
143 
3 2 
70 
260 
59 
7 6 
-
555 
Three years after resection of the right adrenal gland diurnal rhythms of plasma aldosterone were 
determined (figure A-2) Plasma aldosterone levels during the night averaged 6 4 ng/100 ml 
Aldosterone showed an increase in response to ambulation in the morning Daytime supine aldoste­
rone values were lower than the corresponding daytime upright values The correlation coefficients 
between the basal values of the three adrenocortical hormones showed that ACTH played an 
important role in the regulation of aldosterone concentration during the night, not, however, during 
night, days 1 and 2 
night night, days 1 and 2 
(n = 12) (n=18 
Aldosterone vs Cortisol 0 67 (p<0 01) 0 27 (n s ) 
Aldosterone vs 18-OH-DOC 0 85 (p<0 001) 0 35 (n s ) 
Cortisol vs 18-OH-DOC 0 85 (p<0 001) 0 95 (p<0 001) 
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Figure Α·2 Diurnal variations of plasma aldosterone, Cortisol and I8-OH DOC m patient vd V 3 
yean after resection of an adenoma 
Dcxamethasone treatment reduced mean nocturnal aldosterone concentration to 2 4 ng/100 ml 
Daytime aldosterone values remained essentially unchanged during dexamethasonc treatment 
Adrenal scintigraphy was performed with '"'l-lÇ-Iodocholestcrol during suppression with dexametha-
sonc Dexamethasonc was given at a dose of 4 mg/day starting 3 days before injection of the 
radiopharmaceutical which was given at a dose of 2 1 mO Accumulation of radioactivity in the right 
adrenal gland was found on the 3rd Sth and 6th days after injection The left adrenal gland was not 
visualized 
Clinical treatment with spironolactone 400 mg/day resulted in a decrease of blood pressure from 184/ 
125 (n=12) to 130-140/90-100 mmHg After discharge from hospital the dosage of spironolactone 
was reduced to 200 mg/day Blood pressure was maintained at a level of 140-150/100-105 mmHg 
during a treatment penod of 5 months The patient experienced no side effects of spironolactone 
treatment 
On April 4th 1974. the right adrenal gland was explored by lumbotomy at the height of the 12th rib 
which had to be surgically removed The right adrenal gland was resected after palpation of a large 
adenoma 
The right adrenal gland harbored a yellow-green adenoma with a maximal diameter of 2 cm The 
adrenal gland weighed 11 5 g I ightmicroscopy the large nodule was partlv encapsulated and at some 
levels not clearly separated from the surrounding adrenal tissue Peripherally the tumor was 
comjwscd of large clear polygonal cells Towards the middle of the tumor the cells showed a more 
eosinophilic and foamy cytoplasm containing pigment granulac The nuclei of these cells showed a 
marked amsokaryosis Spironolactone bodies were not found Mitoses were sporadically present The 
adrenal cortex outside the tumor showed focally a nodular architecture Both clear cells and small 
eosinophilic cells were found Conclusion adrenocortical adenoma composed of zona fasciculate and 
zona reticularis cells Micronodular hyperplasia of the adrenal cortex outside the tumor 
Blood pressure and aldosterone secretion rate were evaluated during a clinical observation 3 weeks 
after operation Blood pressure had decreased to 130/94 mmHg (n=7) PUsma electrolytes were 
normal and aldosterone secretion rate measured during a 115 mmol sodium diet, was 39 μg/24 hr At 
regular control visits during a follow-up period of three years diastolic blood pressures measured 
without antihypertensive treatment, remained slightly elevated, varying form 90 to 105 mmHg 
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Patient 7 ( 9 . O-K, 25 02 19) 
1 The patient woman was referred to the department of endocrinology in March 1974. when she was 55 
years old She was known to have been hypertensive for 18 years and had been treated with 
mcthyldopa and chlorthalidone In 1973 she was referred to an internist elsewhere, because of 
progressive fatigue and an unsatisfactory response of blood pressure to medical treatment Hyperten­
sion analysis had revealed a blood pressure of 170/120 mmHg, persistent hypokalemia (2 2 and 2 β 
mmol/l). hypernatremia (146 and 147 mmol/l) and a suppressed plasma renin activity Treatment with 
spironolactone 200 mg/day had resulted m a fall of blood pressure to 135/95 mmHg The tentative 
diagnosis of primary aldosteronism was made and the patient was referred to our institute for further 
analysis and treatment Her previous history recorded recurrent epileptic insults since the age of 21, 
and urinary tract infections with roentgenologic characteristics of a chronic pylonephntis of the right 
kidney Blood pressure had been normal dunng each of her four pregnancies Al her first visit she 
complained of headache, fatigue, muscle weakness, ankle edema, nycturia, paresthesia and palpita­
tions In 1973 a cholecystectomy was performed with postoperative paroxysmal atrial fibrillation 
Blood pressure at the first visit was 180/120 mmHg Fundoscopic examination revealed no signs of 
hypertensive retinopathy Central venous pressure was normal (R-5 cm H 2 0) and edema was absent 
The heart was slightly enlarged No vascular abdominal bruits were heard Laboratory Urine culture 
remained sterile The urine contained no protein or glucose Plasma electrolytes were markedly 
disturbed sodium 146 mmol/l potassium 2 1 mmol/l Renal function was unimpaired Electrocardio­
graphy sinus rhythm with marked U-wavcs Roentgenography of the chest gave a heart-to-lung 
quotient of 14 5 29 Intravenous pyelography showed a dilation of pelvis and calyces on cither side 
The renal parenchyma, however, was not reduced and both kidneys were of normal size 
2 Clinical measurements of aldosterone secretion rates before and after sodium loading established 
unequivocally the diagnosis of primary aldosteronism (table A 7) 
Table A-7 
Aldosterone secretion rates and additional clinical and biochemual findings m patient O-K 
SODIUM INTAKE 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (μιηοΙ/Ι) 
LV sodium (ттоГ24 hr) 
UV potassium (mmoI/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/l() ml/I hr) 
ASR (Hg/24 hr) 
15 ттоГ24 hr 
143 
2 2 
61 
10 
63 
11 1 
25 
-
IIS mmol/24 hr 
154/100 (n = 
144 
1 9 
67 
118 
92 
10 1 
-
1944 
•10) 
315 mmol 24 hr 
145 
2 2 
62 
341 
151 
110 
-
1721 
Diurnal rhythms of plasma aldosterone (figure A 3) were determined in 1978, 4 years after surgical 
resection of an aldostcront-producing adenoma of the left adrenal gland and subsequent disappea­
rance of signs and symptoms of primary aldosteronism Plasma aldosterone values during the night 
averaged 13 1 ng/100 ml and showed htlle variation A slight increase of aldosterone in response to 
upright posture was observed Daytime supine values were lower than the corresponding upright 
values The correlation coefficients between the basal values of aldosterone Cortisol and 18-OH-DOC 
did not show any significant influence of ACTH on the regulation of aldosterone during the night, nor 
during the night davs 1 and 2 
night night, days 1 and 2 
(n = l l ) (n=17) 
Aldosterone vs Cortisol 0 27 (n s ) 0 31 (η s ) 
Aldosterone vs 18-OH-DOC 0 22 (n s ) 0 24 (η s ) 
Cortisol vs 18-Oll-DOC 0 71 (p<0 01) 0 53 (p<0 05) 
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Figure A-3 Diurnal variations of plasma aldosterone, Cortisol and 18-OH-DOC in patient O-K 4 
years after resection of an adenoma 
Dexamcthasone treatment reduced the mean nocturnal aldosterone value from 13 1 ng/100 ml to 6 1 
ng/100 ml Daytime upright and supine aldosterone values did not show a reduction during dexame-
thasone treatment 
Adrenal scintigraphy was performed with ,31I-19-Iodocholeslerol 2 2 mCi ι ν after 8 days pretreat­
ment with dexamelhasone 4 mg/day Adrenal scintigrams were obtained on the 2nd, 4lh, 5th and 7th 
days after injection On the 7th day ρ ι the left adrenal gland showed an accumulation of 
radioaclivily, while the right gland was not visualized These findings suggested the presence of an 
aldosterone-producing adenoma in the left adrenal gland 
On June 6th 1974 the left adrenal gland was explored by a lumbotomy on the left side at the height of 
the 12th rib An adrenal adenoma could be easily palpated The adenoma was freed from the 
surrounding adrenal tissue and surgically removed 
The adrenocortical adenoma measured 2 cm and was surrounded by a thin capsule Some subcapsular 
hemorrhages were found Light microscopy the tumor was largely composed of large polygonal cells 
with a clear cytoplasm and a round nucleus The cells located peripherally in the tumor were generally 
smaller and contained hypcrchromatic nuclei Conclusion Adrenocortical adenoma composed of 
zona fasciculata type cells 
Postoperatively, blood pressure values decreased to 118/88 mmHg (n=6), measured during clinical 
admission 3 weeks after operation Plasma electrolytes were restored to normal Dunng a 6-years 
follow-up period, blood pressures remained normal without antihypertensive treatment, varying from 
130 to 140/85 to 95 mmHg 
Patient 8 ( 9 , vd K-M. 14 1126) 
The patient is a woman aged 48 years who in September 1974 was referred by an internist elsewhere 
to the department of endocrinology, because of hypertension and hypokalemia A tentative diagnosis 
of primary aldosteronism had been made The patient was found to be hypertensive during each of 
her three pregnancies in 1955,1957 and 1959 In 1961 she had been treated medically for hyperthyroi­
dism Blood pressures at that lime were occasionally high and varied from 150 to 170/90 to 100 mmHg 
In 1964 the patient had an abortion Blood pressure, measured shortly afterwards was 200/120 mmHg 
From 1964 to 1974 the patient did not receive anv medical antihypertensive treatment In 1974 a blood 
pressure of 230/110 mmHg was found at a routine medical examination Treatment was started with 
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methyldopa and chlorthalidone 100 mg twice a week After one week of medical treatment the patient 
had to be admitted to another hospital as she had developed severe muscle weakness and even 
intermittent paralysis Blood pressure was 200/140 mmHg Laboratory findings revealed hypernatre-
mia (153 mmol/1), hypokalemia (1 7 mmol/1) resistent to potassium supplction. and marked elevations 
of the enzyme activities of SGOT, SGPT and CPK, probably due to hypokalemic myopathy On 
admission to our hospital the patient complained of fatigue, headache, muscle weakness, paresthesia 
and nyctuna Blood pressure on admission was 225/110 mmHg No edema Central venous pressure 
R-5 cm H2O The heart was not enlarged No abdominal bruits were he.ird 
Aldosterone secretion rates and other relevant clinical and biochemical data are given in table A-8 
These findings were in accordance with the diagnosis of primary aldosteronism 
Table A-8 
Aldosterone secretion rates and additional clinical and biochemical findings in patient vd K-M 
SODIUM INTAKE 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potassium (mmol/1) 
Creatinine (μιηοΙ/Ι) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR ^g/24 hr) 
15 nimol/24 hr 
142 
2 8 
84 
9 
56 
Π 1 
53 
-
115 mmol/24 hr 
212/127 (n=15) 
142 
2 7 
70 
50 
56 
10 5 
-
851 
315 mmol/24 hr 
144 
27 
68 
192 
95 
9 9 
-
981 
3 The diurnal rhythms of plasma aldosterone (Figure A-4) were determined 3 years after removal of the 
left adrenal gland, which contained a classical aldostcronc-producing adenoma Plasma aldosterone 
concentrations during the night were considerably lower than during the day and upright posture (day 
/ d К M 14 11 26 
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Figure A -4 Diurnal variations of plasma aldosterone, Cortisol and 18-OH-DOC in patient vd K-M. 3 
years after resection of an adenoma 
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1) Daytime recumbent values (day 2) were about comparable to the nightly aldosterone values 
Plasma aldosterone increased markedly in response to ambulation m the morning The correlation 
coefficients between the basal values of the three adrenocortical hormones demonstrate that the 
influence of ACTH on the regulation of plasma aldosterone is only limited 
Aldosterone vs Cortisol 
Aldosterone vs 18-OH-DOC 
Cortisol vs 18-OH-DOC 
night 
(n=12) 
0 32 (n s ) 
0 61 (p<0 05) 
0 79 ( p < 0 01) 
night, days 1 and 2 
(n=18) 
0 16 (n s ) 
0 31 (η s ) 
0 91 ( p < 0 001) 
Dexamcthasonc treatment reduced the mean nocturnal aldosterone value from 13 5 ± 3 2 ng/100 ml 
to 3 2 ± 1 6 ng/100 ml Daytime aldosterone concentrations were not influenced by denamethasonc 
treatment 
4 Adrenal scintigraphy using "'I-^-lodocholestcrol was performed during treatment with dexamctha­
sonc 4 mg/day Dexamethasonc treatment was started 2 days before intravenous injection of 2 mCi 
l3lI-19-lodocholeslcrol Accumulation of radioactivity in the adrenal glands was found on the 6th day 
after injection Although radioactivity showed an asymmetrical distribution (more accumulation in 
the left than in the right adrenal gland), the results were considered not to be conclusive with respect 
to (he presence or absence of an adrenal adenoma The adrenal scintigrams were therefore repeated 
in 1975 l3,I-19-IodocholesieroI at a dose of 1 5 mCi was injected on the 4th day of treatment with 
dexamethdsone 4 mg/day On the 4th and 5lh days after injection of the radiopharmaceulical. uptake 
of radioactivity was found in the left adrenal gland and virtually no uptake in the right adrenal gland 
These findings led to the tentative diagnosis of adenoma of the left adrenal gland 
5 The effect on blood pressure of treatment with high doses of spironolactone (400 mg/day) was 
evaluated during a 3 months treatment period Blood pressure measurements at monthly control visits 
showed slowly decreasing values 208/130 mmHg, 190/122 mmHg and 160/112 mmHg Remarkably, 
only after 3 months treatment blood pressure responded favourably to spironolactone treatment, 
although the values did not return to normal Side effects of spironolactone treatment included 
menstrual irregularities and Raynaud's phenomenon 
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Figure A-5 Response of blood pressure values to medicamentous treatment durtng 5 years after 
resection of an adenoma in patient vd K-M 
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6 On June 6th 1975 the left adrenal gland was surgically removed through a flank incision A typical 
yellow adrenocortical adenoma measuring 3x2x1 cm protruded above the surface of the gland 
7 Adrenal pathology the adrenal cortex adjacent to the tumor was relatively narrow and showed a 
normal zonation in three layers The zona glomerulosa was broad while both the zona fasciculata and 
the zona reticularis were decreased in size The tumor was not sharply separated from the surrounding 
adrenocortical tissue It was composed of polygonal cells, which were arranged in alveoli, trabcculac 
or nodules The cvtoplasm was eosinophilic and showed a fine granulation Spironolactone bodies 
were not found Conclusion adrenocortical adenoma composed of cells of the zona fasciculata-type 
8 Postoperatively, plasma electrolytes normalized within 5 days after adrenalectomy (sodium 140 mmol/ 
1, potassium 4 1 mmol/l) Unnarv aldosterone excretion decreased to 1 7 μg/24 hr, measured on the 
8th day after surgery On discharge from hospital blood pressure was still markedly elevated (190/118 
mmHg) Aldosterone secretion rale, measured one month after adrenalectomy during a sodium 
intake of 115 mmol/day was 31 μ§/24 hr and still well below values found in normal individuals Blood 
pressures measured during a 5 years follow-up, are depicted in figure A 5 Because of a persistent high 
blood pressure, antihypertensive treatment with chlorthalidone and subsequently propranolol, redu­
ced blood pressure to near-normal values Hnally, blood pressure normalized during a relatively small 
dose of metoprolol of 50-100 mg/day 
Patient 9 (Ç. W-S, 29 12 58) 
1 The patient is a girl 16 years old, who was referred by an internist elsewhere to the department of 
nephrology on October 10th 1974 Hypertension was detected in September 1974 at a routine medical 
examination Subsequent analysis in another hospital had revealed a marked hypertension (190/145 
mmHg), normal renal function and a normal intravenous pyelogram The patient was referred to our 
hospital for further analysis and treatment Al her first visit she was free of complaints Her previous 
history was uneventful, except for a paresis of the nervous facialis at the age of seven Blood pressure 
on admission was 200/135 mmHg Body weight 67 kg Height 1 73 m Fundoscopic examination did 
not reveal hemorrhages, exudates or other signs of hypertensive retinopathy The heart was not 
enlarged Vascular abdominal bruits were absent Laboratory urine negative for protein and glucose 
Plasma electrolytes sodium 142 mmol/l potassium 3 2 mmol/l. chloride 102 mmol/l. and bicarbonate 
25 2 mmol/l Renal function was unimpaired creatinine 60 μιτιοΙ/Ι Electrocardiogram sinus rhythm 
IJ-waves No signs of left ventricular hypertrophy An X-ray of the chest showed a heart-to-lung 
quotient of 12 28 Scldinger arteriography of the renal arteries excluded the presence of renal artery 
stenosis 
2 Aldosterone secretion rates before and after sodium loading are presented in table A-9 Hyperten­
sion hypokalemia, hyporenmemia and elevated aldosterone secretion rates established the diagnosis 
of primary aldosteronism Aldosterone secretion rates were repeatedly measured in August 1975, 7 
months after surgical resection of the right adrenal, which, unfortunately, had not contained an 
Table A-9 
Aldosterone secretion rates and additional clinical and biochemical findings m patient W-S 
SODIUM INTAKE 
15 mmol'24 hr 115 mmol/2<f hr 115 mmol/24 hr 
193/127 (n=9) 
145 143 144 
37 2 9 3 2 
60 54 
9 76 339 
106 78 135 
15 5 12 0 12 0 
44 
440 455 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Crtatinine (цтоі/і) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR (μ§/24 hr) 
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Table A-IO 
Aldosterone secretion rates and additional clinical and biochemical findings m panent W S, 7 months 
after surgical resection of the right adrenal gland 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (цтоІ/І) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/l() ml'3 hr) 
ASR (μ^24 hr) 
15 mmol 24 hr 
140 
3 4 
70 
20 
85 
11 1 
25 
-
SODIUM INTAKE 
115 mmol^hr 
185Ί20 (n = 
139 
2 8 
75 
205 
122 
11 3 
-
348 
= 10) 
31 ί mmol/24 hr 
144 
2 9 
65 
375 
129 
12 3 
-
301 
adrenocortical adenoma (sec also 6 and 7) The results of these determinations indicate that signs and 
symptoms of primary aldosteronism were still present after resection of the right adrenal (table A-10) 
4 Adrenal scintigraphy was performed, using "'MÇ-lodocholcsterol. which was given intravenous at a 
dose of 1 9 mCi on the 3rd day of treatment with dcxamcthasonc 4 mg/day On the 6th and 7th days 
after injection, accumulation of radioactivitv was found in the right adrenal gland, while the left 
adrenal gland was completely suppressed These findings were considered to be due to an aldostc-
rone-producing adenoma in the right adrenal gland The right adrenal gland was therefore surgically 
removed (sec also 6) The uptake of radioactivity measured in the removed gland, was about 1 μΟ 
One year after operation a second adrenal scintigram - using '3'1-19-Iodocholesterol - was performed 
because of persistent hyperaldostcronism 'JII-19-lodocholesterol was injected intravenously at a 
dose of 2 mCi on the third day of dcxamcthasonc 4 mg/da> Adrenal scintigrams on the 2nd, 5th and 
7th days did not show any accumulation of radioactivity in the left adrenal gland 
5 The effects on blood pressure of successive treatment with spironolactone, and amilondc were 
evaluated by automated blood pressure recordings which showed a favourable response to spirono­
lactone. and a moderate response to amilondc 
spironolactone no medication amilondc 
4Ш mg/day 40 mg/day 
(4 wks) (4 wks) 
158/94 191/115 171/101 
(n = 7) (n=8) (n = 7) 
6 On January 2nd 1975 the right adrenal gland was explored through a right lumbotomy Although the 
right adrenal did not contain a palpable tumor, it was resected The decision to remove this gland was 
based on the unequivocal accumulation of radioactivity in the right adrenal gland as seen on the 
adrenal scintigram No tumor, however, was found on dissection of the gland On December 11th 
1975 the left adrenal gland was explored via a lumbotomy and an adenoma with a diameter of 1 5 cm 
was resected from the left adrenal gland 
7 Light microscopy of the right adrenal gland, which weighed 2 6 g, showed a normal zonalion of the 
adrenal cortex in three layers The width of the zona glomerulosa was locally increased The tumor, 
resected from the left gland weighed 1 6 g and was surrounded by a thin connective tissue capsule It 
was composed of different cell types Peripherally, polygonal cells with clear and vacuolated 
cytoplasm were found, arranged in solid trabeculac Centrally in the tumor the cells were smaller and 
contained an eosinophilic granulated cytoplasm and a relatively large nucleus Forms intermediate 
between both cell types were found Conclusion adrenocortical adenoma composed of zona fascicu-
lata-type zona glomcrulosa-type and hybrid cells 
8 After right adrenalectomy, signs and symptoms of pnmary aldosteronism were unaltered (see also 2) 
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After reseclion of ihe adenomj from the left ddrenal plasma electrolytes normalised within d few 
days Aldosterone excretion decreased to 0 9 μg/2A hr on the ninth postoperative ddv On discharge 
from hospital, blood pressure was 130/90 mmHg At the subsequent control visits, however, blood 
pressure remained shghtlv elevated After a follow-up of five years, blood pressure was 138/98 mmHg 
dunng treatment with chlorthalidone 
Patient 1 0 ( 2 , S-R. 21 10 31) 
1 This patient is a woman aged 42 years who was referred to the department of internal medicine in May 
1974 because of hypertension and hypokalemia Hypertension had been found for the first time 2 
months earlier when she visited her family doctor as she had developed ankle edema Subsequent 
examination by an internist elsewhere had revealed marked hypernatrcmia (145 and 147 mmol/l)and 
hypokalemia (2 6 and 3 1 mmol/1) Besides ankle edema she complained of headache and fatigue 
There was no muscle weakness or polyuria or nycturia The previous history was uneventful During 
the first of her three pregnancies (1958.1960 and 1963), she had taken a salt-restricted diet on account 
of a slight hypertension Menstrual cycles were regular She had never taken oral contraceptives 
Physical examination at the first visit revealed severe hypertension (240/125 210/140 210/140 mmHg). 
slight edema of the left ankle and a slight increase of the heart size Examination of the fundus ocuh 
disclosed neither hemorrhages nor exudates X-rays of the chest manifested a hcart-to-Iung quotient 
of 15 30 Intravenous pyelography was normal Seldinger arteriography showed no abnormalities of 
the renal arteries The right and left adrenal glands were incompletely visualized (via the right arteria 
phremca dextra and the left arteria suprarenalis inferior, respectively) blcctrocardiogram showed U-
waves, abnormal repolansations in leads I II, V5 and V6 and no signs of left ventricular hypertrophy 
2 Some of the relevant clinical and biochemical data are summarized in table A-ll Remarkably the 
aldosterone secretion rate was supprcssible by increasing the dietary sodium intake, although 
aldosterone secretions were elevated for each of the three levels of sodium intake It should be noted, 
however, that the collections of the 24 hours urine were not optimal, as can be derived from the 
urinary creatinine excretions 
Table A-ll 
Aldosterone secretion rates and additional clinical and biochemical findings in patient S-R 
SODILM ΙΝΤΑΚΓ 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potassium (mmol/1) 
Creatinine (цтоі/і) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR (μ
Β
/24 hr) 
IS mnral'24 hr 
140 
2 8 
86 
37 
75 
15 5 
20 
920 
115 mmol'24 hr 
198Ί21 (n = 
143 
2 9 
82 
83 
54 
110 
-
544 
16) 
115 mmol/24 hr 
145 
2 9 
69 
235 
84 
8 4 
-
266 
The diurnal plasma aldosterone pattern (figure A-6) showed high values during the late night (mean 
36 9 ± 5 0 ng/100 ml) with a subsequent decline during the day (to 14 6 ng/100 ml at 08 00 hr ρ m ) 
Plasma aldosterone failed to increase during ambulation in the morning The diurnal decline of 
plasma aldosterone occurred also in the supine position (day 2) Dexamcthasonc treatment jnduccd a 
fall of mean nocturnal plasma aldosterone from 36 9 to 23 6 ng/100 ml During dcxamethasone. a 
diurnal fall of plasma aldosterone was observed only during the supine position (day 2) Remarkably, 
plasma aldosterone increased dunng dcxamethasone and upright posture (day 1) Correlation 
coefficients between the basal values of the three adrenocortical hormones plasma aldosterone. 
Cortisol and 18-OH-DOC were as follows 
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figure A-6 Diurnal vanations of plasma aldosterone, Cortisol and I8-OH-DOC in patient S-R with 
an aldosterone-producmg adenoma 
Aldosterone vs Cortisol 
Aldosterone vs 18-OH-DOC 
Cortisol vs 18-OH-DOC 
night 
(n=12) 
0 58 (p<0 05) 
0 67 (p<0 05) 
0 88 (p<0 001) 
night, days 1 and 2 
(n=18) 
0 82 (p<0 001) 
0 85 (p<0 001) 
0 95 (p<0 001) 
These correlation coefficients suggest an important role for АСГН in the secretion of aldosterone in 
this patient 
During suppression with dexamcthasone adrenal scintigraphy was performed, using '"I-19-lodocho-
lesterol Dcxamethasonc was given at a dose of 4 mg per day. starling one day before the intravenous 
administration of I mCi of the radiopharmaceutical The adrenal scintigrams on the 5th and 6th days 
after the injection showed an almost equal accumulation of radioactivity in the two adrenal glands 
Adrenal scintigrams were repeated 3 years later after the newer radiopharmaceutical "Ί-οβ-
lodomethyl-19-Nor-Cholcsterol had become available Adrenal scintigraphy was performed during 
dexamcthasone treatment, which was started 13 days before administration of the radiopharmaceuti­
cal The adrenal scintiscans obtained on the 5th. 7th and 9th days after injection of the radiopharma­
ceutical at a dose of 1 9 mCi. showed accumulation of radioactivity m the left adrenal gland and only 
minimal accumulation in the right adrenal gland 
Medical treatment with spironolactone at a dose of 100 mg per day resulted in a good, but slowly 
initiating effect on blood pressure Blood pressure values measured at monthly intervals during this 
treatment were 180/110, 160/120. 160/110, 146/%. 142/105. 150/98 mmHg Side effects of spironolac­
tone treatment were nausea and irregular menstrual cycles A low dose of spironolactone (50-100 mg/ 
day) combined with propranolol 3x80 mg also had a favourable effect on blood pressure (134/82.130/ 
80 and 140/90 mmHg) The effects of spironolactone 400 mg/day compared with amiloncle 40 mg/day. 
on blood pressure and some biochemical parameters arc shown m table A-12 Amiloride had a 
marked lowering effect on blood pressure, almost comparable to that of spironolactone and without 
side effects The increase of aldosterone excretion after amilondc treatment is probably caused by the 
increase of potassium, since PRA and body weight remained essentially unchanged 
On March 10th 1978. the left adrenal gland was surgically removed The adrenal gland was explored 
via a left sided lumbotomy between the 10th and 11th ribs The adrenal gland weighed 3 85 g and 
contained a round yellow tumor with a maximal diameter of 1 5 cm, and an additional cortical nodule 
of 3 mm 
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Table A 12 
Comparison of the effects of treatment with spironolactone versus amilonde on some clinical and 
biochemical findings m patient S R 
Body weight (kg) 
Blood pressure (mmHg)* 
Sodium (mmol/1) 
Potassium (mmol/1) 
Creatinine (μπιοΙ/Ι) 
PRA (ng/10 ml/3 hr) 
Aldosterone excretion 
spironolactone 
400 mg/day 
(6 wks) 
62 0 
123/91 
139 
4 1 
9') 
331 
38 
placebo 
(6 wks) 
65 5 
179/114 
144 
2 2 
61 
94 
25 
amilonde 
40 mg/day 
(6 wks) 
660 
139/95 
137 
4 3 
75 
84 
71 
^g/24 hr) 
" Measured by artcnosonde 
7 Adrenal pathology a well defined cortical tumor protruding above the surface of the gland The 
tumor was composed of clear polygonal cells with a fine vacuolated cytoplasm Mitoses were absent 
The adrenal cortex outside the tumor showed a normal architecture Only at one level a nodular 
proliferation was found composed of clear cells comparable to those found in the tumor Conclusion 
a large and a small adrenal adenoma composed of cells as found normally in the zona fasciculala 
8 On the first day after operation urinary aldosterone excretion decreased to 1 3 μg/24 hr Blood 
pressure during the first 10 days after operation varied from 135/90 to 180/120 mmHg At the monthly 
visits during the first half year after operation blood pressures remained slightly elevated (160/110 
182/122 146/106 154/106 156/108 170/120 mmHg) During treatment with mctoprolol 2x100 mg/day 
and chlorthalidone 100 mg/day blood pressure decreased gradually lo 124/86 mmHg m April 1980 2 
years after operation 
Patient 11 ( 9 S Кг 10 11 31) 
1 This woman was 41 years old when she was referred by her family doctor to the department of 
internal medicine in July 1972 because of hypertension Treatment of hypertension with methyldopa 
and rauwolfia alkaloids had not resulted in a satisfactory response of blood pressure Hypertension 
was detected for the first time during her second pregnancy in 1965 She was also found to be 
hypertensive during her third pregnancy in 1966 and the blood pressure remained elevated after the 
delivery She had complaints of fatigue palpitations occasionally headache m the morning nycturia 
2 3 times and paresthesia She had neither muscle weakness nor edema There was a history of 
asthmatic bronchitis psoriasis and low back pain At her first visit she was not having any medication 
From 1968 to 1969 she had taken oral contraceptives Blood pressure values at the first visit showed a 
moderate hypertension 200/120 170/120 170/120 and 200/120 mmHg Fundoscopy revealed no signs 
of hypertensive retinopathy Central venous pressure was R 4 cm H,0 No edema was found The 
heart size was just within normal limns An early systolic murmcr at the apex was noted No vascular 
bruits were heard over the abdomen Several psoriatic skin manifestations were found Laboratory 
no proteinuria Urine culture remained sterile Endogenous creatinine clearance was 130 ml/mm A 
glucose tolerance test was normal X rays of the chest showed a heart of normal size The heart to-
lung quotient was 12 5 28 Intravenous pyelography was normal Seldingcr arteriography demonstra 
ted 2 renal arteries on each side without abnormalities CT scanning of the adrenals (performed in 
1978) visualized the left adrenal gland which was normal with respect to size and shape The right 
adrenal gland was not visualized The electrocardiogram demonstrated a sinus rhythm flattening of 
the ST Τ segments m all leads and U waves No signs of left ventricular hypertrophy were found 
2 Aldosterone secretion rates were measured at two different levels of sodium intake The results in 
combination with other relevant clinical and biochemical data arc presented in table A 13 With these 
clinical and biochemical data the diagnosis of primary aldosteronism was established 
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Table A-13 
Aldosterone secretion rates and additional clinical and biochemical findings in 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potassium (mmol/1) 
Credlimne (цтоі/і) 
UV sodium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/K) ml/3 hr) 
ASR (ng/24 hr) 
15 mmol/24 hr 
142 
3 7 
76 
41 
12 9 
29 
-
SODIUM INTAKE 
J15mmo|i24hr 
174/110 (n=9) 
143 
3 3 
62 
197 
13 5 
-
862 
patient SKr 
3l5mniol/24hr 
140 
3 2 
66 
348 
13 4 
-
793 
Plasma aldosterone values (figure A-7) during the late night were high and showed marked 
fluctuations After ambulation in the morning plasma aldosterone increased from 32 2 ng/100 ml to 
54 6 ng/100 ml Since plasma Cortisol concentration decreased in the morning (from 07 45 hr to 12 00 
hr noon), it might be that this increase of plasma aldosterone occurred in response to upright posture 
Plasma aldosterone decreased from 12 00 to 20 00 hr both on day 1 and day 2 The correlation 
coefficients between the basal values of the three adrenocortical hormones aldosterone, Cortisol and 
18-OH-DOC. showed poor correlations between aldosterone and each of the ACTH-dependenl 
hormones 
Aldosterone vs Cortisol 
Aldosterone vs 18-OH-DOC 
Cortisol vs 18-OH-DOC 
night 
(n=12) 
0 48 (n s ) 
0 27 (η s ) 
0 24 (η s ) 
night, days 1 and 2 
(n=18) 
0 57 (p<0 05) 
0 45 (n s ) 
0 76 (p<0 001) 
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Figure A-7 Diurnal variations of plasma aldosterone, Cortisol and 18-OH-DOC m patient S-Kr with 
an aldosterone-producing adenoma 
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Although these correlation coefficients suggest that aldosterone in this patient is relatively ACTH-
independent. dexamethasone reduced the mean nocturnal plasma aldosterone from 46 7 ng/100 ml to 
8 6 ng/100 ml The nse of plasma aldosterone values on day 2, suggest an escape from the suppressive 
action of dexamethasone 
4 Adrenal scintigraphy using u'l-19-lodocholestcrol was performed in 1976 Dexamethasone treatment 
was started one day before administration of the tracer at a dose of 2 mg/day and continued during the 
investigations Adrenal scintigrams on the 5th, 6th, 7th and 8th days after injection of 2 mO of the 
radiopharmaceutical, were of poor quality Accumulation of radioactivity in the right adrenal, and to 
a lesser degree in the left adrenal, was noted The investigations were inconclusive with respect to the 
presence or absence of an adrenal adenoma One year later, adrenal scintigrams were repeated, using 
(he newer radiopharmaceutical '"I-öß-Iodomethyl-^-Nor-Cholesterol Dexamethasone was admi-
nistered at a dose of 2 mg/day, starting 9 days before injection of the tracer at a dose of 1 7 mCi 
Adrenal scintigrams on the 4ih. 7th and 9th days showed unequivocal visualization of the right adrenal 
gland and almost complete suppression of the left adrenal gland 
5 Antihypertensive treatment with spironolactone in doses gradually increasing from 100 to 400 mg/day, 
resulted in a stepwise decrease of blood pressure from 180/120 to 130/80 mmHg after 2 months 
treatment Medical treatment with spironolactone was continued for more than three years Blood 
pressure remained under good control after the dose of spironolactone had been reduced to 50 mg/ 
day With the higher spironolactone doses (more than 200 mg/day) the patient experienced side 
effects, including itching and dead fingers Comparison of the effects of spironolactone and amilondc 
on blood pressure and other parameters, yielded the following results (table A-14) Amiloride caused 
a decrease of blood pressure comparable to the decrease of blood pressure observed after spironolac-
tone treatment Urinary aldosterone excretion increased to a greater extent after amilonde than after 
spironolactone treatment, despite (1) the finding that spironolactone caused a greater volume 
depletion (body weight') than amilonde and (2) the absence of an increase of PRA after amilonde 
Table A-14 
Comparison of the effects of treatment with spironolactone versus amilonde on some clinical and 
biochemical findings in patient S-Kr 
Body weight (kg) 
Blood pressure (mmHg)* 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (μπιοΐ/ΐ) 
PRA (ng/10 ml/3 hr) 
Urinary aldosterone 
spironolactone 
4(10 m '^day 
(6 wks) 
63 3 
106/73 
136 
3 8 
88 
306 
68 
placebo 
(6 wks) 
682 
141/92 
142 
2 7 
68 
75 
59 
amilonde 
4U mg.day 
(6 wks) 
65 0 
113/79 
137 
4 3 
83 
61 
90 
• Measured by artenosonde 
6 On March 31st 1978 the right adrenal gland was surgically removed Adrenal exploration was 
performed via a lumbotomy between the 10th and 11th ribs on the right side An adrenal adenoma 
could be easily palpated The surgical procedure was without complications 
7 The adrenal gland weighed 4 1 g An oval yellow tumor, measuring 13x8 mm. was located at one side 
of the gland The cut surface of the adrenal cortex outside the tumor was thin and did not show any 
abnormalities Light microscopy the tumor was well defined and partially surrounded by a thin 
capsule The tumor was composed of large polygonal clear cells with a fine vacuolated cytoplasm The 
adrenal cortex adjacent to the tumor showed a normal zonation of a relatively atrophic cortex 
Conclusion Adrenocortical adenoma composed of cells of the zona fasciculata-type 
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The urinary aldosterone excretion decreased to 1 4 μ^24 hr on the first day after operation The 
aldosterone secretion rate, measured 10 days after operation during a 115 mmol sodium diet, was 29 
μ(>/24 hr Blood pressure decreased to 136/80 on the third postoperative day and to 118/80 mmHg on 
discharge from hospital Blood pressure remained normal at regular control visits during a follow-up 
period of 2 years 
Patient 12 (Ç, H-S, 24 08 19) 
This patient. a woman aged 57 years, was referred to the department of endocrinology on January 7th 
1977, for evaluation of primary aldosteronism During each of her 10 pregnancies (1945-1959) she was 
found to be hypertensive, but only after her last delivery in 1959 did her blood pressure remain 
elevated She was treated with mefruside In 1976 severe hypokalemia was found, during her stay in a 
hospital elsewhere for surgical treatment of a breast carcinoma stage Τ,ΝοΜο After operation (left 
ablatio mammae) and parasternal irradiation, hypertension analysis was performed Mild hyperten­
sion (160/90-180/110 mmHg), hypokalemia (2 2-2 7 mmol/1) hypernatremia (147-149 mmol/1) and 
hyporenincmia (84 ng/10 ml/3 hr after ambulation during sodium restriction) suggested the presence 
of primary aldosteronism At her first visit she complained of fatigue and nycturia (5 times/night) She 
had no muscle weakness, edema or headache Previous history 1970, diabetes mellitus, treated with 
oral antidiabetics until 1975 and with diet thereafter From 1968 to 1976 she had been under the 
control of a neurologist because of epileptic manifestations, for which she had been treated with 
prominal up to 1976 The patient was not under any medication at her first visit Physical examination 
Blood pressure at the first visit was 240/120 mmHg Body weight 54 2 kg Height 1 63 m Centra) 
venous pressure R-6 cm H;0 No edema Normal size of heart No abdominal bruits were heard 
Laboratory no proteinuria or glucosuria Blood glucose 6 2 mmol/1 Endogenous creatinine clearance 
was diminished to 62 ml/mm Electrocardiography regular sinus rhythm Prominent U-wavcs No 
signs of left ventricular hypertrophy X-rays of the chest no abnormalities of heart or lungs 
Intravenous pyelography a slight disparity in renal size was found the left kidney measured 11 cm 
and the right 13 cm There was a delayed appearance of the contrast medium on the left side The left 
renal cortex was reduced as compared to the right 
Table A-15 presents the values of the aldosterone secretion rates together with other relevant clinical 
and biochemical data From these results the diagnosis of primary aldosteronism was established 
Table A-15 
Aldosterone secretion rales and additional clinical and biochemical findings in patient H-S 
SODIUM INTAKE 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potassium (mmol/1) 
Creatinine (цтоІЛ) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR (Hg/24 hr) 
15 inmol/24 hr 
141 
25 
-
36 
56 
6 0 
63 
-
115 mmol/24 hr 
183/106 (n = 
144 
2 8 
-
123 
97 
8 3 
-
642 
=24) 
3l5imnol/24hr 
142 
1 9 
96 
340 
117 
7 3 
-
1079 
The plasma aldosterone concentrations (figure A-8) showed a diurnal rhythm with markedly elevated 
plasma aldosterone values during the late night, declining during the day to a normal value of 7 ng/100 
ml at 20 00 hr on day 1 A diurnal fall of plasma aldosterone was also observed during the recumbent 
position (day 2) Plasma aldosterone did not response with a postural increase after ambulation in the 
morning The correlation coefficients between the basal values of the adrenocortical hormones 
aldosterone, Cortisol and 18-OH-DOC suggested that the role of ACTH in the regulation of 
aldosterone was of only little importance 
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Aldosterone vs Cortisol 
Aldosterone vs 18-OH-DOC 
Cortisol vs 18-OH-DOC 
night 
(n=12) 
0.52 (n.s.) 
0.27 (n.s ) 
0 73 (p<0 01) 
night , days 1 and 2 
(n=18) 
0 44 (n s ) 
0.72 (p<0 001 
0 63 (p<0.01 
Short term treatment with dexamethasone resulted in a marked reduction of the nocturnal level of 
plasma aldosterone. The diurnal fall of plasma aldosterone during the taking of dexamethasone was 
preserved, although at a lower level of plasma aldosterone concentrations. 
Adrenal scintigraphy was performed with l3'I-19-Iodocholesterol during dexamethasone treatment. 
Dexamethasone 2 mg/day was started 6 days before administration of the radiopharmaceutical. The 
scintigrams obtained on the Sth, 6th, 7th and 8th days after injection of 2 mCi ,3lI-19-Iodocholesterol, 
showed accumulation of radioactivity in both adrenal glands. The tentative diagnosis of "primary 
aldosteronism due to bilateral adrenal hyperplasia" was therefore made One year later, in 1978, 
adrenal scintigraphy was repeated, using the newer radiocholcsterol "'I-oß-Iodomethyl-N-Nor-
Cholesterol Adrenal scintigraphy was performed during treatment with dexamethasone 2 mg/day, 
whiéh was started 13 days before injection of the isotope On the 5th, 7th, 9th and 12th days after 
injection of the radiopharmaceutical at a dose of 1 8 mCi. a marked asymmetrical distribution of 
radioactivity m favour of the left adrenal gland, was found. These results were considered to be in 
accordance with a left adrenal adenoma 
The effects on blood pressure and other parameters of medical treatment with high doses of 
spironolactone for 6 weeks were compared with the effects of 6 weeks treatment with high doses of 
amilonde The results arc presented in tabic A-16 Treatment with spironolactone reduced blood 
pressure to normal values Remarkably, urinary aldosterone excretion decreased, despite a marked 
volume depletion (body weight reduction), a rise of PRA and a rise of plasma potassium. Amilonde 
treatment induced only a slight reduction of blood pressure. Aldosterone excretion also decreased 
after amilonde treatment despite a concomitant rise of plasma Kf and PRA. No side effects of 
amilonde treatment were observed Spironolactone temporarily caused abdominal discomfort and 
diarrhea 
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Figure A-8 Diurnal variations of plasma aldosterone, corttsol and 18-OH-DOC in patient Η-S with 
an aldosterone-producing adenoma 
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Table A-16 
Comparison of the effects of treatment vuth spirolactone versus amilonde on some clinical and 
biochemical findings m patient H-b 
Body weight (kg) 
Blood pressure (mmHg)' 
Sodium (mmol/1) 
Potassium (mmol/l) 
Creatinine (μπιοΐ/ΐ) 
PRA (ng/10 ml/3 hr) 
Aldosterone excretion 
spironolactone 
400 mg/dav 
(6 wks) 
56 4 
125/87 
135 
4 6 
153 
91 
14 
placebo 
(6 wks) 
58 2 
168/102 
147 
3 3 
86 
59 
26 
amilonde 
40 ms/day 
(6 wks) 
59 5 
152/97 
137 
3 8 
107 
109 
19 
(Mg/24 hr) 
* Measured by artenosondc 
6 On April 14th 1978 the left adrenal gland was surgically removed, after lumbotomy on the left side 
between the 10th and 11th ribs an adrenal adenoma could be easily palpated The adrenal gland 
weighed 8 4 g and harbored an adenoma with a maximal diameter of 2 cm 
7 The circumscribed encapsulated tumor was composed of large polygonal cells arranged in alveoli or 
solid fields The centrally located nuclei exhibited some pleomorphism Mitoses were absent The 
cells were indistinguishable from normal zona fasciculala cells Locally, the cells were smaller with a 
dark and eosinophilic cytoplasm The adrenal cortex outside the tumor showed locally a nodular 
broadening caused by an increase of both clear large cells and smaller eosinophilic cells Conclusion 
adrenocortical adenoma composed of cells normally found m ihe zona fasciculala Nodular hyperpla­
sia of the adjacent adrenal cortex 
8 Postoperatively, urinary aldosterone excretion decreased to 0 51 μ§/24 hr. measured on the second 
day after operation Aldosterone secretion rate on the 10th postoperative day measured during a 115 
mmol sodium diet, was only 7 5 Hg/24 hr Plasma electrolytes on that day were in accordance with a 
mineralocorticoid deficiency plasma sodium 133 mmol/l, plasma potassium 5 3 mmol/l Blood 
pressure on discharge from hospital was still slightly elevated, 158/100 mmHg 
Patient 13 (Ç K-H, 27 02 45) 
1 This woman was 28 years old in November 1973, when she was referred by the department of 
gynecology to the department of cardiology of this institute At that time she was 15 weeks pregnant 
In March 1972 she had been operated elsewhere for an atrial septum defect Blood pressure was 
elevated on admittance to that hospital in March 1972 (180/120 mmHg) but normal on discharge (125/ 
90 mmHg) Plasma sodium and potassium concentrations were normal During her pregnancies in 
1969 and 1970 blood pressures were normal She had taken oral contraceptives from 1970 to February 
1972 Blood pressure at the first visist in 1973 was 130/80 mmHg Cardiologie examination revealed no 
abnormalities except for evidence of a right bundle branch block on the electrocardiogram The 
pregnancy and delivery were uneventful However, blood pressures appeared to be elevated at the 
control visits to the out-patient department of cardiology in 1974 (170/110 mmHg). 1975 (150/100 
mmHg) and 1976 (165/110 mmHg) Diuretic treatment with chlorthalidone had to be suspended, 
because of severe muscle weakness and paresis of the lower limbs Antihypertensive therapy with 
propranolol 240 mg/day did not result in a significant decrease of blood pressure After discontinua-
tion of antihypertensive therapy, the patient was admitted to the department of internal medicine in 
November 1977 At that time she had no complaints Fundoscopic examination was normal X-rays of 
the chest revealed that the heart-to-lung-quotient, which was normal in 1974, had increased to 
16 27 5 The urogram was normal Scldinger arteriography showed no stenosis of the renal artenes 
2 Aldosterone secretion rates obtained at three different levels of sodium intake, were in accordance 
with the diagnosis of primary aldosteronism (table A-17) 
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Table A-17 
Aldosterone secretion ratet and additional clinical and biochemical findings in patient K-H 
SODIUM INTAKF 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potassium (mmol/1) 
Creatinine (μπιοΐ/ΐ) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR (Hg/24 hr) 
15 inmol/24 hr 
143 
2 8 
58 
26 
35 
9 8 
38 
400 
111 mmol/24 hr 
177/115 (n = 
143 
2 4 
58 
114 
53 
9 7 
-
331 
:17) 
315 mmol/24 hr 
147 
3 0 
54 
209 
95 
10 0 
-
459 
The nocturnal and diurnal plasma aldosterone, Cortisol and 18-OH-DOC patterns before and during 
dexamethasone, arc depicted in figure A-9 Plasma aldosterone values were high, especially in the 
night, and showed marked fluctuations The highest aldosterone value was found during the night 
(66 0 ng/100 ml) and the lowest during the recumbent position at 16 00 hr (10 2 ng/100 ml) 
Aldosterone decreased during the upright posture in the morning from 47 5 to 18 3 ng/100 ml 
Dexamethasone treatment induced a marked fall of mean plasma aldosterone during the night, from 
51 3 ± 113 ng/100 ml to 7 9 ± 17 ng/100 ml Daytime aldosterone values were slightly lower 
during dexamethasone as compared with the basal daytime values The basal values of the three 
adrenocortical hormones were significantly correlated with each other 
night night, days I and 2 
(n=12) (n=18) 
Aldosterone vs Cortisol 0 80 (p<:0()01) 0 90 (p<0 001) 
Aldosterone vs 18-OH-DOC 0 89 (p<0 001) 0 96 (p<0 001) 
Cortisol vs 18-OH-DOC 0 77 (p<0 (Ю1) 0 89 (p<0 001) 
These Figures suggest a marked influence of ACTH on the regulation of aldosterone Plasma Cortisol 
and 18-OH-DOC were normally suppressed during dexamethasone treatment Diurnal and nocturnal 
plasma aldosterone patterns were repeatedly assessed 6 months after surgical removal of an aldoste-
ronc-producing adenoma (figure A-10) The mean plasma aldosterone concentration during the night 
was 11 4 ± 2 3 ng/100 ml There was a postural increase of plasma aldosterone after ambulation m 
the morning, from 7 4 to 13 1 ng/100 ml The highest aldosterone value was found after ambulation at 
16 U0 hr Dexamethasone treatment induced a fall of mean plasma aldosterone during the night from 
11 4 ± 2 3 ng/100 ml to 2 2 ± 0 6 ng/100 ml The correlation coefficients between the three 
adrenocortical hormones under basal conditions did not reveal a role for ACTH in the control of 
plasma aldosterone 
night night, days 1 and 2 
(n = 12) (n=18) 
Aldosterone vs Cortisol - 0 42 (n s ) () 02 (η s ) 
Aldosterone vs 18-OH-DOC 0 41 (n s ) 0 40 (η s ) 
Cortisol vs 18-OH-DOC 0 07 (η s ) 0 70 (p<0 001) 
Adrenal scintigrams using BII-6ß-Iodomethyl-19-Nor-Cholesterol as radiopharmaceutical, were per-
formed after long-term dexamethasone treatment Dexamethasone was given at adose of 2 mg/day. 
starting 3 weeks before injection of the tracer The scintigrams made on the third day after injection 
showed a discernable accumulation of activity in the left adrenal gland The scintigrams on the 6(h and 
8th days after injection, showed an unmistakable accumulation in the left adrenal region The right 
adrenal gland was almost completely suppressed 
Medical treatment of blood pressure with chlorthalidone 50 mg/day and amilonde 15 mg/day for 3 
weeks resulted in a decrease of blood pressure from 158/111 mmHg (n=16) to 113/88 mmHg 
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Figure A-9. Diurnal variations of plasma aldosterone. Cortisol and 18-OH-DOC in patient K-Η with 
an aldoslerone-producmg adenoma 
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Figure A-10. Diurnal variations of plasma aldosterone, Cortisol and 18-OH-DOC in patient K-H. 6 
months after resection of an adenoma 
(n=30), as measured by arteriosonde. This antihypertensive treatment was given concomitantly with 
the dcxamethasone treatment (see 4). Therapy with spironolactone. 400 mg/day for 3 weeks, resulted 
in a decrease of blood pressure to 117/80 mmHg (n=25| During this medication the patient 
developed a transient eruption of the skin accompanied by itching. In addition she had irregularities 
of the menstrual cycle 
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6 On Apnl 28th 1978, the left adrenal gland was explored by a lumbotomy between the 10th and 11th 
nbs on the left side The left adrenal gland was removed and weighed 7 35 g A circumscribed yellow 
tumor with a maximal diameter of 1 4 cm was found after dissection of the gland 
7 The adrenal cortex adjacent to the tumor showed no abnormalities The tumor was composed for the 
greater part of large polygonal cells with foamy cytoplasm and centrally located nuclei The nuclear 
chromatin was finely dispersed and regularly contained a large nucleolus There were only few 
mitoses In the more peripheral areas and sub-capsularly. the cells were smaller, without eosinophilic 
cytoplasm These cells had the appearance of zona glomcrulosa cells In the adrenal cortex adjacent to 
the tumor, a normal zonation was found with only local broadening of the zona fasuculata 
ConJusion an adrenocortical adenoma, for the greater part composed of zona fasciculata-type cells 
8 The aldosterone secretion rate decreased to 8 ngí24 hr on the 10th day after operation Plasma sodium 
and potassium were restored within 9 days to 140 and 4 4 mmol/l. respectively Blood pressure was 
126/88 on discharge and remained normal at regular control visits thereafter, throughout a 2 years 
follow-up period 
Patient 14(0". H, 07 01 41) 
1 This patient was referred to the departement of endocrinology in January 1976, when he was 35 years 
old Eight months previously he had been found to be hypertensive (240/130 mmHg), while in 1974 his 
blood pressure was normal (140/75 mmHg) Since 1975 he had had complaints of severe headache 
Antihypertensive treatment with chlorthalidone 100 mg/day did not result in a significant fall of blood 
pressure However, plasma potassium levels during this treatment decreased to values as low as 2 1 
mmol/l. despite the use of potassium supplements Since plasma potassium was not restored to 
normal after discontinuation of diuretic treatment, the presumptive diagnosis of primary aldostero-
nism was made Hypertension analysis, performed in a hospital elsewhere, yielded the following 
results PRA, measured after 5 days chlorthalidone 100 mg/day was 53 ng/10 ml/3 hr Renal function 
unimpaired X-rays of the chest and urogram were normal Seldinger arteriography showed a slight, 
hemodynamically insignificant stenosis of the main right renal artery Adrenal scintigrams performed 
with "'1-19 lodocholesterol showed an equal accumulation of radioactivity in both adrenal regions 
The scintigrams repeated after pretreatment with dexamcthasonc, did not show any accumulation of 
activity in the adrenal glands Antihypertensive treatment with spironolactone 450 mg/day and 
propranolol 240 mg/day resulted in a decrease of blood pressure to 140/100 mmHg During this 
treatment the patient began to have a loss of potency and developed gynecomastia On March 5th 
1976. he was admitted to our hospital for measurements of aldosterone secretion rates Antihyperten-
sive treatment was withheld for one month In that time he developed headache, fatigue and nycturia 
Blood pressure on admission was 230/140 mmHg Fundoscopic examination was normal The 
electrocardiogram showed prominent U-waves The radiological heart-to-lung quotient was 14 31 
2 The aldosterone secretion rates were markedly elevated at three different levels of sodium intake 
(table A-18) 
Table A-18 
Aldosterone secretion rates and additional clinical and biochemical findings m patient H 
SODIUM INTAKfc 
15 mmul/24 hr 115 mmol/24 hr 315 mmol/24 hr 
199/125 (n = 16) 
141 
30 
75 
37 
33 
87 
32 
702 
143 
29 
72 
403 
90 
13 0 
_ 
666 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (μπιοΙΊ) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/H) ml/3 hr) 
ASR ^g/24 hr) 
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Figure A-11 Diurnal variations of plasma aldosterone, Cortisol and I8-OH-DOC ¡n panent Η with an 
aldosterone-produang adenoma 
The nocturnal and diurnal variations of plasma aldosterone in relation to plasma Cortisol and 18-OH-
DOC are depicted in figure A-11 Aldosterone values »ere markedly elevated and showed a wide 
variation during the night and the day The highest aldosterone value (80 7 ng/100 ml) was found 
during the night and the lowest (17 8 ng/100 ml) during daytime at 20 00 hr There was a slight 
increase of aldosterone in the morning during upright posture (from 60 7 to 72 1 ng/100 ml) 
Dexamelhasone treatment suppressed the mean aldosterone value during the night from 6 1 5 + 1 4 5 
ng/100 ml to 29 4 ± 9 0 ng/100 ml The daytime values were slightly suppressed by dexamelhasone 
The correlation coefficients between the basal concentrations of the three adrenocortical hormones 
demonstrate that ACTH plays an important role in the regulation of aldosterone in this patient 
Aldosterone vs Cortisol 
Aldosterone vs 18-OH-DOC 
Cortisol vs 18-OH-DOC 
night 
(n = l l ) 
0 56 (p<0 05) 
0 75 (p<0 01) 
0 79 (p<0 01) 
night, days 1 and 2 
(n=17) 
0 53 (p<0 05) 
0 72 (p<0 001) 
0 85 (p<0 001) 
The dexamelhasone suppression scintigrams of the adrenal glands, performed on the 6th, 7th and 8th 
days after intravenous administration of 1 9 mCi "Ί-19-lodocholesterol. did not show any apprecia­
ble accumulation of radioactivity over cither adrenal gland Dexamelhasone was administered at a 
dose of 4 mg/day. starting 3 days before administration of the tracer When the isotope ,3ιΙ-6β-
lodomcthyl-19-Nor-Cholesterol became available, the adrenal scintigrams were repeated After two 
weeks pretreatment with dexamelhasone 2 mg/day, the isotope was administered at a dose of 1 6 mCi 
Scintigrams on the 3rd, 4th. 5th and 6th days after injection did not show any accumulation of 
radioactivity in the adrenal glands 
The results of 6 weeks medical treatment with spironolactone 400 mg/day, compared to 6 weeks 
treatment with amilonde 40 mg/day are presented in table A-19 In contradistinction to treatment 
with spironolactone, blood pressure did not respond to amilonde Plasma potassium and aldosterone 
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Table A-19 
Comparison of ihe effects of /réarment »ιίΛ spironolactone versus amiloride on some clinical and 
biochemical findings in patteni Η 
Body weight (kg) 
Blood pressure ( m m H g ) * 
Sodium (mmol/1) 
Potassium (mmol/1) 
Creatinine (цтоі/і) 
PRA (ng/10 ml/3 hr) 
Aldosterone excretion 
spironolactone 
400 mg'day 
(6 wks) 
62 9 
137/91 
138 
3 8 
89 
216 
52 
placebo 
(6 »ks) 
65 1 
172/110 
145 
2 5 
72 
75 
32 
amilonüc 
40 mg.da\ 
(6 wks) 
643 
172/112 
118 
3 7 
79 
103 
46 
(Mg/24 hr) 
' Measured bv artenosondc 
excretions were comparable after cither treatment PRA increased markedly after spironolactone, not 
however after amilonde Serious side effects were noted only after spironolactone treatment such 
were gynecomastia and stomach complaints The patient was subsequently treated for one year with 
spironolactone 100 mg/day in combination with mcthyldopa, propranolol and prasozine With this 
therapeutic regimen, blood pressure remained slightly elevated (140/100 mmHg) 
6 Al operation on June 23rd 1978. a lumbotomy between the 10th and 11th ribs was performed on the 
left side (because of the slalistical preference of aldostcrone-producing adenomas for localization in 
the left adrenal gland) A 1 5 cm nodule was palpable in the left adrenal, which was subsequently 
removed in toto During surgery, the left pleural cavity was accidenlly opened Postoperatively. X-
rays of the chest showed a pneumothorax, for which the patient was treated successfully with suction 
drainage 
7 The tumor that was partly surrounded by a thin capsule, compressed the adjacent adrenocortical 
tissue The tumor cells were arranged in alveoli and showed, in the peripheral areas, a clear and foamy 
cytoplasm However, also smaller tumor cells with a more eosinophilic cytoplasm were noted There 
was little or no anisokaryosis No areas with bleeding or necrosis were found The adjacent adrenal 
cortex showed a normal zonation with a relatively broad zona glomcrulosa The adrenal medulla was 
normal Conclusion a solitary adrenocortical nodule, composed of zona fasciculata- and zona 
reticularis-typc cells 
8 After operation. Ihe aldosterone secretion rate fell to 19 |ig/24 hr (measured on the 10th day after 
operation, during a sodium intake of 115 mmol/24 hr) Plasma sodium and potassium were restored 
spontaneously to normal values within one week Blood pressures, however, remained markedly 
elevated during the postoperative penod (152 to 200/100 to 120 mmHg), and slightly elevated at the 
control visits during the first year after operation (146 to 150/96 to 104 mmHg) Treatment with 
propranolol 80 mg/day lowered blood pressure to almost normal values ( 124 to 142/92 to 96 mmHg) 
during a follow-up period of 2 years 
Patient 15(Ç,M-G, 13 06 20) 
1 The patient is a woman aged 57 years, who was referred to the department of endocrinology on 
December 13lh 1977 She was known to have been hypertensive for 15 to 20 years Blood pressure 
was normal during her 7 pregnancies of which two terminated with an abortion In 1975 she developed 
complaints of angina pectoris for which she was examined in the department of internal medicine of 
another hospital Marked hypertension, concomitant with hypokalemia were repeatedly found From 
1975 to 1977 she was admitted 5 times to that hospital for further examinations During these 
observations the clinical and biochemical findings were not always m favour of the diagnosis of 
primary aldosteronism Plasma potassium varied from 1 9 mmol/1 to normal values PRA was low and 
unresponsive to stimulation with sodium restriction and ambulation Unnarv aldosterone excretion 
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was normal on several occasions Adrenal scintigraphv with " Ί 19 lodocholcsterol showed an equal 
uptake of radioactivity in both adrenal glands However after prctrcalmenl with dcxamcthasonc an 
asymmetrical uptake was found with a more pronounced accumulation in the right adrenal gland The 
patient was referred to the endocrine unit of this institute for further evaluation of primary 
aldosteronism or other syndromes of mincralocorticoid excess At the first visit she complained of low 
back pain headache nycturia muscle weakness and muscle cramps Further she had atypical angina 
pectoris palpitations and profuse perspirations Part of the complaints resulted from the taking of 
spironolactone 200 mg/day Because of severe headache she had abused analgetics and tranquilizers 
for many years She smoked 40 cigarettes per day Her family history recorded a high prevalence of 
hypertension mother and 2 sisters developed a cerebral vascular accident At the first visit the blood 
pressure was 225/130 mmHg Pulse rate 74'min with frequent premature beats Central venous 
pressure was normal No edema Fundoscopic examination showed a venous occlusion in the right 
fundus ocuh with several small hemorrhages The heart was enlarged and an atherosclerotic souffle 
was heard over the aorta Ί he electrocardiogram showed pathologic repolansations in leads I AVL 
V5 V6 and left ventricular hypertrophy The heart to lung quotient on an X ray of the chest was 
16 S 29 <> 
Figure A-12 presents the most relevant clinical and biochemical data obtained at three different levels 
of sodium intake The findings arc in accordance with the diagnosis of primary aldosteronism 
hypertension increase of kaliurcsis and hypokalemia after sodium loading low PRA unresponsive to 
stimulation and a lack of aldosterone suppressibihty after sodium loading It is to be noted that the 
aldosterone secretion rate during sodium restriction is within the lower range of normal 
Plasma aldosterone concentrations showed high values during the late night with a subsequent fall 
during the day despite the stimulus of upright posture (figure А Π) The highest aldosterone value 
was found during the night (17 9 ng/lOO ml) and the lowest during day 1 at 16 00 hr (6 8 ng/100 ml) 
The correlation coefficients between the basal values of the three adrenocortical hormones show thai 
the plasma aldosterone concentrations arc not significantly influenced by ACT1I 
night night days 1 and 2 
(n=l l ) (n=17) 
Aldosterone vs Cortisol 021 ( n s ) 0 34 ( n s ) 
Aldosterone vs 18 Oil DOC 0 28 (n s ) 0 28 (η s ) 
Cortisol vs 18 OH DOC 0 90 (p<0001) 0 82 (p<0U01) 
Dexamethasone treatment however reduced mean nocturnal PA values from 32 3 ± 4 0 ng/100 ml 
to 9 4 ± 2 8 ng/100 ml Daytime aldosterone values were slightly lower than under basal circumstan 
ces The plasma aldosterone concentrations were rcpcatcdlv assessed 5 months after right adrenalec­
tomy and subsequent recurrence of biochemical characteristics of pnmarv aldosteronism (see also 8) 
ΊΊιε diurnal pattern of aldosterone (figure A 14) appeared unchanged as compared to the findings 
before operation There was a diurnal fall of aldosterone despite upright posture Nocturnal 
aldosterone values were even higher than before operation (SI 7 ± 6 6 vs 32 3 ± 4 0 ng/HX) ml) 
Aldosterone did not correlate significantly with Cortisol during the night (r=0 57 n=8 η s ) nor 
during the night days 1 and 2 (r=0 34 n=14 n s ) Dexamethasone reduced mean nocturnal 
aldosterone from 517 + 6 6 ng/100 ml to 31 6 ± 2 0 ng/100 ml 
Adrenal scintigraphy using l l | l 6β lodomethyl-19 Nor Cholesterol was performed after 2 weeks 
prclrcatmenl with dexamethasone 2 mg/day The radiopharmaceutical was administered at a dose of 2 
mCi On the 6th and 7th days after injection the right adrenal gland was clearly visualized The left 
adrenal gland showed almost absent accumulation of radioactivity 
Treatment with spironolactone at a dose of 400 mgidav for 4 weeks resulted in onlv a slight decrease 
of blood pressure from 207/123 mmHg (mean value during clinical admission) to 178.112 mmHg 
Long-term treatment with dexamethasone 2 mgday for 3 weeks exerted no influence on blood 
pressure level (216/122 mmHg before and 215/120 after dexamethasone treatment) although urinary 
aldosterone excretion decreased from 25 0 to 8 3 μg/24 hr 
On June 2nd 1978 the nght adrenal gland was surgically removed by lumbotomy between the 10th and 
11th ribs The gland removed weighed 9 5 g and contained an adenoma with a maximum diameter of 
2 5 cm 
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Figure A-13 Diurnal variations of plasma aldosterone. Cortisol and 18-OH-DOC in patient M-G with 
an aldosterone-producing adenoma 
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Figure A 
resection 
•14. Diurnal variations of plasma aldosterone and Cortisol in patient M-G, 5 months after 
of an adenoma and recurrence of primary aldosteronism 
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7 The adrenal cortex surrounding the tumor showed л macronodular hyperplasia Dissection of the 
gland demonstrated besides a classical yellow adenoma, partly atrophic and partly hypertrophic areas 
in the attached adrenal cortex Microscopy the adenoma was not sharply separated from the adjacent 
adrenal tissue The adenoma was composed of predominantly clear cells, arranged in cords, trabecu-
lae and acini There was no cellular nor nuclear polymorphism In some transverse sections the 
adjacent cortex showed a nodular hyperplasia caused by an increase of alveolarly or trabecularly 
arranged clear cells Conclusion adrenocortical adenoma and macro- and micronodular hyperplasia 
At postmortum examination the left adrenal gland appeared to contain a yellow tumor measuring 18 
mm in diameter Besides, a small white tumor of 6 mm was found after dissection of the gland Light 
microscopy of the adrenal revealed a normal zonation of the cortex A t one level a nodular 
proliferation of large clear cells with an alveolar arrangement was found Within this proliferation 
many capillaries were present At another level a proliferation of atypical glandular and alveolar 
structures with a central necrosis and a proliferation of connective tissue were found The cells did 
show a marked atypia and nuclear polymorphism Mitoses were numerous Conclusion adrenocorti­
cal adenoma and a metastasis of an adenocarcinoma 
8 Postoperatively, urinary aldosterone excretion fell to 1 5 μg/24 hr on the second day after operation 
Aldosterone secretion rate measured on the 10th dav after operation during a 1 IS mmol sodium diet, 
was 78 μg/24 hr Blood pressure however, remained elevated 192/122 mmHg and 170/130 mmHg, 
measured at 6 weeks and 3 months respectively, after operation 
Surprisingly two months postoperatively plasma sodium values were found to be increased (142-144 
mmol/1) with low plasma potassium values (2 5-2 9 mmol/1) Recurrence of hyjjeraldosteromsm was 
suspected and the patient was readmitted to the hospital in November 1978 She complained of 
headache and low back- and muscle pains Blood pressure on admission was 218/130 mmHg Physical 
examination yielded no additional new findings as compared with earlier examinations Radiography 
of the chest revealed a round lesion 3 cm in diameter located in the left lung adjacent lo the arch of 
the aorta On mediastinoscopy. several paratrachcal and tracheobronchial lymph nodes were found 
Pathologic examination of biopsies revealed lymph node metastases of an adenocarcinoma Cytologic 
examination of sputum raised the suspicion of an adenocarcinoma Bronchoscopic examination was 
negative On bronchography, a compression of the dorsal branch of the left apico-poslenor branch 
was delected The tentative diagnosis was made of a bronchial carcinoma with mediastinal lymph 
node metastases As described in the section "diurnal rhvthms of plasma aldosterone", the patient 
had a recurrence of primary aldosteronism The profile of the diurnal plasma aldosterone concentrati­
ons was in accordance with the presence of an aldosteronc-producing adenoma in the remaining left 
adrenal gland However, it was decided not to explore the left adrenal gland because of the patient's 
poor clinical prognosis On September 18lh 1980 she died At autopsy, extensive tumor growth in (he 
nght and left lung with metastases m the mediastinal and parabronchial lymph nodes were found The 
left adrenal cortex contained a classical adenoma with a diameter of 1 8 cm 
Patient 16. ( ? , N - M , 02 01 23) 
1 The patient is a 54 years old woman, who was referred to the department of nephrology of our 
institute on September 27th 1977, because of hvfiertcnsion and pathology of the right kidney The 
patient had a history of hypertension during each of her 5 pregnancies (1946, 1951, 1953 1957,1961) 
Blood pressure returned to normal after each delivery In 1961 she developed unexplained ankle 
edema Blood pressure at that time was 120/80 mmHg In 1971 hypertension was detected, when she 
was admitted to a hospital for a cholecystectomy Antihypertensive treatment with various medica­
ments did not result in a satisfactory response of blood pressure During treatment with Clonidine. 
melhyldopa and triamterene a moderate hypokalemia was found Intravenous pyelography had 
revealed a deformation of the calyces and pvclum of the right kidney, probably caused by chronic 
pyelonephritis Because of a diabetes mellitus, established in 1971 the patient took a sugar-free diet 
and tolbutamide 500 mg b ι d The patient had no complaints of muscle weakness, nycturia, edema, 
palpitations or headache Blood pressure measured at her Tirsi visit, during medication with Clonidine 
150 γ b ι d , melhyldopa 250 mg q ι d and triamterene 50 mg. was markedly elevated 240/125 
mmHg Central venous pressure was R-b'/i cm Η,Ο No edema Examination of the fundus oculi 
revealed no signs of hypertensive rclmopathy The heart size was slightly increased A systolic bruit 
was heard over the left abdomen Laboratory slight proteinuria (0 2-0 6 g/24 hr) Urine culture 
remained stenle Plasma electrolytes sodium 130 mmol/1. potassium 3 3 mmol/1, chloride 97 mmol/1, 
bicarbonate 33 0 mmol/1 Renal function was unimpaired Plasma creatinine 64 μιποΙ/Ι Blood sugar 
slightly elevated to 11 8 mmol/1 Flectrocardiography regular sinus rhythm Prominent U-waves No 
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signs of left ventricular hypertroph) X-ray of the chest showed a heart-to-lung quotient of 14 5 26 5 
Scldinger arteriography of the renal arteries showed normal renal arteries on both sides The right 
renal cortex showed a scar retraction On computer assisted tomography neither of the adrenal glands 
could be visualized 
Aldosterone secretion rates were measured at three different levels of sodium intake The results are 
presented in table A-20 together with additional relevant data The aldosterone secretion rale was 
elevated during a sodium intake of 115 and 315 mmol·24 hr, but normal during a sodium free-diet The 
supprcssibihty of aldosterone after sodium loading was partially preserved although ASR's were 
elevated for each level of sodium intake With these results the diagnosis of primary aldosteronism 
was established 
Table A-20 
Aldoiierone lecrenon rates and additional clinical and biochemical findings in 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (μπιοΙ/Ι) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/l() ml/3 hr) 
ASR (Hg/24 hr) 
15 mmol/24 hr 
143 
3 1 
62 
34 
86 
9 6 
66 
470 
SODIUM INTAKE 
lis mmol/24 hr 
237,138 (n=19) 
143 
2 3 
58 
140 
99 
9 7 
-
353 
patient N-M 
315 mmol 24 hr 
139 
2 0 
64 
272 
66 
110 
-
253 
Plasma aldosterone concentrations during the late night (figure A-15) vaned from 15 5 to 26 8 ng/100 
ml The mean nocturnal aldosterone concentration was 19 6 ± 3 5 ng/100 ml A diurnal fall of 
plasma aldosterone concentration was observed on dav 1 and day 2 Plasma aldosterone did not 
respond to the stimulus of 4 hours of ambulation in the morning (day 1) The correlation coefficients 
between the basal values of plasma aldosterone Cortisol and 18-OH-DOC strongly suggest an 
influence of ACTH on the regulation of plasma aldosterone concentrations 
night night davs 1 and 2 
(n=12) (n=18) 
Aldosterone vs Cortisol 0 67 (p<0 05 ) 0 44 (n s ) 
Aldosterone vs 18-OH-DOC 0 84 (p<0(X)l) 0 65 (p<0 01 ) 
Cortisol vs 18-OH-DOC 0 84 (p<0(K)l) 0 92 (p<0 001) 
Dcxamcthasone treatment did not result in a reduction of the nocturnal aldosterone concentration 
On the contrary mean plasma aldosterone was even higher (25 7 ± 2 4 ng/K)0 ml) than under basal 
circumstances (19 6 ± 3 5 ng/100 ml) The diurnal decline of aldosterone remained preserved during 
dexamethasone treatment Determination of the diurnal rhythm of aldosterone was repeated 2 
months after surgical resection of the right adrenal gland, which contained a classical adrenal 
adenoma Mean nocturnal aldosterone concentration (figure A-16) had decreased from 19 6 ± 3 5 
ng/100 ml before to 10 5 ± 4 9 ng/100 ml aftci operation Plasma aldosterone increased markedly in 
response to 4 hours of ambulation in the morning The correlation coefficients between the basal 
values of aldosterone. Cortisol and 18-OH-DOC demonstrate that the influence of ACTH on the 
control of plasma aldosterone was apparent onlv during the night 
night night days I and 2 
(n=12) (n = 18) 
Aldosterone vs Cortisol 0 63 (p<0 05) 0 10 (n s ) 
Aldosterone vs 18-OH-DOC 0 66 (p<0 05) - 0 03 (n s ) 
Cortisol vs 18-OH-DOC 0 75 (p<0 01) 0 85 (p<0 001) 
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Dcxjmclhasonc ircatmenl reduced mean nociurnal plasma aldosterone from 10 5 ± 4 9 ng/100 ml 
lo 3 6 ± 16 ng/lOO ml Aldosterone values during the dav remained unchanged during dexamctha-
sonc 
4 Adrenal scintigraphy was performed using the radiophannaccutical l3lI 6ß-Iodomelhyl-19-Nor-Cho-
leslerol during dcxamelhasone suppression Dexamethasonc was given in a dose of 2 mg/day starting 
14 davs before injection of the isotope The dose administered was only 0 6 mCi, because the patient 
felt unwell during injection Scintigrams on the 6th 7th and 8th davs showed an accumulation of 
radioddiviiv over the righi adrenal region Only a minimal accumulation was found on the left side 
These findings were indicative of the presence of a right adrenal adenoma 
5 Treatment with spironolactone 400 mg/day did not result in a significant fall of blood pressure 237/ 
138 mmHg (mean value during slay in the clinic) to 199/116 mmHg after 1 month treatment 
Dcxamelhasone administered during 3 weeks, caused a fall of aldosterone excretion to 5 1 μg/24 h 
Blood pressure however remained unchanged A few days after withdrawal of dexamethasonc, the 
patient was admitted to the hospital because of visus complaints Ophthalmologic examination of the 
fundus ocuh revealed several cotton wool exudates and small hemorrhages A rapid decrease of blood 
pressure was achieved by treatment with diazoxidc infusion and subsequently with spironolactone 400 
mg/day and propranolol 240 mg/day The fundoscopy showed a marked improvement after 2 weeks 
treatment Treatment with spironolactone and propranolol was continued during 6 months Blood 
pressures during this medication varied from 170 to 196/98 to 116 mmHg 
6 On July 27th 1978 the right adrenal gland was surgically removed and appeared to contain an 
eccentrically located adenoma measuring 1 cm 
7 The adrenal gland weighed 12 6 g Locally macronodular hyperplasia was noted in the adrenal cortex, 
adjacent to the lumor I ighl microscopy the adenoma partially surrounded by a capsule, was 
composed of different cell types large and small cells with a clear or eosinophilic cytoplasm, identified 
as so called 'hybride cells' and large cells with a clear cytoplasm and a small nucleus, identified as 
zona fasciculata-typc cells The adrenal cortex adjacent to the tumor showed locally, a micronodular 
hyperplasia Conclusion adenoma composed of 'hvbride ' cells and zona fasciculata-typc cells 
Focally micro- and macronodular hyperplasia of the adrenal cortex 
8 Aldosterone excretion decreased to 4 2 μg'24 hr on the second day after operation ASR, measured 
on the 10th day after operation during a sodium intake of 115 mmol/day, was 63 μg/24 hr Plasma 
electrolytes normalized within л few days Blood pressure values, however remained elevated varying 
from 170 to 190/100 to 110 mmHg Blood pressures measured at regular control visits from July 1978 
to April 1981 varied from 164 to 200/96 to 120 mmHg, during various antihypertensive treatment 
regimens 
Patient 1 7 ( 9 PR, 13 05 31) 
1 A 48 years old woman was referred to the department of internal medicine of our institute on January 
17th 1979 because of hypertension Blood pressure was first found to be elevated in 1976 
Antihypertensive treatment with propranolol 120 mg/day and chlorthalidone 100 mg twice a week, 
had not resulted in a decrease of blood pressure I-or 10 years she had suffered from severe attacks of 
migraine with nausea and emesis At the first visit she had no complaints There was no nyctuna or 
muscle weakness hut she had a slight ankle edema in the evening Menstrual cycles were regular She 
had never laken oral contraceptives Hypertension did not occur during her two pregnancies in 1957 
and 1961 At the first visit she had not any antihyperlcnsivc treatment Physical examination blood 
pressure 200/120 mmHg Fundoscopic examination did not reveal exudates or hemorrhages Pulse 
rate 68 regular No edema Venous insufficiency of the legs was noted Laboratory shghl to marked 
hypokalemia (2 1 to3 3 mmol/1) and hypcrnalremm (142 lo 144 mmol/1) Plasma renin activity alter 5 
days chlorthalidone 100 mg/day was lowered lo 38 ng/10 ml/3 hr blectrocardiography sinus rhythm 
with prominent U-wavcs X-ray of the chest hcart-to-lung quotient was normal 
2 Ί he most relevant clinical and biochemical data found during three different levels of sodium intake 
arc summarized in table A-21 The elevated ASR without supprcssibility after sodium loading along 
with a low PRA after stimulation wilh a sodium restricted diet, confirmed the diagnosis of primary 
aldosteronism 
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Table A-21 
Aldosterone secretion rates and 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potassium (mmol/1) 
Creatinine (μπιοΙ/Ι) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR (μ§/24 hr) 
additional clinical and biochemical findings m 
15 mmol/24 hr 
139 
3 4 
69 
32 
86 
16 0 
26 
-
SODIUM INTAKE 
1И mmol/24 hr 
185/121 (n=21) 
141 
3 3 
68 
93 
90 
12 0 
-
385 
panent P-R 
315 mmol/24 hr 
144 
3 2 
72 
267 
122 
16 2 
-
387 
The diurnal and noclural plasma aldosterone concentrations (figure A-17) showed wide variations 
with a tendency to fall during the day High values were found during the night, averaging 36 4 ± 5 9 
ng/100 ml Aldosterone decreased during the morning, despite upright posture, from 35 9 to 13 0 ng/ 
100 ml Dexamethasone treatment induced a fall of mean plasma aldosterone during the night from 
36 4 ± 5 9 ng/100 ml to 20 7 ± 3 2 ng/100 ml The effects of dexamethasone on daytime 
aldosterone values were inconsistent Contrary to the findings before dexamethasone, plasma 
aldosterone increased during ambulation in the morning from 22 0 to 40 0 ng/100 ml From the 
correlation coefficients between the values of the three adrenocortical hormones, as found under 
basal conditions, no conclusions can be drawn with respect as to the role of ACTH in (he regulation of 
plasma aldosterone in this patient The correlation coefficients between aldosterone and Cortisol on 
the one hand, and aldosterone and 18-OH-DOC on the other hand, revealed contradictory results. 
which is probably related to the fact that the ACTH-dependent hormones Cortisol and 18-OH-DOC 
also did not show a strong correlation 
night night, days 1 and 2 
(n = l l ) (n = 17) 
Aldosterone vs Cortisol 0 25 (n s ) 0 21 (η s ) 
Aldosterone vs 18-OH-DOC 0 68 (p<0 05) 0 70 (p<0 001) 
Cortisol vs 18-OH-DOC 0 36 (n s ) 0 56 (p<0 05) 
Adrenal scintigraphy was performed with ml-6ß-Iodomcthyl-19-Nor-Cholesterol Treatment with 
dexamethasone 2 mg/day was started three weeks before injection of the isotope The radiopharma-
ceutical was administered at a dose of 1 9 mCi On the 7th day after injection, a clear visualization of 
the left adrenal gland was obtained The right adrenal gland was almost completely suppressed 
Two weeks treatment with amilonde 20 mg/day and chlorthalidone 50 mg/day. given concurrently 
with the dexamethasone treatment, resulted in a decrease of blood pressure to 140/88 mmHg in the 
recumbent and 100/80 mmHg in the upright position The patient developed complaints of orthostatic 
hypotension, which disappeared after withdrawal of the chlorthalidone medication Blood pressure 
after 2 weeks amilonde treatment was 171/108 mmHg 
On June 6th 1979, the left adrenal gland was surgically removed by way of a left lumbotomy between 
the 10th and 1 Uh ribs The adrenal gland weighed 11 5 g and contained an adenoma with a maximal 
diameter of 1 β cm 
A circumsenpt adenoma protruded above the surface of the gland The adenoma was predominantly 
composed of large polygonal clear cells with small vesicles as found in a normal zona fasciculata 
There was a slight anisokaryosis and hyperchromasia of the nuclei Small, dark eosinophilic cells, 
located centrally and in the periphery of the adenoma were also found Locally, a beginning 
infiltration of the thin capsule by clear cells was noted Mitotic activity was found only sporadically 
Necrosis, hemorrhages or infiltrations of vessels were absent The adrenal tissue outside the tumor, 
however, showed an irregular broadening of the cortex with a nodular hyperplasia of the zona 
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Figure A-17 Diurnal variations of plasma aldosierone. corliwl and 18-OH DOC in patient P-R with 
an aldosterone-produang adenoma 
fasciculata The ¿ona glomemlosd was slightly increased and showed locally a wedge-shaped exten-
sion between the cells of the zonj fasciculata Conclusion adrenocortical adenoma with micronodular 
hyperplasia of the adjacent cortex 
Postoperatively, the aldosterone secretion rate decreased to 8 μg/24 hr as measured on the 10th day 
after operation during a daily sodium intake of IIS mmol Plasma sodium and potassium were 
restored to normal Blood pressure was still elevated to 164/118 mmHg on discharge from hospital. 
but was normal (126/88 mmHg) at the first visit one month after operation and at the regular control 
visits thereafter During the first two months after operation the patient had complaints of orthostatic 
hypotension, which resolved spontaneously Attacks of headache disappeared 
Patient 18(9.S-K1. 27 11 33) 
The patient is a 45 years old woman, who was referred in 1979 by her family doctor to the department 
of internal medicine, because of hypertension She had taken oral contraceptives from 1961 to 1973 
During this period blood pressure was normal In 1973 treatment with oral contraceptives was 
discontinued and a laparascopic tubal coagulation was performed A few months later hypertension 
was detected on the occasion of a neurologic examination on account ot persistent headache for many 
years From 1974 to 1979 she had been treated bv an internist elsewhere with medical antihyperten­
sive treatment (propranolol, methyldopa and chlorothiazide) without a satisfactory decrease of blood 
pressure being achieved The patient discontent with the results of antihypertensive treatment, asked 
her family doctor for a reference to a university centre At her first visit she complained of chronic 
fatigue, muscle weakness and palpitations Attacks of headache had disappeared 4 years previously 
She had no paresthesia, tetany, polydipsia or polyuria Occasionally she had edema of the ankles 
Her previous history was uneventful Blood pressures had been normal during each of two pregnan­
cies (1958 and 1959) At her First visit blood pressure, measured during antihypertensive treatment 
with methyldopa and chlorothiazide 500 mg/day. was 210/110 mmHg Fundoscopv revealed a mild 
hypertensive retinopathy with increased light reflexes and arteriovenous crossing defects No ankle 
edema Normal central venous pressure The heart was not enlarged Abdominal vascular bruits were 
absent Laboratory urinary protein and glucose were negative Plasma electrolytes sodium 141 
mmol/l, potassium 2 5 mmol'l. chloride 96 mmol'! and bicarbonate 37 6 mmol/l Renal function was 
unimpaired Radiologic examination of the chest hcart-to-lung quotient 13 29 5 Intravenous 
pyelography revealed no abnormalities Electrocardiography sinus rhythm and marked U-waves 
The finding of a marked hypokalemia was erroneously attributed to the use of the weak diuretic 
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chlorothiazide The patient was treated with metoprolol 300 mg/day hydralazine ISO mg/day and 
chlorothiazide 500 mg/day The blood pressure did not respond to this therapeutic regimen 
Hypernatremia and hypokalemia with values as low as 2 2 mmol'l were repeatedly found After 10 
months treatment antihypertensive medication was discontinued because the patient was still discon­
tent about the results of treatment and asked for a thorough analysis of her hypertension Persistent 
hypernatrcmia and hypokalemia after withdrawal of medication led to the tentative diagnosis of 
primary aldosteronism 
Clinical evaluation with measurements of aldosterone secretion rates and other clinical and biochemi­
cal data (table A 22) confirmed this diagnosis 
Table A-22 
Aldmterone secretion rales and additional clinical and biochemical findings in panent S Kl 
SODIUM INTAKE 
Blood pressure (mmHg) 
bodium (mmol/l) 
Potassium (mmol/1) 
Creatinine (μπιοΐΐ) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/1 hr) 
ASR ^g/24 hr) 
15 mmol/24 hr 
136 
3 3 
6« 
34 
86 
S« 
43 
240 
114 mmol/24 hr 
205/117 (n = 
117 
3 4 
67 
130 
84 
9 1 
34 
259 
= 12) 
HS mmol 24 hr 
141 
3 0 
63 
389 
116 
8 4 
_ 
244 
Adrenal scintigraphy using "'I 6p lodomcthyl 19 Nor-Choleslcrol was performed during dexamctha-
sonc suppression Dexamethasonc was given at a dose of 2 mg/day starting 14 days before injection of 
the radiopharmacLUlical which was given at a dose of 2 I mCi On the 5th 7th and 9th days ρ ι the 
right adrenal gland was clearly visualized No adrenal uptake was found on the left side These 
findings were highly suggestive of an aldosterone producing adenoma in the nghl adrenal gland 
Treatment with spironolactone 400 mg/day resulted in a decrease of blood pressure from 205/117 to 
150/112 mmHg Side effects of the treatment included fatigue and Ravnoud s phenomenon After 
lowering the dose to 150 mg and 1(X) mg day blood pressures remained within the normal range (125/ 
90 mmHg) Side effects however did not subside Medical treatment with amilonde 20 mg day and 
chlorthalidone 50 mg every 2 days resulted in a fall of blood pressure to 135/95 mmHg after 2 weeks 
treatment This medication was given concurrently with dexamethasonc 
On October 3rd 1980 the right adrenal gland was surgically removed via a right lumbotomy between 
the 10th and 1 Ith ribs Ί he right pleural cavity was accidcntly opened After operation the patient was 
treated for a pneumothorax by suction drainage through an intrapleural catheter 
The right gland weighed 8 2 g and contained a yellow adenoma measuring 1 9 cm The adjacent 
adrenal cortex was flat Light miLroscop\ the adenoma was sharply separated from the adjacent 
adrenal cortex by a broad connective tissue capsule The tumor was composed of relatively large cells 
with a small round nucleus and abundant foamy and eosinophilic cytoplasm The cells were arranged 
in solid fields divided by thin connective tissue septa The tumor did not show any evidence of 
malignancy The adrenal cortex outside the tumor was normal Conclusion adrenocortical adenoma 
composed of zona fascicular tvpc cells 
Postoperatively plasma electrolvtcs were restored within a few days to normal values Urinary 
aldosterone excretion measured on the first day after operation was 0 1 μξ/24 hr Aldosterone 
secretion rate measured on the 10th day after operation during a 115 mmol sodium diet was23μg/24 
hr Blood pressure decreased to 160 100 mmHg on discharge from hospital and to 140/90 mmHg 2 
weeks after operation 
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Patient 19 (Cf. ν Ν, 25 05 16) 
The patient is a 52 years old man, who was referred to the department of internal medicine on March 
8th 1968 Hypertension was detected in July 1966 dt a routine medical examination He was treated 
medically (methyldopa. chlorothiazide, guanethidmc) without a satisfactory decrease of blood pres­
sure In January 1968 he was admitted to a hospital elsewhere for hypertension analysis Blood 
pressure values averaged 263/131 mmHg Plasma potassium values varied from 3 3 to 3 8 mmol/l 
Primary aldosteronism was suspected, for the analysis of which the patient was referred to our 
hospital On admission the patient had no complaints He had no headache, muscle weakness, 
nycturia or paresthesia His previous history was uneventful, except for a hypersensitivity nephritis 
after the use of sulfonamides (1947) Physical examination Blood pressure on admission was 270/135 
mmHg Central venous pressure was R-1 cm H2O There was no edema Fundoscopy revealed no 
hemorrhages or exudates The heart was not enlarged A late-systolic murmur was found at the apex 
of the heart Abdominal bruits were absent Laboratory no proteinuria or glucosuria Plasma 
electrolytes sodium 144 mmol/l, potassium 3 6 mmol/l, chloride 103 mmol/l, bicarbonate 34 6mmol/l 
Renal function was unimpaired Electrocardiography sinus rhythm without signs of left ventricular 
hypertrophy X-ray of the chest heart-to-lung quotient was 15 32 Intravenous pyelography was 
normal Scldingcr arteriography revealed a slight stenosis at the ongin of the right renal artery with a 
post-stcnotic dilatation Retroperitoneal gas insufflation did not reveal a tumor in the adrenal regions 
Aldosterone secretion rates were clinically measured before and after moderate sodium loading (table 
A-21) High aldosterone secretion, unresponsive to sodium loading, dexamethasonc and DOC 
treatment, together with mild hvpokalcmia and hyporenmemia established the diagnosis of primary 
aldosteronism The slight stenosis of the right renal artery was considered to be hcmodynamically 
unimportant 
Table A-23 
Aldosterone secretion rates and additional clinical and biochemical findings m patient ν N 
SODIUM INTAKE 
IS mmol 24 hr 115 nimol/24 hr 
Blood pressure (mmHg) 243/124 (n=14) 
Sodium (mmolЛ ) 144 149 
Potassium (mmol/l) 3 6 3 5 
Creatinine (цтоі/і) 85 87 
PRA (ng/10 ml/3 hr) 85 
ASR ^g/24 hr) 481 476 
On September 5th 1968 the left adrenal gland was surgically explored via a left lumbotomy with 
resection of the 12th and part of the 11th ribs The left adrenal gland was enlarged (7x2x1 cm) but did 
not contain a palpable tumor A part of the left gland was resected and about Ix'Ax'A cm was left m 
situ Subsequently the right adrenal gland was explored after a right lumbotomv and resection of the 
12th rib No tumor was found in the right adrenal, which was enlarged to the same extent as the left 
adrenal The right adrenal gland was resected in tolo 
The macroscopic aspect of the removed adrenal tissue did not show a macronodular architecture of 
the cortex Light microscopy the adrenal cortex was of normal width, without adrenocortical nodules 
The outer adrenocortical layer was composed of alvcolarly arranged cells of the zona glomcrulosa - or 
zona fasciculata - type The presence of numerous spironolactone bodies in the outer cortex suggested 
a well-developed and broad zona glomcrulosa Conclusion hyperplasia of the zona glomcrulosa with 
numerous spironolactone bodies 
Postoperatively, the patient was followed up at the out-patient clinic at irregular intervals for 12 years 
Blood pressure did not normalize after operation (180/110 - 230/130 mmHg) However, blood 
pressures responded well to treatment with rauwolfia alkaloids and chlorothiazide (140/85-180/105 
mmHg) Aldosterone secretion rate measured in 1969, one year after operation, was normal (70 μg/24 
hr) In 1980 blood pressure was 160/85 mmHg during treatment with chlorothiazide 50 mg'day and 
triamterene 25 mg/dav 
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Patient 20 (cf, S. 30 03 10) 
The patient is a man who was 56 years old when he was referred to the department of internal 
medicine in 1966 Hypertension (180/110 mmHg) was detected in 1965 His previous history was 
uneventful Blood presure did not respond to medical treatment with rauwolfia alkaloids for 2 years 
Mild spontaneous hypokalemia was repeatedly found He had no complaints of nycturia, muscle 
weakness paresthesia or telanv On physical examination at admittance to the hospital for clinical 
evaluation m 1968, his heart was found to be enlarged Fundoscopy revealed no signs of hypertensive 
retinopathy No vascular abdominal bruits were heard The electrocardiogram did show a sinus 
rhythm with a sign of a left ventricular strain On X-ray of the chest the heart appeared to be enlarged 
with a hcart-to-lung quotient of 19 32 5 Intravenous pyelography and arteriography were not 
performed 
Aldosterone secretion rates were measured at two different levels of sodium intake An elevated 
aldosterone secretion at a sodium intake of 115 mmol Na /24 hr mild hypokalemia and a suppressed 
renin activity confirmed the diagnosis of primary aldosteronism (table A-24) 
Table A-24 
Aldosterone secretion rates and additional clinical and biochemical findings in patient S 
SODIUM INTAKE 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (μιηοΙ/Ι) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR (μ£/24 hr) 
IS mmoI'M hr 
143 
3 8 
88 
-
-
-
42 
281 
184/96 
ll5imnol/24hr 
147 
3 6 
92 
147 
48 
15 3 
_ 
401 
On postmortum examination both adrenal glands appeared enlarged and weighed 50 g (L+R) No 
adrenocortical adenoma was found Light microscopic examination revealed a marked broadening of 
the adrenal cortex with focally a nodular architecture The cortex was mainly composed of clear 
vacuolated cells as found in the zona fasciculata Subcapsularly. the cells could be identified as zona 
glomemlosa-type cells More inwards, however no histologic distinction could be made between zona 
glomemlosa-type cells and zona fasciculata-typc cells devoid of lipoid 
On January 31th 1971 the patient died from an acute pancreatitis Postmortum examination revealed 
an acute hemorrhagic pancreatitis, peritoneal fat necrosis and a hypertrophy of the left myocardium 
Patient 21 ( ? , L. 03 10 14) 
The patient is a 54 years old woman, who was referred to the department of internal medicine on June 
25th 1969 for analysis and treatment of hypertension High blood pressure was detected in January 
1968, when she visited her family doctor with complaints of a pulsatile swelling above the right 
clavicle Angiography of the aortic arch had revealed an elongation of the aorta with a hitch of the 
right carotid and left subclavian arteries Surgical correction was not performed Antihypertensive 
treatment had been unsuccessful At the first visit she complained of fatigue, headache and nycturia 
There was a long history of backache She had undergone four operations for prolapses of both 
thoracic and lumbar (fiscs Physical examination blood pressure was 230/130 mmHg Central venous 
pressure was R-6 cm H^O No edema Fundoscopy revealed no hemorrhages or exudates A pulsatile 
swelling with a diameter of 6 cm was found above the right clavicle The heart was enlarged and an 
exaggerated apical impulse was found Abdominal vascular bruits were absent The spleen was 
enlarged to 5 cm under the left costal margin The liver was not palpable Laboratory the unne was 
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normal Plasma elcctrolylcs sodium 146 mmol/1 potassium 3 1 mmol/1, chloride 106 mmol/1 
bicarbonate 29 8 mmol/1 Renal function »as moderately impaired with a creatinine clearance of 55 
ml mm Intravenous pyelography showed a delayed appearance time of the contrast material The 
renal pelvis and calyces in the upper pole of the right kidney and in the left kidney were dilated The 
renal cortex was relatively small on both sides The radiologic features were characteristic of chronic 
pyelonephritis Seldinger arteriography of the renal arteries did not disclose renal artery stenosis 
blectrocardiography sinus rhythm, signs of left ventricular hypertrophy, and sporadically ventricular 
premature beats, T-mvcrsion in leads III. AVF and V4-V6. U-waves 
Aldosterone secretion rates were measured both during sodium restriction and after moderate sodium 
loading (table A 25) Aldosterone secretion rate after moderate sodium loading was slightly elevated 
This finding, together with hypertension hypokalemia and hyporcnmemia confirmed the diagnosis of 
primary aldosteronism It was decided not to explore the adrenal glands because 1 Signs and 
symptoms of primary aldosteronism were relatively mild and 2 The impairment of renal function 
diminished the prospects of successful adrenal surgery 
Table A 25 
Aldosterone secretion rates and additional clinical and biochemical findings in patient L 
SODIUM INTAKb 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (μπιοΜ) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/lO ml'3 hr) 
ASR ^g/24 hr) 
IS mmol/24 hr 
215/131 
141 
3 4 
163 
9 
18 
7 3 
32 
418 
IIS mmol/24 hr 
(n = 22) 
141 
3 3 
117 
101 
29 
9 1 
-
222 
Postmortum examination of the adrenal glands revealed no adrenocortical adenoma Macroscopically 
the adrenal cortex did not show macronodular hyperplasia Total adrenal weight, however was 
increased to 20 g Light microscopic examination showed a zona glomerulosa. which was present over 
the full length of the preparation The cells of the zona glomerulosa were arranged in solid fields One 
solitary adrenocortical nodule that was found was composed of cells with a fine vacuolated cytoplasm 
and a round nucleus The nodule was clearlv separated from the adjacent tissue, although it was not 
surrounded by a capsule The zona fasciculata showed only focally a slight increase of the number of 
cells The zona reticularis was normal Conclusion micronodular adrenocortical hyperplasia 
During regular control visits to the out-patient clinic from October 1969 to February 1971 the blood 
pressure remained elevated and did not respond to medical treatment with rauwolfia alkaloids and 
hydralazine On February 25th 1971 the patient was admitted to the hospital because of fever severe 
abdominal pain radiating to the right shoulder jaundice and vomiting A tentative diagnosis of acute 
cholecystitis was made, and she was referred to the department of surgery On March 5th she died 
suddenly Postmortum examination disclosed a dissecting aneurysm of the aorta extending from the 
aortic valves to the cocliac trunk chronic pyelonephritis hypertrophy of the heart and splcnomegalv 
Patient 22 ( 9 . S-B. 13 08 28) 
The patient is a 42 years old woman who was referred to the department of internal medicine in 
October 1970 for analysis and treatment of high blood pressure Hypertension was detected in June 
1970, when she visited the department of surgery because of rectal hemorrhages Extensive examina­
tion. including rectoscopy and radiography of the gastro-intcstinal tract had revealed no abnormali­
ties Blood pressure was still normal in February 1969. when an abdominal hysterectomy was 
performed At the first visit, she complained of hot flushes and attacks of dizziness and generalized 
sweating In addition she complained of fatigue, ankle edema in the evening and nycturia She had no 
224 
muscle weakness or headache She had a long history of heavy cigarette smoking and chronic 
bronchitis She had never been pregnant and had never taken oral contraceptives Physical examina­
tion at the first visit revealed a blood pressure of 230/120 mmHg Central venous pressure was R-6 cm 
Η,Ο hdema was absent Fundoscopy revealed a mild hypertensive retinopathy with arteriovenous 
crossings and copper-wire arteries No hemorrhages or exudates were found The heart was not 
enlarged No abdominal vascular bruits were heard Laboratory no proteinuria or glucosuria Plasma 
electrolytes sodium 145 mmol/l potassium 3 3 mmol/l chloride 101 mmol/l bicarbonate 26 6 mmol·! 
Renal function was unimpaired X ray of the chest showed that the heart was not enlarged 
Intravenous pyelography was normal Scldingcr arteriography did not disclose narrowing of the renal 
arteries The adrenal glands were not visualized Imaging of the adrenal glands by adrenal venography 
was unsuccessful Electrocardiograph) sinus rhvthm and marked U-wavcs No signs of left ventricu­
lar hypertrophy 
Adoslcronc secretion rates before and after sodium loading are presented in table A-26 The clinical 
and biochemical findings are in accordance with a relatively mild primary aldosteronism 
Table A-26 
Aldosterone secretion rates and additional clinical and biochemical findings m patient S В 
SODILM INTAKF 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (μπιοΙ/Ι) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmül/24 hr) 
PRA (ng/10 ml'l hr) 
ASR ^g/24 hr) 
IS m!m>l/2-Hir 
143 
38 
82 
2 
27 
126 
21 
-
11S mmol/24 hr 
173/105 ( η -
147 
3 4 
92 
176 
85 
14 9 
-
242 
12) 
3|S mmol 24 hr 
143 
3 1 
62 
460 
92 
13 9 
-
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Antihypertensive treatment with spironolactone 400 mg/day resulted in a decrease of blood pressure 
from 173/105 (mean value during clinical admission) to 125/85 mmHg after 4 weeks treatment and 
140/80 mmHg after 8 weeks treatment (values measured at the out-patient clinic) During treatment 
the patient developed Ravnaud s phtnomenon which is a known side effect of spironolactone 
treatment 
On July 7th 1971 the left adrenal gland was explored via a left lumbotomy and resection of the 12lh 
rib The left adrenal gland was firmly attached to the diaphragm No palpable adrenal tumor was 
found Subsequently the right adrenal gland was explored via a right lumbotomy This gland appeared 
to have grown together with the upper pole of the right kidney The right adrenal also did not contain 
a palpable tumor 1 he right gland was resected in toto Subsequently two-thirds of the left adrenal 
were resected 
The right adrenal gland weighed 4 g An adrenocortical adenoma was not found on dissection of the 
gland The adrenal cortex had width of 1 mm The tissue resected from the left adrenal gland weighed 
3 g and showed on its outer surface a pattern comparable with that found in the right gland An 
adrenocortical adenoma was not found Light microscopy the zonae glomcrulosae of both adrenal 
glands were widened and contained large cells with a clear cvloplasm and a centrally located nucleus 
Many of these cells contained spironolactone bodies It was found difficult to differentiate these cells 
from those normallv found in the zona fasciculata С onclusion hyperplasia of (he zona glomerulosa of 
both adrenal glands Spironolactone bodies 
One month after operation the patient was admitted to the hospital for evaluation of the results of the 
operative procedure Mean blood pressure on admission was 115/81 mmHg (n = 10) Aldosterone 
secretion rate measured during a 115 mmol sodium diet was in the low to normal range (79 μg/24 hr) 
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Plasma renin actmty. however, showed a high value of 1475 ng/10 ml/3 hr on a sodium-restncted diet, 
while plasma sodium decreased lo 130 mmol/l, plasma potassium increased to 5 2 mmol/1 and plasma 
creatinine increased to 100 μπιοΐ/ΐ In addition, a 30-40 mmol sodium loss per day was noted on the 
sodium-rcstnctcd diet These findings were suggestive of a relative mineralocorticoid deficiency 
Substitution therapy with 9-a-fluoro-hydrocortisone 0 1 to 0 2 mg/day was started and continued until 
1975 At that time aldosterone secretion rate measured during a sodium-restncted diet after 
discontinuation of mineralocorticoid substitution, was normal (252 μg/24 hr), together with normal 
values for PRA (453 ng/10 тЬЗ hr). plasma sodium (139 mmol/l), plasma potassium (3 9 mmol/1) and 
plasma creatinine (77 цтоі/і), while urinary sodium excretion decreased to values lower than 15 
mmol/24 hr The mean blood pressure value during clinical admission was 127/85 mmHg (n=17) In 
1974 and 1975 a rapid deterioration of pulmonary function was noted On January 5th 1976 she died as 
a consequence of an exacerbation of her chronic bronchitis with respiratory insufficiency 
Patient 23 (Cf, J, 09 07 27) 
The patient is a 46 years old man, who was referred to the department of internal medicine on April 
25lh 1973 Hypertension (210/130 mmHg) was detected in January 1973 by his family doctor At a 
routine medical examination in 1969 blood pressure was found to be normal Antihypertensive 
treatment with chlorothiazide 500 mg per day and a salt-restncted diet had resulted in an insufficient 
decrease of blood pressure to 170 to 180/104 to 120 mmHg The patient had no complaints, except that 
for a few months he felt overworked He had no headache, muscle weakness, nycturia or paresthesia 
In January 1973 he had developed ankle edema, which had subsequently disappeared spontaneously 
His previous history revealed a lung tuberculosis in 1944 and 1950 In 1964, 1966 and 1970 he had 
recurrent nephrolithiasis Physical examination blood pressure values at his first visit varied from 180/ 
105 to 210/110 mmHg Central venous pressure was normal, R-5 cm H2O No edema Fundoscopy 
revealed no signs of hypertensive retinopathy The heart was not enlarged Vascular abdominal bruits 
were absent Laboratory no proteinuria or glucosuria Unne culture sterile Plasma electrolytes 
sodium 143 mmol/1, potassium 2 9 mmol/1. chloride 99 mmol/l, bicarbonate 34 0 mmol/1 Renal 
function was unimpaired Electrocardiography sinus rhythm Signs of left ventricular hypertrophy 
Sporadically, ventricular premature beats and U-waves Radiography of the chest showed a heart-to-
lung quotient of 13 30 Intravenous pyelography did not reveal any abnormality Seldinger arterio­
graphy disclosed no renal artery stenosis The right adrenal gland was visualized, but looked normal 
The left adrenal was not visualized An attempt to visualize the adrenal glands by percutaneous 
venography was unsuccessful, due to a failure to cannulate the central adrenal vein on each side 
Clinical measurements of aldosterone secretion rate before and after sodium loading and other 
relevant clinical and biochemical data arc presented in table A-27 These findings established the 
diagnosis of primary aldosteronism 
Table A-27 
Aldoiterone secretion rates and additional clinical and biochemical findings m patient J 
SODIUM ΙΝΙΑΚΕ 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/1) 
Creatinine (μιηοΙ/Ι) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
\JV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR ^g/24 hr) 
15 nimol/24 hr 
141 
2 7 
94 
63 
62 
10 0 
62 
426 
IIS mmol/24 hr 
169/118 (n = 
139 
3 3 
80 
271 
81 
17 0 
-
340 
16) 
315 mmol/24 hr 
147 
2 6 
78 
386 
100 
17 5 
-
388 
Medical treatment with spironolactone 400 mg/day resulted in a decrease of blood pressure from 169/ 
118 mmHg (mean blood pressure value dunng clinical admission) to 135/95 mmHg (measured at the 
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out-patient clinic after 4 weeks treatment) During treatment the patient experienced upper abdomi­
nal discomfort and diarrhoea 
6 On November 8th 1973 the right adrenal gland was surgically explored via a right lumbotomy The 
adrenal gland was not enlarged and did not contain a palpable tumor Half of the gland was resected 
The left adrenal gland, explored via a left lumbotomy, also did not harbor a palpable tumor The left 
adrenal gland was resected in toto 
7 The macroscopic material consisted of a large number of tissue fragments The tissue removed was 
not weighed Light microscopy the adrenal cortex of all tissue fragments was relatively thin The 
cortical zonation showed an irregular architecture Focally the clear cells of the zona fasciculate 
reached up to the capsule The zona glomcrulosa did not show a diffuse or nodular widening Several 
fresh and old hemorrhages were found between the zona reticularis and the adrenal medulla 
Conclusion focal increase of zona glomerulosa cells No adenoma or nodular hyperplasia were found 
8 Postoperatively the plasma electrolytes normalized Aldosterone secretion rates were not measured 
Blood pressures, measured during stay in the clinic one month after operation varied from 120 to 150/ 
95 to 110 mmHg At the subsequent control visit during a follow-up period of 7 years, blood pressures 
remained slightly elevated (140 to 150/95 to 105 mmHg) The patient was not treated with antihyper­
tensive medicaments 
Patient 24 (d, T, 19 02 24) 
1 The patient is a 48 years old man. who was referred to our institute on May 25th 1972, because of 
hypertension High blood pressure was detected in 1968 in the course of a medical sports examination 
No medical treatment was presenbed His body weight increased from 90 to 110 kg brom 1970 on he 
developed complaints of fatigue, shortness of breath, nycturia 3 to 4 times and ankle edema 
Hypertension analysis in a hospital elsewhere, revealed high blood pressure (185 to 200/115 to 120 
mmHg), absence of heart failure, electrocardiogram without signs of left ventricular hypertrophy, a 
slight radiographic increase of heart size and a normal intravenoub pyclogram Medical treatment with 
catapressan and chlorthalidone had to be withdrawn because of hypokalemia When the patient was 
subsequently referred to our institute,.he complained of fatigue, polyuria and nycturia He had no 
muscle weakness, edema or tetany He had not had any antihypertensive medication for at least one 
month The previous medical history was uneventful Physical examination Blood pressure 230/130 
mmHg No edema Slight increase of heart size No abdominal bruits Laboratory no proteinuria 
Plasma electrolytes sodium 142 mmol/1. potassium 3 1 mmol/l. chloride 104 mmol/1. bicarbonate 32 4 
mmol/1 Creatinine 107 цтоі/і Fasting cholesterol 6 1 mmol/I triglyceride 5 48 mmol/1 Glucose 5 0 
mmol/l Impaired carbohydrate tolerance after oral glucose loading Heart-to-lung quotient on 
radiogram of the chest was 17 36 Intravenous pyclogram was normal Antihypertensive treatment 
with chlorthalidone 50 mg/day and mcthyldopa for 3 months did not result in a satisfactory decrease of 
blood pressure Plasma electrolytes repeatedly showed hypernatremia (144-144-144 mmol/1) and 
hypokalemia (3 1-2 8-2 7 mmol/1), despite addition of potassium supplements Unfortunately, these 
findings did not lead to further investigations into the presence of primary aldosteronism All 
hypertensive medications were withdrawn after the finding of a normal blood pressure value (125/75 
mmHg) by direct intraarterial measurement The patient was discharged from the out-patient clinic 
One year later, in April 1975, he was again referred to our hospital after the finding of severe 
hypertension (240/150 mmHg) at a routine medical examination The patient complained of heada­
che Polyuria and nycturia were still present Phycical examination weight 114.2 kg. blood pressure 
250/160 mmHg Fundoscopy showed no hemorrhages or exudates Laboratory plasma sodium 148 
mmol/1, potassium 2 8 mmol/1, chloride 98 mmol/1, bicarbonate 29 1 mmol/l Creatinine 119 цтоІЛ 
Electrocardiography flattening of the ST-T segments in leads I, AVL, V1-V6 Prominent U-waves 
The radiographic heart-to-lung quotient was 18 36 5 Intravenous pyclogram was normal Seldingcr 
arteriography no vascular abnormalities of the renal arteries 
2 The patient was admitted to the hospital for clinical examination and determinations of plasma renin 
activity and aldosterone secretion rate The results are presented in the table A-28 The clinical data 
are in accordance with the diagnosis of primary aldosteronism 
3 Surprisingly, in view of the marked elevation of aldosterone secretion rates, plasma aldosterone 
values, both by night and by day, were within the normal range (figure A-I8) Plasma aldosterone 
227 
Table A-28 
Aldosterone secretion rates and additional clinical and biochemical findings m patient Τ 
SODIUM INTAKE 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potassium (mmol/1) 
Creatinine (цтоІ/І) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 ml/3 hr) 
ASR (μ$/24 hr) 
15 mnlol/24 hr 
144 
3 3 
152 
14 
44 
20 5 
34 
-
US mmo!/24 hr 
199/127 (n = 
147 
2 8 
150 
146 
80 
219 
-
474 
27) 
315 nimol/24 hr 
144 
2 5 
105 
353 
106 
18 6 
-
432 
values during the day were somewhat higher than during the night A slight postural increase of 
aldosterone was found after 4 hours of ambulation in the morning Aldosterone correlated signifi­
cantly with Cortisol and 18-OH-DOC during the night During the night and the days, aldosterone was 
also significantly correlated to Cortisol, not however to 18-OH-DOC 
Aldosterone vs Cortisol 
Aldosterone vs 18-OH-DOC 
Cortisol vs 18-OH-DOC 
night 
(n=12) 
0 74 (p<0 01) 
0 72 (p<0 01) 
0 91 (p<OU01) 
night, days 1 and 2 
(n=18) 
0 55 (p<0 05) 
- 0 06 ( n s ) 
0 56 (p<0 05) 
Thus, the influence of ACTH on the regulation of aldosterone was apparent, especially during the 
night Dcxamethasonc treatment did not influence the level of plasma aldosterone concentrations 
during the night and the day 
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Figure Α-18 Diurnal variations of plasma aldosterone, Cortisol and 18-OH-DOC in patient Τ with 
idiopathic aldosteronism 
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Dexamethasone suppression scans of the adrenal glands were performed, using n'I-19-Iodocholeste-
rol Dexamethasone was given at a dose of 2 mg/day. starting 3 days before injection of 1 mCi of " Ί -
19-Iodocholesterol Adrenal scintigrams on the 3rd, 5th. 6th and 7th days did not show any 
discernable accumulation of radioactivity in either of the adrenal regions On the 8th day a slight 
accumulation was detected over both adrenal areas The absence of unilateral accumulation of 
radioactivity excluded the presence of an aldosterone-producing adenoma Therefore, primary 
aldosteronism in this patient was considered to be caused by bilateral adrenal hyperplasia 
The effects of medical treatment with high doses of spironolactone (400 mg/day) for 6 weeks were 
compared with the effects of 6 weeks treatment with high doses of amilonde (40 mg/day) (table A-29) 
Amiloride was not as effective as spironolactone in lowering the blood pressure Renin and 
aldosterone were stimulated by either drug to the same extent The patient experienced considerable 
side effects during spironolactone treatment gynecomastia, impotency and abdominal discomfort 
Amiloride caused a mild diarrhea After the spironolactone vs amilonde trial, medical treatment was 
continued with spironolactone at doses of НЮ to 200 mg/day Despite these low doses the patient 
developed abdominal complaints, which appeared to be based on a duodenal ulcer Therefore, 
spironolactone was withdrawn for half a year 
Table A-29 
Comparison of the effects of treatment with spironolactone versus amilonde on some clinical and 
biochemical findings in patient Τ 
SODIUM INTAKE 
Body weight (kg) 
Blood pressure ( m m H g ) * 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (цтоі/і) 
PRA (ng/10 ml/3 hr) 
Aldosterone excretion 
(Mg/24 hr) 
• Measured bv arlenosondc 
spironolactone 
401) mg/dav 
(6 wks) 
107 
112/92 
139 
5 0 
148 
297 
51 
placebo 
(A wks) 
110 8 
154/104 
141 
1 8 
119 
47 
20 
amilonde 
m mp/day 
(6 wks) 
110 6 
129/90 
139 
4 6 
120 
253 
46 
Patient 25 ( 9 . ν Ε-v U. 11 03 37) 
This patient, a 35 years old woman, was referred to the out-patient clinic of our institute by her family 
doctor on August 23th 1971. because of a mild hypertension and a non-toxic struma Hypertension 
was detected during her third pregnancy in 1972. while during her first two pregnancies blood 
pressures had been normal Blood pressure remained elevated after the delivery and during the 
subsequent use of oral contraceptives The second reason for her referral was an enlarged thyroid for 
the previous 2 years She had no complaints of hyperthyroidism nor complaints due to enlargement of 
the thyroid Her previous history had been uneventful, except for an appendectomy in 1956 At the 
control visits to the out-patient clinic, after withdrawal of the oral contraceptives, blood pressures 
remained elevated 150 to 160/110 to 115 mmHg Treatment with chlorthalidone 50 to 100 mg/day for 
almost 2 years resulted m a decrease of blood pressure to levels of 120 to 150/85 to 90 mmHg During 
diuretic treatment plasma sodium levels were repeatedly above normal (141 to 147 mmol/l) concomi­
tantly with mild hypokalemia (3 4 to 3 6 mmol/l) After discontinuation of medical treatment the 
patient was admitted to the hospital in 1974 for evaluation of her blood pressure On admittance she 
was free of complaints she had no headache, no polyuria, no nycturia, no paresthesia and no tetany 
Physical examination Blood pressure 160/120 mmHg Fundoscopy no signs of hypertensive retinopa­
thy The thyroid was asymmetrically enlarged, and had a smooth surface No pathologic lymph nodes 
were found Central venous pressure was normal The heart was not enlarged No abdominal bruits 
were noted Radiologic examination of the chest revealed a normal heart size with a heart-to-lung 
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quotient of 13 28 Intravenous pvclography was normal Scldingcr arteriography showed a normal 
renal artery on both sides No abnormalities were found in the adrenal regions The electrocardio­
gram demonstrated a sinus rhythm and absence of left ventricular hypertrophy 
Aldosterone secretion rates, plasma renin activity and other relevant data are presented in table A-30 
The findings of a hypertension, normal plasma sodium levels, normal to mildly decreased plasma 
potassium levels, slightly decreased plasma renin activity and insufficient suppressibility of aldoste­
rone secretion after sodium loading, were all in agreement with the diagnosis of mild primary 
aldosteronism 
Table AW 
Aldosterone secretion rates and additional clinical and biochemical findings in panent ν E-v V 
SODIUM INTAKF 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potassium (mmol/l) 
Creatinine (μιποΙ/Ι) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/10 min hr) 
ASR (μ6/24 hr) 
15 mmol/24 hr 
140 
3 9 
64 
28 
72 
10 В 
112 
426 
115 mmol/24 hr 
150/100 (n = 
141 
3 4 
50 
250 
110 
15 4 
-
250 
=9) 
315 mmol/24 hr 
140 
3 9 
58 
331 
B6 
12 4 
_ 
199 
The nocturnal plasma aldosterone concentrations (figure A 19) ranged from 4 2 to 14 β ng/100 ml 
Aldosterone increased markedly during subsequent ambulation (day 1) to 28 1 ng/100 ml at 12 00 
hours a m and to 30 7 ng/100 ml at 16 (X) hours Recumbent aldosterone concentrations (day 2) 
ν E-vU 11 ОЭ- 37 
""**"î—Î—J**O-<0-ftW* »< 1 J }»»CHO-<M» 
Figure A-19 Diurnal variations of plasma aldosterone, Cortisol and 18-OH-DOC in patient ν Ε-v U 
with idiopathic aldosteronism 
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remained lower than the value during ambulation (day 1) The correlation coefficients between the 
three adrenocortical hormones demonstrdted a role for ACTH in the regulation of aldosterone during 
the night, not however for the regulation of the nocturnal and daytime values together 
night night days 1 and 2 
(n = l l ) (n = 17) 
Aldosterone vs Cortisol 0 75 (p<0 01) 0 34 (n s ) 
Aldosterone vs 18-OH-DOC 0 79 (p<0 01) 0 03 (n s ) 
Cortisol VS18 0H-DOC 0 71 (p<0 01) 0 62 (p<0 01) 
Dcxamethasone treatment reduced mean nocturnal aldosterone from 10 0 ± 3 6 to 1 4 ± 0 4 ng/ 
100 ml The daytime aldosterone values during dexamethasonc were only slightly lower than the 
values obtained under basal circumstances 
Adrenal scintigraphy was performed with 131l-6ß-lodomcthyl-19-Nor-Choleslerol after long term 
pretreatment with dcxamethasone (2 mg/day) which was started 2 weeks before administration of 1 8 
mCi of the radiopharmaceutical Adrenal scintigrams on the 2nd, Sth and 6th days after injection, 
showed no accumulation of radioactivity in the adrenal glands 
The effects of 6 weeks treatment with spironolactone 400 mg/day on blood pressure and other clinical 
and biochemical parameters were compared to the effects of 6 weeks treatment with amilonde 40 mg/ 
day (table A-31) Amiloride did not decrease blood pressure to a level as low as that found after 
spironolactone treatment Stimulation of PRA after spironolactone occurred concomitantly with a 
marked decrease of body weight After amilonde treatment body weight and PRA remained 
essentially unchanged Aldosterone excretions increased after either treatment The patient expe-
nenced no side effects from cither of the drugs, or urinary aldosterone excretions Since this patient 
was considered to have primary aldosteronism without adrenocortical adenoma ( idiopathic aldostc 
ronism") it was decided not to explore the adrenal glands Medical treatment with low doses of 
spironolactone (SO mg/day) together with low doses of amilonde (IS mg/day) maintained diastolic 
blood pressures lower than 100 mmHg 
Table A 31 
Comparison of the effects of treatment with spironolactone versus amilonde on some clinical and 
biochemical findings m patient ν l· ν U 
Body weight (kg) 
Blood pressure (mmHg)* 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (цтоі/і) 
PRA (ng/10 ml/3 hr) 
Aldosterone excretion 
№g/24 hr) 
* Measured by anenosonde 
spironolactone 
4Ш mflcJav 
(6 wks) 
71 8 
102/61 
137 
4 4 
68 
322 
53 
placebo 
(6 wks) 
75 1 
130/92 
142 
3 4 
60 
103 
14 
amilonde 
40 mg/day 
(6 wks) 
75 5 
115/81 
137 
3 5 
56 
56 
34 
Patient 26 ( 9 , C-J, 05 04 23) 
The patient is a woman of 36 years old, who was admitted to our hospital in 1959 because of 
hypertension High blood pressure was detected by her family doctor in 1953 when she complained of 
ankle edema Earlier she was found to be hypertensive during each of her three pregnancies (1946 
1948 and 1951) Antihypertensive treatment with rauwolfia alkaloids had to be withdrawn because of 
side effects On admission the patient complained of fatigue She had no nycturia muscle weakness, 
tetany or paresthesia Blood pressure was 235/145 mmHg Fundoscopy revealed only crossing 
phenomena No vascular abdominal bruits were heard Laboratory plasma electrolytes were normal 
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After three day;, therapy with chlorothiazide, plasma potassium decreased from 4 0 to 2 4 mmol/l 
Electrocardiogram was normal Heart-to-lung quotient was 13 27 5 Intravenous pyelogram was 
normal During medical treatment with rauwolfia alkaloids, chlorothiazide and a sodium-restncted 
diet blood pressure decreased to 160/95 mmHg At the second admission to our hospital in 1965,the 
aldosterone secretion rate, measured during a sodium-restncted diet and 5 days of sodium loading 
with 9 g NaCl/day, revealed a high rate of 347 μg/24 hr Blood pressures at that time were still 
markedly elevated (230/140 mmHg), concurrent with intermittent hypokalemia (3 2 to 4 1 mmol/l) 
Scldingcr arteriography showed normal renal arteries Hyperaldosteronism was also found during the 
third admission in 1967 when she complained of ankle edema, paresthesia and fatigue Aldosterone 
secretion rates during a daily sodium intake of 6 g per day were elevated to 2fi5, 286 and 364 μg/24hг 
during a sodium restricted diet 
Aldosterone secretion rates were repeatedly measured during a clinical admission in 1979 The results 
together with other relevant parameters arc presented m table A-32 The data presented are m 
agreement with the diagnosis of mild primary aldosteronism 
Table A-U 
Aldosterone secretion rates and additional clinical and biochemical findings m patient C-J 
SODIUM INTAKE 
Blood pressure (mmHg) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Creatinine (цтоІ/І) 
UV sodium (mmol/24 hr) 
UV potassium (mmol/24 hr) 
UV creatinine (mmol/24 hr) 
PRA (ng/l() ml/3 hr) 
ASR ^g/24 hr) 
15 mmol/24 hr 
140 
3 4 
84 
30 
79 
10 6 
147 
468 
115 mmol/24 hr 
186/106 (n = 
142 
3 2 
-
79 
48 
9 2 
-
143 
10) 
115 ІШПОІ/24 hr 
138 
34 
71 
290 
86 
13 1 
-
163 
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Figure Α-20 Diumal variations of plasma aldosterone, commi and 18-OH-DOC m patient C-J with 
idiopathic aldosteronism 
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Nocturnal plasma aldosterone concentrations were within the range of values found in patients with 
normal aldosterone secretion (figure A-20). Upright posture in the morning caused a marked increase 
of aldosterone from 13.3 to 49.6 ng/100 ml. with a subsequent decline, despite a persistent upright 
posture. The daytime recumbent aldosterone values were considerably lower than the comparative 
upright values. The correlation coefficients for the basal values of the three adrenocortical hormones 
showed a role for ACTH during the nocturnal control of aldosterone, not however, for the regulation 
of aldosterone during the night and days 1 and 2: 
night night, days 1 and 2 
(n = l l ) (n=17) 
Aldosterone vs Cortisol 0.79 (p<0.001) -0.14 (n.s.) 
Aldosterone vs 18-OH-DOC 0.78 (p<0.001) -0.12 (n.s.) 
Cortisol vs 18-OH-DOC 0.96 (p<0.001) 0.98 (p<0.(X)l) 
Dexamethasone slightly reduced the mean nocturnal aldosterone concentration from 13.4 ± 2.5 to 
10.2 ± 3.9 ng/lOO ml. Daytime aldosterone values were slightly higher during dexamethasone, 
especially during the upright posture. 
Adrenal scintigrams were performed using '"I-6p-Iodomethyl-19-Nor-Choleslerol. during long-term 
suppression of the adrenal function with dexamethasone. Dexamethasone treatment was given at a 
dose of 2 mg/day. starting 15 days before injection of 1.8 mCi of the isotope. Adrenal scintigrams on 
the Slh and 7th days after injection showed an equal accumulation of radioactivity in both adrenal 
glands. The findings were considered to be in accordance with the diagnosis of primary aldosteronism 
due to bilateral adrenal hyperplasia. 
From 1971 to 1979 the patient was treated medically with spironolactone at doses varying from 100 to 
300 mg/day. With this therapeutic regimen diastolic blood pressure levels remained between 90 and 
100 mmHg. Spironolactone did not cause any side effects. 
Patient 27 (Cf. К. 21.04.13) 
In 1977. when he was 66 years old. the patient was referred by an internist elsewhere to our institute. 
Hypertension had been detected in 1960 at a routine medical examination. Blood pressure was treated 
with several medicaments (rauwolfia alkaloids, hydrochlorothiazide, methyldopa). The effects of this 
treatment could not be evaluated, as the patient regularly withdrew from control visits. In 1975 he was 
referred to an internist elsewhere, who found a severe hypertension (190 to 210/110 to 120 mmHg) 
and spontaneous hypokalemia. The patient withdrew from control visits until 1977. when he was 
referred to our institute because of the repeated finding of severe hypertension with concurrent 
hypokalemia (2.7 to 3.4 mmol/l). Scldingcr arteriography had excluded secondary hypcraldostero-
nism due to renal artery stenosis. He complained of polydipsia, polyuria, nycturia (3 times) and 
muscle weakness. In the last 2 years he had not taken antihypertensive or other medicaments. Blood 
pressure on admission was 234/138 mmHg. Fundoscopy revealed no hemorrhages or exudates. The 
heart was slightly enlarged. Central venous pressure was normal and no edema was found. No 
vascular abdominal bruits were heard. Electrocardiography: sinus rhythm with signs of left ventricular 
hypertrophy. X-ray of the chest: heart-lo-lung quotient 14.5:29. 
Aldosterone secretion rates at three different levels of sodium intake and other clinical and 
biochemical data arc presented in table A-33. The findings of hypertension, hypokalemia, increase of 
kaliurcsis in response to sodium loading and a low PRA unresponsive to sodium- restriction and 
upright posture, suggest the presence of primary aldosteronism. However, ASR is normal at a sodium 
restricted diet and after moderate sodium loading. The elevated ASR after a 315 mmol sodium diet 
illustrates that aldosterone production lacks the normal supprcssibilily by sodium loading. Therefore, 
the diagnosis of primary aldosteronism seems inevitable, despite the relatively low rates of aldoste­
rone secretion. 
Plasma aldosterone concentrations were within thr lormal range, both during the night and the days 
(figure A-21). Aldosterone did respond to the stimulus of upright posture in the morning. The 
daytime recumbent aldosterone values were lower than the comparable upright values. The correla­
tion coefficients between the basal values of the three adrenocortical hormones excluded a significant 
influence of ACTH on the regulation of aldosterone. 
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Table A-33 
Aldosterone secretion rates and additional clinical and biochemical findings in patient К 
SODIUM INTAKE 
Blood pressure (mmHg) 
Sodium (mmol/1) 
Potdssium (mmol/l) 
Creatinine (μιηοΙ/Ι) 
UV sodium (mmol/24 hr) 
UV poldssium (mmol/24 hr) 
UV crejtinine (mmol/24 hr) 
PRA (ng/10 min hr) 
ASR (μ6/24 hr) 
15 mmol/24 hr 
140 
27 
115 
16 
38 
13 1 
69 
160 
( 
- 0 20 
0 44 
0 47 
night 
n=12) 
(n 
(n 
115 mmol'24hr 
223/139 (n = 
s ) 
s ) 
( n s ) 
145 
2 6 
108 
185 
59 
12 2 
-
108 
14) 
315 mmol/24 hr 
141 
2 8 
100 
445 
90 
15 5 
-
108 
night, days 1 and 2 
( 
011 
0 46 
0 77 
n=18) 
( n s ) 
(p<0 05) 
(p<0 001) 
Aldosterone vs Cortisol 
Aldosterone vs 18-OH-DOC 
Cortisol vs 18-OH-DOC 
Treatment with dcxamethasonc, however, reduced the mean nocturnal aldosterone concentration 
from 14 4 + 5 2 to 2 4 1 0 7 ng/100 ml The daytime aldosterone values remained essentially 
unchanged during dexamcthasone treatment 
Adrenal scintigrams were made on the 2nd. 5th 7th and 9th days after injection of 1 6 mCi of '}ι1-6β-
lodomcthyl 19 Nor-Cholesterol dunng suppression with dexamcthasone 2 mg/day Dexamcthasone 
was started 14 days before administration of the radiopharmaceutical Accumulation in the adrenals 
was found only on the 9th day The left adrenal gland was clearly visualized and the right gland 
showed only a minimal accumulation of activity The results were therefore considered to point to 
adenoma in the left adrenal gland 
d" К 21- 04 13 
07 1ΓΊ6^0 12 16 
•l—ï-î·*0-"«««· 
Figure A-21 Diurnal variations of plasma aldosterone, Cortisol and 18-OH DOC m patient К with 
idiopathic aldosteronism 
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7 At postmortum examination of the adrenal glands both adrenals appeared enlarged, with broadening 
of the cortex, especially thai of the left gland The adrenals weighed 30 and 40 g Light microscopy 
Both adrenal glands were surrounded by a broad capsule of connective tissue The adrenals showed a 
marked nodular broadening of the cortex The predominating cells were arranged in an alveolar 
pattern and characterized by a partly vacuolated, partly eosinophilic cytoplasm The cells could be 
identified as of the zona glomenilosa-type Locally, small areas were found, composed of large clear 
cells of the zona fasciculata-type Conclusion macro- and micro-adrenocortical hyperplasia of both 
adrenals glands No adrenal adenoma 
8 On January 15th 1978 the patient suddenly developed nausea, vomiting, speech disturbances and a 
transient motor dysfunction of the lower limbs He did not have headache or loss of consciousness 
Visual acuity was unimpaired The patient was off antihypertensive treatment and took dexametha-
sone 2 mg/day for 18 days (see also 3) On admission, the blood pressure was 240/150 mmHg 
Fundoscopy revealed no papilledema, hemorrhages or exudates No manifest paralysis or paresis was 
found The diagnosis of hypertensive encephalopathy was made, and blood pressure was treated by 
intravenous infusion of diazoxidc and metoprolol Despite the maintenance of blood pressure at a 
level of 160 to 180/90 to 110 mmHg by subsequent oral diazoxide 200 mg/day and propranolol 240 mg/ 
day, the patient developed a complete expressive aphasia and paresis of the nghl arm and leg In 
addition, a myocardial infarction of the anterior wall occurred on the 8th day of admission After a 
long-lasting clinical recovery of 3 months duration with only a partial remission of the neurologic 
symptoms, the patient could be discharged from hospital He died one year later from bronchopneu-
monia with cardiac and respiratory insufficiency 
235 

WOORDEN VAN WAARDERING 
Aan de totstandkoming van dit proefschrift hebben velen een belang-
rijke bijdrage geleverd. De dank die ik hiervoor verschuldigd ben gaat 
in de eerste plaats uit naar de patiënten, die bereid waren mee te 
werken aan de vaak belastende protocollen. 
De bereidwillige houding van de verpleegkundige afdeling Endocrino-
logie (Hoofd: Mw. C.J. Willemsen), heeft mede garant gestaan voor de 
kwaliteit van het klinisch onderzoek. Mw. B. van Koolwijk-Renet 
heeft met grote nauwkeurigheid zorg gedragen voor het verzamelen 
van bloed en urine bij de opgenomen patiënten. De verpleegkundigen 
van de polikliniek (destijds Hoofd: Mw. T.M.M. Hoogenbosch) ben ik 
dankbaar voor de medewerking aan de poliklinische studies. 
Dhr. J.A. Hofman van het endocrinologisch laboratorium (Hoofd: 
Prof. Dr. Th.J. Benraad) heeft met grote inzet en enthousiasme een 
nauwkeurige bepaling van aldosteron in plasma ontwikkeld. Zijn kriti-
sche interpretatie van de meetresultaten was voor mij onontbeerlijk. 
Voor de vele hormoonbepalingen verdienen met name genoemd te 
worden: Mw. C.G.M. Camp-van Berkel, Mw. A.A.C, van Geel, Dhr. 
D.C. Lozekoot, Dhr. F .MA. van Rosmalen, Mw. A.M. Thissen-
Jansen, Mw. W.H.M, van de Velde-van LeeuWen, Mw. O.M.M. 
Voesten en Dhr. J.J. Willemsen. 
Het scintigrafisch onderzoek van de bijnieren kon plaats vinden dank-
zij de medewerkers van de afdeling Radiotherapie (Hoofd: Prof. Dr. I. 
Kazem). 
Dhr. J. Konings van de afdeling Medische Illustratie heeft het teken-
werk met grote zorg uitgevoerd. De afdeling Medische Fotografie 
(Hoofd: Dhr. A.Th.A. Reynen) heeft de fotografie verzorgd. 
Dhr. E. de Graaff en medewerkers maakten dat het vergaren van 
literatuur op een verantwoorde en plezierige wijze kon plaats vinden. 
De vertaling van een deel van dit proefschrift werd verzorgd door Dr. 
H.L. Beale te Amsterdam. 
De pentekening op het omslag, waarmee de gelijkenis tussen een 
adenomateuze bijnier en een eikeblad met galappel wordt uitgedrukt, 
is van de hand van Ineke Kruuk, kunstenares te Valkenswaard. 
Mw. L.W.M. Tempelman heeft met grote accuratesse alle versies van 
het manuscript getypt en meegewerkt aan de correctie van de druk-
proeven. 
Mw. W.M. Straten en Mw. S.J.M. v.d. Werf-Morssinkhof hebben het 
typewerk van de publikaties verzorgd. 
De collegae Frank Gribnau, Ad Kerremans en Theo Thien waren zo 
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vriendelijk om bij de afronding van dit proefschrift „bij te springen", 
wanneer de klinische werkzaamheden in het gedrang dreigden te 
komen. 
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CURRICULUM VITAE 
De auteur van dit proefschrift werd geboren op 10 augustus 1943 te 
Arnhem. Hij behaalde in 1962 het diploma gymnasium β aan het 
Katholiek Gelders Lyceum te Arnhem. Hij studeerde vervolgens 
geneeskunde aan de Katholieke Universiteit te Nijmegen, waar hij in 
1968 het doctoraal examen en in 1970 het arts-examen aflegde. In 1970 
trouwde hij met Els Kersten. Na een korte periode als waarnemer te 
hebben gewerkt in de huisartsenpraktijk van J.F.A. van Rijn te 
Arnhem, begon hij in 1970 aan zijn opleiding tot internist aan de 
universiteitskliniek voor Inwendige Ziekten (destijds Hoofd: Prof. Dr. 
C.L.H. Majoor) te Nijmegen. De registratie tot internist vond plaats in 
oktober 1975. Van 1974 tot 1978 was hij werkzaam op de afdeling 
Endocrinologie (Hoofd: Prof. Dr. P.W.C. Kloppenborg), alwaar de 
basis voor zijn promotie werd gelegd. Hij is sinds 1978 werkzaam als 
internist op de afdeling Algemene Interne Geneeskunde (Hoofd: Prof. 
Dr. C.L.H. Majoor). 
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STELLINGEN 
BEHORENDE BIJ HET PROEFSCHRIFT 
CLINICAL AND PATHOLOGICAL ASPECTS 
OF PRIMARY ALDOSTERONISM 
IN HET OPENBAAR TE VERDEDIGEN 
OP DONDERDAG 26 NOVEMBER 1981 
DES NAMIDDAGS TE 2 UUR 
DOOR 
W.H.L. HOEFNAGELS 
I 
Het diurnale rithme van aldosteron bij patiënten met adenomateus 
aldosteronisme onderscheidt zich van dat bij patiënten met idio-
pathisch aldosteronisme in het voorkomen van hoge concentraties 
van dit hormoon gedurende de nacht en vroege ochtend. 
dit proefschrift 
II 
Langdurige toediening van dexamethason, voorafgaand aan scin-
tigrafisch onderzoek van de bijnieren, verhoogt de sensiviteit van 
dit onderzoek met betrekking tot het opsporen van aldosteron-
producerende adenomen. 
dit proefschrift 
III 
Behandeling met Spironolacton leidt tot een relatieve inhibitie van 
de synthese van aldosteron, met name bij patiënten met primair 
aldosteronisme. 
dit proefschrift 
IV 
Het frequent ontbreken van een atrofie van de zona glomerulosa in 
bijnieren van patiënten met een aldosteron-producerend adenoom, 
doet de vraag rijzen of deze vorm van aldosteronisme wel "primair" 
is. 
dit proefschrift 
V 
Behandeling van de ziekte van Addison met uitsluitend glucocorti-
coïden kan een gevaarlijke stijging van de concentratie van kalium 
in plasma tot gevolg hebben. 
Hoefnagels WHL, üraycr JIM, Kloppenborg PWC, Smals AGH, 
Pieters GFF, Bcnraad ThJ. Hydrocortisone-induced hyperkalemia in a 
case of Addison's disease. Neth J Med 21, 120-123, 1978 
VI 
Idiopathisch aldosteronisme is een variant van essentiële hyperten-
sie en niet van het syndroom van Conn. 
Padfield PL, Davies D, Lever AF, Brown JJ, Fraser R, Morton JJ, 
Robertson JIS. The myth of idiopathic aldosteronism. Lancet II, 83-84, 
1981 
VII 
De mineralocorticoïde effecten van glycyrrhetinezuur worden ge-
antagoneerd door gelijktijdige toediening van dexamethason. 
Eigen waarneming 
UV N Q * lV0L .D 
(mmol/(ml/24hl 
24h) 
September 
2Д 26 28 30 
2 v.O.-G. 10-02-1955 
October 1979 
8 10 12 
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weight 
(kgl 
57 
56 H 
55 
54 H 
53 
52 
51- 1 
40H 
80 
120 
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200 
240- 2400 
Plasma Κ + 
(mmoi/ l l /_ 
UVcreat.(mmol/24 h) ,Ш 
m ti 
RR i mm Hgl 
UVK 
, m m o l / o n 
24h) ¿OV 
[PEXAMËTHAS0N£ ï wg dd" 
Vili 
Carriers van het hepatitis-B virus bij wie een integratie van het 
virus-DNA in het genoom van de levercel heeft plaats gevonden, 
hebben een verhoogde kans op de ontwikkeling van een hepato-
cellulair carcinoom. 
Shafritz DA, Kew MC Identification of integrated hepatitis В virus DNA 
sequences in human hepatocellular carcinomas Hepatology 1, 1-8, 1981 
IX 
Bij postmenopauzale patiënten met een oestradiol-receptor-
positief mammacarcinoom en tumor-positieve okselklieren is 
adjuvante chemotherapie niet geïndiceerd. 
Raemaekers JMM, Beex LVAM, Koenders AJM, Smals AGH, 
Pieters GFFM, Benraad ThJ, Kloppenborg PWC De prognostische 
betekenis van onderzoek naar receptor activiteit voor oestradiol in het 
tumorweefsel van patiënten met een primair mammacarcinoom Ned Τ 
Geneesk, In press 
NIH consensus - development statement Adjuvant chemotherapy of 
breast cancer New Engl J Med 303, 831-832, 1980 
X 
Melkzuuracidose bij cardiale beriberi heeft een aanmerkelijk gun­
stiger prognose dan melkzuuracidose tengevolge van andere oor­
zaken. 
Majoor CL H, Hillen HFP Cardiale beriberi met melkzuuracidose en car­
diovasculaire collaps (Shoshin), een bij alcoholici met zeldzaam ziekte­
beeld, dat gemakkelijk wordt miskend Ned Τ Geneesk, in press 
XI 
Het plotseling en onverwacht overlijden van een baby ("wiege-
dood") dient direkt te leiden tot een tevoren zorgvuldig voorbereid 
diagnostisch, pediatrisch en patholoog-anatomisch onderzoek. 
XII 
Artsen in de individuele gezondheidszorg, die dokteren aan wel­
zijnsproblemen doen een kwakzalverij en dragen bij tot een nog 
verdergaande medicalisering van het bestaan. 
Mertcns AThLM De medicus in de individuele gezondheidszorg, de 
sociale gezondheidszorg, de wel/iinszorg Afscheidscollege, 1981, 
Nijmegen 
XIII 
Het verdient onderzoek of de toename van alcoholisme onder de 
jeugd verband houdt met het feit dat het geven van borstvoeding op 
de fles is gegaan. 
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